IMMUNOLOGY Thesis Program of the PhD

Transcription

-1-
IMMUNOLOGY
Thesis Program of the PhD Curriculum N094
CONTENT
1. Coordinator
2
2. Introduction
2
2.1 Aim of the PhD Program Immunology
2
2.2 Recommended Literature
2
3. Courses
3
3.1 Medical Propedeutics
3
3.2 Basic Seminar (2 X 2 Semester hours)
3
3.3 Journal Club and Progress Reports
4
3.4 Program for Elective Courses
5
4. Participating Faculty (Lectures)
7
4.1 PhD Thesis Supervisors
7
4.2 Teachers
9
5. PhD Thesis Projects
5.1 Description of Research Interests of Supervisors and
available Techniques
Barbara Bohle
Wilfried Ellmeier
Erika Jensen-Jarolim
Syliva Knapp
Herwig Kollaritsch
Rudolf Öhler
Winfried F. Pickl
Marcus Saeman
Wolfgang Schreiner
Hannes Stockinger
Herbert Strobl
Julia Walochnik
Thomas Wekerle
Ursula Wiedermann-Schmidt
Gerhard Zlabinger
6. Curriculum Vitae
6.1 PhD Thesis Supervisors (index, in alphabetical order)
6.2 Teachers (index, in alphabetical order)
10
10
10
11
12
13
14
15
16
18
19
21
22
23
24
25
26
28
28
132
-2-
1. COORDINATOR
Wilfried Ellmeier, PhD, Professor of Immunobiology, Division of Immunobiology, Institute of
Immunology, Center for Physiology, Pathophysiology and Immunology , Medical University of
Vienna , Lazarettgasse 19, 1090, Vienna, Austria. Phone: +43-1-40160-65003, Fax: +43-140160-965006
E-mail: [email protected]
2. INTRODUCTION
2.1 Aim of the PhD Program Immunology
Molecular and cellular defense mechanisms of the innate and the adaptive immune system
protect organisms against harmful pathogens and against the development of malignant
cells. However, overreactions of the immune system are responsible for the establishment of
immune-mediated diseases such as allergy, rheumatoid arthritis, inflammatory bowel
disease, multiple sclerosis, diabetes, psoriasis and atherosclerosis. It is of enormous
importance for contemporary biomedical science to increase the knowledge about the mode
of action of the immune system in order to design better therapies for the cure of these lifethreatening diseases. The objective of the PhD Program in Immunology is to provide to
students excellent training opportunities in the field of immunology. This will be achieved by
offering students the opportunity to work with faculty members on cutting-edge research
projects in stimulating research environments. Furthermore, students will obtain an in-depth
education and training on various immunological topics to obtain a broad knowledge in the
field of immunology. This should help to prepare the students for a successful scientific
career within academia and/or industry.
2.2 Recommended Literature
• Janeway’s Immunobiology – The Immune system in health and disease. Seventh Edition,
Kenneth M Murphy, Paul Travers, Mark Walport, Garland Science Textbook 2008 (as
alternative: Immunobiology, Charles Janeway, Paul Travers, Mark Walport, Mark Shlomchik,
Garland Science Textbooks, 2004).
• Molecular and Cellular Immunology, 6th Edition, Abul Abbas, Andrew Lichtman, Shiv Pillai.
Saunders, 2007.
-3-
3. COURSES
There are four types of courses offered in the N094 PhD program:
1. Medical Propedeutics (6 Semester hours)
2. Basic Lecture (2 x 2 Semester hours)
3. Journal Clubs and Progress reports (6 x 2 Semester hours)
4. Elective Courses (4 x 2 Semester hours)
3.1 Medical Prodedeutics (6 Semester hours)
The propedeutics are an obligatory part of the PhD studies (irrespective of the chosen
program). They have to be completed by the end of the fourth semester and comprise a
choice of medical and basic courses, of which 6 semester hours are obligatory. The selection
has to be done under the supervision of the thesis committee and the program coordinator
and is dependent on the undergraduate education and the selected thematic program.
Further information about the propedeutics can be found on the PhD N094 homepage.
3.2 Basic Seminar (2 X 2 Semester hours)
The aim of the Basic Lecture is to give students an advanced but still broad overview about
various immunological topics, which is a prerequisite for a successful career in the field of
immunology. The Basic Lecture will be held in two parts, each 2 semester hours during the
winter and summer semester. The lectures will take place as two blocks during two weeks in
January (winter semester) and June (summer semester). The topics include mechanisms of
innate and adaptive immune responses, as well as the immunopathology of important
immunologically-mediated diseases.
BASIC SEMINAR 1 (Winter semester, 2 Semester hours)
Topic
I. Overview of the immune system (1h)
1. General principles, cell subsets and lymphoid architecture (1)
II. Lymphocyte development and subset generation (2h)
1. B and T cell development (2h)
III. Innate Immunity (7h)
1. Basic principles of innate immune responses (2h)
2. Pattern recognition receptors (2h)
3. Radicals as effectors of innate immune cells (2h)
4. Phagocytosis and endocytosis (1h)
IV. Lymphocyte Activation (10h)
1. Antigen processing and presentation (2h)
2. The biology of antigen presenting cells (2h)
3. Structure, function and signaling of immune receptors (4h)
4. Costimulatory molecules (2h)
V. Effector Mechanisms (5h)
1. The role of cytokines in the immune response (3h)
2. Cell-mediated Immunity and peripheral T cell subsets (1h)
3. Humoral Immunity (1h)
VI. Tolerance mechanisms (2h)
1. Central and peripheral Tolerance (2h)
Lecturer
Wilfried Ellmeier
Wilfried Ellmeier
Sylvia Knapp
Marcus Saeman
Rudolf Öhler
Renate Fuchs
Winfried Pickl
Herbert Strobl
Hannes Stockinger
Peter Steinberger
Martin Wilheim
Wilfried Ellmeier
Gerhard Zlabinger
-4-
VII. Special tissues of the adaptive immune system (3h)
1. Skin Immunity (1h)
2. Mucosal Immunity (2h)
Adelheid Elbe Buerger
BASIC SEMINAR 2 (Summer semester, 2 Semester hours)
Lecturer
Topic
I. Type I allergy (4h)
1. General principles (2h)
2. Therapeutic approaches (2h)
II. Autoimmunity and inflammatory diseases (6h)
2. Clinical aspects of autoimmune diseases (2h)
3. Molecular and cellular mechanism of inflammatory diseases (2)
III. Transplantation immunology (5h)
2. Experimental protocols for transplantation tolerance (2h)
3. Immunogenetic selection criteria (1h)
IV. Immunodeficiencies (3h)
1. Primary immunodeficiencies (2h)
2. HIV (1h)
V. Lymphoproliferative diseases and tumor immunology (4h)
1. Experimental systems for studying lymphomas and leukemia (1h)
2. Clinical insight into leukemia (1h)
3. Immune responses to tumors (1h)
4. Mouse models in cancer research (1h)
VI. Immunotherapy (5h)
2. Clinical strategies for immunotherapy (2h)
VII. Infection immunology (Immunity to Microbes) (3h)
1. Viruses and the Immune system (1h)
2. Strategies for vaccinations (2h)
Rudolf Valenta
Barbara Bohle
Günther Steiner
Clemens Scheinecker
Peter Pietschmann
Gerhard Zlabinger
Thomas Wekerle
Gottfried Fischer
Winfried Pickl
Johannes Stöckl
Veronika Sexl
Ulrich Jäger
Maria Sibilia
Elisabeth Förster-Waldl
Thomas Felzman
Johannes Stöckl
3.3 Journal Clubs & Progress Reports (6 x 2 semester hours)
During the 6 semesters of their PhD studies, students have to participate in Immunology
Journal Clubs that will be held regularly at the institutions of the participating faculty
members. The topics of the Journal Club should be in accordance (or related) with the thesis
subjects of the student, however each Journal Club should be open for all students of the
immunology program. The primary aim of the Journal Clubs is to learn critical reading and
discussion of scientific papers. Therefore, students will have to read scientific publications, to
present them to the other participants and to discuss the presented results, methods and
interpretations under the guidance of the university teacher. The objective of the Journal
Clubs is to get familiar with the design of experimental studies and the interpretation of
results. In addition, Journal Clubs should train students in writing scientific papers. The
selection of the papers to be discussed can be made by the faculty member as well as by the
students.
Another important educational aspect of the PhD program immunology are Progress
Reports that should be given at least once a year by the PhD students. The Progress
Reports should serve as a basis for the evaluation of the PhD thesis. In addition to the
-5-
members of the PhD thesis committee, other faculty members and students from the host
institutions should listen to the seminar given by the PhD student. As a critical audience they
should stimulate the successful development of the PhD thesis, help to critically discuss the
data and provide suggestions for new experiments. Ideally, there should be a regular
Progress Report Series at each host institution of the participating faculty members. This
would allow a regular discussion of ongoing projects and studies of the host institution in
front of a rather broad audience and this will prepare the PhD students for future
presentations of their own scientific results to a larger and critical audience.
Journal Club/Progress Report (Winter and summer semester, 2 Semester hours each)
Title
Lecturer
Current topics in parasitology
Immune responses to allergens
Current topics in immune cell development and function
Structural requirements of antigens and allergens for disease
mechanisms and therapy.
Journal Club of the Surgical Research Laboratories
Integration of genome- and clinical data for immunology
Journal Club & Progress Report
901840 Journal Club und Progress Report
Aspöck, Auer, Hassl,
Walochnik (WS, SS)
Bohle (WS, SS)
Ellmeier (WS, SS)
Jensen-Jarolim (WS, SS)
Oehler (WS, SS)
Renauld, Regele,
Schreiner (WS, SS)
Roth, Spittler, Oehler,
Wekerle, Weigel, Brostjan
(WS, SS)
Stockinger (WS, SS)
Clinical and basic aspects of human hematopoietic stem cells
and dendritic cells
Strobl (WS, SS)
Journal Club and Progress Report
Zlabinger, Pickl, Stöckl
(WS, SS)
3.4 Program for Elective Courses /Thesis Seminars (4 x 2 semester hours)
The purpose of these seminars is to improve and deepen the knowledge in a particular field
of immunology. Topics covered in the seminars go beyond textbook knowledge and will
cover recent developments in a particular field. The topics of the seminars are grouped into
several subject categories (see below). Ideally, the majority of seminars chosen by the PhD
student should be in the subject of the individual thesis, however it is recommended to
choose at least one seminar in a subject that is not related to the topic of the student’s PhD
thesis.
Subject Categories
THESIS SEMINARS (each 2 Semester hours)
Lecturer
Allergy (Immediate Hypersensitivity)
Title of Seminar: Therapeutic concepts for Type I allergies
Immunological Methods
Title of Seminar: Immunological methods in allergy research
Lymphocyte Development
Title of Seminar: Transcriptional control of immune cell development
Bohle (WS)
Bohle (SS)
Ellmeier (WS)
Activation and Regulation of Lymphocytes
Title of Seminar: Molecular mechanisms of immune cell function
Ellmeier (SS)
-6-
Tumorimmunology
Title of Seminar: TBA
Allergy (Immediate Hypersensitivity)
Innate Immunity
Immunity to Microbes
Dendritic cells/ Tumorimmunology
Title of Seminar: antigen-presenting cells as adjuvants for
tumortherapy
Signal Transduction in Immune Cells
Title of Seminar: DissertantInnenenseminar: Molecular basis of
interaction- and communication mechanisms of immune cells (topic of
seminar varies from semester to semester)
Title of Seminar: Recognition mechanisms in immunity (topic of
seminar varies from semester to semester)
Neutrophils, Monocytes/Macrophages and Dendritic Cells
Title of seminar: Differentiation and function of myelomonocytic cells
Hematopoiesis
Title of Seminar: Hematopoietic stem cell pathophysiology and lineage
decisions in the hematopoietic system
Tolerance and Autoimmunity
Title of Seminar: Preclinical protocols for tolerance induction upon
organ transplantation
Immunity to Microbes/ Immunological Methods
Title of Seminar: Medical Parasitology Practical
Basics in Molecular Parasitology
Tolerance and Autoimmunity
Title of Seminar: Immune Tolerance
Transplantation
Title of Seminar: Immunosuppression
Jensen-Jarolim (WS)
Jensen-Jarolim (WS)
Knapp (WS)
Knapp (SS)
Pickl (WS & SS)
Stockinger (WS)
Stockinger (SS)
Strobl (WS)
Strobl (SS)
Wekerle (WS)
Walochnik, together with
Auer (WS, SS)
Walochnik (SS)
Zlabinger (WS, SS)
Zlabinger (SS)
-7-
4. PARTICIPATING FACULTY MEMBERS (LECTURES)
Faculty members participating in the PhD program Immunology can be grouped into either
PhD thesis supervisors or teachers. PhD thesis supervisors are offering internationally
peer-reviewed PhD projects to students and are actively supervising the research of the
students. Furthermore, PhD thesis supervisors are teaching in the various courses and
lectures. In contrast, Teachers do not offer a PhD project to the Immunology program
students, however they provide expertise in a particular field of immunology and therefore
help to cover a large variety of immunology topics.
4.1 PhD Thesis Supervisors
Surename, first name,
academic title
Research Institution
Research Interests
Bohle Barbara, PhD
Univ. Doz. DI. Dr.
Division of Immunopathology,
Dept. of Pathophysiology, Center
for Physiology, Pathophysiology
and Immunology
Allergen-specific immune
responses,
Immunomodulation,
Vaccine development
Homepage: http://www.meduniwien.ac.at/ipp/allergyresearch
Ellmeier Wilfried, PhD
Division of Immunobiology,
Univ.Prof.Mag.Dr.
Institute of Immunology, Center
and Immunology
Lymphocyte Development,
Signal transduction in
immune cells
Homepage: http://www.meduniwien.ac.at/immunologie/ellmeier/index.html
Jensen-Jarolim Erika, MD
Division of experimental
Allergy, Food allergy
Univ.Prof.
Immunology and Oncology, Dept. AllergoOncology, Oncology
of Pathophysiology, Center for
Physiology, Pathophysiology and
Immunology
Homepage: http://www.meduniwien.ac.at/ipp; www.allergology.at
Knapp Sylvia, MD, PhD
Division of Infectious Diseases
a.o. Univ.Prof.Dr. PhD
and Tropical Medicine,
Department of Internal Medicine 1
and Center for Molecular
Medicine
Innate Immunity; Immunity to
Microbes; Neutrophils,
Monocytes/Macrophages and
DC
Homepage: http://www.meduniwien.ac.at/med1/infektiologie ; http://www.cemm.at
Kollaritsch, Herwig
Division of Specific Prophylaxis
Travel Medicine,
Univ-Prof. Dr.
and Tropical Medicine, Center for Vaccinology, Epidemiology
Immunology
Homepage: http://www.meduniwien.ac.at/tropenmedizin/
-8-
Oehler Rudolf PhD
Ao.Univ-Prof.Mag.Dr.
Department of Surgery, Research
Laboratories
Pickl Winfried F, MD
Division of Cellular Immunlogy
Ao.Univ.Prof.Dr.
and Immunehematology, Center
and Immunology
Homepage: http://www.meduniwien.ac.at/immunologie/
Säemann Marcus, MD
Internal III/Clinical Division of
Doz. Dr.
Nephrology & Dialysis
Schreiner Wolfgang, PhD
Division of Biomedical
o.Univ.Prof.Dr.
Computersimulation and
Bioinformatics
Homepage: http://www.meduniwien.ac.at/msi/biosim/
Stockinger Hannes, PhD
Department of Molecular
Univ.Prof. Dipl.-Ing. Dr.
Immunology, Center for
Immunology
Homepage: http://www.meduniwien.ac.at/immunology
Strobl Herbert, MD
Ao.Univ.Prof
and Immunology
Homepage: http://www.meduniwien.ac.at/immunologie
Walochnik Julia, PhD
Department of Medical
Univ.Doz.Mag.Dr.
Parasitology, Clinical Institute of
Hygiene and Medical
Microbiology
Homepage: http://www.meduniwien.ac.at/hygiene/?s=parasitologie
Wekerle, Thomas, MD
Div. of Transplantation, Dept. of
Ao.Univ.Prof.Dr.med.univ.
Surgery
Homepage: http://www.muw.ac.at/transplant-lab
Transplantation Immunology,
Tumorimmunology,
Neutrophils,
Monocytes/Macrophages and
Dendritic Cells
Activation and Regulation of
Lymphocytes, Tumor
Immunology, Immunity to
Mocrobes
Transplantation Biology,
Innate Immunity,
Immunosuppression
Informatics and Modeling in
Medicine, Models,
Immunological Computational
Biology
Activation and Regulation of
Lymphocytes,
Signal Transduction in
Immune Cells, Immunological
Methods
Human hematopoietic stem
cells, dendritic cells,
transcription control of
differentiation, gene therapy,
leukemia, autoimmune
diseases, inflammation
Tolerance induction in
transplantation and allergy
Tolerance and Autoimmunity,
Transplantation Immunology,
-9-
Wiedermann-Schmidt Ursula,
MD, PhD, Univ.Prof. Dr.
Department of Specific
Prophylaxis and Tropical
Medicine, Center for Physiology,
Pathophysiology and Immunology
Homepage: http://www.meduniwien.ac.at/tropenmedizin
Gerhard J. Zlabinger, MD
Division of Clinical and
Univ. Prof. Dr.
experimental Immunology,
and Immunology
Mucosa Immunity
Allergy
Allergy,
Food allergy
AllergoOncology,
Oncology
Homepage: http://www.meduniwien.ac.at/immunologie/content/research/zlabinger.htm
4.2 Teachers
Ao.Univ.Prof.Dr. Herbert Auer
Department of Medical Parasitology, Clinical Institute of Hygiene and Medical Microbiology
Ao.Univ.Prof. Dr. Adelheid Elbe-Buerger
Department of Immundermatology, University Clinic of Dermatology
Univ.Doz. Dr. Thomas Felzmann
Children Cancer Research Institute
Ao.Univ.Prof. Dr. Gottfried Fischer
University Clinic for Blood Group Serology and Transfusion Medicine
Ao.Univ.Prof. Dr. Elisabeth Förster-Waldl
Department of Pediatrics and Adolescent Medicine
Ao.Univ.Prof. DI. Dr. Renate Fuchs
Dept. of Pathophysiology, Center for Physiology, Pathophysiology and Immunology
Univ.Prof. Dr. Ulrich Jäger
Clinical department of Hematology und Hämostaseology, University Clinic for Internal Medicine I
Ao.Univ.Prof. Dr. Peter Pietschmann
Ao.Univ.Prof. Dr. Clemens Scheinecker
Department of Rheumatology, University Clinic for Internal Medicine III
Univ.Prof. Dr. Veronika Sexl
Institute of Pharmacology, Center for Biomolecular Medicine and Pharmacology
Univ.Prof.Dr. Maria Sibilia
Institute of Cancer Research, University Clinic for Internal Medicine I
Ao.Univ.Prof. Dr. Günter Steiner
Department of Rheumatology, University Clinic for Internal Medicine III
Univ.Doz. Dr. Peter Steinberger
Immune Receptors and T-cell Activation, Institute of Immunology, Center for Physiology,
Ao.Univ.Prof.Dr. Johannes Stöckl
Division of Immune Regulation, Institute of Immunology, Center for Physiology, Pathophysiology and
Immunology
Ao.Univ.Prof. Dr. Martin Willheim
- 10 -
5. PhD THESIS PROJECTS
5.1 Description of Research Interests of Supervisors
Barbara Bohle, Division of Immunopathology, Department of Pathophysiology, Center for
Physiology, Pathophysiology and Immunology
Characterization of allergen-specific immune responses
Abstract
The long-term research interest of the Allergy Research group is to elucidate the
immunological mechanisms underlying the induction, maintenance and immunotherapy of
Type I allergy and to develop novel concepts for an efficient and safe specific
immunotherapy of Type I allergy.
(1) Cellular and molecular basis of Type I allergies
We have a long lasting expertise in the isolation and characterization of allergen-specific T
cells. Allergen-specific T cell cultures are applied to gain insights into the cellular response to
allergens. We have shown that the immune response in allergic individuals is dominated by
allergen-specific Th2 cells and lacks counter-regulating allergen-specific Th1 and regulatory
T cells. On the other hand, we employ allergen-specific T cell cultures to characterize
allergens with regard to their T cell epitopes and cellular cross-reactivity. These data lay the
foundation for the development of novel vaccines for allergen-specific immunotherapy, such
as hypoallergenic variants with reduced IgE-binding and retained T cell stimulatory capacity.
(2) Novel vaccines for allergen-specific immunotherapy
Allergen-specific immunotherapy (SIT) is the only treatment of Type I allergy that induces a
modulation of the disease-eliciting immune response. Conventional SIT consists of multiple
subcutaneous injections of crude allergen extracts into allergic individuals in order to induce
a state of clinical tolerance to natural allergen exposure. However, the administration of
allergens bears the risk to induce local and systemic side effects. Furthermore, SIT is not
always effective. Therefore, a major goal of my group is to develop more efficient and safer
vaccines for specific immunotherapy. For this purpose we link allergens with agents targeting
the innate immune system in order to modulate the disease-eliciting immune response
towards a more physiological response.
Techniques
“State of the art” immunological, biochemical and molecular biology techniques, such as the
production and purification of recombinant allergens, RT-PCR, real-time PCR, ELISA,
ELISPOT, SDS-PAGE, Western blotting, different applications of flow cytometry including
cell surface staining, intracellular cytokine detection and determination of cell proliferation by
CFSE staining; basic tissue culture techniques, isolation and characterization of allergenspecific T cells; allergen-induced mediator-release experiments with rat basophil leukemia
cells (RBL) transfected with the human Fc epsilon receptor I and human basophils, basic
allergological methods, i.e. skin prick tests, prick to prick tests and rhinomanometric
measurements.
- 11 -
Wilfried Ellmeier, Division of Immunobiology, Institute of Immunology, Center for
Physiology, Pathophysiology and Immunology
Molecular mechanisms of immune cell development and function
Abstract
Our long-term research interest is to understand molecular mechanisms that regulate the
development and function of immune cells. The research in our laboratory focuses on studies
to understand epigenetic and transcriptional control mechanisms that regulate CD8
coreceptor gene expression, on the identification of genes that control developmental
processes such as CD4/CD8 cell fate decisions during T cell differentiation, and on studies to
reveal the various roles of Tec family kinases in different cell lineages of the immune system.
(1) Epigenetic gene regulation during T cell development
Our laboratory is studying the regulation of CD8 coreceptor expression, a key molecule in the
immune system for the development of the cytotoxic T cell lineage. CD8 coreceptor
expression is tightly regulated during thymocyte development by the activity of at least five
different cis-regulatory elements. We recently linked Cd8 enhancer function with chromatin
remodelling of the adjacent genes Cd8a and Cd8b1 (Cd8) and demonstrated epigenetic
control of the Cd8 gene complex. We have further identified that the zinc finger protein
MAZR is an important regulator of CD8 expression. Ongoing studies in the laboratory aim to
further characterize Cd8 cis-regulatory elements and to study MAZR function in more detail.
(2) The role of Tec family kinases for immune cell function
Members of the Tec kinase family (Bmx, Btk, Itk, Rlk and Tec) form the second largest class
of non-receptor protein tyrosine kinases. The analysis of mice lacking Tec family kinases has
uncovered important functions for Tec kinases in cells of lymphoid origin. In addition,
numerous reports exist that describe the expression and activation of Tec kinases in every
cell type of the myeloid compartment. Tec family kinases can get activated by a broad range
of signalling pathways including also non-immune-globulin like receptors such as: receptor
tyrosine kinases, interleukin and toll-like receptors, integrins, G-protein coupled receptors
and so-called "death" receptors. In order to shed further light into the function of Tec kinases
in myeloid cells, we are analysing the function of a variety of primary myeloid cell types (e.g.
mast cells and monocytes/macrophages) lacking single and/or multiple Tec kinase family
members. Since some of the Tec family kinases are also involved in processes that when
deregulated (such as Th1/Th2 differentiation, mast cell activation) can lead to diseases such
as autoimmunity or allergy in man. Thus, the molecular analysis of the various Tec family
kinase-deficient mice may not only contribute to our basic understanding of the role of Tec
kinases in cells of the immune system, but may also help to indicate ways for potential
therapeutic intervention.
Techniques
„State of the art“ basic molecular and cellular biology techniques, biochemical analysis of
signal transduction pathways, yeast one-hybrid screens, chromatin immunoprecipitations,
RNAi approaches, FACS, in vitro and in vivo immunological assays, retroviral-mediated gene
transduction of bone marrow stem cells followed by the generating of bone marrow chimeras,
(conditional) ES cell technology, and mouse molecular genetics tools (knockout and
transgenics).
- 12 -
Erika Jensen-Jarolim, Division of Experimental Immunology and Oncology, IPP - Dept. of
Pathophysiology, Center for Physiology, Pathophysiology and Immunology
Allergology, oncology, allergooncology
Abstract
The group analyses the molecular features of allergens and antigens leading to sensitization
and immunity. Both, mechanistic and therapeutic principles are being investigated.
Techniques
Molecular and cellular biology techniques, in vitro and in vivo immunological assays, and
mouse models of allergy and tumor disease.
- 13 -
Sylvia Knapp, Division of Infectious Diseases and Tropical Medicine, Department of Internal
medicine 1, Medical University Vienna; and Center for Molecular Medicine of the Austrian
Academy of Sciences
Innate Immune Response to Bacterial Infections
Abstract
Our research projects are addressing important clinical problems and focusing on innate
immune mechanisms with relevant bacterial infections simulated under laboratory conditions.
While our general objectives are in furthering our understanding of clinically relevant
pathogens and host-pathogen interactions; our primary objectives are to positively impact
and substantially enhance the current diagnostic procedures and ultimately influence
therapies and survival.
(1) Host recognition receptors and signaling pathways
Our laboratory is investigating the role of pattern recognition receptors during clinically
relevant bacterial infections, such as pneumonia induced by Streptococcus pneumoniae and
Pseudomonas aeruginosa or septic infections like peritonitis. In doing so we were able to
identify and characterize the distinct roles of e.g. TLRs, CD14, or LBP in vivo. Ongoing
studies are aimed at a better understanding of the biological role of co-receptors such as
TREM-1 or CD36.
In a second line we are interested in understanding the impact of pre-existing tissue
alterations on the course of infection. This question specifically addresses clinically important
situations observed in hospitalized patients that are at increased risk for infections. Our
studies are based on the concept that tissue damage (e.g. trauma, mechanical ventilation or
non-infectious inflammation) results in the release and/or modification of endogenous
molecules that in turn impact the function of immune effector cells. In accordance with this
idea we recently demonstrated that oxidized phospholipids seriously impact host defense
against E. coli in vivo. It is the aim of current projects to explore the generation of these lipid
products in humans and to better characterize elicited effects in vitro and in vivo.
(2) The role of bacterial virulence factors (toxins) during pneumonia.
Pathogenic bacteria developed mechanisms to counteract host defense pathways. Among
those, the secretion of pore-forming toxins is known to be a potent mechanism and
associated with aggravated disease, tissue damage and potentially lethal outcome. We aim
at understanding the molecular mechanism by which selected bacterial toxins attack host
cells in order to identify novel targets for therapeutic interventions.
Techniques
In vitro and in vivo bacterial infection models (pneumonia, and peritonitis), basic cellular and
molecular biology techniques, biochemical analysis of signal transduction pathways, RNAi
approaches, FACS, in vitro immunological assays, basics in confocal microscopy.
- 14 -
Herwig Kollaritsch, Division of Travel Medicine and Infectious Disease Epidemiology,
Institute for Specific Prophylaxis and Tropical Medicine, Center for Physiology,
Epidemiology and Travel Medicine
Abstract
Our group is working in 2 major research fields:
(1) Clinical Studies with new vaccines and proof of concept of recommended vaccination
schedules: Clinical phase II-IV studies as well as post marketing surveillance and
observational studies are performed. Currently, the focus is on immunogenicity and
tolerability of different vaccinations such as a new genereation of bird flu vaccines or new
vaccinations against Japanese Encephalitis. Ongoing projects are long term surveillance of
antibody decline after TBE vaccination and seroprevalence of vaccine derived antibodies in
5-7 year old children.
(2) Epidemiological Studies: In a nationwide surveillance system the epidemiology of
vaccine-preventable diseases (Pertussis, Rotavirus, invasive pneumococcal disease,
Hepatitis A, B, C, Measles, Mumps Rubella, Haemophilus influezae B) has been monitored
for more than ten years by now. Data from this surveillance are used to i) evaluate current
vaccination concepts, ii) establish and monitor new vaccination recommendations, iii)
observe replacement phenomena under vaccination pressure, iv) give cost-benefit analyses
for established vaccination programs and v) use the data from this project to induce new
research projects in basic research and applied science.
- 15 -
Rudolf Oehler, Department of Surgery, Research laboratories
Response of the immune system to therapy in surgical patients
Abstract
Our long-term research interest is to utilise the understanding of the response of the immune
system to therapy in order to improve the clinical outcome.
(1) Effect of chemotherapy on the immune response
Our aim is to avoid undesired immunosuppression by chemotherapy and boost the immune
response to cancer. Chemotherapeutic treatment of cancer patients supposedly mediates its
effect via direct elimination of tumor cells. However, there is growing evidence that activation
of immune cells in tumour's micro environment is essential for tumour regression. Our focus
is the effect of chemotherapeutics on the immune response in cancer patients. Therefore we
investigate circulating as well as tumour-infiltrating immune cells in patients during
chemotherapy. Special emphasis is given to monocytes/macrophages and their
responsiveness to stimuli. In addition we perform in vitro models with primary cells to
investigate the hypotheses raised on the basis of the analysis of the clinical samples.
(2) Non-HLA donor-specific antigens in transplantation immunology
Our interest is to improve the donor-recipient matching in renal transplantation to prolong
graft survival. About the half the renal graft recipients encounter late loss of organ transplants
in renal transplantation. Although it is well established that major histo-compatibility
complexes (HLA) are the main targets of humoral immunity there is evidence that non-HLA
specific antibodies contribute substantially to late loss of organ transplants. Using proteomics
technologies we identify antigens of pre-existing as well as transplantation-induced non-HLA
donor-specific antibodies and develop analytical application platforms for their analysis.
These platforms are then used to investigate the association of the specific antibodies with
graft survival.
Techniques
„State of the art“ quantitative electrophoretic proteomics techniques, in vitro and in vivo
immunological assays, FACS, biochemical analysis.
- 16 -
Winfried F. Pickl, Division of Cellular Immunology and Immunhematology, Institute of
Immunology, Center for Physiology, Pathophysiology and Immunology
The immunological synapse
Abstract
T cell activation is the result of a sustained antigen-specific interaction of a T lymphocyte with
a professional antigen-presenting cell (pAPC) in a secondary lymphatic tissue. The detailed
description of the molecular and functional events within the immunological synapse formed
by T cells and pAPC is one of the keys to the better understanding of adaptive immune
responses and their modulation. Model systems in which the immunological synapse can be
rebuilt with receptors relevant for human diseases shall enable us to study the
pathophysiology of allergies, autoimmune and infectious diseases as well as cancer in
greater detail and may thus lead to novel strategies for their cure.
(1) Direct stimulation of T lymphocytes by immunosomes: virus-like particles decorated with
TCR/CD3 ligands plus costimulatory molecules
Inducible virus-like particles (VLP), decorated with T cell ligands of choice can be directly
immunogenic for purified T lymphocytes. We found that lipid rafts are the keys to inducible
VLP production and the selective enrichment on VLP of immunologically relevant molecules.
VLP expressing combinations of T cell ligands plus antigen were produced and their impact
on T cell activation was evaluated. Functional analyses showed, that they mediate strong,
accessory cell-independent, antigen-specific T lymphocyte activation. Our data move virus
biology, lipid rafts and aspects of lymphocyte activation into a novel biological context. We
expect that both basic and applied research will profit from our reductionist system for
antigen presentation and T lymphocyte activation.
(2) A general strategy for decoration of virus (like) particles with functionally active lipidmodified cytokines
Augmentation of immune responses against antigens by co-administration of appropriate
adjuvants became general practice following the demonstration by Ramon more than 80
years ago that increased antitoxin responses in the presence of “helper substances” can be
achieved. In proof of principle studies we have evaluated the ability of membrane anchored
human and murine cytokines to “pseudotype” Moloney murine leukemia virus (MoMLV)
particles. Based on this mechanism we have developed a system for the predictable
decoration of enveloped viruses (or VLP) with functionally active cytokines that circumvents
the need to modify viral proteins themselves. Virus (like) particles decorated with lipidmodified cytokines might help to improve viral strains for vaccination purposes, improve
artificial antigen presenting platforms, facilitate the propagation of factor-dependent cell
types, as well as gene transfer by viral systems in the future.
(3) Molecular and functional analysis of antigen receptors of allergen-specific helper T
lymphocytes
T lymphocytes play a central role in the pathogenesis of allergic diseases. During the
sensitization phase, priming of allergen-specific (CD4+) T helper 2 (TH2) cells results in the
production of TH2 cytokines, which are responsible for class switching to the epsilon Ig heavy
chain, allowing IgE production by B-cells. Although TCR gene usage by allergen-specific T
lymphocytes has been studied to a considerable degree in the past, no molecular or
functional analyses of cloned and ectopically expressed human allergen-specific TCR have
been reported so far. Consequently, biological model systems based on human allergenspecific TCR were still missing. Hence, one of our research-interests is devoted to test the
feasibility of engineering allergen-specific T lymphocytes by genetic TCR transfer.
Expressible allergen-specific TCRs may contribute to a better definition of the ‘allergenspecific synapse’ and thus the processes leading to allergic diseases and their cure in the
- 17 -
future. In a next step, w e plan to clone TCRs specific for other relevant allergens within the
Christian Doppler Laboratory “Immunomodulation”.
(4) Novel biomarkers to identify active chronic graft-versus-host disease patients with severe
immunodeficiency
Chronic graft-versus-host-disease (cGVHD) is a major complication of allogeneic
hematopoietic stem cell transplantation (HSCT) and a leading cause of nonrelapse mortality
resulting from profound immunodeficiency. Currently, biology-based markers both for
diagnosis and monitoring activity of cGVHD as well as its functional consequences on the
immune system are lacking. In close cooperation with the research group of Prof. Hildegard
Greinix, Department of Internal Medicine I, Medical University of Vienna, we have identified
memory B cell subsets a novel biomarkers to identify patients with severe immunodeficiency.
A prospective study is currently being initiated in order to confirm and extend our earlier
findings.
Techniques
Cellular and molecular biological techniques for the expression and functional evaluation of
immune receptor molecules including retroviral gene transfer and transgenesis and flow
cytometry. Immunological characterization of patients with leukemia and primary and
acquired immunodeficiencies.
- 18 -
Marcus Säemann , Internal Medicine III, Clin. Division of Nephrology & Dialyis
Experimental Immunsuppression and regulation of innate immunity
Abstract:
Our research is primarily devoted to understand immunological effector arms that can be
manipulated in order benefit the host, e.g. to down-regulate immune responsiveness against
alloantigens in organ transplantation. Furthermore, molecular mechanisms and targets of
currently employed immunosuppressants are analyzed to gain more insights into the
molecular drug action and also the basic regulation of the immune response. Another part of
our research is focused on the potential link between arteriosclerosis and inflammation. In
particular we study the potent immunomodulatory capacity of high-density lipoprotein
hypothesizing that its atheroprotective and thereby life-enhancing potency is due to its antiinflammatory action rather than being a simple cholesterol transport molecule. Finally, we
have a prime interest in the diverse immunological mechanisms operative during host cell
evasion also to take advantage from evolutionary driven strategies that can be mimicked for
therapeutic purposes.
(1) Regulation of innate immunity by mTOR
Our laboratory is studying the regulation innate immune responses evoked by monocytes
and peripheral dendritic cells by the mammalian target of rapamycin, a key molecule
traditionally associated with translational control of eukaryotic cells, cell-cycle regulation and
cell survival and currently therapeutically targeted by its naturally occurring inhibitor
rapamycin or its dereivatives as immunosuppressant and anticancer drug. We recently
identified mTOR as negative regulator of proinflammatory cytolkines as IL-12 and IL-23 but
suppressor of the prototypical anti-inflammatory cytokine IL-10 in murine and human
monocytes and peripheral myeloid dendritic cells. We have further identified that its
regulatory role is exerted by the specific control of NF-kB activity, a pivotal proinflammatory
transcription factor. Finally, in a relevant murine disease model employing Listeria
monocytogenes we demonstrated that genetically-susceptible mice display an increased
survival after mTOR inhibition by differentially regulating protective cytokine production.
Ongoing studies in the laboratory aim to further elucidate the relative contribution of the
mTOR subunits mTORC1 or Raptor versus mTORC2 or Rictor in dictating the final outcome
of innate and adaptive immune responses including studies on optimized vaccination
protocols or preventing virally-mediated immune escape.
(2) The role of HDL as immunomodulatory molecule
Several pivotal studies indicate that the quality rather than the quantity of HDL is decisive for
its atheroprotective potency. Our studies could demonstrate that HDL exerts very potent
effects on innate immune cells like monocytes/macrophages and dendritic cells by
suppressing e.g. the production of various inflammatory cytokines. Interestingly, this potent
immunomodulatory role is lost in high-risk populations such as end-stage renal disease
patients exhibiting both a state of chronic inflammation and an excessively increased
mortality rate. This study project aims to define the molecular pathways underlying this
peculiar property of HDL envisioning a translational approach in patients with qualitatively
inferior HDL and also identifying such high-risk patients with immunological methods.
Techniques
Current basic molecular and cellular biology techniques, biochemical analysis of signal
transduction pathways (western blooting, immunoprecipitation, EMSA), RNAi approaches,
FACS, in vitro and in vivo immunological assays and cell culture and finally mouse molecular
genetics tools (knockout mouse models).
- 19 -
Wolfgang Schreiner, Division of Biomedical Computer Simulation and Bioinformatics, Core
facility of Medical Statistics and Informatics
Informatics and Modeling in Medicine
Abstract
My overall goal is the application of IT (information-techniques) within biomedical settings. It
is achieved by combining and applying relevant IT to specific biomedical fields, in an
interdisciplinary approach. Projects may relate to biomedical research as well as to clinical
settings close to patient treatment.
Research & Research Support: In the more simple cases, novel IT-tools are adapted and
made available to support particular biomedical research projects within interdisciplinary
cooperations. Within these projects, the IT then becomes an indispensable part of the final,
overall achievement. In more advanced cases, those IT-tools already available are found
insufficient, and new tools (algorithms) have to be developed so as to meet the needs of a
given biomedical research endeavour. Then, IT-research and development in its own right is
carried out. Finally, the most intriguing scenario is modeling of biomedical systems, with the
intention to acquire further clues about a biomedical system’s internal functionality. For
example, biomolecules can be modeled, the mutual forces and movements computed so as
to understand and predict binding affinities and even enzyme functions in silico before being
tested in a wet lab-setting. Or else, vascular models may be generated via optimization rules
and then be checked to which extent resulting models match reality. We then make
implications if the optimization rules applied may be similar to those criteria relevant in
evolutionary shaping of physiological structures.
Clinical Settings and Patient Treatment: Modern IT, if designed properly, lends itself as a
very efficient support of patient treatment. The IT-people’s task is then to listen, pick up the
clinician’s need and re-formulate it in a way that can be cast into an IT-application. Examples
are applications for patient documentation and signal acquisition in clinical research.
Integration of heterogeneous data sources, such as gene-sequence, gene-expression,
proteomics, bio-signals and images is an ongoing an ever changing challenge. Another
important aspect is consulting clinicians in IT-projects, such as AKIM, that are carried out by
third parties. AKIM aims at renewing and fully integrating the IT-infrastructure of the 2000bed Vienna General Hospital, including the research facilities of Medical University of
Vienna.
(1) Computational immunomics, also known as in-silico immunomics
Our main interest is on the molecular interaction between T-cell-receptor (TCR), T-cellepitope, and major-histocompatibility-complex (MHC). For that purpose we apply software
engineering, mathematical and statistical methods on experimental x-ray data (see
techniques). Investigations regard side chain placement of the peptide inside the MHCbinding-groove and prediction of the binding affinity of a TCRpMHC molecule for high
throughput screening without pre-assigned calibration. We also perform stochastic simulation
to investigate TCR activation. In particular, we evaluate how cooperative mechanisms
between TCRs amay be essential in providing a high discrimination power between different
peptides, despite binding affinities are rather similar.
(2) Blood vessel modelling and visualization
Vessel trees are generated by the algorithm of "Constrained Constructive Optimization"
(CCO), which has been developed by our group. For a suitable choice of boundary
conditions and constraints, each model tree is generated by stepwise adding new segments
and optimizing the tree according to a given target (cost) function. The resulting trees are
highly realistic structures, resembling corrosion casts of real arterial trees. Visualizations are
- 20 -
made in high-quality 3-D-representation, with optional shading and lighting. Recently, an
interactive tool to manipulate and slice the model structures has been developed.
(3) Medical Informatics consultancy and project management.
I take part as a consultant to MUW in several IT-projects, among others AKIM (Allgemeines
Krankenhaus Informations Management). The main challenge is to integrate different
sources of data and enable the clinician to handle them in a seamless fashion.
Techniques
Modeling of peptides (side chain placement, backbone adjustment), scoring conformations
(structureand
sequence-based),
molecular
dynamics
simulations
blood vessel modelling, stochastic simulations of particle- and molecule interactions,
hemodynamic modeling, statistics, graphical display, data-integration of genome and patientrelated data within the AKIM-framework at MUW-AKH, IT-consultancy for biomedical
projects. Programming languages: FROTRAN, Java, SAS, Matlab.
- 21 -
Hannes Stockinger, Department of Molecular Immunology, Center for Physiology,
Analysis of T cell antigen receptor and accessory receptor signaling to understand T
cell regulation
Abstract
Hannes Stockinger is the chairman of the D e pa rt me nt of M ol ec ul ar I m m u n ol o gy o f
the M e di c a l U niv ers ity of V ie n na th at has outstanding expertise in the field of
leukocyte biology with special emphasis on the function and signal transduction of plasma
membrane receptors of T cells.
For an immune response to occur, T cells must be exposed to two types of stimuli. The first
signal, an antigen, ensures the specificity of activation and is transduced via the T cell
antigen receptor. Second signals for T cells are transmitted via costimulatory receptors and
cytokines that promote clonal expansion of the specific T cells and their differentiation into
effector and memory cells. In addition, the immune system provides for control mechanisms,
which maintain homeostasis after active immune responses to foreign antigens, and prevent
or abort responses to self-antigens. The Department is particularly interested to uncover
latter pathways aiming to identify targets to correct pathological and unwanted immune
reactions, which occur during autoimmunity, allergy or transplantation. As tools for the
experiments, a team of 16 young enthusiastic scientists generated a large panel of
monoclonal antibodies towards immune cells receptors and established a number of “gain of
function” and “loss of function” assays by using recombinant and tagged forms as well as
siRNA sequences of membrane receptors and submembrane signaling molecules. In the
course of these studies we contributed also substantially to the identification and
characterization of lipid rafts, special membrane microdomains that control signal
transduction across the plasma membrane.
Currently, together with the Institute for Biophysics from the Johannes Kepler University in
Linz, we are developing methods for detecting and tracking single molecules in living cells.
We are now able to trace individual fluorescently labeled molecules in living cells in real time
as well up to 1000-fold time lapse. The ability to follow molecules on the microsecond time
scale and locate them with a resolution of a few dozen nanometers proves extremely useful
when studying reorganization processes of membrane components or compartments within
the membrane. The use of these high-resolution microscopy techniques are thought to open
completely new vistas for studying signaling processes in living cells and develop novel
diagnostic assays.
The results of our studies were published in approximately 130 scientific papers, a variety of
them in the very top journals such as Cell, Science and The Journal of Experimental
Medicine that were cited nearly 5000 times. Four patents are currently active.
Thesis Subjects
Molecular interactions and transmembrane signaling of surface receptors of T cells.
Techniques and infrastructure
Cell culture, flow cytometry, molecular cloning, transfection and infection techniques, siRNA
technology, immunological techniques (isolation, cultivation and stimulation of immune cells,
ELISA, immunofluorescence, Western blotting, immunoprecipitation, etc), chromatography,
advanced imaging (single molecule analysis, confocal microscopy).
- 22 -
Herbert Strobl, Division: “Molecular Biology of Hematopoietic Stem Cells and Dendritic
Cells”, Institute of Immunology, Center for Physiology, Pathophysiology and Immunology
Human hematopoietic stem cells and dendritic cell biology
Abstract
We focus on questions in cell biology applied to human immunology and molecular
hematopoiesis. We aim to elucidate the transcriptional mechanismsunderlying the lineage
differentiation of granulocytes, monocyte and dendritic cells from common myeloid
progenitor/ stem cells. Furthermore, we study how certain dendritic cell subsets such as
environmental exposed epithelial Langerhans cells get activated, and how they might be
involved in tolerance induction. As a main model cytokine dependent unilineage
differentiation cultures of human CD34 pos.cord blood progenitor/stem cells are combined
with inducible retroviral vector systems. Furthermore, we performed functional genetic
screens to identify novel regulatory proteins involved in myeloid progenitor/stem cell
differentiation and leukemia.
Techniques
Differentiation cultures of primary human CD34 pos. hematopoietic progenitor cells,
multiparamter FACS, molecular/biochemical analyses, DNA cloning, construction of retroviral
gene transfer vectors, functional genetic cDNA libarary screens. In all our projects we use
retroviral/lentiviral gene transfer experiments.
Specific ongoing projects:
Role of transcription factors in lineage decidisons of hematopoietic stem- and progenitor
cells:
We are currently studying several transcription factors: the role of Aryl hydrogen carbon
receptor in myelopoiesis and dendritic cell differentiation; Interplay between nuclear hormone
receptors VDR/RXRα with the master transcription factors GATA-1 and PU.1 in the lineage
decisions of normal and leukemic stem cells; how are lineage decisions between
monopoiesis versus granulopoiesis regulated?
Dendritic cells
We study transcriptional regulators of DC subset differentiation and maturation. Among
several questions: How do common monocytic precursors develop into Langerhans cells in
the steady state versus into monocyte-derived DCs in inflammatory lesions? What is the role
of microRNAs in DC subset differentiation and activation? What is the role of RelB during
Langerhans cell activation? Identify novel transcriptional regulators in Langerhans cell
differentiation. How are epithelial adhesion molecules induced during Langerhans cell
differentiation. Apply organotypic epidermal cultures for studying Langerhans cell function.
Clinical leukemia immunophenotyping
Identify novel markers for identifying monocytic leukemias and Langerhans cell histiocytosis.
Identify novel approaches for monitoring residual leukemic blasts after therapy, by using flow
cytometry. Multicenter standardization efforts within the European group of Immunologic
Leukemia lassification (EGIL).
- 23 -
Julia Walochnik, Department of Medical Parasitology, Clinical Institute of Hygiene and
Medical Microbiology
Molecular parasitology
Abstract
The broader field of our working group is medical protozoology, with a general focus on
molecular biological questions. Our main research topics are pathomechanisms,
immunobiology, phylogeny and biocide susceptibility mainly in Leishmania spp., Toxoplasma
gondii, Trichomonas vaginalis, and, particularly also in Acanthamoeba spp. Moreover,
considerable research work has been done on vector-borne pathogens. During the past
years we have established an extensive protozoal strain collection of well-defined clinical and
environmental isolates.
(1) Pathomechanisms and immunobiology of Acanthamoeba infections
Our long-term research goal is to understand what makes certain Acanthamoeba strains
virulent and what makes certain individuals susceptible to infection. Acanthamoebae are the
causative agents of two very different disease entities. On one hand they evoke the so-called
Acanthamoeba keratitis, a very often seriously progressing inflammation of the cornea
occurring predominantly in contact lens wearers. On the other hand acanthamoebae are
responsible
for
several
highly
destructive disseminating
infections
in
the
immunocompromised host, including dermatitis, pneumonitis and the usually fatal
granulomatous amoebic encephalitis. We are currently the only department in Austria with an
Acanthamoeba research group. The focus of our hitherto work has been the characterisation
and classification of pathogenic and nonpathogenic Acanthamoeba strains employing
morphological, physiological, molecular biological and immunological methods and the
correlation of various characters with respect to pathogenicity. We also want to understand
the regulation of cyst formation, because the cysts are the major problem in therapy.
Moreover, we have been working on the immunoreactivities of Acanthamoeba spp. and on
the serological reactivities of patients.
(2) Anti-protozoal biocides
Another major aim of our working group is to find substances active against Acanthamoeba
and other parasitic protozoa as there currently is no specific treatment available for any of
the different Acanthamoeba infections and also in other protozoal diseases treatment is
highly problematic. We have been involved in several projects on biocides, including contact
lens disinfectants, antibiotics and bioactive substances, and their activities on various
parasitic protozoa.
(3) Phylogeny of the amoebozoa
The classification of the amoebae is especially controversial and has been revised many
times. In the recent years molecular biological investigations, particularly rDNA sequencing,
have brought some astonishing changes concerning the diversity and also the evolutionary
and systematic positions of numerous amoebic lineages. But the vast majority of amoebae
has not been thoroughly investigated or is even known to date. Our aim is to contribute to the
elucidation of amoebozoan phylogeny.
Techniques
Cell culture, microscopy, „state of the art“ basic molecular techniques, PCR, DNA
sequencing, 2D-electrophoresis, ÄKTA purification, in vitro immunological assays.
- 24 -
Thomas Wekerle, Division of Transplantation, Deptartment of Surgery
Abstract
The research efforts of my group focus on translational research in the area of two common
immunological conditions: organ transplantation and allergy. We are interested in the
development of experimental tolerance regimens with relevance for these two indications
and the in-depth mechanistic analysis of such models. In particular, we pursue the concept of
chimerism induction through the transplantation of hematopoietic stem cells which leads to
robust, lasting tolerance towards antigens expressed on the transplanted cells. Protocols of
allogeneic mixed (cellular) chimerism generated through the transplantation of donor bone
marrow for the induction of donor-specific tolerance in transplantation, and protocols of
molecular chimerism generated through the transplantation of syngeneic hematopoietic stem
cells that have been retrovirally transduced ex vivo with a disease-causing antigen are being
investigated.
- 25 -
Ursula Wiedermann-Schmidt Tropical Medicine, Center for Physiology, Pathophysiology
and Immunology
The research unit focuses on immunoprophylaxis and vaccination against infectious
diseases, allergies and cancers, the development and validation of novel vaccine candidates
and antigen delivery systems and the assessment of immediate and memory immune
responses as well as vaccination failure after immunization. Vaccine development from
bench to bedside in cooperation with clinical departments is performed with support of
international vaccine companies.
The following topics are being focused on:
•
•
•
•
•
•
•
New antigen-delivery systems for vaccination:
Lactic acid bacteria as edible vaccines; expression of recombinant allergens, tumor
antigens (her-2/neu) and protozoal antigens (e.g. Toxoplasma gondii)
Virosomes as adjuvants for systemic and mucosal vaccination with tumor
antigens/peptides, allergen peptides etc.
Use of mucosal adjuvants for enhanced immunogenicity, e.g. cholera B subunit, LTB
from E. coli
Development of a polyvalent allergy vaccine: development of novel allergen-chimers
for nasal or oral vaccination against multisensitivities
Development of a cancer vaccine against breast cancer and melanoma
Immunological assessment of phase I clinical trial with cancer vaccines
Characterization of cellular and humoral immune responses in responder versus
non/low-responder vaccinees
Immunological tolerance as vaccination strategy against immunological
hyperresponsiveness (incl. allergy, autoimmunity)
- 26 -
Gerhard J. Zlabinger, Division of Clinical and experimental Immunology, Institute of
Immunology, Center for Physiology, Pathophysiology and Immunology
Bacterial and experimental Immunomodulation
Abstract
A longstanding interest of my research group concentrates on the issue of naturally occurring
ways of immunomodulation as particularly operating in local immunity and on clinical
conditions in consequence of inappropriate immune reactivity as observed after
transplantation or in autoimmune diseases. Identification of immunological deregulation as
early as possibly and the understanding of the ongoing processes are pivotal for early
diagnosis and the development as well as implementation of purposeful interference
strategies.
(1) Mediators of Local Immunity
Tamm Horsfall Protein (THP) is a heavily glycosylated protein, which is exclusively
expressed in the thick ascending limb of the Henle’s loop in the kidney in amounts of 30 – 50
mg/day and therefore comprises the most abundant protein in the urine. THP is normally
expressed only at the luminal surface of renal tubular epithelial cells and excreted to the
urine. Considering the properties of THP, this protein is thought to be an essential defense
molecule against UTI for at least two reasons: 1) Recent data unequivocally demonstrated
that THP is pivotal to combat bacterial infection in vivo. THP-/- mice were shown to be
profoundly hampered to combat colonization of the bladder tissue when infected with
uropathogenic type-1 fimbriated E. coli. In addition, it has been demonstrated that the
absence of THP predisposes the host to severe urinary tract infection. 2) Additionally to this
physical - competitive action, which takes place in the lumen of the urinary tract, we have
recently identified THP as an endogenous molecule that potently mediates
immunomodulation. Because of its restricted expression the activity of THP can be expected
to exclusively take place in the genitourinary tract. We found that THP is a strong activator of
human DCs and initiates the upregulation of costimulatory molecule and MHC expression,
inducing de novo cytokine production and optimal T cell stimulation. Interestingly, THP was
shown to induce DC maturation via activating a TLR4 dependent cell signaling machinery.
(2) Hallmarks of Antibody-mediated rejection
In clinical transplantation, up to now, diagnostic and therapeutic efforts have mainly focused
on T-cell-mediated immunity. However, over the last fifteen years there has been an increase
in evidence for a critical role of B cell immunity and antibody-mediated effector mechanisms
on graft loss. Although in the early days of transplantation humoral immunity was recognised
to be causal for hyperacute graft rejection due to preformed anti-donor antibodies, only
recently the important contribution of alloantibodies to more “common” rejection types could
be established, e.g. acute or chronic rejection. Pivotal for the progress in the field have been
the definition of acute Antibody-Mediated Rejection (AMR) as a novel clinical entity, the
description of capillary deposition of C4 complement split product C4d as marker of AMR,
and the establishment of efficient “anti-humoral” treatment, most importantly apheresis. Since
it would be of great benefit if the reactivity of donor specific B cells (i.e. alloantibody
production) could be accurately assessed prior to transplantation as well as for monitoring
purposes in the post transplant phase we have started to implement a test procedure for ex
vivo testing of alloantibody production. Appropriate stimulation of B-cells reveals the release
of particular alloantibody specificities both in healthy individuals and in sensitized transplant
patients. Follow-up studies in transplant patients will demonstrate the clinical relevance of
such testing.
Techniques
- 27 -
„State of the art“ basic molecular and cellular biology techniques, biochemical analysis of
signal transduction pathways, FACS, in vitro immunological assays.
- 28 -
6. CURRICULUM VITAE
6.1 PhD Thesis Supervisor
Barbara Bohle
29
Wilfried Ellmeier
38
44
Sylvia Knapp
51
Herwig Kollaritsch
57
Rudolf Öhler
70
Winfried F. Pickl
73
Marcus Saeman
78
Wolfgang Schreiner
86
Hannes Stockinger
89
Herbert Strobl
96
Julia Walochnik
101
Thomas Wekerle
107
115
Gerhard Zlabinger
126
- 29 -
Curriculum Vitae
Barbara Bohle
Division of Immunopathology, Dept. of Pathophysiology, Center for Physiology,
Pathophysiology and Immunology, Medical University of Vienna, Waehringer Guertel 18-20,
1090 Vienna, Austria;
Phone: +43-1-40400-5114, Fax: +43-1-40400-5130;
Email: [email protected];
Homepage: www.meduniwien.ac.at/ipp/allergyresearch
Personal Data
Date of Birth:
15.09.1967
Place of Birth:
Bregenz
Nationality
Austria
Education
1997 - 2000
PhD thesis at the Institute of General and Experimental
Pathology, University of Vienna, with distinction
1992 – 1997
Undergraduate study "Food- and Biotechnology" at the
University
of
Natural
Sciences,
Vienna,
Resources
awarded
and
Master
of
Applied
Life
Food
and
Biotechnology with distinction
1985 - 1987
Academy for Medical and Technical Assistants, Vienna,
with distinction
1985
Highschool degree at the Bundesgymnasium Dornbirn with
distinction
Career History
Since 01/2008
Head of the Christian Doppler Laboratory for
Immunomodulation
Since 2002
Associate Professor
since 2002
Head of the research group “Allergy Research” in the
Dept. of Pathophysiology, Medical University of Vienna,
Vienna
2002
Venia docendi in Immunology
2000
University Assistant at the Dept. of Pathophysiology
- 30 -
(formerly: Inst. of General and Experimental Pathology)
1985 – 1990
Medical Technical Assistant at the Institute of General and
Experimental Pathology, University of Vienna, Vienna
Career-related Activities
Since 2007
Managing Editor for “International Archives of Allergy and
Immunology”
Since 2006
Treasurer of the Austrian Society of Allergology and
Immunology
Since 2006
Scientific Advisory Board member of the Paul Ehrlich
Institute, Langen, BRD
Since 2005
Secretary of the Immunology Section of the European
Academy of Allergology and Clinical Immunology (EAACI)
Awards
2007
WAO Henning Loewenstein Award 2007
2007
“Förderungspreis für Wissenschaft”, City of Vienna
2006
Clemens von Pirquet Award by the Austrian Society of
Immunology and Allergology (ÖGAI)
2006
International Award of the Pharmacia Allergy Research
Foundation (PhARF)
2005
Novartis Prize in Biology, Austria
2005
Allergopharma Award for allergy research
2004
Special Award “Food allergy. New insight in crossreactivity” by the Foundation for Allergy Research in
Europe (FARE)
2002
Dr. Karl Schleinzer Award of the University of Agricultural
Sciences, Vienna
2001
Allergopharma Award for allergy research
2000
Thesis prize of the Austrian Society of Immunology and
Allergology (ÖGAI)
Memberships
Austrian Society for Allergology and Immunology
European Academy of Allergology and Clinical Immunology (EAACI)
Sources of funding in last 6 years (2002-2008)
- 31 -
Period
Organization
2008 - 2015 CDG + Biomay
Short Title
K€/year
Christian Doppler Laboratory for
370
Immunomodulation
2008 - 2011 FWF
SFB F01807-B13 "The role of cell-mediated
446
immunity in Type I food allergies"
2007 - 2010 FWF + MUW
DK W1212: Inflammation and Immunity
44
2007
Federal Bank of
ÖNB 12158 “Immunological characteristics
67
Austria
of monomeric and self-assembled allergen-S
layer fusion proteins”
2005 - 2007 FWF
SFB F01807-B04 "The role of cell-mediated
48
2005 - 2007 Biomay
Entwicklung von Impfstoffen und
108
Toleranzstrategien für Typ I Allergien
2001 - 2004 FWF
FWF-SFB F01807 "The role of cell-mediated
42
2004 - 2005 FWF
SS 8808-MED
186
Dr.rer.nat., Dr.sci.med. Dr. techn. or PhD supervisions in last 6 years (2002-2008)
Period
Name of student
Topic
Since 2008
Marija Geroldinger-Simic
In vivo immune responses to pollen-related food
allergens
Since 2007
Veroniqué Schulten
Characterization of in vivo absorbed food
allergens
Since 2004
Marianne Gerstmayr
Novel adjuvants for specific immunotherapy of
Type I allergies
2006 - 2008 Sonja Mutschlechner
Characterization of naturally processed peptides of
Bet v 1 and hypoallergenic Bet v 1 isoforms isolated
from MHC class II molecules
2004 - 2006 Eva Maria Schimek
Effects of cooking on the immunological
properties of food allergens
Publications
65 peer reviewed publications in scientific journals, 9 reviews and book chapters, > 40 invited
lectures, 3 patents
Peer reviewed manuscripts 2002-2008 (original research and reviews)
- 32 -
First, last or corresponding author manuscripts:
Gerstmayr, M., N. Ilk,I. Schabussova, B. Jahn-Schmid, E.M. Egelseer, U.B. Sleytr, C. Ebner
and B. Bohle. A Novel Approach to Specific Allergy Treatment: The Recombinant Allergen-SLayer Fusion Protein rSbsC-Bet v 1 Matures Dendritic Cells that Prime Th0/Th1 and IL-10Producing Regulatory T Cells. J Immunol, 179:7270, 2007
Bohle, B., Kinaciyan, T., M. Gerstmayr, A. Radakovics, B. Jahn-Schmid, and C. Ebner.
Sublingual immunotherapy induces IL-10-producing T regulatory cells, allergen-specific T cell
tolerance and immune deviation. J Allergy Clin Immunol, 120:707, 2007
Kinaciyan, T., B. Jahn-Schmid, A. Radakovics, B. Zwölfer, C. Schreiber, J.N. Francis, C.
Ebner and B. Bohle. Successful sublingual immunotherapy with birch pollen has limited
effects on concomitant food allergy to apple and the immune response to the Bet v 1homolog Mal d 1. J Allergy Clin Immunol, 119:937, 2007
Bohle, B., B. Zwölfer, A. Heratizadeh, B. Jahn-Schmid, Y. Dall Antonia, M. Alter, W. Keller, L.
Zuidmeer, R. van Ree, T. Werfel and C. Ebner. Cooking birch pollen-related food: divergent
consequences for IgE- and T cell-mediated reactivity in vitro and in vivo. J Allergy Clin
Immunol 118:242, 2006
Schimek, E.M., B. Zwölfer, P. Briza, B. Jahn-Schmid, L. Vogel, S. Vieths, C. Ebner and B.
Bohle. Gastrointestinal digestion of Bet v 1-homologous food allergens destroys their
mediator-releasing but not T cell-activating capacity. J Allergy Clin Immunol 116:1327, 2005
Jahn-Schmid, B., A. Radakovics, D. Lüttkopf, S. Scheurer, S. Vieths, C. Ebner and B. Bohle.
Bet v 1142-156 is the dominant T cell epitope of the major birch pollen allergen and important
for cross-reactivity with Bet v 1-related food allergens. J Allergy Clin Immunol 116:213, 2005
Bohle, B., A. Radakovics, D. Lüttkopf, S. Vieths and C. Ebner. Characterisation of the T cell
response to the major hazelnut allergen, Cor a 1.04: evidence for a relevant T cell epitope
not cross-reactive with homologous pollen allergens. Clin Exp Allergy 35:1392, 2005
Bohle, B., B. Zwölfer, G.F. Fischer, U. Seppälä, T. Kinaciyan, C. Bolwig, M.D. Spangfort and
C. Ebner. Characterisation of the human T cell response to Antigen 5 from Vespula Vulgaris
(Ves v 5). Clin Exp Allergy 35:367, 2005
- 33 -
Konakci, K.Z., B. Bohle+, R. Blumer, W. Hoetzenecker, G. Roth, B. Moser, G. BoltzNitulescu, M. Gorlitzer, W. Klepetko, E. Wolner and H.J. Ankersmit. Alpha-Gal on
Bioprostheses: Xenograft Immune Response In Cardiac Surgery. J Eur Clin Invest 35:17,
2005. +both authors contributed equally
Bohle, B., A. Breitwieser, B. Zwölfer, B. Jahn-Schmid, M. Sára, U. B. Sleytr and C. Ebner. A
Novel Approach to Specific Allergy Treatment: The recombinant fusion protein of a bacterial
cell surface (S-layer) protein and the major birch pollen allergen Bet v 1 (rSbsC-Bet v1)
combines reduced allergenicity with immunomodulating capacity. J Immunol 172:6642, 2004
Bohle, B., A. Radakovics, B. Jahn-Schmid, K. Hoffmann-Sommergruber, G. F. Fischer, and
C. Ebner. Bet v 1, the major birch pollen allergen, initiates sensitization to Api g 1, the major
allergen in celery: evidence at the T cell level. Eur J Immunol 33:3303, 2003
Bohle, B., W. Hirt, P. Nachbargauer, H. Ebner, and C. Ebner. Allergy to millet: another risk
for atopic bird keepers. Allergy 58:325, 2003
Co-author manuscripts:
Mittermann, I., R. Reininger, M. Zimmermann, K. Gangl, J. Reisinger, K.J. AichbergerJ, E.K.
Greisenegger, V. Niederberger, J. Seipelt, B. Bohle, T. Kopp, C.A. Akdis, S. Spitzauer, P.
Valent, and R. Valenta. The IgE-Reactive Autoantigen Hom s 2 Induces Damage of
Respiratory Epithelial Cells and Keratinocytes via Induction of IFN-gamma. J Invest
Dermatol, in press
Leb, V.M., B. Jahn-Schmid, K.G. Schmetterer, H. J. Kueng, D. Haiderer, A. Neunkirchner,
G. F. Fischer, K. Nissler, A. Hartl, J. Thalhamer, B. Bohle, B. Seed, W. F. Pickl. Molecular
and functional analysis of the antigen receptor of Art v 1-specific helper T lymphocytes. J
Allergy Clin Immunol. In press
Admyre, Ch., B. Bohle, S.M. Johansson, M. Focke-Tejkl, R. Valenta, A. Scheynius, and S.
Gabrielsson. B-cell-derived exosomes can present allergen peptides and activate allergenspecific T-cells to proliferate and produce Th2-like cytokines. J Allergy Clin Immunol,
120:1418, 2007
Wallner, M., A. Stöckliner, T. Thalhamer, B. Bohle, L. Vogel, P. Briza, H. Breiteneder, S.
Vieths, A. Hartl, A. Mari, C. Ebner, P. Lackner, P. Hammerl, J. Thalhamer, and F. Ferreira.
Allergy multi-vaccines created by DNA shuffling of tree pollen allergens. J Allergy Clin
- 34 -
Immunol, 120:374, 2007
Fuchs, H.C, B. Bohle, Y Dall'Antonia, C. Radauer, K. Hoffmann-Sommergruber, A. Mari, O.
Scheiner, W. Keller and H. Breiteneder. Natural and recombinant molecules of the cherry
allergen Pru av 2 show diverse structural and B cell characteristics but similar T cell
reactivity. Clin Exp Allergy 36:359, 2006
Ma,Y., L. Zuidmeer, L., B. Bohle, S.T. Bolhaar, G. Gadermaier, E. Gonzalez-Mancebo, M.
Ferdandez-Rivas, A.C. Knulst, M. Himly, R. Asero, C. Ebner, R. van Ree, F. Ferreira, H.
Breiteneder and K. Hoffmann-Sommergruber. Characterization of recombinant Mal d 4 and
its application for component-resolved diagnosis of apple allergy. Clin Exp Allergy 36:1087,
2006
Ma,Y., G. Gadermaier, B. Bohle, S. Bolhaar, A. Knulst, Z. Markovic-Housley, H. Breiteneder,
P. Briza, K. Hoffmann-Sommergruber and F. Ferreira. Mutational analysis of amino acid
positions crucial for IgE-binding epitopes of the major apple (Malus domestica) allergen, Mal
d 1. Int Arch Allergy Immunol 139:53, 2006
Fernandez-Rivas, M., S. Bolhaar, E. Gonzlez-Mancebo, R. Asero, A. van
Leeuwen, B. Bohle, Y. Ma, C. Ebner, N. Rigby, A.I. Sancho, S. Miles, L. Zuidmeer, A. Knulst,
H. Breiteneder, C. Mills, K. Hoffmann-Sommergruber and R. van Ree. Apple allergy across
Europe: How allergen sensitization profiles determine the clinical expression of allergies to
plant foods. J Allergy Clin Immunol 118:481, 2006
Dehlink, E., T. Eiwegger, M. Gerstmayr, E. Kampl, B. Bohle, K.W. Chen, S. Vrtala, R.
Urbanek, and Z. Szépfalusi. Absence of systemic immunologic changes during dose-build-up
phase and early maintenance period in effective specific sublingual immunotherapy in
children. Clin Exp Allergy, 36:32, 2006
Roth-Walter, F., B. Bohle, I. Schoell, E. Untersmayr, O. Scheiner, G. Boltz-Nitzlescu, F.
Gabor, D. Brayden, and E. Jensen-Jarolim. Targeting antigens to murine and human M-cells
with Aleuria aurantia lectin-functionalized microparticles. Immunol Lett 100:182, 2005
Jahn-Schmid, B., GF. Fischer, B. Bohle, I. Faé, G. Gadermaier, A. Dedic, F. Ferreira and C.
Ebner. Antigen-presentation of the immunodominant T cell epitope of the major mugwort
pollen allergen, Art v 1, is associated with the expression of HLA-DRB1*01. J Allergy Clin
Immunol 115:399, 2005
- 35 -
Ballmer-Weber, B.K., A. Wangorsch, B. Bohle, S. Kaul, T. Kündig, K. Fötisch, R. van Ree,
and S. Vieths. Component-resolved in vitro diagnosis in carrot allergy: Does the use of
recombinant carrot allergens improve the reliability of the diagnostic procedure? Clin Exp
Allergy, 35:970, 2005
Reisinger J., A. Triendl, Kuchler E, B. Bohle, MT. Krauth, I. Rauter, P. Valent, F. Koenig, R.
Valenta, and V. Niederberger. IFN-gamma-enhanced allergen penetration across respiratory
epithelium augments allergic inflammation. J Allergy Clin Immunol, 115:937, 2005
Aichberger, K.J., I. Mittermann, I., R. Reininger, R., S. Seiberler, I. Swoboda, S. Spitzauer, T.
Kopp, G. Stingl, W. R. Sperr, P. Valent, A. Repa, B. Bohle, D. Kraft and R. Valenta. Hom s 4,
an IgE-reactive autoantigen belonging to a new subfamily of calcium-binding proteins can
induce T helper cell type 1-mediated autoractivity. J Immunol, 175:1286, 2005
Batard, T., A. Didierlaurent, H. Chabre, N. Mothes, L. Bussieres, B. Bohle, M.N. Couret, T.
Ball, P. Lemoine, M. Focke-Teijkl, A. Chenal, G. Clement, F. Dupont, P. Valent, M.T. Krauth,
C. Andre, R. Valenta and Moingeon, P. Characterization of Wild-Type Recombinant Bet v 1a
as a Candidate Vaccine against Birch Pollen Allergy. Int Arch Allergy Immunol, 136:239,
2005
Novak, N., R. Valenta, B. Bohle, S. Laffer, J. Haberstok, S. Kraft, and T. Bieber. FcepsilonRI
engagement of Langerhans cell-like dendritic cells and inflammatory dendritic epidermal celllike dendritic cells induces chemotactic signals and different T-cell phenotypes in vitro. J
Allergy Clin Immunol 113:949, 2004
Repa, A., C. Wild, K. Hufnagl, B. Winkler, B. Bohle, A. Pollak and U. Wiedermann. Influence
of the route of sensitization on local and systemic immune responses in a murine model of
type I allergy. Clin Exp Immunol 137:12, 2004
Wagner, M., H. Poeck, B. Jahrsdoerfer, S. Rothenfusser, D. Prell, B. Bohle, E. Tuma, T.
Giese, J. W. Ellwart, S. Endres, and G. Hartmann. IL-12p70-Dependent Th1 Induction by
Human B Cells Requires Combined Activation with CD40 Ligand and CpG DNA. J Immunol
172:954, 2004
Reininger, R., I. Swoboda, B. Bohle, A. Hauswirth, P. Valent, H. Rumpold, R. Valenta, and S.
Spitzauer. Characterization of recombinant cat albumin. Clin Exp Allergy 33:1695, 2003
- 36 -
Jahn-Schmid, B., C. Harwanegg, R. Hiller, B. Bohle, C. Ebner, O. Scheiner, and M. Mueller.
Allergen
microarray:
comparison
of
microarray
using
recombinant
allergens
with
conventional diagnostic methods to detect allergen-specific serum immunoglobulin E. Clin
Exp Allergy 33:1443, 2003
Himly, M., B. Jahn-Schmid, K. Pittertschatscher, B. Bohle, K. Grubmayr, F. Ferreira, H.
Ebner, and C. Ebner. IgE-mediated immediate-type hypersensitivity to the pyrazolone drug
propyphenazone. J Allergy Clin Immunol 111:882, 2003
Sengoelge, G., J. Kletzmayr, M. Papagiannopoulos, B. Bohle, W. H. Horl, M. Fodinger, and
G. Sunder-Plassmann. TGF-beta1 impairs homocysteine metabolism in human renal cells:
possible implications for transplantation. Transpl Int 16:843, 2002
Loibichler, C., J. Pichler, M. Gerstmayr, B. Bohle, H. Kisst, R. Urbanek, and Z. Szepfalusi.
Materno-fetal passage of nutritive and inhalant allergens across placentas of term and preterm deliveries perfused in vitro. Clin Exp Allergy 32:1546, 2002
Jahn-Schmid, B., P. Kelemen, M. Himly, B. Bohle, G. Fischer, F. Ferreira, and C. Ebner. The
T cell response to Art v 1, the major mugwort pollen allergen, is dominated by one epitope. J
Immunol 169:6005, 2002
Fritsch, R., D. Eselbock, K. Skriner, B. Jahn-Schmid, C. Scheinecker, B. Bohle, M. TohidastAkrad, S. Hayer, J. Neumuller, S. Pinol-Roma, J. S. Smolen, and G. Steiner.
Characterization of autoreactive T cells to the autoantigens heterogeneous nuclear
ribonucleoprotein A2 (RA33) and filaggrin in patients with rheumatoid arthritis. J Immunol
169:1068, 2002
Breitwieser, A., E. M. Egelseer, D. Moll, N. Ilk, C. Hotzy, B. Bohle, C. Ebner, U. B. Sleytr, and
M. Sara. A recombinant bacterial cell surface (S-layer)-major birch pollen allergen-fusion
protein (rSbsC/Bet v1) maintains the ability to self-assemble into regularly structured
monomolecular lattices and the functionality of the allergen. Protein Eng 15:243, 2002
Rausch-Fan, X., F. Leutmezer, M. Willheim, A. Spittler, B. Bohle, C. Ebner, E. JensenJarolim, and G. Boltz-Nitulescu. Regulation of cytokine production in human peripheral blood
mononuclear cells and allergen-specific Th cell clones by 1alpha,25-dihydroxyvitamin D3. Int
Arch Allergy Immunol 128:33, 2002
- 37 -
Invited Talks 2002-2008
2006
• XXV EAACI 2006, Vienna
• Hautklinik Johannes Gutenberg-Universität Mainz, Germany
• University of Salzburg, Austria
• Paul Ehrlich Institut, Langen, Germany
• 1st International Symposium on Molecular Allergology, Rome, Italy
• IV European Asthma Congress, Teneriffe, Canary Islands
2007
• Interdisziplinäres Freiburger Allergiesymposium, Freiburg, Germany
• 2.Gemeinsamer Allergiekongress Lübeck , Germany
• Pirquet-Club, Kinderklinik, Medical University of Vienna
• XXVI EAACI 2007 Göteborg, Sweden
• Gesellschaft der Ärzte Wien
• 5th EAACI GA2LEN Davos Meeting in Davos, Switzerland
• AAAAI, San Diego, USA
• 2nd International Symposium on Molecular Allergology, Rome, Italy
2008
• 12th International Paul Ehrlich Seminar, Bad Homburg, Germany
• World Immune Regulation Meeting WIRM II, Davos, Switzerland, 17.3.-20.3.2008
• AAAAI, Philadelphia, USA
• Paul Ehrlich Seminar, Bad Homburg, Germany
• 3rd International Symposium on Molecular Allergology, Salzburg, Austria
• XXVII EAACI 2008 Barcelona, Spain
• Symposium on Specific Allergy (SOSA) , Copenhagen, Denmark
- 38 -
Curriculum Vitae
Wilfried Ellmeier
Division of Immunobiology, Institute of Immunology, Center for Physiology, Pathophysiology and
Immunology, Medical University of Vienna, Lazarettgasse 19, 1090 Wien, Austria; Phone: +43-140160-65003, Fax: +43-1-40160-965006;
Homepage: www.meduniwien.ac.at/immunologie/ellmeier
Personal Data
Date of Birth:
09.09.1966
Place of Birth:
Mödling
Nationality
Austria
Education
1990 – 1994
PhD studies (Biochemistry, Molecular Biology), University of
Vienna, with distinction
1989 – 1990
Diploma thesis at the Institute for Molecular Pathology (IMP) in
Vienna
1985 – 1990
Studies in Biochemistry, University of Vienna
1985
University entrance qualification, HTL-Mödling
Career History
Since 07/2007
Full Professor of Immunobiology
2005 - 2007
Associate Professor (a.o.Univ.Prof)
12/2002
Habilitation in Immunology, University of Vienna Medical
School
2000
Group Leader, Institute of Immunology, University of Vienna
1995 - 1999
Postdoctoral Fellow at the Skirball Institute, Howard Hughes
Medical Institute, New York University Medical Center, New
York, NY, USA
1999 - 1994
PhD Thesis performed at the Institute for Molecular Pathology
(IMP) in Vienna
2006 – present
Member of the APART and DOC committee of the Austrian
Academy of Sciences
2005 - present
Speaker and Coordiantor of the FWF Special Research
Program (Spezialforschungsbreich) SFB F23 „Immunological
- 39 -
Tolerance“
Awards
2005
2005
Novartis prize 2004 in Biology
2003
Habilitation prize “Verein zur Förderung von Wissenschaft und
Forschung in den Neuen Universitätskliniken am AKH der
Stadt Wien” (VFWF).
2001
START Prize, BMBWK und FWF
2000 - 2002
APART Habilitation Fellowship, Austrian Academy of Sciences
1997 - 1999
Postdoctoral Fellowship of the Howard Hughes Medical
Institute
1995 - 1997
Erwin-Schrödinger Postdoctoral Fellowship, FWF
1993
EMBO "short-term" Fellowship, EMBO
Memberships
Period
Organization
2007 - 2010 FWF
Short Title
Molecular characterization of the transcriptional
K€/year
130
regulator MAZR
2007 - 2010 FWF + MUW
DK W1212: Inflammation and Immunity,
44
subproject 3
2005 - 2009 FWF
SFB F23 Immunological Tolerance:
100
SFB Coordination
2005 - 2009 FWF
SFB F23 Immunological Tolerance: Subproject 5
110
2006 - 2009 EU
EU Marie Curie Research & Training Network
100
(MRTN-CT-2006-035733)
2004 - 2006 Federal Bank of
Austria
Molecular Anaylsis of the function of a C2H2
30
zinc finger containing DNA binding molecules
during T cell development
2003 –
FWF
2007
2002
Epigenetic and transcriptional regulation of
100
CD8a and CD8b gene expression
Federal Bank of
The regulation of T cell development:
Austria
Identification and characterization of candidate
80
genes
2001 - 2008 FWF and BM:WF
START
Molecular mechanisms of Lymphocyte
Development and Activation
150
- 40 -
2000 - 2004 K-Plus BMT
Molecular Analysis of Dendritic Cell Function
100
2000 - 2003 FWF
Molecular characterization of CD8 coreceptor
110
Gene Expression and Lineage Decisions During
T cell Development
Period
Name of student
2000 - 2004 Colin Feik
Topic
Molecular and functional characterization of the CD8
enhancer E8III
2001 - 2005 Christina Kösters
Gain and Loss of Function Approaches to Study
Immune Cell Development and Function: B-4C- a Key
Player in Dendritic Cell Biology?
2001 - 2005 Bernd Unger
Molecular Analysis of dendritic cells and
macrophages
2000 - 2005 Ivan Bilic
Epigenetic mechanisms in the transcriptional
regulation of CD8 coreceptor expression during T cell
development
2001 -2006
Martin Melcher
The role of Tec family kinases in macrophages
2004 –
Shinya Sakaguchi
Molecular Analysis of CD8 gene expression
Julia Raberger
Tec family kinases and T cell function
Wolf Gebhardt
Identification of MAZR interacting factors
Derya Köprölü
The role of Tec family kinases in myeloid cells
Anastasia Abramova
Transcriptional regulation of CD8 gene expression
present
2005 –
present
2007 –
present
2007 –
present
2007 –
present
Publications
33 peer reviewed publications in scientific journals, 2 book chapters, > 30 invited lectures, 4
patents
Ellmeier, W., Sunshine, M.J., Maschek, R. and Littman, D.R. (2002). Combined deletion of CD8
locus cis-regulatory elements affects initiation but not maintenance of CD8 expression. Immunity,
5, 623-34.
Kioussis D. and Ellmeier, W. (2002) Chromatin and CD4, CD8A and CD8B gene expression
- 41 -
during thymic differentiation. Nat Rev Immunology, 12, 909-19.
Taniguchi, I., Ellmeier, W., and Littman, D.R. (2004). The CD4/CD8 Lineage Choice:
Insights into Epigenetic Regulation During T Cell Development. Adv Immunol, 83, 55-89.
New
Feik, N., Bilic, I., Tinhofer, J., Unger, B., Littman, D.R. and Ellmeier, W. (2005). Functional and
Molecular Analysis of the Double-Positive Stage-specific CD8 Enhancer E8III During Thymocyte
Development. The Journal of Immunology, 174, 1513-2.
Bilic, I., Kösters, K., Unger, B., Hertweck, A., Maschek, R., Wilson, C.B. and Ellmeier, W. (2006)
Negative regulation of CD8 expression via CD8 enhancer-mediated recruitment of the zinc finger
protein MAZR. Nature Immunology, 7, 392-400.
Christina Koesters, C. Bernd Unger, B. Bilic, I., Bluml, S., Lichtenberger, B., Schreiber, M., Stockl,
J. and Ellmeier, W. (2007). Regulation of dendritic cell differentiation, maturation and subset
distribution by the zinc finger protein CTCF. Immunology Letters, 109, 165-74.
Bilic, I, and Ellmeier, W. (2007). The role of BTB domain-containing zinc finger proteins in T cell
development and function. Immunology Letters, 108, 1-9.
Melcher M, Unger B, Schmidt U, Rajantie IA, Alitalo K, Ellmeier W. 2008. Essential Roles for the
Tec Family Kinases Tec and Btk in M-CSF Receptor Signaling Pathways That Regulate
Macrophage Survival. Journal of Immunology, 180: 8048-56
Keppler, O.T., Welte, F.J., Ngo, T.A., Kathryn S. Patton, K.S., Tsou, C.L., Abbey, N.W., Sharkey,
M.E., Yun You, Y., Scarborough, J.D., Ellmeier, W., Littman, D.R., Stevenson, M., Charo, I.F.,
Herndier, B.G., Speck, R.F., and Goldsmith, M.A. (2002). Progress Toward a Human
CD4/CCR5-Transgenic Rat Model for de Novo Infection by Human Immunodeficiency Virus Type
1. The Journal of Experimental Medicine, 195, 719-36.
Atkinson, B., Ellmeier, W., Watson, S.P. (2003). Tec regulates platelet activation by GPVI in the
absence of Btk , Blood, 3592-9.
Madakamutil, L.T., Gangadharan, D., Chrtisten, U., Lena, C.J., Wang-Zhu, Y., Attinger, A.,
Ellmeier, W., von Herrath, M.G., Jensen, P., Littman, D.R. and Cheroutre, H. CD8aa+ primary
effector cell selectively differentiate into memory CD8 T cells. (2004). Science, 304, 590-93.
Schmidt, U., van den Akker, E., Parren-van Amelsvoor, M., , Litos, G., de Bruijn, M., Hendriks,
R.W., Ellmeier, W., Beug, H. and von Lindern, M. Btk is required for an efficient response to
erythropoietin and for SCF-controlled protection against TRAIL in erythroid progenitors. Journal
of Experimental Medicine,199, 785-95.
Wu, P.Y., Tabuchi, R.S., Kato, R.M., Astrakan, A., Humblet-Baron, S., Kipp, K., Chae, K.,
Ellmeier, W., Witte, O.N., and Rawlings, D.J. (2004) Sustained correction of B cell development
and function in a murine model of X-linked agamaglobulinemia (XLA) using retroviral.mediated
gene transfer. Blood, 104, 1281-90.
Sarafova, S.D., Erman, B., Yu, O., Van Laethem, F., Guinter, T., Sharrow, S.O., Feigenbaum, L.,
Wildt, F.L., Ellmeier, W. and Singer, A. (2005). Transcriptional Modulation of Coreceptor
Expression during Positive Selection Dictates Lineage Fate Independently of TCR Specificity and
Coreceptor Protein Identity, Immunity, 23:75-87.
Marquez, M.E., Ellmeier, W., Sanchez-Guajardo, V., Freitas, A.A:, Acuto, O. and Di Bartolo, V.
- 42 -
(2005). CD8 T cell sensory adaptation dependent on TCR avidity for self-antigens. The Journal of
Immunology, 175, 7388-97.
Taschner, S., Koesters, C., Platzer, B., Jörgl, A., Ellmeier, W., Benesch, T. and Strobl, H.
(2007). Downregulation of RXR expression is essential for neutrophil development from
granulocyte/monocyte progenitors. Blood, 109, 971-9.
Park JH, Adoro S, Lucas PJ, Sarafova SD, Alag AS, Doan LL, Erman B, Liu X, Ellmeier W,
Bosselut R, Feigenbaum L, Singer A. (2007). 'Coreceptor tuning': cytokine signals
transcriptionally tailor CD8 coreceptor expression to the self-specificity of the TCR. Nat Immunol.
10:1049-59.
Hantschel O, Rix U, Schmidt U, Burckstummer T, Kneidinger M, Schutze G, Colinge J, Bennett
KL, Ellmeier W, Valent P, Superti-Furga G. (2007). The Btk tyrosine kinase is a major target of
the Bcr-Abl inhibitor dasatinib. PNAS, 104:13283-8.
Shinohara M, Koga T, Okamoto K, Sakaguchi S, Arai K, Yasuda H, Takai T, Kodama T, Morio T,
Geha RS, Kitamura D, Kurosaki T, Ellmeier W, Takayanagi H. 2008. Tyrosine kinases Btk and
Tec regulate osteoclast differentiation by linking RANK and ITAM signals. Cell, 132, 794-806.
2002
• St. Anna Kinderspital, Wien
• Institut für Molekulare Pathologie, Wien
• Universität Würzburg, Deutschland
2003
• Institute for Medical Biology and Human Genetics, University of Innsbruck
• Institute for Pathophysiology, AKH Wien
• Institut für Entwicklungsbiologie, Marseille, Frankreich
• Talk at the “ThymOz” Conference on Heron Island, Australia
2004
• Technical University of Munich
• Selected talk at the Cold Spring Harbor Conference "Gene Expression and Signaling in the
Immune System", Cold Spring Harbor, New York, USA
• Invitation to Chair and to talk at the minisymposium „Chromatin remodeling during lymphocyte
differentiation“ at the 12th International Congress of Immunology, Montreal,
2005
• University of Erlangen, Germany
• RIKEN Institute of Allergy and Immunology
• Tokyo Medical and Dental University
• University of Salzburg
• Invited talk at the T cell workshop: “The immunological synapse – kinases in T cell signaling as
potential drug targets”. Grossziethen, Germany
2006
• University of Munich, Germany
• Karolinska Institute, Sweden
• Selected to talk at the Cold Spring Harbor Conference "Gene Expression and Signaling in the
Immune System", Cold Spring Harbor, New York, USA
• Invited talk at the 3rd Aegean conference on “gene regulation in lymphocyte development.
• Invited talk at the 7th EFIS Tatra Immunology Conference.
• Invited talk at the EU MC RTN Minisymposium on Immunological mouse models
- 43 -
2007
• University of Oxford, England
• Invited talk at the RIKEN workshop on “T cell development and transcription factors”, RIKEN,
Yokohama, Japan.
- 44 -
Curriculum Vitae
Division of Experimental Immunology and Oncology, IPP - Dept. of Pathophysiology, Center for
Physiology, Pathophysiology and Immunology, Medical University of Vienna, Währinger Gürtel
18-20, 1090 Wien, Austria;
Phone: +43-1-40400 - 5110, Fax: +43-1-40400-5130;
Homepage: www.meduniwien.ac.at/ipp; www.allergology.at
Personal Data
Date of Birth:
10.04.1960
Place of Birth:
Vienna
Nationality
Austria
Education
1978 – 1985
MD studies, University of Vienna
Career History
02/2008
Council member of the Veterinary University Vienna
Since 02/2007
Full Professor of Pathophysiology
07/2006
Head of IPP – Dept. Of Pathophysiology
1999 - 2006
05/1999
Habilitation in General and Experimental Pathology, Vienna
Medical School
1999
Leader of AllergoOncology Group, IPP
1990-1991
Postdoctoral Fellow at the Inselspital, University of Berne,
Switzerland
1989-1990
Postdoctoral Fellow at Rigshospitalet, Allergy laboratory,
University of Copenhagen, Denmark
Awards
05/2006
Teacher of the Month, Medical University Vienna
12/2005
Great Central-European Prize for Innovative Interdisciplinary
Cancer Research of the Funds of the City of Vienna
05/2005
Researcher of the Month, Medical University of Vienna
03/2005
Award of the ECARF (European Centre for Allergy Research
Foundation), Clinical Allergology.
2004
Bronze Medal of the Slovac Academy of Sciences.
- 45 -
2002
Research Prize of the Austrian Association for Crohn´s
disease and Colitis ulcerosa (ÖMCCV).
2000
Pirquet Prize of the Austrian Society of Allergology and
Immunology.
1999
Habilitation Prize of the VFWF (Association for the Promotion
of Science and Research at the New University Departments
of the Vienna General Hospital).
1998
Research Prize of the ÖMCCV (Austrian Association for
Crohn´s disease and Colitis ulcerosa).
1990
Research Prize of the Hoechst AG, Frankfurt/Main, Germany
(later continued by Aventis Foundation).
1989
Research Prize of the Danish Allergy Foundation (founded in
1981), University Hospital, Copenhagen, Denmark.
Memberships
Collegium Internationale Allergologicum
Verein zur Förderung von Wissenschaft und Forschung in den Neuen Universitätskliniken am
AKH der Stadt Wien (VFWF).
Period
Organization
Short Title
2000-2003
Biomay
“Neue Impfstrategien bei Typ I Allergie”
2002-2004
FWF
“The role of allergen-specific antibodies and
K€/year
293
75
anti-antibodies in molecular models of type I
allergy“
2001-2007
BioLifeSciences
“Mimotope zur Therapie maligner Tumore”
2002
FWF
FWF P14339-B08 „Mimotopes for
101
56
Immuntherapy of Allergic Disease II“
2003-2005
2003-2005
Fördergesellschaft
“GD2 Mimotope DANN-vaccines for active
Kinderkrebs
immunotherapy of neuroblastoma”
Jubiläumsfonds der
ÖNB 10326 “Generation of mimotopes of the
ÖNB
major fish allergen parvalbumin for the
25
53
treatment of food allergy – application of
phage display peptide libraries”
2004
Jubiläumsfonds der
ÖNB 10965 “Development of an active
ÖNB
immunotherapy for childhood neuroblastoma
55
- 46 -
with mimotope technology”
2004-2005
Hans und Blanca
“Translation of disialoganglioside epitope in
Moser-Stiftung
an immunogenic mimotope for
9
immunotherapy of neuroblastoma”
2005-2008
FWF
“Allergen mimotopes for epitope studies and
105
vaccination”
2005-2007
2005-2006
Wiener Wirtschafts-
FA648A0201 “Biokompatible Partikel für
förderungsfonds
Schluckimpfung gegen Allergien”
Institut Danone
“Das Sensibilisierungspotential von Bet v 1-
36
14
Homologen in älteren Patienten und Mäusen
beeinflusst durch antiazide Therapie“
2005-2008
FWF
FWF P18238-B13 “Development of an oral
85
mimotope vaccine against tumors“
2005-2006
Medizinisch
2484 “Development of an active
Wissenschaftlicher
immuntherapy against carcinoembryonic-
Fonds des
antigen (CEA-) overexpressing tumors
24
Bürgermeisters der
Stadt Wien
2005-2007
Jubiläumsfonds der
ÖNB 11375 “The effect of total gastrectomy
ÖNB
on the development of food allergy in
49
humans”
2005
DAAD
A/04/42152 “Magensäure-supprimierende
4
Medikamente während der Schwangerschaft
führen zur Sensibilisierung gegen
Nahrungsmitteln bei neugeborenen Mäusen”
2005
Alexander-von-
OST/11119407S “Magensäure-hemmende
Humboldt-Stiftung
Medikamente während der Schwangerschaft
13
führen zu Nahrungsmittelallergie im
Mausmodell“
2005-2006
2005-2006
Hans und Blanca
“Orale Mimotop-Immunisierungen zur IgE
Moser-Stiftung
Induktion gegen Tumorantigene“
Hans und Blanca
“Testung der anti-Tumor-Wirkung von
Moser-Stiftung
Pertuzumab-Epitop-spezifischen anti-HER-2-
7
5
Impfstoffen“
2006
FWF
FWF H220-B13 “Mechanisms in the
sensitization and effector phase of food
allergy“
38
- 47 -
2006-2009
FWF, CCHD
FWF W1205-B09 “Cellular interactions
31
decisive for the type of immune response to
orally applied antigens”
2006-2007
2006-2009
Funds of the City of
AP00181OFF “Immunogenicity and
Vienna for Innovative
therapeutic potency of mimotopes for the
Interdisciplinary
carcinoembryonic antigen (CEA) in
Cancer Research
transgenic mouse tumor models”
FWF
FWF T283-B13 “Antazida induzieren
10
58
Nahrungsmittelallergie in Neugeborenen”
2006-2007
Hochschuljubiläums-
H-2182/2006 “IgE induzierte Ausschüttung
stiftung der Stadt
von TNF alpha bei Mastzellen und
Wien
basophilen Granulozyten und die Wirkung
5
auf Tumorzellen“
2006-2007
Funds of the City of
“Testung der anti-Tumor-wirkung von epitop-
Vienna for Innivative
spezifischen HER-2 Impfstoffen in human-
Interdisciplinary
HER-2 transgenen Mäusen”
20
Cancer Research
2007-2008
Hans und Blanca
AP00253OFF “Charakterisierung der
Moser-Stiftung
molekularen Mechanismen von Antikörpern
9
nach aktiver Impfung gegen das
Carcinomembryonale Antigen“
2007-2008
2007-2010
Hochschuljubiläums-
H-02325/2007 “Effektorzellen der IgE-
stiftung der Stadt
vermittelten Überwachung des
Wien
Tumorwachstums“
FWF, CCHD
FWF FA102A004 “Cellular interactions
5
44
decisive for the type of immune response to
orally applied antigens“
2008-2009
Hans und Blanca
AP00326OFF “Investigating the tumoricidic
Moser-Stiftung
properties of an anti HER-2 antibody of the
5
IgE subclass
2008-2012
FWF
“Allergen mimotopes for epitope studies and
vaccination”
Period
Name of student
Topic
2001-2004
Schöll, Isabela
PhD: Mechanism of type I allergy and novel
154
- 48 -
vaccination strategies for treatment.
2003-2006
Schöll, Isabella
MDSci: Characterization of conformational epitopes
of allergenic molecules and generation of mimotopes
for active immunotherapy of type I allergies.
2002-2004
Riemer, Angelika B.
PhD: Generation of epitope mimics of tumorinhibitory monoclonal antibodies: Targeting HER-1
and HER-2.
2003-2006
Untersmayr-Elsenhuber,
MDSci: Mechanisms of food allergy.
Eva
2001-2005
Hantusch, Brigitte
PhD: Epitope mimics of grass pollen allergen Phl p 5
from phage display libraries: tools for anti-allergen
immunizations.
2002-2004
Walter, Franziska
PhD: Design of an oral vaccine against birch pollen.
2003-2005
Walter, Franziska
MDSci: Oral immunisation of allergen-loaded
microsphere with bioadhesive properties and their
impact on the immune system.
2003- in
Szalai, Krisztina
progress
MDSci: Mapping and characterization of epitopes of
prevalent inhalative allergens with the mimotope
technology.
2004- in
Szalai, Krisztina
progress
PhD: Generation of peptide-mimotopes to allergenspecific IgE treatment of food allergy. Application of
phage display libraries.
2005 – in
Kntittelfelder, Regina
progress
2006- in
tumor antigen HER-2: a target for immunotherapy.
Brämswig, Kira
progress
2006- in
PhD: Molecular and immunological aspects of the
PhD: Therapeutic potency of mimotopes in a
transgenic tumor mouse model.
Wallmann, Julia
progress
PhD: Immunotherapeutical approaches with different
constructs of grass pollen mimotopes in allergic
asthma.
2008- in
Lukschal, Anna
PhD: Epitop specific IgE detection.
Starkl, Philipp
PhD: Cellular and molecular mechanisms of the
progress
2007- in
progress
2007- in
intestinal uptake of food allergens.
Krishnamurthy, Durga
progress
2008- in
progress
PhD: The role of the liver in the induction and control
of food allergy.
Weichselbaumer, Marlene
Dr. med. Vet.: Immunization with carcinoembryonic
antigen (CEA) mimotope vaccine inhibits growth of
- 49 -
CEA positive mammary carcinomas in canine
patients.
Publications
>100 peer reviewed publications in scientific journals, 57 invited lectures, patents see depatisnet
Jensen-Jarolim E, Untersmayr E. Gender Medicine Aspects in Allergology. Allergy, in press.
Hantusch B, Jensen-Jarolim E. Von der Allergenerkennung durch Antikörper zu neuen
therapeutischen Konzepten. Wiener Med. WSchr, in press.
Untersmayr E, Diesner S, Brämswig KH, Bakos N, Wallmann J, Knittelfelder R, Szalai K, Schöll
I, Scheiner O, Duschl A, Jensen-Jarolim E. Characterization of intrinsic and extrinsic risk factors
for celery allergy in immuno-senescence. Mechanisms of Ageing and Development, in press.
Untersmayr E, Lukschal A, Hemmer W, Jarisch R, Jensen-Jarolim E. Exercise with latex sport
bands represents a risk for latex allergic patients. Immunol. Letters, in press
Szalai, K., Fuhrmann J, Pavkov T, Keller W, Wallmann J, Vrtala S, Scheiner O, Saint-Remy J-M,
Neumann D, Pali-Schöll I, Jensen-Jarolim E*. Mimotopes identify conformational B-cell epitopes
on the two major house dust mite allergens Der p 1 and Der p 2. Mol Immunol, 2007 Oct 25;
(Epub ahead of print).
Brämswig KH, Knittelfelder R, Riemer AB, Gruber S, Szalai K, Horvat R, Kammerer R,
Zimmermann W, Zielinski CC, Scheiner O, Jensen-Jarolim E. Mimotope immunization prevents
growth of CEA-positive tumors in BALB/c mice. Clin Cancer Res, 2007 Nov 1; 13(21): 65016508.
Riemer AB, Untersmayr E, Knittelfelder R, Duschl A, Pehamberger H, Zielinski CC, Scheiner O,
Jensen-Jarolim E. Active induction of tumor-specific IgE antibodies by oral mimotope
vaccination. Cancer Research 2007, Cancer Res. Apr.1; 67 (7): 3406-11. 2007.
Brunner R, Wallmann J, Szalai K, Karagiannis P, Kopp T, Scheiner O, Jensen-Jarolim E, PaliSchöll I. The impact of aluminum in acid-suppressing drugs on the immune response of BALB/c
mice. Clin. Exp. Allergy, 2007 Oct;37(10):1566-73. Epub 2007 Sep 10.
Schöll I, Ackermann U, Blümer N, Özdemir C, Dicke T, Sel Se, Sel Sa, Wegmann M, Szalai K,
Knittelfelder R, Untersmayr E, Scheiner O, Garn H, Jensen-Jarolim E, Renz H. Anti-ulcer
treatment during pregnancy induces food allergy in mouse mothers and a Th2 bias in their
offspring. FASEB, Apr;21(4):1264-70, 2007.
Riemer AB and Jensen-Jarolim E. Mimotope vaccines: Epitope mimics induce anti-cancer
antibodies. Immunology Letters. 113(1): 1-5. 2007.
Roth-Walter F, Jensen-Jarolim E. Oral immunotherapy against type I allergy. Allergy & Clinical
Immunology International., J World Allergy Org, vol. 19, no. 1, pp. 21-26. 2007
- 50 -
Jensen-Jarolim E and Riemer AB. Small mimotopes are big in identifying B-cell epitopes. Blood,
15 Sept 2006, 108 (6): 1794-1795. 2006.
Bakos N, Schöll I, Szalai K, Kundi M, Untersmayr E, Jensen-Jarolim E. Risk assessment for
elderly to develop respiratory and food allergy. Immunol. Letters 107 (1): 15-21. 2006.
Untersmayr E and Jensen-Jarolim E. Mechanisms of Type I food allergy. Pharmacol. Ther.
2006, Jul 26 (Epub ahead of print).
Untersmayr E and Jensen-Jarolim E. The effect of gastric digestion on food allergy. Curr.
Opinion in Allergy & Clin Immunol. 6 (3): 214-9. 2006.
Schöll I, Kopp T, Bohle B, Jensen-Jarolim E. Biodegradable PLGA particles for improved
systemic and mucosal treatment of type I allergy. Immunol Allergy Clin North Am, 26 (2): 349-64.
2006.
Riemer AB, Förster-Waldl E, Brämswig K, Pollak A, Zielinski CC, Pehamberger H, Lode HN,
Scheiner O, Jensen-Jarolim E. Induction of IgG antibodies against the GD2 carbohydrate tumor
antigen by vaccination with peptide mimotopes. Eur. J. Immunol 36 (5): 1267-74. 2006.
Hantusch B, Knittelfelder R, Wallmann J, Krieger S, Szalai K, Untersmayr E, Volgel M, Stadler
BM, Scheiner O, Boltz-Nitulescu G, Jensen-Jarolim E. Internal images: Human anti-idiotypic Fab
antibodies mimic the IgE epitopes of grass pollen allergen Phl p 5a. Mol. Immunol. 43 (14):
2180-7. 2006.
Riemer AB, Kurz H, Klinger M, Scheiner O, Zielinski CC, Jensen-Jarolim E. Vaccination with
Cetuximab mimotopes induces anti-EGFR antibodies with similar biological properties as the
original antibody. J Nat.Cancer Inst 97 (22): 1663-70. 2005.
Schöll I, Kalkura N, Sheziankova Y, Bergmann A, Verdino P, Knittelfelder R, Kopp T, Betzel C,
Dierks K, Hantusch B, Scheiner O, Boltz-Nitulescu G, Keller W, Jensen-Jarolim E. Dimerization
of the major birch pollen allergen Bet v 1 is important for its in vivo IgE crosslinking potential in
mice. J. Immunol 175 (10): 6645-50. 2005.
Untersmayr E, Szalai K, Riemer AB, Hemmer W, Swoboda I, Hantusch B, Schöll I, Spitzauer S,
Scheiner O, Jarisch R, Boltz-Nitulescu G, Jensen-Jarolim E. Mimotopes identify conformational
epitopes on parvalbumin, the major fish allergen. Mol Immunol. 2006, 43 (9): 1454-61. Epub
Sept. 5 2005..
Jensen-Jarolim E, Untersmayr E. Food safety: In vitro digestion assays are non predictive for
allergenic potential of food in stomach insufficiency. View letter. Immunol. Letters 102 (1): 118119. 2005, Epub 2005 Aug 18.
Szalai K, Schöll I, Förster-Waldl E, Polito L, Bolognesi A, Untersmayr E, Riemer AB, BoltzNitulescu G, Stirpe F, Jensen-Jarolim E. Occupational sensitization to ribosomal-inactivating
proteins (RIPs) in researchers. Clin. Exp. Allergy, 35 (10): 1354-60.
Untersmayr E, Jensen-Jarolim E. In vitro tests zur Bestimmung der allergenen Potenz von "novel
foods" und GVOs (genetisch modifizierten Organismen): Relevanz in vivo? Wiener Klin.
Wochenschrift (117. Jg), 13-14: 437-439. 2005.
Roth-Walter F, Bohle B, Schöll I, Untersmayr E, Scheiner O, Boltz-Nitulescu G, Gabor F,
Brayden D, Jensen-Jarolim E. Targeting antigens to murine and human M-cells with Aleuria
aurantia lectin-functionalized microparticles. Immunol. Letters 2005, May 20 [Epub ahead of
- 51 -
print]
Untersmayr E, Jensen-Jarolim E. Anti-azide Therapie und verdauungslabile Allergene.
Allergologie Jg. 28/4: 134-142. 2005.
Schöll I, Boltz-Nitulescu G, Jensen-Jarolim E. Review of novel particulate antigen delivery
systems with special focus on treatment of type I allergy. J Contr. Release 2005; 104 (1): 1-27.
Rausch-Fan X, Ulm C, Jensen-Jarolim E, Schedle A, Boltz-Nitulescu G, Matejka M. IL-1binduced PGE2 production by human gingival fibroblasts is up-regulated by glycine. J.
Periodontology 76(7): 1182-1188. 2005.
Roth-Walter F, Schöll I, Untersmayr E, Ellinger A, Boltz-Nitulescu G, Scheiner O, Gabor F,
Jensen-Jarolim E. Mucosal targeting of allergen-loaded microspheres by Aleuria aurantia lectin.
Vaccine 23(21): 2703-10. 2005.
Riemer AB, Kraml G, Scheiner O, Zielinski CC, Jensen-Jarolim E. Matching of the trastuzumab
(Herceptin) epitope mimics onto the surface of Her-2/neu: a new method for epitope definition.
Mol. Immunol. 42 (9): 1121-24. 2005. Epub 2005 Jan 8.
Untersmayr E, Poulsen LK, Platzer MH, Pedersen MH, Boltz-Nitulescu G, Skov PS, JensenJarolim E. The effects of gastric digestion on codfish allergenicity. J Allergy Clin Immun 115 (2):
377-382. 2005.
Untersmayr E, Bakos N, Schöll I, Kundi M, Roth-Walter F, Szalai K, Riemer AB, Ankersmit HJ,
Scheiner O, Boltz-Nitulescu G, Jensen-Jarolim E. Anti-ulcer drugs promote IgE formation toward
dietary antigens in adult patients. FASEB J. 19 (6): 656-8. 2005 Jan 25; [Epub ahead of print]
Schöll I, Untersmayr E, Bakos N, Roth-Walter F, Gleiss A, Boltz-Nitulescu G, Scheiner O,
Jensen-Jarolim E. Antiulcer drugs promote oral sensitization and hypersensitivity to hazelnut
allergens in BALB/c mice and humans. Am J Clin Nutr. 2005 Jan;81(1):154-60.
Hantusch B, Schöll I, Harwanegg C, Krieger S, Becker WM, Spitzauer S, Boltz-Nitulescu G,
Jensen-Jarolim E. Affinity determinations of purified IgE and IgG antibodies against the major
pollen allergens Phl p 5a and Bet v 1a: discrepancy between IgE and IgG binding strength.
Immunol Lett. 2005 Feb 15;97(1):81-9.
Förster-Waldl E, Riemer AB, Dehof AK, Neumann D, Bramswig K, Boltz-Nitulescu G,
Pehamberger H, Zielinski CC, Scheiner O, Pollak A, Lode H, Jensen-Jarolim E. Isolation and
structural analysis of peptide mimotopes for the disialoganglioside GD2, a neuroblastoma tumor
antigen. Mol Immunol. 2005 Feb;42(3):319-25.
Riemer AB, Hantusch B, Sponer B, Kraml G, Hafner C, Zielinski CC, Scheiner O, Pehamberger
H, Jensen-Jarolim E. High-molecular-weight melanoma-associated antigen mimotope
immunizations induce antibodies recognizing melanoma cells. Cancer Immunol Immunother. 54
(7): 677-684. 2005. [Epub] 2004 Nov 24;
Schöll I, Jensen-Jarolim E. Allergenic potency of spices: hot, medium hot, or very hot. Int Arch
Allergy Immunol. 2004 Nov;135(3):247-61. Epub 2004 Nov 03. Review.
Roth-Walter F, Schöll I, Untersmayr E, Fuchs R, Boltz-Nitulescu G, Weissenbock A, Scheiner O,
Gabor F, Jensen-Jarolim E. M cell targeting with Aleuria aurantia lectin as a novel approach for
oral allergen immunotherapy. J Allergy Clin Immunol. 2004 Dec;114(6):1362-8.
- 52 -
Hantusch B, Krieger S, Untersmayr E, Schöll I, Knittelfelder R, Flicker S, Spitzauer S, Valenta R,
Boltz-Nitulescu G, Scheiner O, Jensen-Jarolim E. Mapping of conformational IgE epitopes on
Phl p 5a by using mimotopes from a phage display library. J Allergy Clin Immunol. 2004
Dec;114(6):1294-300.
Untersmayr E, Ellinger A, Beil WJ, Jensen-Jarolim E. Eosinophils accumulate in the gastric
mucosa of food-allergic mice. Int Arch Allergy Immunol. 2004 Sep;135(1):1-2. Epub 2004 Jul 29.
No abstract available.
Riemer AB, Klinger M, Wagner S, Bernhaus A, Mazzucchelli L, Pehamberger H, Scheiner O,
Zielinski CC, Jensen-Jarolim E. Generation of Peptide mimics of the epitope recognized by
trastuzumab on the oncogenic protein Her-2/neu. J Immunol. 2004 Jul 1;173(1):394-401.
Brunner M, Krenn C, Roth G, Moser B, Hetz H, Dworschak M, Jensen-Jarolim E, Wolner E,
Spittler A, Sautner T, Bonaros N, Boltz-Nitulescu G, Ankersmith HJ. Increased levels of soluble
ST2 protein and IgG1 production in patients with sepsis and trauma. Intensive Care Med., 30 (7):
1468-73. 2004. Epub 2004 Feb 28.
Riemer A, Scheiner O, Jensen-Jarolim E. Allergen mimotopes. Methods. 2004 Mar;32(3):321-7.
Review.
Walter F, Schöll I, Untersmayr E, Ellinger A, Boltz-Nitulescu G, Scheiner O, Gabor F, JensenJarolim E. Functionalization of allergen-loaded microspheres with wheat germ agglutinin for
targeting enterocytes. Biochem Biophys Res Commun, 315/2, 281-287. 2004.
Schoell I, Weissenböck A, Foerster-Waldl E, Untersmayr E, Walter F, Willheim M, BoltzNitulescu G, Scheiner O, Gabor F, Jensen-Jarolim E. Allergen-loaded biodegradable PLGA
nanoparticles down-regulate an ongoing Th2-response in the BALB/c mouse model. Clin Exp
Allergy, 34(2):315-21. 2004.
Foerster E, Marchetti C, Focke M, Schoell I, Boltz-Nitulescu G, Scheiner O, Schmid E.R,
Jensen-Jarolim E. Type I allergy to elderberry is elicited by a 33.2 kDa allergen with significant
homology to ribosomal inactivating proteins (RIPs). Clin Exp Allergy, 33(12): 1703-1710. 2003.
Untersmayr E, Schöll I, Swoboda I, Beil WJ, Förster-Waldl E, Walter F, Riemer A, Kraml G,
Spitzauer S, Kinaciyan T, Boltz-Nitulescu G, Scheiner O, Jensen-Jarolim E. Antacid medication
inhibits digestion of dietary proteins and causes food allergy: An fish allergy model in Balb/c
mice. J Allergy Clin Immun, 112: 616-623. 2003.
Schöll I, Boltz-Nitulescu G, Jensen-Jarolim E. Mimotope und ihre Bedeutung für die Allergologie.
Allergo Journal 6: 339-404. 2003.
Jensen-Jarolim E, Gscheidlinger R, Oberhuber G, Neuchrist C, Lucas T, Bises G, Radauer C,
Willheim M, Scheiner O, Liu FT, Boltz-Nitulescu G. The constitutive expression of galectin-3 is
downregulated in intestinal epithelia of Crohn's disease patients, and tumour necrosis factor
alpha decreases the level of galectin-3-specific mRNA in HCT-8 cells. Eur J Gastroenterol
Hepatol 14: 145-152. 2002.
Jensen-Jarolim E, Schmid B, Bernier F, Berna A, Kinaciyan T, Focke M, Scheiner O, BoltzNitulescu G. Allergologic exploration of germins and germin-like proteins, a new class of plant
allergens. Allergy 57: 805-810. 2002.
Untersmayr E, Focke M, Kinaciyan T, Poulsen LK, Boltz-Nitulescu G, Scheiner O, JensenJarolim E. Anaphylaxis to Russian Beluga caviar. J Allergy Clin Immunol 109: 1034-5. 2002.
- 53 -
Schöll I, Ganglberger E, Förster-Waldl E, Vermes M, Baier K, Boltz-Nitulescu G, Scheiner O,
Ebner C, Wiedermann U, Jensen-Jarolim E. Phage-displayed Bet mim 1, a mimotope of the
major birch pollen allergen Bet v 1, induces B-cell responses to the natural allergen using
bystander help of T-cells. Clin Exp Allergy, 32: 1583-1588. 2002.
Roth-Walter F, Berin CM, Arnaboldi P, Escalante C, Dahan S, Jensen-Jarolim E, Mayer L.
Pasteurization of milk proteins promotes allergic sensitization in mice by enhancing uptake
through Peyer’s patches. J Allergy Clin Immun., in press.
Untersmayr E, Vestergaard H, Malling H-J, Bjerremann Jensen L, Platzer MH, Boltz-Nitulescu G,
Scheiner O, Skov PS, Jensen-Jarolim E, Poulsen LK. Indigestion of codfish represents a risk
factor for anaphylaxis in allergic patients. JACI 119(3): 711-7. 2007.
Brunner R, Wallmann J, Szalai K, Karagiannis P, Kopp T, Scheiner O, Jensen-Jarolim E, PaliSchöll I. The impact of aluminum in acid-suppressing drugs on the immune response of BALB/c
mice. Clin. Exp. Allergy, 2007 Oct;37(10):1566-73. Epub 2007 Sep 10.
Jin C, Bencurova M, Borth N, Ferko B, Jensen-Jarolim E, Altmann F, Hantusch B.
Immunoglobulin E specifically bind plant N-glycans with high affinity could be generated in
rabbits but not in mice. Glycobiology 16 (4): 349-57. 2006. [Epub 2005 Dec 21].
Fest S, Huebner N, Weixler S, Bleeke M, Zeng Y, Strandsby A, Volkmer-Engert R, Landgraf C,
Gaedicke G, Riemer AB, Michalsky E, Jaeger IS, Preissner R, Förster-Waldl E, Jensen-Jarolim
E, Lode HN. Characterization of GD2 peptide mimotope DNA vaccines effective against
spontaneous neuroblastoma metastases. Cancer Res 66 (21): 1-9. 2006.
Roth GA, Moser B, Krenn C, Roth-Walter F, Hetz H, Richter S, Brunner M, Jensen-Jarolim E,
Wolner E, Boltz-Nitulescu G, Ankersmit HJ. Heighthened levels of circulating S20 proteasome in
critically ill patients. J. Clin. Invest. 35: 399-403. 2005.
Wagner S, Radauer C, Hafner C, Fuchs H, Jensen-Jarolim E, Wuthrich B, Scheiner O,
Breiteneder H. Characterization of cross-reactive bell pepper allergens involved in the latex-fruit
syndrome. Clin Exp Allergy. 2004 Nov;34(11):1739-46. PMID: 15544599
Beil W, McEuen AR, Schulz M, Wefelmeyer U, Kraml G, Walls AF, Jensen-Jarolim E, Pabst R,
Pammer J. Selective alterations in mast cell subsets and eosinophil infiltration in two types of
intestinal inflammation: Ascariasis and Crohn´s disease. Pathobiology. 2002-2003;70(6):303-13.
Mota G, Manciulea M, Cosma E, Popescu I, Hirt M, Jensen-Jarolim E, Calugaru A, Galatiuc C,
Regalia T, Tamandl D, Spittler A, Boltz-Nitulescu G. Human NK cells express Fc receptors for
IgA which mediate signal transduction and target cell killing. Eur J Immunol, 33: 2197-2205.
2003.
Ankersmith HJ, Moser B, Roth G, Bruinner M, Buchta C, Wolner E, Jensen-Jarolim E, BoltzNitulescu G, Volf I. CD32-mediated platelet aggregation in vitro by anti-thymocyte globulin:
implication of therapy-induced in vivo thrombocytopenia. Am J Transplant. 3: 754-759. 2003.
Hafner C, Samwald U, Wagner S, Felici F, Heere-Ress E, Jensen-Jarolim E, Wolff K, Scheiner
O, Pehamberger H, Breiteneder H. Selection of mimotopes of the cell surface adhesion molecule
Mel-CAM from a random pVIII-28aa phage peptide library. J Invest Dermatol 119:865-869. 2002.
Rausch-Fan X, Leutmezer F, Spittler A, Bohle B, Jensen-Jarolim E, Ebner C, Boltz-Nitulescu G.
Regulation of cytokine production in human peripheral blood mononuclear cells and allergen-
- 54 -
specific Th cell clones by 1alpha,25-dihydroxyvitamin D3. Int Arch Allergy Immunol 128:33-41.
2002.
- 55 -
Curriculum Vitae
Sylvia Knapp, MD, PhD
Center for Molecular Medicine (CeMM) of the Austrian Academy of Sciences and
Department of Medicine 1, Division of Infectious Diseases & Tropical Medicine, Medical
University Vienna; Währinger Gürtel 18-20, 1090 Vienna
Phone: +43-1-40400-5139 or 5140, Fax: +43-1-40400-5167
Personal Data
Date of Birth:
15.09.1968
Place of Birth:
Innsbruck
Nationality
Austria
Education
24.11.2006
Ph.D. degree conferred by the University of Amsterdam, the
2001-2005
Netherlands
Ph.D. studies at the Academic Medical Center, University of
Amsterdam, the Netherlands
29.3.2004
Habilitation in Internal Medicine
1.5.2000
Licence in Internal Medicine
1994-2000
Residency in Internal Medicine, MUW
12.7.1993
M.D. degree conferred by the University of Vienna
1986 – 1993
Study of Medicine, University Vienna, Austria
03/91 – 10/91
Study of Medicine, Free University Berlin, Germany
Career History
10/2006 –
Appointment as Head of Laboratory of the Division of Infectious
Diseases, Medical University Vienna
04/2006 –
Principle Investigator at the Research Center for Molecular Medicine
(CeMM) of the Austrian Academy of Sciences
2005 – 9/2006
Staff member Intensive Care Unit, Dept. of Internal Med. I, Medical
Univ. Vienna: clinical duties and set-up of research lab
2001 – 2005
PhD study at the University of Amsterdam, Lab. of Experimental
Internal Medicine: research topic: Role of Toll-like receptors during
bacterial infections, supervisor: Prof. Dr. T. van der Poll
1994 – 2001
Residency in Internal Medicine, Medical University Vienna
1992 – 1994
Research fellow at Dept. of Internal Med. I, supervisor: Prof. Dr. U.
Jäger; topic: t14;18 breakpoint region binding proteins in follicular
lymphomas
- 56 -
08/1991
Summer Training Course in Laboratory Virology, National Institute of
Health, Department of Pathology, Tokyo, Japan, Prof. Dr. T. Kurata
05-07/1989
Undergraduate Research Training in the field of Kinins, Institute of
Physiology, University of Vienna, Prof. Dr. B. Binder
Career-related
Activities
2003 –
Reviewer for: J. Immunol, J. of Leukocyte Biology, Am. J. Physiol,
Clin. Immunol., J. of Endotoxin Res., Microbes and Infection, Expert
Review of Clinical Immunology, FEBS Letters, Scand. J. of Infectious
Diseases
2007 –
Editorial Board Member: Clinical Immunology
2006
Member of Local Organizing Committee: International Cytokine
Conference, held in Vienna, 08/06
2004 –
Reviewer for Hongkong Grant Council Review Board, Austrian
Academy of Sciences
2005 –
Lecturer Tertial: Emergency and Intensive Care Medicine, MUW
2006 –
PhD Supervisor (2)
1998 –
(Co-)Supervision of MD-thesis students (6)
1994 –
Attendance of various clinical courses, such as bronchoscopy,
gastroscopy, pacemaker, respirator,..
1996 –
Various lectures for students and postgraduate lectures for clinicians
Awards
2007
Forschungspreis der Erste Bank
2006
Förderpreis of the Austrian Society of Antimircobrial Chemotherapy
2005
Förderpreis of the Austrian Society of Antimicrobial Chemotherapy
2005
Erwin Deutsch Award by the Austrian Society of Intensive Care
Medicine
1999
Award for Emergency Medicine
1994
Türck-Award by the Austrian Society of Hematology
1993
Hans and Blanca Moser Student’s fellowship
1990
Scholarship (Leistungsstipendium) of the University of Vienna
Memberships
Austrian Society of Internal Medicine
Austrian Society of Hematology
Austrian Society for antimicrobial Chemotherapy
Society of Critical Care Medicine
- 57 -
Austrian Society of Intensive Care Medicine
K€/year
8
Period
Organization
Short Title
2000-
Bürgermeister Stadt
Intracellular Cytokines in Sepsis
2003
Wien
2001-
FWF (Schrödinger)
The role of TLRs in infection
24
FWF (Schrödinger)
The role of TLRs in infection
24
FWF (P18232-B11)
Immunmodulatory role of oxidized
2002
20022003
20062009
90 *
phospholipids (together with V.
Bochkov, * = 45% share)
2006-
CeMM
2009
Innate immune response to bacterial
230
infections
2006-
Jubiläumsstiftung Stadt
2007
Wien, via Österr. Akad.
Leukozyte-migration during pneumonia
45
Wissenschaften
PhD supervision in last 5 years (2003-2008)
Period
Name of student
Topic
2003 –
Ulrich Matt
Endogenous modulators of inflammation
– impact on infectious diseases
2003 –
Ana Zivcovic
Role of PVL in S. aureus pneumonia
Publications
58 peer reviewed publications in scientific journals, 2 book chapters, 22 invited lectures
Knapp, S., von Aulock, S., Leendertse, M., Haslinger, I., Draing, C., Golenbock, D., van der
Poll, T. (2008) Lipoteichoic Acid-induced Lung Inflammation depends on TLR2 and the
concerted action of TLR4 and Platelet-activating Factor Receptor. J Immunol 180, in press
Knapp, S., Matt, U., Leitinger, N., van der Poll, T. (2007) Oxidized phospholipids inhibit
phagocytosis and impair outcome in gram-negative sepsis in vivo. J Immunol 178, 993-1001
Knapp, S., Florquin, S., Golenbock, D. T., and van der Poll, T. (2006) Pulmonary LPSbinding protein inhibits the LPS-induced lung inflammation in vivo. J Immunol 176, 31893195
Knapp, S., Wieland, C. W., Florquin, S., Pantophlet, R., Dijkshoorn, L., Tshimbalanga, N.,
Akira, S., and van der Poll, T. (2006) Differential role of CD14 and Toll-like receptors 2 and 4
during Acinetobacter pneumonia. Am J Respir Crit Care Med 173, 122-129
- 58 -
Knapp, S., Schultz, M. J., and Poll, T. V. (2005) Host defense mechanisms in murine
pneumoniae models. Shock 24 Suppl 1, 12-18
Knapp, S., van der Poll, T. (2004) Update on CD14, LBP and Toll-like receptors in acute
infections. Yearbook of Intensive Care and Emergency Medicine (Vincent, J. L., ed), pp. 314, Springer Verlag, Brussels
Knapp, S., Wieland, C. W., van 't Veer, C., Takeuchi, O., Akira, S., Florquin, S., and van der
Poll, T. (2004) Toll-like receptor 2 plays a role in the early inflammatory response to murine
pneumococcal pneumonia but does not contribute to antibacterial defense. J Immunol 172,
3132-3138
Knapp, S., Gibot, S., de Vos, A., Versteeg, H. H., Colonna, M., and van der Poll, T. (2004)
Cutting Edge: Expression Patterns of surface and soluble TREM-1 in Human Endotoxemia. J
Immunol 173, 7131-7134
Knapp, S., Hareng, L., Rijneveld, A. W., Bresser, P., van der Zee, J. S., Florquin, S.,
Hartung, T., and van der Poll, T. (2004) Activation of Neutrophils and Inhibition of the
Proinflammatory Cytokine Response by Endogenous Granulocyte Colony-Stimulating Factor in
Murine Pneumococcal Pneumonia. J Infect Dis 189, 1506-1515
Knapp, S., De Vos, A. F., Florquin, S., Golenbock, D. T., and Van Der Poll, T. (2003)
Lipopolysaccharide binding protein is an essential component of the innate immune
response to Escherichia coli peritonitis in mice. Infect Immun 71, 6747-6753
Knapp, S., Leemans, J. C., Florquin, S., Branger, J., Maris, N. A., Pater, J., van Rooijen, N.,
and van der Poll, T. (2003) Alveolar macrophages have a protective antiinflammatory role
during murine pneumococcal pneumonia. Am J Respir Crit Care Med 167, 171-179.
Knapp, S., Branger, J., and van der Poll, T. (2002) Advances in research of the inflammatory
response: The importance of Toll-like receptors. Wien Med Wochenschr 152, 552-554
Dessing, M., Knapp, S., Florquin, S., de Vos, A.F., van der Poll, T. (2007) CD14 facilitates
invasive respiratory tract infections by Streptococcus pneumoniae. Am J Respir Crit Care
175, 604-611
Renckens, R., Roelofs, J. J., Knapp, S., de Vos, A. F., Florquin, S., and van der Poll, T.
(2006) The acute phase response and serum amyloid A inhibit the inflammatory response to
Acinetobacter. J Infect Dis 193, 187-195
van Westerloo, D. J., Knapp, S., van't Veer, C., Buurman, W. A., de Vos, A. F., Florquin, S.,
and van der Poll, T. (2005) Aspiration pneumonitis primes the host for an exaggerated
inflammatory response during Klebsiella pneumonia: the role of tumor necrosis factor-α. Crit
Care Med 33, 1770-1778
Branger, J., Knapp, S., Weijer, S., Leemans, J. C., Pater, J. M., Speelman, P., Florquin, S.,
and van der Poll, T. (2004) The role of Toll-like Receptor 4 in Gram-positive and Gramnegative pneumonia in mice. Infect Immun 72, 788-794
Branger, J., Florquin, S., Knapp, S., Leemans, J. C., Pater, J. M., Speelman, P., Golenbock,
D. T., and van der Poll, T. (2004) LPS-Binding Protein-deficient mice have an impaired Host
Defense against Gram-negative but not Gram-postive pneumonia. Int. Immunol. 16, 16051611
- 59 -
Wieland, C. W., Knapp, S., Florquin, S., De Vos, A. F., Takeda, K., Akira, S., Golenbock, D.
T., Verbon, A., and Van Der Poll, T. (2004) Toll-like Receptor (TLR) 2, but not LBP, CD14 or
TLR4, mediates lung inflammation by non-capped lipoarabinomannan: relevance for atypical
mycobacterial infections. Am J Respir Crit Care Med 170: 1367-1374
von Aulock, S., Morath, S., Hareng, L., Knapp, S., van Kessel, K. P., van Strijp, J. A., and
Hartung, T. (2003) Liopteichoic acid from Staphylococcus aureus is a potent stimulus for
neutrophil recruitment. Immunobiology 208, 413-422
Schultz, M. J., Knapp, S., Florquin, S., Pater, J., Takeda, K., Akira, S., and Van Der Poll, T.
(2003) nterleukin 18 impairs the pulmonary host response against Pseudomonas
aeruginosa. Infect Immun 71, 1630-1634.
Delle Karth, G., Koreny, M., Binder, T., Knapp, S., Zauner, C., Valentin, A., Honninger, R.,
Heinz, G., and Siostrzonek, P. (2002) Complicated infective endocarditis necessitating ICU
admission: clinical course and prognosis. Crit Care 6, 149-154
2003
• Toll-like receptors: Week of Allergy, EAACI, Ghent, Belgium, 18. Nov 2003
• The role of LBP in the innate immune response to bacteria, Seminar of the Dept. of
Infectious Diseases, Academic Medical Center, Univ. Amsterdam, 13. Feb 2003
• Role of alveolar macrophages during pneumococcal pneumonia: Van Loghem Research
Meeting, Amsterdam, The Netherlands, Jan 2003
2004
• The role of Toll-like Receptors during pulmonary inflammation: International Symposium on
Thrombocyte and Leukocyte Immunobiology, Rust, Austria, May 2004
• The role of TLR2 during pneumococcal pneumonia: Van Loghem Research Meeting,
Amsterdam, the Netherlands, 9. Feb. 2004
2005
• Treatment of Sepsis: Euroconference: Interactions between innate and adaptive immunity
in mammalian defense against bacterial infections, Joachimstal (Berlin), Germany, June
2005
2006
• Innate Immune response to bacterial infections, Vet. Med. Seminars of the Institute of
genetics and animal breeding, Vienna, 4.12.2006, Host: Prof. Dr. M. Mueller
• Host defense mechanisms during bacterial pneumonia: Innate Immunity, Receptors,
Response, Regulation: Joint Meeting of the Society of Leukocyte Biology and Int. Endotoxin
and Innate Immunity Society, San Antonio, Texas, 11. Nov. 2006
• Pneumonie auf der Intensivstation: Expertpanel on Pneumonia, Linz, 26. June 2006
• Pathophysiologie der Sepsis: Wiener Intensivmedizinische Tage, Vienna, Feb. 2006
• Deutsch-österr. Kongress für Intensivmedizin, Saarbrücken, Germany, June 2006
2007
• Novel treatment options in sepsis, Annual Meeting of the Austrian Society of Lung
diseases, Salzburg, 5.10.2007
• Toll and Toll-free Receptors in Sepsis: Sepsis workshop, Austrian Sepsis Society, Vienna,
5.5.2007, Host: Prof. Dr. H. Burgman
• Innate Immune Response Mechanisms during bacterial infections: Infection and
Immunology Seminars, University of Innsbruck, 7.2.2007, Host: Prof. Dr. G. Weiss
• Role of Toll-like Receptors during bacterial Pneumonia: Seminar of the Max Perutz
- 60 -
Laboratory, Inst. of Microbiology and Immunology, 26.1.2007, Host: Prof. Dr. T. Decker
• Abwehrmechanismen bei Pneumonie: Fortbildung der CeMIC, Vienna, 16.1.2007
2008
• Innate Immunity, KIT (Meeting of Infectios Diseases and Tropical Medicine), Innsbruck
28.2.2008
• TLR and NLR in Sepsis, Wilheminenspital Vienna, 14.1.2008
- 61 -
Curriculum Vitae
Herwig Kollaritsch
Division of Travel Medicine and Infectious Disease Epidemiology, Institute for Specific
Prophylaxis and Tropical Medicine, Center for Physiology, Pathophysiology and Immunology,
Medical University of Vienna, Kinderspitalgasse 15, 1090 Wien, Austria;
Phone: +43-1-40490 64850, Fax: +43-1-403 83 43 90;
Email: [email protected]
Personal Data
Date of Birth:
11.02.1956
Place of Birth:
Vienna
Nationality
Austria
Education
1993
Tropical Medicine update, London School of Hygiene and
Tropical Medicine
1991
Intensive Course on Tropical Medicine, Liverpool, UK
1990
Speciality in Hygiene, Microbiology and Preventive
Medicine
1989
Speciality in Specific Prophylaxis and Tropical Medicine
1985-1987
Field education Tropical Medicine, Nigeria
1982
DTM at Bernhard Nocht Institute for Tropical Medicine,
Hamburg, Germany
1981-
Assistant Institute of Specific Prophylaxis and Tropical
Medicine, Univ.Vienna
1980/1981
Assistant, Infectious Disease Unit, Kaiser Franz Josef
Spital, Vienna
1974-1980
Medical doctor, University of Vienna
1974
University entrance qualification, Theresianum Wien
Career History
2004-
Group Leader, Travel Medicine and Infectious Disease
Epidemiology
1997-2004
Head, Institute of Specific Prophylaxis and Tropical
Medicine
1996-
1989
Habilitation in Specific Prophylaxis and Tropical Medicine,
University of Vienna Medical School
- 62 -
2007-
Member of the Scientific Board of the Ministry of Defense
Republic of Austria
2007-
Member of the Scientific Board of the Ministry of Defense,
Republic of Austria
2003-
Board Member of the Comission for International
Development at the Austrian Academy of Sciences
1999-
Co-chair of the Advisory Board for Immunization Practices
of the Republic of Austria
1999-
Member of the “Arzneimittelsicherheitsausschuss”
(supreme board for supervision of adverse drug reactions)
of Austria
1996-
Member of TROPMEDEUROP (association of the Tropical
Institutes in Europe)
2000 -
Board Member and Founding Member Austrian Society for
Travel- and Touristic Medicine
1984 -
Local Secretary, The Royal Society of Hygiene & Tropical
Medicine, UK
1983 -
Board Member, Austrian Society of Tropical Medicine and
Parasitology
Period
Organization
Short Title
K€/year
2000-2003
FWF
Field validation of a HRP2-assay
30
1999-2003
Federal Bank of
Surveillance of vaccine preventable diseases
15
Austria
in Austria (Project 6165)
Period
Name of student
2003-2005
Ulrich Gerstner
2003-2005
Kamala Thriemer
2003-2005
Leila Kyavar
2005-2006
Peter Starzengruber
Topic
Interactions between bloodchizontocidal
arylaminoalkohols and other substance classes
against Plasmodium falciparum in Thailand
Interaction of Retinal and other antimalarials in
Plasmodium falciparum
In vitro investigations of sensititvity of fresh
isolates of Plasmodium vivax against chloroquin
and other bloos schizonotocidals
In vitro sensitivity of Plasmodium falciparum
against Artemisinin, Chloroquine, Quinine and
Mefloquine. Pharmacodynamic interactions
between Lumefantrine and MonodesbutylBenflumetol
- 63 -
2005-2006
Maria Parizek
In vitro sensitivity of Plasmodium falciparum
against Lumefantrine and Desbutyl-Benflumetol.
Pharmacodynamic interactions between DesbutylBenflumetol and Retinol
Publications
Currently ~320 publications overall, 112 in peer-reviewed and Medline indexed
scientific journals, 10 books, more than 20 book articles
Publications total: 53 (2002-2007)
a) first, corresponding or last author
total: 24
Top journals: 12
Bröker M, Kollaritsch H.
After a tick bite in a tick-borne encephalitis virus endemic area: Current positions about postexposure treatment.
Vaccine. 2008 Feb 13;26(7):863-8. Epub 2007 Dec 4.
Tauber E, Kollaritsch H, Korinek M, Rendi-Wagner P, Jilma B, Firbas C, Schranz S, Jong E,
Klingler A, Dewasthaly S, Klade CS.
Safety and immunogenicity of a Vero-cell-derived, inactivated Japanese encephalitis
vaccine: a non-inferiority, phase III, randomised controlled trial.
Lancet. 2007 Dec 1;370(9602):1847-53.
Rendi-Wagner P, Paulke-Korinek M, Stanek G, Khanakah G, Kollaritsch H.
Impact of a pertussis booster vaccination program in adolescents and adults on the
epidemiology of pertussis in Austria.
Pediatr Infect Dis J. 2007 Sep;26(9):806-10.
Rendi-Wagner P, Korinek M, Mikolasek A, Vécsei A, Kollaritsch H.
Epidemiology of travel-associated and autochthonous hepatitis A in Austrian children, 1998
to 2005.
J Travel Med. 2007 Jul-Aug;14(4):248-53.
Rendi-Wagner P, Paulke-Korinek M, Kundi M, Wiedermann U, Laaber B, Kollaritsch H.
Antibody persistence following booster vaccination against tick-borne encephalitis: 3-year
post-booster follow-up.
Vaccine. 2007 Jun 28;25(27):5097-101. Epub 2007 Feb 20.
Kollaritsch H, Wiedermann U.
[Examples for vaccines against diarrheal diseases--rotavirus and traveller's diarrhea]
Wien Med Wochenschr. 2007;157(5-6):102-6. Review. German.
Wiedermann U, Kollaritsch H.
Vaccines against traveler's diarrhoea and rotavirus disease - a review.
Wien Klin Wochenschr. 2006;118(19-20 Suppl 3):2-8. Review.
Kollaritsch H, Maurer W.
[Rabies: epidemiology, pre- and postexposure immunization]
Wien Klin Wochenschr. 2006 Jun;118(11-12):312-20. Review. German.
Rendi-Wagner P, Kundi M, Mikolasek A, Mutz I, Zwiauer K, Wiedermann U, Vécsei A,
- 64 -
Kollaritsch H.
Active hospital-based surveillance of rotavirus diarrhea in Austrian children, period 1997 to
2003.
Wien Klin Wochenschr. 2006 May;118(9-10):280-5.
Rendi-Wagner P, Kundi M, Mikolasek A, Vécsei A, Frühwirth M, Kollaritsch H.
Hospital-based active surveillance of childhood pertussis in Austria from 1996 to 2003:
estimates of incidence and vaccine effectiveness of whole-cell and acellular vaccine.
Vaccine. 2006 Aug 14;24(33-34):5960-5. Epub 2006 May 23.
Rendi-Wagner P, Zent O, Jilg W, Plentz A, Beran J, Kollaritsch H.
Persistence of antibodies after vaccination against tick-borne encephalitis.
Int J Med Microbiol. 2006 May;296 Suppl 40:202-7. Epub 2006 Mar 9. Review.
Rendi-Wagner P, Shouval D, Genton B, Lurie Y, Rümke H, Boland G, Cerny A, Heim M,
Bach D, Schroeder M, Kollaritsch H.
Comparative immunogenicity of a PreS/S hepatitis B vaccine in non- and low responders to
conventional vaccine.
Vaccine. 2006 Apr 5;24(15):2781-9. Epub 2006 Jan 19.
Rendi-Wagner P, Jeschko E, Kollaritsch H; österreichische Expertengruppe für
Reisemedizin.
[Travel vaccination recommendations for Central and Eastern European countries based on
country-specific risk profiles]
Wien Klin Wochenschr. 2005;117 Suppl 4:11-9. Review. German.
Rendi-Wagner P, Hoeller K, Kollaritsch H; Osterreichische Expertengruppe für Reisemedizin.
[Immunization recommendations for travel in the Mediterranean area]
Wien Klin Wochenschr. 2004 Oct 30;116(19-20):652-60. German.
Rendi-Wagner P, Kundi M, Zent O, Banzhoff A, Jaehnig P, Stemberger R, Dvorak G,
Grumbeck E, Laaber B, Kollaritsch H.
Immunogenicity and safety of a booster vaccination against tick-borne encephalitis more
than 3 years following the last immunisation.
Vaccine. 2004 Dec 9;23(4):427-34.
Loebermann M, Kollaritsch H, Ziegler T, Rendi-Wagner P, Chambonneau L, Dumas R,
Lafrenz M.
A randomized, open-label study of the immunogenicity and reactogenicity of three lots of a
combined typhoid fever/hepatitis A vaccine in healthy adults.
Clin Ther. 2004 Jul;26(7):1084-91.
Rendi-Wagner P, Kundi M, Zent O, Dvorak G, Jaehnig P, Holzmann H, Mikolasek A,
Kollaritsch H.
Persistence of protective immunity following vaccination against tick-borne encephalitis-longer than expected?
Vaccine. 2004 Jul 29;22(21-22):2743-9.
Ambrosch F, Finkel B, Herzog C, Koren A, Kollaritsch H.
Rapid antibody response after vaccination with a virosomal hepatitis a vaccine.
Infection. 2004 Jun;32(3):149-52. Erratum in: Infection. 2004 Aug;32(4):249.
Rendi-Wagner P, Georgopoulos A, Kundi M, Mutz I, Mattauch M, Nowak J, Mikolasek A,
Vecsei A, Kollaritsch H.
Prospective surveillance of incidence, serotypes and antimicrobial susceptibility of invasive
Streptococcus pneumoniae among hospitalized children in Austria.
- 65 -
J Antimicrob Chemother. 2004 May;53(5):826-31. Epub 2004 Apr 8.
Eder G, Kollaritsch H.
Antigen dependent adverse reactions and seroconversion of a tick-borne encephalitis
vaccine in children.
Vaccine. 2003 Sep 8;21(25-26):3575-83.
Rendi-Wagner P, Wiedermann G, Stemberger H, Kollaritsch H.
New vaccination strategies for low- and non-responders to hepatitis B vaccine.
Wien Klin Wochenschr. 2002 Mar 28;114(5-6):175-80. Review.
Wiedermann G, Kollaritsch H, Kundi M, Wernsdorfer WH.
Relationships between mefloquine blood levels, gender, and adverse reactions.
Am J Trop Med Hyg. 2002 May;66(5):445-6; author reply 446-7. No abstract available.
Rendi-Wagner P, Kollaritsch H.
Drug prophylaxis for travelers' diarrhea.
Clin Infect Dis. 2002 Mar 1;34(5):628-33. Epub 2002 Jan 16.
Rendi-Wagner P, Noedl H, Wernsdorfer WH, Wiedermann G, Mikolasek A, Kollaritsch H.
Unexpected frequency, duration and spectrum of adverse events after therapeutic dose of
mefloquine in healthy adults.
Acta Trop. 2002 Feb;81(2):167-73.
b) co-author
total: 29
Topjournals: 9
Nothdurft HD, Dahlgren AL, Gallagher EA, Kollaritsch H, Overbosch D, Rummukainen ML,
Rendi-Wagner P, Steffen R, Van Damme P; ad hoc Travel Medicine Expert Panel for
ESENEM.
The risk of acquiring hepatitis A and B among travelers in selected Eastern and Southern
Europe and non-European Mediterranean countries: review and consensus statement on
hepatitis A and B vaccination.
J Travel Med. 2007 May-Jun;14(3):181-7. No abstract available.
Lütgendorf C, Rojanawatsirivet C, Wernsdorfer G, Sirichaisinthop J, Kollaritsch H,
Wernsdorfer WH.
Pharmacodynamic interaction between atovaquone and other antimalarial compounds
against Plasmodium falciparum in vitro.
Wien Klin Wochenschr. 2006;118(19-20 Suppl 3):70-6.
Kyavar L, Rojanawatsirivet C, Kollaritsch H, Wernsdorfer G, Sirichaisinthop J, Wernsdorfer
WH.
In vitro interaction between artemisinin and chloroquine as well as desbutyl-benflumetol in
Plasmodium vivax.
Wien Klin Wochenschr. 2006;118(19-20 Suppl 3):62-9.
Rendi-Wagner P, Korinek M, Winkler B, Kundi M, Kollaritsch H, Wiedermann U.
Persistence of seroprotection 10 years after primary hepatitis A vaccination in an unselected
study population.
Vaccine. 2007 Jan 15;25(5):927-31. Epub 2006 Sep 18.
Weinke T, Liebold I, Burchard GD, Frühwein N, Grobusch MP, Hatz C, Kollaritsch H,
Nothdurft HD, Reisinger E, Rieke B, Schönfeld Ch, Steffen R, Stich A.
- 66 -
[Prophylactic immunization against enterotoxin-forming Escherichia coli travellers' diarrhea
and cholera: does it make sense and for whom?]
Dtsch Med Wochenschr. 2006 Jul 28;131(30):1660-4. Review. German. No abstract
available.
Thriemer K, Wernsdorfer G, Rojanawatsirivet C, Kollaritsch H, Sirichainsinthop J,
Wernsdorfer WH.
In vitro activity of artemisinin alone and in combination with retinol against Plasmodium
falciparum.
Wien Klin Wochenschr. 2005;117 Suppl 4:45-8.
Samal D, Rojanawatsirivet C, Wernsdorfer G, Kollaritsch H, Sirichaisinthop J, Wernsdorfer
WH.
Synergism of desbutyl-benflumetol and retinol against Plasmodium falciparum in vitro.
Attlmayr B, Kollaritsch H, Wernsdorfer WH, Miller RS, Sirichaisinthop J, Noedl H.
Drug sensitivity of Plasmodium falciparum along the Thai-Myanmar border using the new
field-deployable HRP2 in vitro assay.
Noedl H, Bronnert J, Yingyuen K, Attlmayr B, Kollaritsch H, Fukuda M.
Simple histidine-rich protein 2 double-site sandwich enzyme-linked immunosorbent assay for
use in malaria drug sensitivity testing.
Antimicrob Agents Chemother. 2005 Aug;49(8):3575-7.
Nothdurft HD, Bialek R, Burchard GD, Hatz C, Jelinek T, Kollaritsch H, Schönfeld C, Volkmer
KJ; Ausschuss "Reisemedizin" der Deutschen Gesellschaft für Tropenmedizin und
Internationale Gesundheit.
[Consensus recommendations for malaria prophylaxis]
Dtsch Med Wochenschr. 2005 Jun 3;130(22):1392-6. Review. German. No abstract
available.
Pirker-Krassnig DK, Wernsdorfer G, Sirichaisinthop J, Rojanawatsirivet C, Kollaritsch H,
Wernsdorfer WH.
Comparative study on the in vitro activity of lumefantrine and desbutyl-benflumetol in fresh
isolates of Plasmodium vivax from Thailand.
Woitsch B, Wernsdorfer G, Prajakwong S, Rojanawatsirivet C, Kollaritsch H, Wernsdorfer
WH.
Comparative study of the in vitro sensitivity of Plasmodium falciparum to artemisinin in two
border areas of Thailand.
Noedl H, Attlmayr B, Wernsdorfer WH, Kollaritsch H, Miller RS.
A histidine-rich protein 2-based malaria drug sensitivity assay for field use.
Am J Trop Med Hyg. 2004 Dec;71(6):711-4.
Noedl H, Wernsdorfer WH, Kollaritsch H, Looareesuwan S, Miller RS, Wongsrichanalai C.
Malaria drug-susceptibility testing. HRP2-based assays: current data, future perspectives.
Wichmann O, Muehlberger N, Jelinek T, Alifrangis M, Peyerl-Hoffmann G, Muhlen M,
Grobusch MP, Gascon J, Matteelli A, Laferl H, Bisoffi Z, Ehrhardt S, Cuadros J, Hatz C,
Gjorup I, McWhinney P, Beran J, da Cunha S, Schulze M, Kollaritsch H, Kern P, Fry G,
- 67 -
Richter J; European Network on Surveillance of Imported Infectious Diseases.
Screening for mutations related to atovaquone/proguanil resistance in treatment failures and
other imported isolates of Plasmodium falciparum in Europe.
J Infect Dis. 2004 Nov 1;190(9):1541-6. Epub 2004 Sep 28.
Mühlberger N, Jelinek T, Gascon J, Probst M, Zoller T, Schunk M, Beran J, Gjørup I,
Behrens RH, Clerinx J, Björkman A, McWhinney P, Matteelli A, Lopez-Velez R, Bisoffi Z,
Hellgren U, Puente S, Schmid ML, Myrvang B, Holthoff-Stich ML, Laferl H, Hatz C,
Kollaritsch H, Kapaun A, Knobloch J, Iversen J, Kotlowski A, Malvy DJ, Kern P, Fry G,
Siikamaki H, Schulze MH, Soula G, Paul M, Gómez i Prat J, Lehmann V, Bouchaud O, da
Cunha S, Atouguia J, Boecken G.
Epidemiology and clinical features of vivax malaria imported to Europe: sentinel surveillance
data from TropNetEurop.
Malar J. 2004 Mar 8;3:5.
Reinthaler FF, Feierl G, Beubler E, Kollaritsch H, Ruckenbauer G, Klem G, Wendelin I, Marth
E.
Treatment of travelers' diarrhea among Austrian tourists.
J Travel Med. 2004 Jan-Feb;11(1):66-8. No abstract available.
Wichmann O, Jelinek T, Peyerl-Hoffmann G, Mühlberger N, Grobusch MP, Gascon J,
Matteelli A, Hatz C, Laferl H, Schulze M, Burchard G, da Cunha S, Beran J, McWhinney P,
Kollaritsch H, Kern P, Cuadros J, Alifrangis M, Gjørup I; European Network on Surveillance
of Imported Infectious Diseases (TropNetEurop).
Molecular surveillance of the antifolate-resistant mutation I164L in imported African isolates
of Plasmodium falciparum in Europe: sentinel data from TropNetEurop.
Malar J. 2003 Jun 25;2:17. Epub 2003 Jun 25.
Lux D, Prajakwong S, Kollaritsch H, Wernsdorfer G, Wernsdorfer WH.
In-vitro sensitivity testing of Plasmodium vivax: response to lumefantrine and chloroquine in
northwestern Thailand.
Ogwang S, Engl M, Vigl M, Kollaritsch H, Wiedermann G, Wernsdorfer WH.
Clinical and parasitological response of Plasmodium falciparum to chloroquine and
sulfadoxine/pyrimethamine in rural Uganda.
Noedl H, Wongsrichanalai C, Miller RS, Myint KS, Looareesuwan S, Sukthana Y,
Wongchotigul V, Kollaritsch H, Wiedermann G, Wernsdorfer WH.
Plasmodium falciparum: effect of anti-malarial drugs on the production and secretion
characteristics of histidine-rich protein II.
Exp Parasitol. 2002 Nov-Dec;102(3-4):157-63.
Melzer H, Baier K, Felici F, von Specht BU, Wiedermann G, Kollaritsch H, Wiedermann U,
Duchêne M.
Humoral immune response against proteophosphoglycan surface antigens of Entamoeba
histolytica elicited by immunization with synthetic mimotope peptides.
FEMS Immunol Med Microbiol. 2003 Jul 15;37(2-3):179-83.
Steffen R, Kollaritsch H, Fleischer K.
Travelers' diarrhea in the new millennium: consensus among experts from German-speaking
countries.
J Travel Med. 2003 Jan-Feb;10(1):38-45. Review. No abstract available. Erratum in: J Travel
Med. 2003 May-Jun;10(3):199.
- 68 -
Mühlberger N, Jelinek T, Behrens RH, Gjørup I, Coulaud JP, Clerinx J, Puente S, Burchard
G, Gascon J, Grobusch MP, Weitzel T, Zoller T, Kollaritsch H, Beran J, Iversen J, Hatz C,
Schmid ML, Björkman A, Fleischer K, Bisoffi Z, Guggemos W, Knobloch J, Matteelli A,
Schulze MH, Laferl H, Kapaun A, McWhinney P, Lopez-Velez R, Fätkenheuer G, Kern P,
Zieger BW, Kotlowski A, Fry G, Cuadros J, Myrvang B; TropNetEurop; Surveillance
importierter Infektionen in Deutschland Surveillance Networks.
Age as a risk factor for severe manifestations and fatal outcome of falciparum malaria in
European patients: observations from TropNetEurop and SIMPID Surveillance Data.
Clin Infect Dis. 2003 Apr 15;36(8):990-5. Epub 2003 Apr 2.
Jelinek T, Peyerl-Hoffmann G, Mühlberger N, Wichmann O, Wilhelm M, Schmider N,
Grobusch MP, von Sonnenburg F, Gascon J, Laferl H, Hatz C, Alifrangis M, Burchard G,
McWhinney P, Schulze M, Kollaritsch H, da Cunha S, Beran J, Kern P, Gjørup I, Cuadros J.
Molecular surveillance of drug resistance through imported isolates of Plasmodium
falciparum in Europe.
Malar J. 2002 Oct 11;1:11. Epub 2002 Oct 11.
Jelinek T, Schulte C, Behrens R, Grobusch MP, Coulaud JP, Bisoffi Z, Matteelli A, Clerinx J,
Corachán M, Puente S, Gjørup I, Harms G, Kollaritsch H, Kotlowski A, Björkmann A,
Delmont JP, Knobloch J, Nielsen LN, Cuadros J, Hatz C, Beran J, Schmid ML, Schulze M,
Lopez-Velez R, Fleischer K, Kapaun A, McWhinney P, Kern P, Atougia J, Fry G, da Cunha
S, Boecken G.
Imported Falciparum malaria in Europe: sentinel surveillance data from the European
network on surveillance of imported infectious diseases.
Clin Infect Dis. 2002 Mar 1;34(5):572-6. Epub 2002 Jan 21.
Melzer H, Fortugno P, Mansouri E, Felici F, Marinets A, Wiedermann G, Kollaritsch H, Von
Specht BU, Duchêne M.
Antigenicity and immunogenicity of phage library-selected peptide mimics of the major
surface proteophosphoglycan antigens of Entamoeba histolytica.
Parasite Immunol. 2002 Jun;24(6):321-8.
Noedl H, Wernsdorfer WH, Krudsood S, Wilairatana P, Wiedermann G, Kollaritsch H,
Looareesuwan S.
Predictive role of laboratory and clinical treatment response parameters and glucose-6phosphate dehydrogenase status in the therapy of falciparum malaria.
Wien Klin Wochenschr. 2002 Feb 28;114(4):158-63.
2002:
22.1.2002, Wien, Ana Grand Hotel, Chiron-Behring
Encepur-Pressekonferenz
30.1.-1.2.2002, Deutschland, Bayern, Spitzingsee
Malaria Expertenworkshop2002
26.2.-2.3.2002, Saalfelden Österr. Apothekertagung,
Reisemedizin update 2001
9.3.2002, Wien, Ärztekammer f.NÖ
Fortbildung Reisemedizin
16.3.2002, Linz, Reisemedizinischer Tag
Impfplan 2002
20.3.2002, Wien, Betriebsärzte-Fortbildung
Hepatitiden
4.4.2002, Wien, Aventis Pasteur
Bezirksärztefortbildung Reisemedizin aktuell
- 69 -
9.4.2002, Glaxo Academy, Hotel Bristol
Infektionen rund ums Mittelmeer
12.4.2002, Salzburg, Öst.Bundesheer
Impfprävention beim Bundesheer
13.4.2002, Salzburg, 11.Öst.Impftag
Pertussisepidemiologie in Österreich
18.4.2002, Pflegeheim Baumgarten, Wien
Hepatitiden
29.5.-31.5.2002, Grado, Fortbildung der öst.Arztakademie
Reisemedizin
29.6.2002, Bregenz, Ärztekammer
Reisemedizin update
3.7.2002, Univ.Kinderklinik Wien
Mittagsfortbildung Malaria
17.9.2002, Burgenland, Bezirksärztefortbildung
Reisemedizin update
26.9.2002, Apotheke Traismauer, Aventis Pasteur
Der österreichische Impfplan
3.10.u.4.10.2002, Gmunden, Impfsymposium
Pertussisepidemiologie
Pneumokokkenepidemiologie
12.10-13.10.2002, Reisemedizinische Konsenstagung Österreich
Malariakonsens
15.10.2002, Linz, Glaxo Academy
Hepatitis und Pertussis
26.10/27.10 2002, Taufers/Südtirol, Herbstgespräche f.Pharmazeuten
Reisen mit Kindern
5.11.2002, Wien, Pflegeheim Liesing
Hepatitiden
2003:
25.1.2003, Wiener Geriartrietage
Spezifische Prophylaxe für Senioren
30.1.2003, Fortbildungszyklus der ÖGTP
Die neuen Malariaempfehlungen
27.2.2003, Saalfelden/Apothekertage
Reisemedizin update
7.3.2003, Bundesministerium f.Inneres
Der Pockenalarmplan
15.3.2003, Linzer Reisemedizinische Tagung
Der österreichische Malariakonsens
20.3.2003, Firma ABB
Impfungen bei Auslandseinsätzen
25.3.2003, MA 15 Gesundheitsamt
Der Pockenalarmplan/Schulung für Amtsärzte
1.4.2003, 2.Bundesheerimpftag
Pockenschutzimpfung
4.4.2003, Österr.Impftag
Die Pockenimpfung
23.4.2003, Sozialmedizinisches Zentrum Ost
Impffortbildungsstunde
5.5.-9.5.2003 8th Int.Conf.for Travel Medicine New York
Traveler’s Vaccines
29.5.-31.5.2003, Grado, Fortbildung der öst.Arztakademie
Reisemedizin
- 70 -
26.6.2003, Wiener Rettung
Pockenalarmplan
1.7.-3.7.2003, Hamburg, Bernhard Nocht Institut
Malariaworkshop 2003-12-16
9.10.2003, Impfsymposium Gmunden
FSME-Ergebnisse einer Immunitätsstudie
13.10.2003, Wiener Ärztekammer
Impffortbildung für Schulärzte
4.11.2003, Laa an der Thaya
Reiseimpfungen/Fortbildung Bezirksärzte
10.11.2003, Salzburg/Renaissance Hotel
Epidemiologie von reiseassoziierten Infektionen
2004:
Reisemedizinisches Update
2.3.2004, Saalfelden Apothekertage
Impfplan 2004 und Reisemedizinisches update
Präsentation des Konsensus für Mittelmeerimpfungen
26.3.2004, Österreichsicher Bundesheerimpftag
Flaviviren in der Reisemedizin
27.3.2004, Österreichischer Impftag
FSME
24.5.-29.5.2004, Öst.Akademie der Ärzte/Grado
Seminar Reisemedizin
Seminar Impfplan
3.6.-6.6.2004, 6th Nordic-Baltic Congress on Infectious Diseases
Oral Presentation: Travelers Diarrhea
17.9.-18.9.2004, 4. Reisemedizinische Konsensustagung (Leogang/Salzburg)
Kongressorganissation
Malarialeitlinien
Oral Presentation: TBE vaccination
2005:
19.1.-22.1.2005, Pädiatrisches Symposium Obergurgl
Hepatitis und Typhus
26.1.2005, Ärztekammer Salzburg
Präsentation des reisemed.Konsensus Osteuropa
17.3.2005, Glaxo Academy
Reisemedizinische Fortbildung
31.3.2005, Apothekerkammer Österreich
Hepatitis als Reiseimpfung
9.4.2005, Österr.Impftag Salzburg
Rotavirusimpfstoffe
Tollwutreferenzstelle für Österreich
22.4.2005, ESIDOG
(Europ.Soc.for Infections in Obstetrics and Gynecology)
Impffortbildung für Gynäkologen
- 71 -
Reisemedizinisches Update
14.5.2005, 9th Intl.Conference of Int.Soc.Travel Med
Vaccine Boosters-Evidence for Current Recommendations
Grazer Impftag (14.5.2005)
Rotavirusepidemiologie in Österreich
24.5.-28.5.2005, Öst.Akademie der Ärzte/Grado
Seminar Reisemedizin
Seminar Impfplan
25.6.2005, Arbeitskreis Vorsorgemedizin Vorarlberg
Reisemedizinisches update 2005
5.10.2005, Bezirksärztefortbildung Zams/Tirol
Impfplan 2005
7.10.-8.10.2005, Impfsymposium Gmunden
Rotavirusepidemiologie in Österreich
Rotavirusimpfstoffe
14.10.2005, ESIDOG
(Europ.Soc.for Infections in Obstetrics and Gynecology)
Impffortbildung für Gynäkologen, Teil 2
20.10.2005, Apothekerkammer Kärnten
Impffortbildung für Apotheker
26.10.2005, Pharmazeutische Herbsttagung Triest
Avian Influenza
5.11.2005, Pädiatrische Impffortbildung Linz
Rotavirusvakzinen
17.11.-19.11.2005, ÖGTP-Jahrestagung 2005
21.11.2005, Karl Landsteiner Gesellschaft
Symposium Vogelgrippe
Vogelgrippe-facts and fiction
2006:
21.2.2006 and 28.2.2006, European Insurance Company, Vienna
Travel risks
23.2.2006, Seminar für Journalisten, Wien
Die wirklichen Infektionsgefahren in den Tropen
16.3.2006, Glaxo Academy
Reisemedizinische Fortbildung
6.4.2006, Wiener Arbeiterkammer
Influenzapandemie
Apothekenfortbildung im Pharmaziezentrum Wien (27.4.2006)
28.4.2006, Impfplan 2006, Rotaviren, Hepatitis
ESIDOG Impfseminar Wien (28.4.2006)
Grundlagen des Impfwesens
5.5.2006, Auswärtiges Amt Berlin, Reise- und Tropenmedizin Tagung
2 Vorträge: Zeckenübertragene Infektionen; Impfungen und Boosterung
11.5.2006, Glaxo Academy Wien
Rotavirusepidemiologie und Rotavirusimpfung
13.5.2006, Pannonischer Impftag Burgenland
Auffrischungen von Impfungen
23.5.-26.5.2006, Fortbildung der Wiener Arztakademie Grado
3 Vorträge: Impfseminar Kinderimpfungen; Impfseminar Reiseimpfungen; Symposium
- 72 -
Rotavirusvakzinen
9.6.2006, Bundeskongress der medizinisch technischen Berufe Wien
Infektionsgefahren im Ausland
15.6.2006, ESIDOG Impfseminar Linz
23.6.2006, Österreichisches Bundesheer Innsbruck
Tropen- und Reisemedizin
24.6.2006, Bregenzer Impftag
Kampf den Durchfallserkrankungen: Rotaviren, Reisediarrhoe
22.8.-23.8.2006, Österreichische Arztakademie, Velden
2 Vorträge: Reiseimpfupdate, neue Impfstoffe
26.8.2006, Österreichische Parkinsongesellschaft, Jahrestagung, Karlstein
Impfnebenwirkungen beim neurologischen Patienten
21.9.2006, Novartis Fortbildung, Baden
Influenza
5.10.2006, Landessanitätsdirektion Tirol, Innsbruck
Fortbildung über neue Impfstoffe
12.10.2006, Novartis Fortbildung Krems
Influenza
19.10.2006, Bundesverband der medizinisch technischen Berufe, Wien
Influenza und Pandemie
10 Jahre Infektionssurveillance – was hats gebracht?
4.11.2006, Jahrestagung der ÖGTP, Linz
Update Reisemedizin
16.11.2006, GlaxoSmithKline Fortbildung, Linz
Reisemedizin update
17.11.2006, ESIDOG Vorarlberg
18.11.2006, ESIDOG Innsbruck, Seefeld
11.12.2006, GlaxoSmithKline Fortbildung Wien
Rotavirusepidemiologie und Impfung
2007:
18.1.2007, Fortbildung Novartis Wien
Tollwut Zecken und Co
12.2.2007, Sauerhof, Baden
Apothekerkammerfortbildung: Impfupdate
15.2.2007, Naturhistorisches Museum Wien
Pharmazeuten: Neue Impfungen
21.2.2007, Krems, Kloster UND
Apothekerkammer NÖ, Fortbildung Tollwut
1.3.2007, Saalfelden
Öst.Apothekertage. Reisemedizin update
9.3.2007, ESIDOG: Impfseminar f. Gynäkologen Oberösterreich
Entsendungseignungsuntersuchung
13.3.2007, GlaxoSmithKline
interne Schulung Hepatitis
17.3.2007, Öst.Kongress für Infektionskrankheiten
Reiseimpfungen
23.3.2007, Öst.Bundesheerimpftag
Japan Encephalitis
24.3.2007, Öst.Impftag
- 73 -
Infektionssurveillance
29.3.2007, Öst.Gesellschaft f.Infektionskrankheiten
Faszination Vakzination
5.5.2007, Bezirksärztefortbildung NÖ
Reisemed.update und Hepatitis
8.5.2007, Ärztekammer Salzburg
Reisemedizin.update
9.5.2007, Mini-Med-Studium Donauuniversität
Impfungen
1.6.2007, ESIDOG
Impfseminar für Gynäkologen Salzburg
7.5.2007, Ärzteakademie Grado
Lunchsymposium Reisemedizin
8.5.2007, Ärzteakademie Grado
Impfupdate öst.Impfplan
23.6.2007, Apothekertage Pörtschach
Kinder und Senioren auf Fernreisen
26.9.2007, Fortbildungsakademie Innsbruck
Impfupdate
Pneumokokkensurveillance
2.10.2007, Ärztekammer Wien
Giftiger Dienstag. Der öst.Impfplan
11.10.2007, Gesellschaft der Ärzte, Novartis
Influenza
19.10.2007, Apotheke Trausmauer
Fortbildung Influenza
23.10.2007, Arbeiterkammer Wien
Fortbildung Impfwesen
6.11.2007, Europ.Reiseversicherung
Mitarbeiterschulung Reisemedizin
7.11.2007, AGES Zukunftskonferenz, Messe Wien:
Klimaveränderungen und Tropenkrankheiten
- 74 -
Curriculum Vitae
Rudolf Oehler
Dept. of Surgery, Medical University of Vienna, Währinger Gürtel 18-20, 1090 Wien, Austria;
Personal Data
Date of Birth:
21.12.1963
Place of Birth:
Brixen/Bressanone, Italy
Nationality
Italian
Education
1990 – 1994
Ph.D. work at the Institute of Biochemistry, University of
Vienna (Prof. A. Barta)
1988 – 1989
Diploma work at the Institute of medical Microbiology,
University of Innsbruck (Prof. G. Stöffler)
1982 – 1989
Studies in Microbiology, University of Innsbruck
1982
High school degree for electric engineering in Bolzano,
Italy
Career History
Since 2001
Associate Professor (a.o.Univ.Prof), Department of
Surgery, University of Vienna
2001
Habilitation in Medical Chemistry, University of Vienna
Medical School
1994-2001
University Assistant, Department of Surgery, University of
Vienna
1989 - 1990
Technical assistant at the Diagnostic Laboratory "Dr.
Rohrer", Innsbruck, Austria
Awards
2000
Forschungsförderungspreis der Arbeitsgemeinschaft für
Klinische Ernährung
Memberships
2006
Founding member of the Austrian Proteomic Association
(AuPA)
1995
Founding member of the Cell Stress Society International
(CSSI)
- 75 -
Period
Organization
20078
European Society of Organ Transplantation
2006
Commission of the European Communities (MTKI-CT-2005-029946;
coordination)
2003
Oestrreichische Nationalbank (#9917), Vienna, Austria
2002
Lorenz Böhler Gesellschaft, Vienna, Austria
2001
ESPEN, Geneva, Switzerland
2000
Oestrreichische Nationalbank (#8311), Vienna, Austria
Period
Name of student
2004-2007
Wolfgang Winkler
2000-2004
Maria Zellner
2007 - present
Anna Michlmayr
2007-present
Suzann Baumann
2006-present
Senada Skeledzic
Publications
27 peer reviewed publications in scientific journals, 1 invited review, 2 book chapters, > 6
invited lectures, 1 patent
Exner, R., Weingartmann, G., Spittler, A., Brabec, M., Roth, E., and Oehler, R. (2002)
Glutamine deficiency renders human monocytic cells more susceptible to specific apptosis
triggers. Surgery 131, 75-80
Oehler, R., Pusch, E., Dungel, P., Zellner, M., Munk-Eliasen, M., and Roth, E. (2002)
Reduced expression of the major inducible 70 kDa heat shock protein in glutamine starved
leukocytes. Brit.J.Nutr. 87, S17-S21
Roth, E., Oehler, R., Manhart, N., Exner, R., Wessner, B., Strasser, E., and Spittler, A.
(2002) Regulative potential of glutamine--relation to glutathione metabolism. Nutrition 18,
217-221
Zellner, M., Hergovich, N., Roth, E., Jilma, B., Spittler, A., and Oehler, R. (2002) Human
monocyte stimulation by experimental whole body hyperthermia. Wien. Klin. Wochenschr.
114, 102-107
Oehler, R., and Roth, E. (2003) Regulative capacity of glutamine. Curr Opin Clin Nutr Metab
Care 6, 277-282.
Oehler, R., and Roth, E. (2003) Glutamine Metabolism. In: Cynober, L., ed. Amino acid
metabolism and therapy in health and nutritional disease, 2nd. Ed., pp. 169-185, CRC Press,
Boca Raton, FL.
- 76 -
Roth, E., Zellner, M., Wessner, B., Strasser, E., Manhart, N., Oehler, R., and Spittler, A.
(2003) Glycine-an inert amino acid comes alive. Nutrition 19, 817-818.
Zellner, M., Gerner, C., Eliasen, M., Wurm, S., Pollheimer, J., Spittler, A., Brostjan, C., Roth,
E., and Oehler, R. (2003) Glutamine starvation of monocytes inhibits the ubiquitinproteasome proteolytic pathway. BBA - Molecular Basis of Disease 1638, 138-148
Zellner, M., Gerner, C., Munk Eliasen, M., Wurm, S., Pollheimer, J., Spittler, A., Brostjan, C.,
Roth, E., and Oehler, R. (2003) Glutamine starvation of monocytes inhibits the ubiquitinproteasome proteolytic pathway. Biochim Biophys Acta 1638, 138-148
Pollheimer, J., Zellner, M., Eliasen, M., Roth, E., and Oehler, R. (2005) Increased
susceptibility of Glutamine-depleted monocytes to fever-range hyperthermia: The role of 70
kDa Heat shock protein. Annals of Surgery 241, 349-355
Zellner, M., Winkler, W., Hayden, H., Diestinger, M., Eliasen, M., Gesslbauer, B., Miller, I.,
Chang, M., Kungl, A., Roth, E., and Oehler, R. (2005) Quantitative Validation of different
Protein Precipitation Methods in Proteome Analysis of Blood Platelets. Electrophoresis 26,
2481-2489
Eliasen, M. M., Brabec, M., Gerner, C., Pollheimer, J., Auer, H., Zellner, M., Weingartmann,
G., Garo, F., Roth, E., and Oehler, R. (2006) Reduced stress tolerance of glutamine-deprived
human monocytic cells is associated with selective down-regulation of Hsp70 by decreased
mRNA stability. J Mol Med 84, 147-158
Eliasen, M. M., Winkler, W., Jordan, V., Pokar, M., Marchetti, M., Roth, E., Allmaier, G., and
Oehler, R. (2006) Adaptive cellular mechanisms in response to glutamine-starvation. Front
Biosci 11, 3199-3211
Skeledzic, S., Ahrer, K., Bohmig, G. A., Muehlbacher, F., and Oehler, R. (2007) Identification
of non-HLA antigens in renal transplantation by proteomics. Transplant-Internat. 20, 40
Winkler, W., Zellner, M., Diestinger, M., Babeluk, R., Marchetti, M., Goll, A., Zehetmayer, S.,
Bauer, P., Rappold, E., Miller, I., Roth, E., Allmaier, G., and Oehler, R. (2008) Biological
variation of the platelet proteome in the elderly population and its implication for biomarker
research. Mol Cell Proteomics 7, 193-203
2002
• 24th Int. Congress of the Eur. Soc. of Enteral and Parenteral Nutrition, Glasgow, UK
2004
• 2nd Austrian Proteome Research Symposium, Vienna, Austria
2006
• 2nd Int. Workshop on Platelet disorders, oxidative stress and ageing, Rome, Italy
2007
• 1st Central and Eastern European Proteomic Conference, Prague
- 77 -
Curriculum Vitae
Ao. Univ. Prof. Dr. Winfried F. PICKL
Division of Cellular Immunology and Immunehematology, Institute of Immunology, Center for
Physiology, Pathophysiology and Immunology, Medical University of Vienna, Borschkegasse
8A, 1090 Vienna, Austria;
Phone: +43-1-4277-64945, Fax: +43-1-4277-9649;
Homepage: www.meduniwien.ac.at/immunologie/
Personal Data
Date of Birth:
20.07.1964
Place of Birth:
Klagenfurt
Nationality
Austria
Education
1991, July 5th
Medical Degree, University of Vienna, Medical School
1989–1991
Doctoral Thesis, Institute for Blood Group Serology and
Tissue Typing, University of Vienna, Medical School
1985 – 1990
1983–1989
Medical Student, University of Vienna, Medical School
st
1983, June 1
A-Level with distinction: High School for Business
Administration, Klagenfurt
Career History
09/2004–present
Head of Research Unit ‘Cellular Immunology and
Immunohematology’, Institute of Immunology, Medical
University of Vienna
09/2002–present
Principal Investigator, Institute of Immunology, University
of Vienna, Medical School, and Medical University of
Vienna
th
2002, Nov. 25
Board Certification in Immunology, Austrian Medical
Association
02/2002–08/2002
Training in Hematology and Internal Medicine, Department
of Internal Medicine I, Division of Hematology and
Hemostaseology, University of Vienna, Medical School
06/2000–01/2002
Principal Investigator, Institute of Immunology, University
of Vienna, Medical School
1999, March 25
th
Habilitation and Associate Professorship in Immunology,
Institute of Immunology, University of Vienna, Medical
- 78 -
School
01/1998–05/2000
Research Fellow in Molecular Biology and Genetics,
Department of Molecular Biology, Harvard Medical School,
Boston (Prof. Brian Seed)
1996, Sept. 1st
Assistant Professor in Immunology, Institute of
Immunology, University of Vienna, Medical School
06/1995–12/1997
Research Fellow, Institute of Immunology, University of
Vienna, Medical School
01/1995–05/1995
Training in Surgery and Dermatology, Austrian Armed
Forces Military Hospital, Vienna
10/1994–12/1994
Training as Military Assistant Doctor, Vienna and
Innsbruck Medical Corps, Austrian Armed Forces
11/1991–09/1994
Research Fellow, Institute of Immunology, University of
Vienna, Medical School
07/1991-10/1991
Research Fellow, Institute for Blood Group Serology and
Tissue Typing, University of Vienna
Awards
2007
Karl Landsteiner Award of the Austrian Society for
Allergology and Immunology
1999
APART
research
fellowship,
Austrian
Academy
of
Sciences
1998
Erwin Schroedinger research fellowship, Austrian Science
Foundation
1993
National Award in Rheumatology, Ministry of Health,
Science and Education, Austria
1991
Best Thesis, Austrian Society of Immunology and
Allergology (ÖGAI)
Memberships
Austrian Society for Rheumatology
European Group for the Immunological Characterization of Leukemias (EGIL)
European Leukemia Network (ELN)
American Association of Immunologist (AAI)
American Society for Hematologist (ASH)
Period
Organization
Short Title
K€/year
- 79 -
2002-2005
Academy of Sciences Better definition of the immunological
150
synapse
2002-2005
FWF
Influencing the allergen-specific immune
80
response
2005-2008
FWF
Allergy-SFB:Further development of
80
Anergosomes
2008 - 2011 FWF
Allergy-SFB: Rebuilding the allergen-specific
90
synapse
2006 -2009
FFG
Membrane anchored cytokines and integral
80
membrane proteins: Novel adjuvants for
virus vaccines
2008-2014
Christian Doppler
CDG Laboratory for Immunomodulation-
Society
Subproject #4
90
Period
Name of student
Topic
2001-2005
Sophia Derdak
Immunosomes: VLP driving primary T cell responses
2003-
Victoria Leb
Anergosomes and TCR transgenic allergen-specific T
present
2004-
cells
Hans Küng
Decoration of enveloped viruses with cytokines
Klaus Schmetterer
Functional genetic screening for immunomodulatory
present
2005present
2006-
molecules
Alina Neunkirchner
present
2006-
Antigen-presenting platforms induced by viral core
proteins
Daniela Haiderer
Development of novel adjuvants for viral vaccines
present
Publications
60 peer reviewed publications in scientific journals, 9 book chapters, 1 patent application
Peer reviewed manuscripts 2002-2008 (original research)
Greinix, H. T., Pohlreich, D., Kouba, M., Kormoczi, U., Lohmann, I., Feldmann, K., Zielinski,
C., and Pickl, W. F. (2008). Elevated numbers of immature/transitional CD21- B lymphocytes
and deficiency of memory CD27+ B cells identify patients with active chronic graft-versushost disease. Biol Blood Marrow Transplant 14, 208-219.
Leb, V. M., Jahn-Schmid, B., Schmetterer, K. G., Kueng, H. J., Haiderer, D., Neunkirchner,
A., Fischer, G. F., Nissler, K., Hartl, A., Thalhamer, J., et al. (2008). Molecular and functional
analysis of the antigen receptor of Art v 1-specific helper T lymphocytes. J Allergy Clin
Immunol 121, 64-71.
- 80 -
Sillaber, C., Mayerhofer, M., Bohm, A., Vales, A., Gruze, A., Aichberger, K. J., Esterbauer, H.,
Pfeilstocker, M., Sperr, W. R., Pickl, W. F., et al. (2008). Evaluation of antileukaemic effects
of rapamycin in patients with imatinib-resistant chronic myeloid leukaemia. Eur J Clin Invest
38, 43-52.
Aichberger, K. J., Mayerhofer, M., Gleixner, K. V., Krauth, M. T., Gruze, A., Pickl, W. F.,
Wacheck, V., Selzer, E., Mullauer, L., Agis, H., et al. (2007). Identification of MCL1 as a novel
target in neoplastic mast cells in systemic mastocytosis: inhibition of mast cell survival by
MCL1 antisense oligonucleotides and synergism with PKC412. Blood 109, 3031-3041.
Attarbaschi, A., Mann, G., Schumich, A., Konig, M., Pickl, W. F., Haas, O. A., Gadner, H., and
Dworzak, M. N. (2007). CD44 deficiency is a consistent finding in childhood Burkitt's
lymphoma and leukemia. Leukemia 21, 1110-1113.
Gleixner, K. V., Mayerhofer, M., Sonneck, K., Gruze, A., Samorapoompichit, P.,
Baumgartner, C., Lee, F. Y., Aichberger, K. J., Manley, P. W., Fabbro, D., et al. (2007a).
Synergistic growth-inhibitory effects of two tyrosine kinase inhibitors, dasatinib and PKC412,
on neoplastic mast cells expressing the D816V-mutated oncogenic variant of KIT.
Haematologica 92, 1451-1459.
Gleixner, K. V., Rebuzzi, L., Mayerhofer, M., Gruze, A., Hadzijusufovic, E., Sonneck, K.,
Vales, A., Kneidinger, M., Samorapoompichit, P., Thaiwong, T., et al. (2007b). Synergistic
antiproliferative effects of KIT tyrosine kinase inhibitors on neoplastic canine mast cells. Exp
Hematol 35, 1510-1521.
Kondo, R., Gleixner, K. V., Mayerhofer, M., Vales, A., Gruze, A., Samorapoompichit, P.,
Greish, K., Krauth, M. T., Aichberger, K. J., Pickl, W. F., et al. (2007). Identification of heat
shock protein 32 (Hsp32) as a novel survival factor and therapeutic target in neoplastic mast
cells. Blood 110, 661-669.
Kueng, H. J., Leb, V. M., Haiderer, D., Raposo, G., Thery, C., Derdak, S. V., Schmetterer, K.
G., Neunkirchner, A., Sillaber, C., Seed, B., and Pickl, W. F. (2007). General strategy for
decoration of enveloped viruses with functionally active lipid-modified cytokines. J Virol 81,
8666-8676.
Mayerhofer, M., Gleixner, K. V., Mayerhofer, J., Hoermann, G., Jaeger, E., Aichberger, K. J.,
Ott, R. G., Greish, K., Nakamura, H., Derdak, S., et al. (2007). Targeting of heat shock
protein 32 (Hsp32) / heme oxygenase-1 (HO-1) in leukemic cells in chronic myeloid leukemia:
a novel approach to overcome resistance against imatinib. Blood.
Rebuzzi, L., Willmann, M., Sonneck, K., Gleixner, K. V., Florian, S., Kondo, R., Mayerhofer,
M., Vales, A., Gruze, A., Pickl, W. F., et al. (2007). Detection of vascular endothelial growth
factor (VEGF) and VEGF receptors Flt-1 and KDR in canine mastocytoma cells. Vet Immunol
Immunopathol 115, 320-333.
Aichberger, K. J., Mayerhofer, M., Vales, A., Krauth, M. T., Gleixner, K. V., Bilban, M.,
Esterbauer, H., Sonneck, K., Florian, S., Derdak, S., et al. (2006). The CML-related
oncoprotein BCR/ABL induces expression of histidine decarboxylase (HDC) and the
synthesis of histamine in leukemic cells. Blood 108, 3538-3547.
Attarbaschi, A., Mann, G., Konig, M., Steiner, M., Strehl, S., Schreiberhuber, A., Schneider,
B., Meyer, C., Marschalek, R., Borkhardt, A., et al. (2006). Mixed lineage leukemiarearranged childhood pro-B and CD10-negative pre-B acute lymphoblastic leukemia
constitute a distinct clinical entity. Clin Cancer Res 12, 2988-2994.
Bilban, M., Heintel, D., Scharl, T., Woelfel, T., Auer, M. M., Porpaczy, E., Kainz, B., Krober,
- 81 -
A., Carey, V. J., Shehata, M., et al. (2006). Deregulated expression of fat and muscle genes
in B-cell chronic lymphocytic leukemia with high lipoprotein lipase expression. Leukemia 20,
1080-1088.
Derdak, S. V., Kueng, H. J., Leb, V. M., Neunkirchner, A., Schmetterer, K. G., Bielek, E.,
Majdic, O., Knapp, W., Seed, B., and Pickl, W. F. (2006). Direct stimulation of T lymphocytes
by immunosomes: virus-like particles decorated with T cell receptor/CD3 ligands plus
costimulatory molecules. Proc Natl Acad Sci U S A 103, 13144-13149.
Gleixner, K. V., Mayerhofer, M., Aichberger, K. J., Derdak, S., Sonneck, K., Bohm, A., Gruze,
A., Samorapoompichit, P., Manley, P. W., Fabbro, D., et al. (2006). PKC412 inhibits in vitro
growth of neoplastic human mast cells expressing the D816V-mutated variant of KIT:
comparison with AMN107, imatinib, and cladribine (2CdA) and evaluation of cooperative drug
effects. Blood 107, 752-759.
Pfistershammer, K., Klauser, C., Pickl, W. F., Stockl, J., Leitner, J., Zlabinger, G., Majdic, O.,
and Steinberger, P. (2006). No evidence for dualism in function and receptors: PD-L2/B7-DC
is an inhibitory regulator of human T cell activation. Eur J Immunol 36, 1104-1113.
Sonneck, K., Florian, S., Bohm, A., Krauth, M. T., Kondo, R., Hauswirth, A. W., Gleixner, K.
V., Aichberger, K. J., Derdak, S., Pickl, W. F., et al. (2006). Evaluation of biologic activity of
tryptase secreted from blast cells in acute myeloid leukemia. Leuk Lymphoma 47, 897-906.
Aichberger, K. J., Mayerhofer, M., Krauth, M. T., Skvara, H., Florian, S., Sonneck, K., Akgul,
C., Derdak, S., Pickl, W. F., Wacheck, V., et al. (2005a). Identification of mcl-1 as a
BCR/ABL-dependent target in chronic myeloid leukemia (CML): evidence for cooperative
antileukemic effects of imatinib and mcl-1 antisense oligonucleotides. Blood 105, 3303-3311.
Aichberger, K. J., Mayerhofer, M., Krauth, M. T., Vales, A., Kondo, R., Derdak, S., Pickl, W.
F., Selzer, E., Deininger, M., Druker, B. J., et al. (2005b). Low-level expression of
proapoptotic Bcl-2-interacting mediator in leukemic cells in patients with chronic myeloid
leukemia: role of BCR/ABL, characterization of underlying signaling pathways, and
reexpression by novel pharmacologic compounds. Cancer Res 65, 9436-9444.
Mayerhofer, M., Aichberger, K. J., Florian, S., Krauth, M. T., Hauswirth, A. W., Derdak, S.,
Sperr, W. R., Esterbauer, H., Wagner, O., Marosi, C., et al. (2005). Identification of mTOR as
a novel bifunctional target in chronic myeloid leukemia: dissection of growth-inhibitory and
VEGF-suppressive effects of rapamycin in leukemic cells. Faseb J 19, 960-962.
Wohrl, S., Loewe, R., Pickl, W. F., Stingl, G., and Wagner, S. N. (2005). EMPACT syndrome.
J Dtsch Dermatol Ges 3, 39-43.
Steinberger, P., Majdic, O., Derdak, S. V., Pfistershammer, K., Kirchberger, S., Klauser, C.,
Zlabinger, G., Pickl, W. F., Stockl, J., and Knapp, W. (2004). Molecular characterization of
human 4Ig-B7-H3, a member of the B7 family with four Ig-like domains. J Immunol 172,
2352-2359.
Selenko-Gebauer, N., Majdic, O., Szekeres, A., Hofler, G., Guthann, E., Korthauer, U.,
Zlabinger, G., Steinberger, P., Pickl, W. F., Stockinger, H., et al. (2003). B7-H1 (programmed
death-1 ligand) on dendritic cells is involved in the induction and maintenance of T cell
anergy. J Immunol 170, 3637-3644.
Javaherian, K., Park, S. Y., Pickl, W. F., LaMontagne, K. R., Sjin, R. T., Gillies, S., and Lo, K.
M. (2002). Laminin modulates morphogenic properties of the collagen XVIII endostatin
domain. J Biol Chem 277, 45211-45218.
- 82 -
Curriculum Vitae
Marcus Säemann
Internal Medicine III, Clin. Division of Nephrology & Dialyis, Medical University of Vienna,
Währinger Gürtel 18-20, 1090 Wien, Austria; Phone: +43-1-404005593, Fax: +43-1404004392; e-mail: [email protected];
Personal Data
Date of Birth:
3.2.1971
Place of Birth:
Vienna
Nationality
Austria
Education
2002-2008
Fellowship Internal Medicine, Spec. Nephrology, Vienna
1998-2002
Postdoctoral fellow at the Inst. of Immunology, Vienna
1995-1998
Diploma thesis at the Institute of Immunology, Vienna
1989-1998
Studies in Human Medicine, University of Vienna
1989
University entrance qualification, G3 Vienna
Career History
2007
Associate Professor (Privat Dozent)
2006
Establishment of the Pancreas-Transplant Program at the
MUV, Minneapolis, Mn, Dep. of Surgery (Prof. DER
Sutherland)
04/2006
Habilitation in Internal Medicine, University of Vienna
Medical School
2002
Group Leader, Exp. Nephrology & Immunosuppression
MUV
1998-2002
Postdoctoral fellow at the Inst. of Immunology, Vienna
Memberships
Member of the Austrian Society of Allergology und Immunology, 1998
General Secretary of the Austrian Society of Allergology und Immunology, 2006-2008
Member of the Austrian Society of Transplantation, Transfusion und Genetics, 2001
Member of the Transplantation Society, 2000
Member of the European Society of Transplantation (ESOT), 2004
Member of the Austrian Society of Nephrology, 2005
Member of the German Society of Nephrology, 2005
Member of the American Association of Immunology, 2000
Associate Editor of the European Journal of Clinical Investigation, 2002
Editorial Board of Transplant International, 2003
Society of Innate Immunity (Founding member), 2006
Member of the Scientific Comittee for ECI 2009 ("Immune Interventions")
- 83 -
Period
Organization
Short Title
K€/year
2007-2009
Else-Köner Fund
HDL as immunomodulator
75000
2007-2008
Else-Köner Fund
THP and the myeoloma kidney
80000
2003-2005
Austrian National
JAK3 as immunosuppressive target
25000
Bank Fund
Period
Name of student
2004 - 2006 Marko Poglitsch
Topic
Insights into the molecular mode of
malonotrilamides on T-cell activation
2006 - 2008 Barbara Vodenik
Inhibition of mTOR prevents the anti-inflammatory
action of glucocorticoids
2007 - 2008 Philipp Steininger
GSK3 as immunosuppressive target
Publications
Säemann M.D., Parolini O., Böhmig G.A., Kelemen P., Krieger P.-M., Knarr K., Kammlander
W., Neumüller F., Hörl W.H., Diakos C., Stuhlmeier K., Zlabinger G.J. Bacterial metabolite
interference with maturation of human monocyte-derived dendritic cells. J Leuk Biol 2002,
71:238-246
Böhmig G., Regele H., Exner M., Derhartunian V., Kletzmayr J., Säemann M.D., Hörl W.H.,
Druml W., Watschinger B. Capillary C4d deposition in kidney allografts: a specific marker of
alloantibody-dependent graft injury. J Am Soc Nephrol 2002, 13(4):1091-1099
Diakos C., Prieschl E., Säemann M.D., Böhmig G.A., Baumruker T., Zlabinger G.J.
Increased nuclear export of NF-AT by the short-chain fatty acid n-butyrate. J Biol Chem
2002, 277:24243-24251
Krieger P.-M., Säemann M.D., Böhmig G.A., Mühlbacher F., Zlabinger G.J. Targeting the
ERK1/2-signalling pathway results in alloantigen-specific anergy in human T-cells.
Transplant Proc 2002, 34:1403-1404
Säemann M.D., Kelemen P., Zeyda M., Böhmig G.A., Staffler G., Zlabinger G.J. CD40triggered human monocyte-derived DC convert to tolerogenic DC when JAK3 activity is
prevented. Transplant Proc 2002, 34:1407-1408
Sanzone S, Zeyda M., Säemann M.D., Soncini M, Holter W, Fritsch G., Knapp W., Candotti
F., Stulnig T.M., Parolini O. SLAM-associated protein deficiency causes imbalanced early
signal transduction and blocks downstream activation in T cells from X-linked
lymphoproliferative disease patients. J Biol Chem 2003, 278(32): 29593-29599
Zeyda M., Szekeres A.B., Säemann M.D., Geyeregger R., Stockinger H., Zlabinger G.J.,
Waldhausl W., Stulnig T.M. Suppression of T cell signaling by polyunsaturated fatty acids:
selectivity in inhibition of mitogen-activated protein kinase and nuclear factor activation. J
Immunol 2003, 170(12):6033-6039
Säemann M.D., Zeyda M., Diakos C., Szekeres A.B., Bohmig G.A., Kelemen P., Parolini O.,
- 84 -
Stockinger H., Prieschl E.E., Stulnig T.M., Baumruker T., Zlabinger G.J. Suppression of early
T-cell-receptor-triggered cellular activation by the Janus kinase 3 inhibitor WHI-P-154.
Transplantation 2003, 75(11):1864-1872
Staffler G., Prager E., Zeyda M., Säemann M.D., Stulnig T., Hilgert I., Zlabinger G.J., Horejsi
V., Stockinger H. Selective inhibition of T cell activation via CD147 through novel modulation
of lipid rafts. J Immunol 2003, 171(4):1707-1714
Säemann M.D., Diakos C., Kelemen P., Kriehuber E., Zeyda M., Böhmig G.A., Hörl W.H.,
Baumruker T., Zlabinger G.J. Prevention of CD40-Triggered Dendritic Cell Maturation and
Induction of T-Cell Hyporeactivity by Targeting of Janus Kinase 3. Am J Transplant 2003,
3(11):1341-1349
Fabrizii V., Winkelmayer W.C., Klauser R., Kletzmayr J., Säemann M.D., Steininger R.,
Kramar R., Hörl W.H., Kovarik J. Patient and graft survival in older kidney transplant
recipients: does age matter? J Am Soc Nephrol 2004, 15(4):1052-1060
Wimmer T., Cohen G., Säemann M.D., Hörl W.H.. Effects of Tamm-Horsfall protein on
polymorphonuclear leukocyte function. Nephrol Dial Transplant 2004, 19(9):2192-2197
Säemann M.D., Kelemen P., Böhmig G.A., Hörl W.H., Zlabinger G.J. Hyporesponsiveness in
alloreactive T-cells by NF-kappaB inhibitor-treated dendritic cells: resistance to calcineurin
inhibition. Am J Transplant 2004, 4(11):1341-1349
Säemann M.D., Weichhart T., Zeyda M., Staffler G., Schunn M., Stuhlmeier K.M., Sobanov
Y., Stulnig T.M., Akira S., von Gabain A., von Ahsen U., Hörl W.H., Zlabinger G.J. TammHorsfall glycoprotein links innate immune cell activation with adaptive immunity via a Toll-like
receptor-4-dependent mechanism. J Clin Invest. 2005, 115(2):468-475
Zeyda M., SäemannM.D., Stuhlmeier K.M., Mascher D.G., Nowotny P.N., Zlabinger G.J.,
Waldhausl W., Stulnig T.M.. Polyunsaturated fatty acids inhibit dendritic cells function without
impairment of NF-kB. J Biol Chem 2005, 280(14):14293-14301
Kirsch B., Zeyda M., Grisar J., Smolen J.S., Watschinger B., Stulnig T.M., Hörl W.H.,
Zlabinger G.J. Säemann M.D. The active metabolite of leflunomide A77 1726 interferes with
dendritic cell function. Arthritis research and therapy 2005, 2005;7(3):R694-703
Zeyda M., Stuhlmeier K.M., Kirsch B., Watschinger B., Hörl W.H., Stulnig T.M., and
Säemann M.D. The malononitrilamide FK778 inhibits Activation of NF-kB in Human Dendritic
Cells. Transplant Proc 2005, 37(4):1970-1971
Zeyda M., Geyerreger R., Poglitsch M., Watschinger B., Hörl W.H., Stulnig T.M., and
Säemann M.D. The novel immunosuppresant FK778 inhibits Formation of the Immunological
Synapse. Transplant Proc 2005, 37(4):1968-1969
Zeyda M., Poglitsch M., Geyeregger R., Smolen J.S., Zlabinger G.J., Hörl W.H., Waldhäusl
W., Stulnig T.M., and Säemann M.D. The Active Leflunomide Metabolite Teriflunomide
Disrupts the Interaction of T Cells with Antigen-Presenting Cells: Involvement of Impaired
Integrin Activation and Immunological Synapse Formation. Arthritis and Rheumatism 2005,
52(9):2730-2739
Zeyda M., Kirsch B., Geyeregger R., Stuhlmeier K., Zlabinger G.J., Hörl, W. H., Säemann
M.D., Stulnig T. M. Inhibition of human dendritic cell maturation and function by the novel
immunosuppressant FK778., Transplantation. 2005 27;80(8):1105-1151
Diakos C., Prieschl E.E., Bohmig G.A., Csonga B,, Sobanov Y., Baumruker T., Säemann
- 85 -
M.D. Zlabinger G.J. n-Butyrate inhibits Jun NH(2)-terminal kinase activation and cytokine
transcription in mast cells. Biochem Biophys Res Commun. 2006;349(2):863-868
Körmöczi G.F., Säemann M.D., Buchta C., Peck-Radosavljevic M., Mayr W.R., Schwartz
D.W., Dunkler D., Spitzauer S., Panzer S. Influence of clinical factors on the haemolysis
marker haptoglobin. Eur J Clin Invest. 2006;36(3):202-209
Kirsch B.M., Geyeregger R., Stuhlmeier K., Säemann M.D. Alemtuzumab (Campath-1H)
induction therapy and dendritic cells: Impact on peripheral dendritic cell repertoire in renal
allograft recipients. Transpl Immunol. 2006;16(3-4):254-257
Zeyda M., Geyeregger R., Poglitsch M, Säemann M.D. Impairment of T cell interactions with
antigen-presenting cells by immunosuppressive drugs reveals involvement of calcineurin and
NF-kappaB in immunological synapse formation. J Leukoc Biol. 2007;81(1):319-327
Geyeregger R., Zeyda M., Bauer W., Kriehuber E., Säemann M.D., Zlabinger G.J., Maurer
D., Stulnig T.M. Liver X receptors regulate dendritic cell phenotype and function through
blocked
induction
of
the
actin
bundling
protein
fascin.
Blood. 2007; 109(10):4288-95
Grisar J.C., Aletaha D., Steiner C.W., Kapral T., Säemann M.D., Steiner S., Schwarzinger I.,
Buranyi I., Steinere G., Smolen J. Endothelial progenitor cells in active rheumatoid arthritis:
Effects of TNF and of glucocorticoid therapy. Ann Rheum Dis. 2007; 66(10):1284-8
Bobacz K., Sunk IG., Hofstaetter JG., Amoyo L., Toma CD., Akira S., T. Weichhart,
Säemann M.D., J. S. Smolen. Toll-like receptors and chondrocytes: The lipopolysaccharideinduced decrease in cartilage matrix synthesis is dependent on the presence of toll-like
receptor 4 and antagonized by bone morphogenetic protein 7. Arthritis Rheum.
2007;56(6):1880-93
Haidinger M., Gyeregger R., Poglitsch M., Weichhart T., Zeyda M., Vodenik B., Stulnig T.M.,
Böhmig G.A,, Hörl W.H., Säemann M.D. Anti-thymocyte globulin impairs T-cell/antigenpresentingcell interaction: disruption of immunological synapse and conjugate formation.
Transplantation 2007;84(1):117-21
Manfred Hecking, Kainz A, Schillinger M., Posch C., Birsan T., Rasoul-Rockenschaub S.,
Böhmig GA, Schmaldienst S., Watschinger B., Hörl W.H., Mühllbacher F., Säemann M.D.
Analysis of liver function in renal transplant recipients undergoing C2-monitoring for
cyclosporine. Transpl Int. 2008;21(3):223-33.
Pfistershammer K, Klauser C., Leitner J., Stöckl J., Majdic O., Weichhart T., Sobanov Y.,
Bochkov V., Säemann M.D., Zlabinger GJ., teinberger P. Identification of the scavenger
receptors SREC-I, Cla-1 (SR-BI), and SR-AI as cellular receptors for Tamm-Horsfall protein.
J Leukoc Biol. 2008;83(1):131-8.
M.D. Säemann, G.A. Böhmig, Zlabinger G.J. Short-chain fatty acids: physiological mediators
of a balanced host-microbial relationship. Wi Kli Wo 2002;8-9: 289-300
M.D. Säemann, Zlabinger G.J. How to make clinical use of bacterial evasion strategies. Eur
J Clin Invest 2003;33(3):189-190
M.D. Säemann. Prevention of allograft rejection by selective JAK3 inhibition. European
Surgery 2004
M.D. Säemann, Zeyda M, Stulnig T.M., Bohmig G.A., Wekerle T, Hörl W.H., Zlabinger GJ.
Janus kinase-3 (JAK3) inhibition: a novel immunosuppressive option for allogeneic
- 86 -
transplantation. Transpl Int. 2004;17(9); 481-489
M.D. Säemann, T. Weichhart, W.H. Hörl, Zlabinger G.J. Tamm-Horsfall Glycoprotein: TammHorsfall protein: a multilayered defence molecule against urinary tract infection. Eur J Clin
Invest. 2005;35(4):227-235
T. Weichhart, Zlabinger G.J, Säemann M.D. The multiple functions of Tamm-Horsfall Protein
in health and disease: a mystery clears up. Wi Kli Wo 2005;117(9-10):316-322
M.D. Säemann, T. Weichhart. Causes of recurrent urinary tract infections: new insights.
Dtsch Med Wochenschr. 2005;130(36):2031-2034
M.D. Säemann, W.H. Hörl, T. Weichhart. Uncovering host defences in the urinary tract:
cathelicidin and beyond. Nephrol Dial Transplant. 2007;22(2):347-349
T. Weichhart, W.H. Hörl, M.D. Säemann, Biological action of rapamycin in renal
transplantation. Am J Kidney Dis. 2008; 51(3):531
Weichhart, M. Haidinger, W.H. Hörl, M.D. Säemann, The current concept of molecular
defense mechanisms operative during urinary tract infection. Eur J Clin Invest 2008; in press
2002
Suppression of early T cell activation by selectivev JAK3 targeting. Säemann M.D.,
Kelemen P., Zeyda M., Böhmig G.A., Staffler G., Zlabinger G.J.. Nieren und
Hochdruckkrankheiten (ERA/EGTA, Denmark)
CD40-triggered human monovyte-derived DC convert to tolerogenic DC when JAK3 activity
is prevented. Säemann M.D., Kelemen P., Zeyda M., Böhmig G.A., Staffler G., Zlabinger
G.J.. Nieren und Hochdruckkrankheiten (Kongress der Gesellschaft f. Nephrologie,
Düsseldorf and ERA/EGTA, Denmark)
Induction of allogeneic regulatory cells by differentiated myeloid dendritic cells. Säemann
M.D., Kelemen P., Böhmig G.A., Hörl W.H., Zlabinger, Nieren und Hochdruckkrankheiten
(Kongress der Gesellschaft f. Nephrologie, Düsseldorf sowie ERA/EGTA, Denmark)
Suppression of early T cell activation by selective JAK3 targeting. Säemann M.D., Kelemen
P., Zeyda M., Böhmig G.A., Staffler G., Zlabinger G.J.. Acta Chirurgica Austriaca 2003
(Austrotransplant)
2003
Selective inhibition of Jun N-terminale kinase in alloreactive human T cells is primarily
immunosuppressive, but enhances activation-induced cell death in conjunction with mTOR
targeting. Säemann M.D., M. Soncini, Zeyda M., Zlabinger G.J., Knapp W., Hörl W.H.,
Parolini O. Nephrol Dial Transplant Vol 18 Suppl 4 2003 (World Congress of Nephrology
2003)
Immunosuppressives in the Pipeline (Seminar at the Dep. of Internal Medicine III 2004)
2004
Säemann M.D. Immunostimulatory effects of Tamm-Horsfall Glycoprotein. (Seminar at the
Institute for Immunology 2004)
- 87 -
Säemann M.D., Human monocyte-derived dendritic cells express high levels of angiotensin
converting enzyme (ACE): modulation by vitamin-D and implications for renal disease (28.
Wiss. Kongress Hypertonie, Hannover)
Säemann M.D. Seminar at the Dep. of Internal Medicine III 2004 (“Tamm-Horsfall
Glycoprotein: A multilayered defense molecule against urinary tract infection”)
Säemann M.D., Geyerreger R., Zeyda M., Weichhart T., Zlabinger G.J., Stulnig T.. NF- B
regulates TCR/CD3 complex recruitment into the immunological synapse (3rd Int Congress
of Immunosuppression, San Diego)
Zeyda M., Poglitsch M., Geyeregger R., Zlabinger G.J., Watschinger B., Hörl W.H., Stulnig
T.M., and Säemann M.D.. Profound disruption of the Immunological Synapse Formation by
the novel immunosuppressant FK778. (3rd Int Congress of Immunosuppression, San Diego)
Zeyda M., Kirsch B., Watschinger B., Stulnig T.M., Hörl W.H., Zlabinger G.J.. Säemann
M.D.. The novel immunosuppressant FK778 prevents activation of NF-kB in human myeloid
dendritic cells. 2005, (3rd Int Congress of Immunosuppression, San Diego)
Säemann M.D., Seminar at the Medical University of Innsbruck 2004 (“Janus kinase-3
inhibition as a novel immunosuppressive option for allogeneic transplantation”)
2005
Säemann M.D., Transplantkonferenz 2005 ("C2-Spiegelmonitoring aus der Sicht des
Nephrologen")
Kirsch B., Zeyda M., Grisar J., Smolen J.S., Watschinger B., Stulnig T.M., Hörl W.H.,
Zlabinger G.J.. Säemann M.D. The active metabolite of leflunomide A77 1726 interferes
with dendritic cell function. (Keystone Symposium on DCs)
Säemann M.D. State of the Art: Kidney and pancreas transplantation. (Seminar at the Dep.
of Internal Medicine III 2005)
Säemann M.D. Zeyda M., Poglitsch M., Geyeregger R., Zlabinger G.J., Watschinger B.,
Hörl W. Initiating allograft immunity: effect of immunosuppression on evolution of the
Immunological Synapse. (5th Basic Science Congress on Transplantation, Nantes, France)
Säemann M.D. Tamm-Horsfall Protein: ein antimikrobielles Protein des Urogenitaltrakt.
(DgfN Saarbrücken)
Säemann M.D. Effect of Immunsuppression the very early manifestations of
alloimmuneresponsiveness. (Austrotransplant)
Kirsch B., Watschinger B., Hörl W.H.,. Säemann M.D., Alemtzumab induction therapy
differentially affects dendritric cell subset distribution in renal transplant patients.
(Austrotransplant)
Säemann M.D. Bedeutung des Tamm-Horsfall Protein als protektives Molekül bei
Harnwegsinfektionen. (KfH Würzburg)
2006
Säemann M.D. Insights into the molecular mechanisms of urinary tract infection (Nephro
School, Freising, Germany)
- 88 -
Säemann M.D. Impact of innate immunity on the process of allogeneic transplantation.
(DfGN, Essen, Germany)
Säemann M.D. Innate immunity: the neglected arm of transplant effector systems (Astellas
TX360 Symposium, Vienna, Austria)
Säemann M.D. Innate immunity and allogeneic transplantation. (ÖGN, Semmering, Austria)
Säemann M.D. Novel insights into immunosuppressive proteocols (NephroMeeting, Fuschl,
Austria)
Säemann M.D. Options for Renal Transplant Immunosuppression .(Seminar at the Dep.
of Internal Medicine III 2005)
Weichhart T, Costantino G., Zeyda M., Poglitsch M., Soleiman A., Watschinger B., Zlabinger
G.A., Hörl W.H., Müller M., and Säemann M.D., The immunosuppressive drug rapamycin
promotes proinflammatory responses in antigen-presenting cells", presented at the Annual
meeting of the Society of Nephrology, Essen, Austria, September 2006, (Oral)
Weichhart T, Hörl W.H., Säemann M.D., Antiinflammatory effects on HDL on innate immune
cells: implications for dialysis HDL and ist lost function, presented at the Annual meeting of
the Austrian Society of Nephrology, Semmering, Austria, October 2006, (invited Oral)
Weichhart T, Costantino G., Zeyda M., Poglitsch M., Soleiman A., Watschinger B., Zlabinger
G.A., Hörl W.H., Müller M., and Säemann M.D.,
Thomas Weichhart, "The
immunosuppressant rapamycin promotes Toll-like receptor-mediated inflammatory
responses", presented at the Annual meeting of the Austrotransplant Society, Fuschl,
October 2006, (Oral)
Vodenik B., Weichhart T, Watschinger B., Hörl W.H., Säemann M.D. Inhibitors of mTOR
prevent the anti-inflammatory effecs of corticosteroids: implications for transplant patients,
presented at the Annual meeting of the Austrotransplant Society, Fuschl, October 2006,
(Oral)
2007
Säemann M.D. MPA and mTOR-Inhibitors: a comprehensive overview (REN, Vienna,
Austria)
Säemann M.D. Individual immunosuppression for the individual renal transplant patient
(Nephro School, Freising, Germany)
Weichhart T., Constantini G., Poglitsch M., Mueller M., Zeyda M., Hörl W.H., Hengstschläger
M., Säemann M.D. The mammalian target of rapamycin is a negative regulator of NF-kB in
professional antigen-presenting cells: impact on innate immunity. (ATC, San Francisco,
USA)
Säemann M.D. Dual effects of proliferation signal inhibitors: impact for renal transplantation.
(PSI Academy, Vienna, Austria)
Haidinger M., Gyeregger R., Poglitsch M., Weichhart T., Zeyda M., Vodenik B., Stulnig T.M.,
Böhmig G.A,, Hörl W.H., Säemann M.D. Anti-thymocyte globulin impairs T-cell/antigenpresentingcell interaction: disruption of immunological synapse and conjugate formation.
ERA-EGTA, June 2007 (Travel Award)
- 89 -
Weichhart T, Costantino G., Zeyda M.,
Poglitsch M., Soleiman A., Watschinger B.,
Zlabinger G.A., Hörl W.H., Müller M., and Säemann M.D., Thomas Weichhart, Inhibition of
mTORC1 promotes Toll-like receptor-mediated inflammation, European Society of Organ
Transplantation, September 2007, (Young Investigator Award)
Säemann M.D. Molecular Mechanisms Operative Durino Urinary Tract Infection (Univ. Klinik
f. Nephrologie, Zürich, CH)
Säemann M.D. Immunsosuppression: now and tomorrow: an overview. (Austrotransplant,
Fuschl, Salzburg)
2008
Säemann M.D. Post-Transplant Diabetes mellitus (Nephroschool, Vienna)
Saemann M.D. Immunosuppression in living-donor Renal Transplantation. (R.E.N. Meeting
Transplant08)
Säemann M.D. Innate Immunity during urinaty tract Infection (Nephrology Meeting, Berlin)
Säemann M.D. Post-Transplant Diabetes mellitus (Int. Med.III/Dep. of Nephrology, Vienna,
MUV)
- 90 -
Curriculum Vitae
Wolfgang Schreiner
Division of Biomedical Computer Simulation and Bioinformatics,Core facility of Medical
Statistics and Informatics, Medical University of Vienna, Spitalgasse 19, 1090 Wien, Austria;
Phone: +43-1-40400-6679, Fax: +43-1-40400-6677;
Homepage: http://www.meduniwien.ac.at/msi/biosim/
Personal Data
Date of Birth:
24.06.1954
Place of Birth:
Wien
Nationality
Austria
Education
1979
Post Doc Research Fellow (Computer Simulation), Royal
Holloway College, London
1978 – 1979
PhD Studies (Computer Simulation), Department of
Experimental of Physics, University of Vienna, Austria
1973 – 1978
Studies in Physics and Mathematics, University of Vienna,
Austria
1972 - 1973
Military service at army hospital, Vienna
1972
University entrance qualification, AHS-Matura with
distinction, Vienna
Career History
Since 05/1995
Full Professor of Medical Computer Sciences
Head of Section for Biomedical Computer Simulation and
Bioinformatics, Core Unit for medical Statistics and
Informatics, Medical University of Vienna.
1991 – 1995
Group leader for Biomedical Computer Simulation,
Department of Medical Computer Sciences, University of
Vienna Medical School
1991
Apointed “Unversitätsdozent” for Medical Informatics,
01/1991
Habilitation in Medical Informatics, University of Vienna
Medical School
1985 – 1991
University Assistant at the 2nd Department of Surgery,
University of Vienna Medical school. Working field:
- 91 -
Statistics and Informatics in support of patient treatment
and medical research. Numerous projects on ITapplications within a clinical and research setting.
1984 – 1985
Assistent at the Assistant at the 2nd Department of
Surgery, University of Vienna Medical school. Working
field: Statistics and Informatics in support of patient
treatment and medical research.
1983
Scientific Writer, Authorship of the TextBook “Radioation
Dose Estimation after Incorporatin of Open
Radionuclides”.
1979 – 1983
Assistant at the Department for Experimental Physics,
University of Vienna, Austria. Research work on computer
simulation of thermodynamic model systems.
1985- 1987
Software Coordinator for the International Working Group
of Coronary Sinus Interventions
1985- 1995
Consultant for IT – support for Ludwig Boltzmann Institute
for Research in Cardiac Surgery, University of Vienna.
1991 - 1995
IT – planning delegate for migration of the 2nd Department
of Surgery –to the new AKH-building. Initiator of the
“Chirurgie-EDV-Paket” (Surgery-IT-software-package),
later to become the research support-facility “ArchiMed”.
Establishment of close cooperation between Department
of Surgery and Department of Medical Computer
Sciences.
1995 - 1997
Member of the Executive Board for Clinical Affairs of the
Medical Faculty. (“Klinikenkonferenz”). This position made
it possible to initiate the AKIM – Projekt together with
heads of several clinical departments, the dean of the
medical faculty, the medical director of AKH, the technical
director of the AKH, administrative director, nursing
directrice of the AKH, the Vienna “Gesundheitsstadtrat”
and head of the “Wiener Krankenanstaltenverbund”. AKIM
was initiated 1997 and ist still ongoing (as of 2008).
1995 - 1999
Member of the Faculty Committee (Fakultätskollegium)
and its executive board (Leitungsausschuß), Faculty of
Medicine.
1995 - 2002
Member of the “Institutskonferenz” of the Department for
- 92 -
Medical Computer Sciences
1995 - 1998
Member of the “Strukturkommission” of the Medical
Faculty.
1995 - 2002
Member of evaluating commissions for appointments of full
professorsof several disciplines
1998 - present
Member of the AKIM – Arbeitsgremium
2002 - 2007
Head of the IT-coordination board if the Department of
Medical ‘Statisitcs and Informatics
2002- 2002
Founder of bioinformatics -coordination board at the MUW
2005 - present
Project leader for AKIM-Bioinformatics - Platform
2006 - present
Member of the executive board for the curriculum in
Medical Informatics at MUW and coordinator for teaching
at MSI.
2006 - present
Coordinator for teaching affairs at the MSI.
Awards
1992
Best presentation award „Gesellschaft für Biomedizinische
Technik“
1993
Staatspreis für Ersatzmethoden zum Tierversuch:
Computersimulation des Coronarkreislaufes
Period
Organization
Short Title
K€/year
2005-2006
BMWF
Austrian Grid: Immunosimulation
41
2008 –2009 BMWF
Austrian Grid: Immunosimulation
36
Period
Name of student
Topic
2006-2008
Bernhard Knapp
Genetic algorithms for pMHC modelling
Publications
Knapp B, Omasits U, Schreiner W: Side chain substitution benchmark for peptide/MHC
interaction. Protein Sci. 17(6):977-82, 2008
Schreiner W, Karch R, Neumann M, Neumann F, Szalowski P, Roedler S: Optimized arterial
- 93 -
trees supplying hollow organs. Med.Eng.Phys. 28:416-429, 2006
Karch R, Neumann M, Neumann F, Ullrich R, Neumüller J, Schreiner W: A Gibbs point field
model for the spatial pattern of coronary capillaries. Physica A. 369:599-611, 2006
Karch R, Neumann F, Ullrich R, Neumüller J, Podesser BK, Neumann M, Schreiner W: The
spatial pattern of coronary capillaries in patients with dilated, ischemic, or inflammatory
cardiomyopathy. Cardiovasc Pathol. 14(3):135-144, 2005
Nadler BA, Karch R, Neumann M, Neumann F, Aharinejad S, Schreiner W: Error estimation of
geometrical data obtained by histomorphometry of oblique vessel sections: a computer model
study. Comput.Biol.Med. 35:829-844, 2005
Karch R, Neumann F, Podesser BK, Neumann M, Szawlowski P, Schreiner W: Fractal
properties of perfusion heterogeneity in optimized arterial trees: A model study. J.Gen.Physiol.
122:307-321, 2003.
Karch R, Neumann F, Neumann M, Szawlowski P, Schreiner W: Voronoi polyhedra analysis of
optimized arterial tree models. Ann.Biomed.Eng. 31:548-563, 2003.
Schreiner W, Karch R, Neumann M, Neumann F, Roedler SM, Heinze G: Heterogeneous
perfusion is a consequence of uniform Shear stress in optimized arterial tree models.
J.Theor.Biol. 220:285-301, 2003.
- 94 -
Curriculum Vitae
Univ.-Prof. Dipl.-Ing. Dr. Hannes Stockinger
Department of Molecular Immunology, Center f or Phy s i ol ogy , Pat h op hys io lo gy a n d
Im m u n ol ogy, Medical University of Vienna, A-1090 Vienna, Lazarettgasse 19, Austria
Tel.: +43-1-40160 33001; Fax: +43-1-40160 933001; E-mail:
[email protected]; Internet: http://www.meduniwien.ac.at/immunology
Personal Data
Date of Birth:
May 8, 1955
Place of Birth:
Ried i. I., Upper-Austria
Nationality
Austrian
Education
1985
Ph.D. (Dr. rer. nat. tech.) University of Natural Resources and Applied Life
Sciences Vienna, Austria
1982-1985
Postgraduate training and Ph.D. thesis at the Institute of Immunology,
University of Vienna, and the Institute of Applied Microbiology, University of
Natural Resources and Applied Life Sciences Vienna, Austria
1982
Biotechnology diploma University of Natural Resources and Applied Life
Sciences Vienna, Austria
1975-1982f
University of Natural Resources and Applied Life Sciences Vienna, Field of
study: Biotechnology
Career History
2004-present
Chairman of the Department of Molecular Immunology, Medical University
of Vienna, Austria
2004-present
Appointment as Full University Professor for Molecular Immunology,
Medical University of Vienna, Austria
2004-present
Director of the Doctoral Programs of the Medical University Vienna
2002-present
CEO Competence Center for Biomolecular Therapeutics Research Vienna
1997-2004
Ao. University Professor, University of Vienna, Austria
1991-1997
Associate Professor, University of Vienna, Austria
1991
Appointment as university lecturer (Univ.-Doz.), University of Vienna,
Austria
1989-2004
Head of independent research unit, Inst. Immunology, Univ. Vienna, Austria
1989-1991
Assistant Professor, University of Vienna, Austria
1987
Visitor scientist. Laboratory Dr. Sanna Goyert, New York University,
Hospital for Joint Diseases, New York, USA;
- 95 -
1985-1989
Research Associate, Inst. Immunology, Univ. Vienna, Austria
2007-present
Treasurer of the Federation of Austrian Scientific Societies (VWGÖ)
2006-present
Treasurer of the European Federation of Immunological Societies (EFIS)
2005-present
Board member of the Austrian Science Fund
2004-present
Member of the International Human Cell Differentiation Molecules Council
2004-2006
Past-president of the Austrian Society for Allergology and Immunology
2003-present
Executive editor of Immunology Letters
2002-2004
President of the Austrian Society for Allergology and Immunology
2000-2002
President-elect of the Austrian Society for Allergology and Immunology
2000-2006
Advisory Board member of Signal Transduction – Receptors, Mediators,
Genes.
2000-2004
Member of the International Advisory Board of Russian Journal of
Immunology
1999-2004
Deputy-chairman of the Institute of Immunology, University of Vienna
1997-present
Member of the Editorial Board of International Archives of Allergy and
Immunology
1997-2002
Member of the Managing Board of the European Confederation of
Laboratory Medicine
1995-present
Member of the Clinical Immunology Group of the European Federation of
Immunological Societies (EFIS-CIG)
1996-1997
Council member of the Austrian Society for Allergology and Immunology
1994-2004
Deputy speaker of the program project grant Microvascular Injury and
Repair
1994-1996
Secretary General of the Austrian Society for Allergology and Immunology
1992-1994
Vice Secretary of the Austrian Society for Allergology and Immunology
1986-1988
Treasurer of the Collegium Immunologicum Vindobonense
Awards
2007
UPPER-AUSTRIAN CULTURE PRIZE FOR SCIENCE
1991
KARL LANDSTEINER-PRIZE of the Austrian Society for Allergology and
Immunology
1990
CLEMENS VON PIRQUET-PRIZE of the Austrian Society for Allergology
and Immunology
1988
WILHELM-TÜRK-PRIZE of the Austrian Society for Hematology and
Oncology
1987
INTERNATIONAL CANCER RESEARCH TECHNOLOGY TRANSFER
Award supported by the National Cancer Institute of the USA and
International Union Against Cancer members
1987
HOECHST-Foundation Prize
- 96 -
1986
WOLFGANG-DENK-PRIZE of the Austrian Society for Hematology and
Oncology
1985
UPPER-AUSTRIAN AWARD for Young Scientists
1985
THESIS-PRIZE of the Austrian Society for Allergology and Immunology
Memberships
American Association of Immunologists
German Society for Immunology
Austrian Biochemical Society
American Society for Biochemistry and Molecular Biology
Austrian Society for Hematology and Oncology
Austrian Society for Biotechnology
Austrian Society for Food- and Biotechnologists
International Union Against Cancer
Period
Organization
Short Title
FWF
Receptor microdomains of cells of the
microvascular unit and their role in signal
transduction and cell function
486,326.61
2000-2005
BMT
Identification of novel pathways for immuneintervention by characterization and molecular
cloning of genes encoding immunoregulatory
proteins of accessory cells and T-cells“
700,000.00
2001-2004
Austrian
Student
Exchange
Service
North South Dialog Program
FWF
Defined stimulation of T cells by combined
force and optical single molecule microscopy:
The design and development of the cellular
part“
2002-2006
GEN-AU
Ultra-sensitive Proteomics and Genomics:
Development of protein microarray chips for
investigation of T cell regulation and diagnosis
of T cell-mediated immunological diseases and
disorders
2004-2007
Austrian
Student
Exchange
Service,
Pakistan
Higher
Education
Commission
North South Dialog Program
2000-2004
2001-2004
K€/year
40,320.00
218,190.74
539,431.00
40,320.00
- 97 -
2005-2006
BMT
Characterization and generation of killer T cells
for treatment of malignant diseases
266,714.00
2006-2009
GEN-AU
Ultrasensitive Proteomics and Genomics II
311,412.00
2006-2009
FWF, MUV
Doctoral program Cell Communication in
Health and Disease
293,853.50
2006-2007
Austrian and
Slovak
Republic
Slovak –Austrian Science and Technology Cooperation
3,500.00
Period
Name of student
Topic
1999-2003
Andreas SZEKERES
Identification of monoclonal antibody recognized
immuno-modulatory leukocyte surface molecules by
retroviral expression cloning
2001-2005
Birgit RICHTER
The role of the CD147 molecule in negative
regulation of T cells
2001-2005
Panida KHUNKAEWLA
Identification and characterization of functional
partners of the CD147 molecule
2002-2007
Elke FUERTBAUER
Identification and characterization of differentaition
factors for natural regulatory T cells
2002-2006
Wolfgang PASTER
Genetically encoded conformation-sensitive
fluorescence reporters of the Src-family kinase Lck
2002-2006
Christa HOLZHAUSER
T cell membrane compartmentalization: Molecular
analysis of the T cell receptor signaling
2004-2007
Arshad MUHAMMAD
Role of CD2 and CD48 in recruitment of signaling
molecules to the TCR/CD3 complex in T cells
Herbert SCHILLER
Characterization of plasma membrane reorganization
and transmembrane signaling underlying migration of
immune cells
2006-
Barbara GRAUWALD,
Spatio-temporal analysis of early signaling events of
T cell activation by live-FRET and single molecule
analysis
2007-
Pavan KUMAR
Influence of adhesion receptors to the T cell antigen
receptor signaling pathway
2008-
Paul ECKERSTORFER
Role of homodimers and -multimers of signaling
molecules for function and signal transduction
2004-
Publications
80 original publications in scientific journals, 47 book chapters, 37 invited lectures 2003-2008,
4 patents
- 98 -
1.
Staffler, G., A. Szekeres, G.J. Schütz, M.D. Säemann, E. Prager, M. Zeyda, K. Drbal,
G.J. Zlabinger, T. Stulnig, and H. Stockinger. 2003. Selective inhibition of T cell
activation via CD147 through novel modulation of lipid rafts. J. Immunol. 171:1707. Impact
Factor: 6,834
2.
Leksa, V., S. Godar, H. B. Schiller, E. Fuertbauer, A. Muhammad, K. Slezakova, V.
Horejsi, P. Steinlein, U. H. Weidle, B. R. Binder, and H. Stockinger. 2005. TGF-beta
induced apoptosis in endothelial cells mediated by M6P/IGFII-R and mini-plasminogen. J.
Cell Sci. 11:4577. Impact Factor: 6.910
3.
Drbal, K., M. Moertelmaier, C. Holzhauser, A. Muhammad, E. Fürtbauer, S. Howorka,
M. Hinterberger, H. Stockinger*, and G. J. Schütz. 2007. Single molecule microscopy
reveals heterogeneous dynamics of lipid raft components upon T cell receptor
engagement. Int. Immunol. 9: 675. *Corresponding author. Impact Factor: 3,317
4.
Khunkaewla, P., H. Schiller, V. Leksa, L. Andera, V. Horejsi, and H. Stockinger. 2008.
LFA-1-mediated leukocyte adhesion regulated by interaction of CD43 with LFA-1 and
CD147. Mol. Immunol: 45: 1703. Impact Factor: 4,768
1. Säemann, M. D., M. Zeyda, C. Diakos, A. Szekeres, G. A. Böhmig, P. Kelemen, O.
Parolini, H. Stockinger and G.J. Zlabinger. 2003. Suppression of early T-cell receptortriggered cellular activation by the Janus kinase 3 inhibitor WHI-P-154. Transplantation
75:1864. Impact Factor: 4,035
2. Schütz,
G.,
M.
Mörtelmaier,
K.
Drbal,
and
H.
Stockinger.
Einzelmolekülmikroskopie an lebenden Zellen. Bio-TecReport 27:6.
2003.
3. Selenko-Gebauer, N., O. Majdic, A. Szekeres, G. Höfler, E. Guthann, U. Korthäuer,
G.J. Zlabinger, P. Steinberger, W. F. Pickl, H. Stockinger, W. Knapp, and J. Stöckl.
2003. B7-h1 (programmed death-1 ligand) on dendritic cells is involved in the induction
and maintenance of T-cell anergy. J Immunol. 170:3637. Impact Factor: 6,834
4. Zeyda, M., A. Szekeres, M. D. Saemann, R. Geyeregger, H. Stockinger, G. J.
Zlabinger, W. Waldhäusl, and T. M. Stulnig. 2003. Suppression of T cell signaling by
polyunsaturated fatty acids: Selectivity in inhibition of mitogen-activated protein kinase and
nuclear factor activation. J .Immunol. 170:6033. Impact Factor: 6,834
5. Prager, G. W., J. M. Breuss, S. Steurer, D. Olcaydu, J. Mihaly, P. M. Brunner, H.
Stockinger, and B. R. Binder. 2004. Vascular endothelial growth factor receptor-2induced initial endothelial cell migration depends on the presence of the urokinase
receptor. Circ. Res. 94:1562. Impact Factor: 8,65
6. Moertelmaier, M., M. Brameshuber, M. Linimeier, H. Stockinger, and G. J. Schütz.
2005. TOCCSL: Thinning Out Clusters while Conserving Stoichiometry of Labeling. Appl.
Phys. Lett. 87: 263903/1-263903/3. Selected for: Virtual Journal of Biological Physics
Research. 11: Jan 1, 2006. Impact Factor: 4,308
7. Chiampanichayakul, S., P. Peng-In, P. Khunkaewla, H. Stockinger, and W. Kasinrerk.
2006. CD147 contains different bioactive epitopes involving the regulation of cell adhesion
and lymphocyte activation. Immunobiology 211:167. Impact Factor: 2,274
8. Madl, J., S. Rhode, H. Stangl, H. Stockinger, P. Hinterdorfer, G. J. Schütz, and G.
Kada. 2006. A combined optical and atomic force microscope for live cell investigations.
Ultramicroscopy 106:645. Impact Factor: 2,215
9. Kirchberger, S., H. Vetr, O. Majdic, H. Stockinger, and J. Stöckl. 2006. Engagement of
ICAM-1 by major group rhinoviruses activates the LFA-1/ICAM-3 cell adhesion pathway in
mononuclear phagocytes. Immunobiology 211: 537. Impact Factor: 2,274
- 99 -
10. Groyer, E., A. Nicoletti, H. Ait-Oufella, J. Khallou-Laschet, A. Varthaman, A. T.
Gaston, O. Thaunat, S. V. Kaveri, R. Blatny, H. Stockinger, Z. Mallad, and G.
Caligiuri. 2007. Atheroprotective effect of CD31 receptor globulin through enrichment of
circulating regulatory T cells. J. Am. Coll. Cardiol. 50: 344. Impact Factor: 9,20
11. Wieser, S., M. Moertelmaier, E. Fürtbauer, H. Stockinger, and G. J. Schütz. 2007.
(Un)confined diffusion of CD59 in the plasma membrane determined by high-resolution
single molecule microscopy. Biophys. J. 92: 3719. Impact Factor: 4,507
12. Wieser, S., M. Cooper, H. Stockinger, and G. J. Schütz. 2007. Single molecule diffusion
analysis on cellular nanotubules – implications on plasma membrane structure below the
diffraction-limit. Appl. Phys. Lett.: 91:233901/1-3. Impact Factor: 3,977
13. Zola, H., B. Swart, A. Banham, S. Barry, A. Beare, A. Bensussan, B. L, C. D. Buckley,
H. J. Bühring, G. Clark, P. Engel, D. Fox, B. Q. Jin, P. J. Macardle, F. Malavasi, D.
Mason, H. Stockinger, and X. Yang. 2007. CD molecules 2006 — Human cell
differentiation molecules. J.Immunol. Meth. 319:1. Impact Factor: 2,572
14. Beare, A., H. Stockinger, H. Zola, and J. Nicholson. 2007. The CD system of leukocyte
surface molecules. Monoclonal antibodies to human cell-surface antigens. In Current
Protocols in Immunol. J. E. Coligan, B. Bierer, D. H. Margulies, E. M. Shevach, W. Strober,
and R. Coico, eds. Wiley-Interscience, New York. In press.
15. Paar, C., W. Paster, H. Stockinger, G.J. Schütz, M. Sonnleitner, and A. Sonnleitner.
2008. Live Cell High Throughput FRET Screening of the Plasma Membrane Based on
TIRFM. Cytometry Part A. In press. Impact Factor: 3.293
Invited Talks:
2003
5th Congress of the Federation of African Immunological Societies, Victoria
Falls, Zimbabwe
2003
15th European Immunology Congress of the European Federation of
Immunological Societies, Rhodes, Greece
2003
4th European Biophysics Congress, Alicante, Spain
2003
12th Symposium on Signals and Signal Processing in the Immune System,
Sopron, Hungary
2003
1st GEN-AU Summer School Ultrasensitive Proteomics and Genomics,
Litschau, Austria
2004
21. Ernährungskongress des Verbandes der Dipl. DiätassistentInnen &
Ernährungsmed. BeraterInnen Österreichs, Vienna, Austria
2004
Faculté de Médecine Necker-Enfants Malades, Paris, France
2004
Minisymposium Advances in Immunology, Academy of Sciences of the Czech
Republic, Prague, Czech Republic
2004
Medizinische Hochschule Hannover, Hannover, Germany
2004
Wörthersee-Symposium “What´s New in Allergy, Velden am Wörthersee,
Austria
2004
6th EFIS Tatra Immunology Conference, Tatranske Zruby, Slovakia
2004
2nd Slovenian Immunology Congress with International Participation - Tumor
Immunology and Immunointerventions. Portoroz, Slovenia
2004
8th International Conference on Human Leukocyte Differentiation Antigens,
Adelaide, Australia
- 100 -
2005
Institute of Molecular Biology, Slovak Academy of Sciences, Bratislava, Slovak
Republic
2005
11th Immunology Seminar, Eötvös Lorand University, Budapest, Hungary
2005
2nd GEN-AU Summer School Ultrasensitive Proteomics and Genomics,
Litschau, Austria
2005
13th Symposium on Signals and Signal Processing in the Immune System,
Balatonöszöd, Hungary
2006
XXIII International Congress of the International Society of Analytical Cytology
(ISAC), Quebec, Canada
2006
4th GEN-AU Summer School Ultrasensitive Proteomics and Genomics,
Litschau, Austria
2006
1st Joint Meeting of European National Societies of Immunology and 16th
European Congress of Immunology, Paris, France
2006
Workshop Clinical Proteomics of the Max Planck Institute of Biochemistry,
Martinsried/Munich, Deutsche Vereinte Gesellschaft für Klinische Chemie und
Laboratorioumsmedizin (DGKL), Deutsche Gesellschaft für Proteomforschung
(DGPF) and Deutsche Gesellschaft für Zytometrie (DGfZ), Munich, Germany
2006
University of Salzburg and Austrian Society for Genetic and Gentechnic,
Salzburg, Austria
2006
PhD Program of the Center for Molecular Medicine of the Austrian Academy of
Sciences, Vienna, Austria
2006
Institute for Molecular and Cell Biology, Porto, Portugal
2006
1st Mediterranean Workshop on Clinical Immunology, Evora, Portugal
2006
XXIIIrd Congress of Czech and Slovak Allergologists and Clinical
Immunologists, and XIth Congress of Czech and Slovak Immunologists, Hradec
Kralove, Czech Republic
2007
Internationales Pädiatrisches Symposium, Obergurgl, Austria
2007
Institute of Molecular Genetics, Academy of Sciences of the Czech Republic,
Prague, Czech Republic
2007
EFIS-EJI Course on Autoimmunity, Tartu, Estonia
2007
Deutsch-Österreichischer AIDS Kongress, Frankfurt, Germany
2007
Otto-von-Guericke-University, Magdeburg, Germany
2007
13th International Congress of Immunology, Rio de Janeiro, Brazil
2007
ORPHEUS 2007, European PhD Programmes in Clinical Medicine, Helsinki,
Finland
2007
14th Symposium on Signals and Signaling Processing in the Immune System,
Balatonöszöd, Hungary
2007
Centre de Recherche des Cordeliers, University Pierre et Marie Curie Paris 6,
Paris, France
2007
Division of Molecular and Experimental Surgery, Department of Surgery,
University of Erlangen, Erlangen, Germany
2008
From Molecules to Clinic, Medical University of Vienna, Vienna, Austria
- 101 -
Curriculum Vitae
Herbert Strobl
Divison: Molecular Biology of Hematopoietic Stem Cells and Dendritic Cells. Institute of
Immunology, Center for Physiology, Pathophysiology and Immunology, Medical University of
Vienna, Lazarettgasse 19, 1090 Wien, Austria; Phone: +43-1-40160-65001, Fax: +43-140160-965006;
Homepage: www.meduniwien.ac.at/immunologie
Personal Data
Date of Birth:
15.11.1964
Place of Birth:
Vienna
Nationality
Austria
Education
2001
MD degree: Facharzt für Immunology
1998 2001
Post-doctoral fellow with Garry P. Nolan, Stanford
University, Department of Molecular Pharmacology
1996-1998
Clinical training, Vienna General Hospital and Lainz
Hospital (Turnusarzt)
1994-1996
Laboratory head, hematopoiesis research laboratory,
Institute of Immunology VIRCC at Novartis Research
Institute Vienna
1991-1996
Training in immunology laboratory diagnosis and research
fellow, Institute of Immunology, University of Vienna
1991
MD University of Vienna
1989-1991
Pre-doctoral research, superivisor: Walter Knapp, Institute
of Immunology, University Vienna
Career History
07/2004-present
Group leader and divison head, Institute of Immunology at
VCC A-1090 Vienna, Medical University Vienna
03/2001-07/2004
Group leader, Institute of Immunology at VIRCC at
Novartis Research Institute Vienna
Since 2002
Since 2008
Head Innovation and process optimazation, Clinical
immunologic laboratory diagnosis at Institute of
- 102 -
Immunology, Medical University Vienna
2006
Listenplatz Professur „Pathophysiologie“ Medical
University Vienna
2006-present
Lecturer at FH Biotechnology, Vienna Biocenter
2006 - present
Deputy director„ PhD program “Inflamation and Imunity“ at
Medical University Vienna.
2004-present
Member of EGIL, European group of immunologic
leukemia diagnosis
2001-present
Clinical consultant in immunologic laboratory diagnosis,
Institute of Immunology, Medical University Vienna
Awards
2000
Memberships
Austrian Society for Allergology and Immunology, European Society of Hematology
Period
Organization
2007 - 2010 FWF
Short Title
K€/year
Transcriptional Networks in human dendritic
117
cell subset differentiation
2007 - 2010 FWF + MUW
DK W1212: Inflammation and Immunity,
44
Subproject
2005 - 2009 FWF
110
Subproject 4
Austria
Austria
Signal integration by epithelial Langerhans
23
cells
Identification of signaling processes that
23
downregulate antigen-specific immune
responses
2001 - 2007 FWF and BM:WF
START
Functional genomic analysis of human
200
dendritic cell development
Period
Name of student
2001 - 2005 Barbara Platzer
Topic
Molecular analysis of human dendritic cell
development
2001 - 2006 Sabine Taschner
Functional analysis of nuclear receptor signaling
- 103 -
in myeloid development
2001 - 2006 Almut Jörgl
Molecular analysis of human dendritic cell
maturation
2003 - 2007 Florian Göbel
Molecular analysis of the differentiation and life
cycle of dendritic cells
2005-2006
Peter Reisner
2005-
Susanne Richter
The role of AhR in Langerhans cell differentiation
Jennifer Jurkin
Identification of regulators of Langerhans cell
present
2006present
2007-
differentiation
Thomas Bauer
The role of RelB in dendritic cells
Yasmin Nighat
Induction of epithelial genes in Langerhans cells
present
Since 2008
Publications
44 peer reviewed publications in scientific journals, 4 book chapters, 6 review articles, 1
patent
A. Original research articles:
Scholz W, Platzer B, Schumich A, Höcher B, Fritsch G, Knapp W, Strobl H. Initial human
myeloid/dendritic cell progenitors identified by absence of myeloperoxidase protein
expression. Exp Hematol. 2004 Mar;32(3):270-6.
Platzer B, Jörgl A, Taschner S, Höcher B, Strobl H. (2004) RelB regulates human dendritic
cellsubset development by promoting monocyte intermediates. Blood, 104(12):3655-63
Heinz LX, Platzer B, Reisner P, Jörgl A, Taschner S, Göbel F and Strobl H. Differential
involvement of PU.1 and Id2 downstream of TGF-b1 during Langerhans cell commitment.
Blood, 2006 Feb 15;107(4):1445-53.
Jörgl, A., B. Platzer, S. Taschner, L. X. Heinz, B. Höcher, P. M. Reisner, F. Göbel, and H.
Strobl. Human Langerhans cell activation triggered in vitro by conditionally expressed MKK6
is counter regulated by the downstream effector RelB. Blood 2007; 1;109(1):185-93,
Taschner S, Koesters C, Platzer B, Jorgl A, Ellmeier W, Benesch, T, Strobl H.
Downregulation of RXRa expression is essential for neutrophil development from
granulocyte/monocyte progenitors. Blood, 2007 109: 971-979
Platzer B, Richter S, Waltenberger D, Wisetschläger M, Strobl H. Aryl hydrocarbon receptor
(AhR) activation perturbs myeloid sublineage differentiation by inhibiting PU.1 upregulation,
- 104 -
submitted
Taschner S, Göbel F, Kumerz M, Jurkin J, Richter S, Mühlbacher C, Jörgl A, Strobl H.
Interplay between the nuclear receptors VDR, RXRα and the master regulators PU.1, GATA1/GATA-1s in normal and leukemic hematopoiesis, submitted
Göbel F, Taschner S, Jurkin J, Vaculik C, Richter S, Bieglmayer C, Elbe-Bürger A, Strobl H.
GATA-1-mediated repression of vitamin D3 receptor is decisive for inflammatory dendritic
cell development, but not for Langerhans cells, submitted
B. Review articles
Strobl H. Molecular mechanisms in dendritic cell sub-lineage development from human
hematopoietic progenitor/stem cells. Int. Archives of Allergy and Immunology. 2003; 131(2):
73-79 (review article)
Strobl, H. and W.Knapp. Myeloid cell-associated lysosomal proteins as flow cytometry
markers for leukocyte lineage classification. Review J. Biol. Regul. Homeost. Agents 18:3359 (2004) (review article)
Strobl, H., B.Platzer, A.Jörgl, S.Taschner, L.Heinz, and P.Reisner. Growth Factors.
Handbook of Dendritic Cells – Biology, Diseases and Therapies. Steinkasserer, Lutz (Eds).
WILEY-VCH, Vol 1, page 27-52 (2006) (book chapter)
Hertel L, Lacaille VG, Strobl H, Mellins ED, Mocarski ES. Susceptibility of Immature and
Mature Langerhans Cell-type Dendritic Cells to Infection and Immunomodulation by Human
Cytomegalovirus. J Virol. 2003;77(13): 7563-74
Mann G, Attarbaschi A, Steiner M, Simonitsch I, Strobl H, Urban C, Meister B, Haas O,
Dworzak M, Gadner H; Austrian Berlin-Frankfurt-Munster (BFM) Group.Early and reliable
diagnosis of non-Hodgkin lymphoma in childhood and adolescence: contribution of
cytomorphology and flow cytometric immunophenotyping. Pediatr Hematol Oncol. 2006 AprMay;23(3):167-76.
Strehl, S.,. K.Nebral, M.König, J.Harbott, H.Strobl, R.Ratei, S.Struski, B.Bielorai, M.Lessard,
M.Zimmermann, O.A.Haas, S.Izraeli ETV6-NCOA2: a novel fusion gene in acute leukemia
associated with coexpression of T-lymphoid and myeloid markers and frequent NOTCH1
mutations. Clinical Cancer Research 14:977-983 (2008)
Selected Invited Talks 2002-2008
2004
• Invited talk at session Stem cell biology ; DgfZ meeting Heidelberg
• Invitation to talk at the 12th International Congress of Immunology, Montreal,
2005
• Invited talk at Langerhans cell workshop, Madeira
2006
• Invited seminar talk at ENII 2006 meeting Carbo Caccio, Italy
• Invited talk at the stem cell workshop, EHA 2006 meeting Amsterdam
- 105 -
2007
• Invited Talk at Institute of Microbiology and Immunology, Technical University Munich
• Invited talk at EHA 2007 meeting Vienna
- 106 -
Curriculum Vitae
Julia Walochnik
Department of Medical Parasitology, Clinical Institute of Hygiene and Medical Microbiology
Medical University of Vienna, Kinderspitalgasse 15, 1095 Wien, Austria;
Phone: +43-1-40490-79446, Fax: +43-1-40490-79435
e-mail: [email protected]
Homepage: www.meduniwien.ac.at/hygiene/?s=parasitologie
Personal Data
Date of Birth:
12.12.1973
Place of Birth:
Berlin
Nationality
Germany
Education
1997-2000
PhD studies (Medical Parasitology, Microbiology, Electron
Microscopy), University of Vienna, with distinction
2000
Training
course
endocytobiosis
at
on
free-living
amoebae
the
Ernst-Rodenwaldt-Institute
and
in
Koblenz
1996-1997
Diploma thesis, University of Vienna
1991-1997
Studies in Biology (Zoology, Microbiology), University of
Vienna
1982-1983
American school of Algiers/ Algeria
Career History
2004
Habilitation in Medical Parasitology, Medical University of
Vienna
since 2001
Full-time scientific collaborator at the Department of
Medical Parasitology
since 2000
Group Leader, Molecular Parasitology, University of
Vienna
since 1998
Supervision of students (MS and PhD) in the field of
molecular biology and immunobiology of parasites
1997-2001
Parttime Scientific collaborator at the Department of
Medical Parasitology, University of Vienna
Since 2006
Collaboration as teacher in a training course for “Médecins
Sans Frontières”
- 107 -
Since 2005
Chief editor of the Austrian Society for Tropical Medicine
and Parasitology
Editor of the Supplement of the Wiener Klinische
Wochenschrift for the Austrian Society for Tropical
Medicine and Parasitology
Election into the board of the Austrian Society for Tropical
Medicine and Parasitology
Since 2003
2003
Awards
2002
2002
Austrian Award of Hygiene
Gerhard Piekarski Award
Memberships
Member of the
Member of the
Member of the
Member of the
Member of the
Member of the
Austrian Proteomics Association
Society for Biological Systematics
Austrian Society for Hygiene and Prevention Medicine
German Society for Protozoology
German Society for Parasitology
Austrian Society for Tropical Medicine and Parasitology
Period
Organization
Short Title
2008-2011
FWF
Glycosilation in Acanthamoeba (FWF20565);
K€/year
collaborator
2007-2010
FFG
Bioactive substances against protozoa and
fungi (FFG814280/13094); collaborator
2007-2010
FWF
En- and excystation in Acanthamoeba
castellanii (FWF19044); project leader
2005-2006
EU
Detection of pathogens in thermal waters
(EU-PHARE); collaborator
2004-2007
EU
Tick-borne pathogens and Borrelia vaccine
development (EU-BOVAC); collaborator
Period
Name of student
Topic
2007-2010
Florian Astelbauer
Bioactive substances against protozoa and fungi
2007-2010
Wilawan Pumidonming
Identification of pathogenicity related proteins in
Acanthamoeba spp.
2004-2008
Ursula Fürnkranz
Effectivity of N-chlorotaurine against protozoa
2004 -2008
Marion Blaschitz
Molecular detection of pathogens in ticks from
Austria
2003-2007
Martina Köhsler
Discrimination, encystment behaviour,
pathogenicity and drug susceptibility of
- 108 -
Acanthamoeba
Publications
49 peer reviewed publications in scientific journals, 20 book chapters, >20 invited lectures
Walochnik J, Duchene M, Seifert K, Eibl HJ, Obwaller A, Aspöck H. 2002. Cytotoxic Activities
of Various Alkylphosphocholines (APCs) against Clinical Isolates of Acanthamoeba.
Antimicrob Agents Chemother 46:695-701.
Walochnik J, Michel R, Aspöck H. 2002. Discrepancy between morphological and
molecularbiological characters in a strain of Hartmannella vermiformis Page, 1967 (Lobosea,
Gymnamoebia). Protistology 2 (3):185-188.
Walochnik J, Sommer K, Haller-Schober EM, Obwaller A, Aspöck H. 2004. Characterisation
and differentiation of pathogenic and non-pathogenic Acanthamoeba strains by their protein
and antigen profiles. Parasitol Res 92(4):289-98.
Walochnik J, Michel R, Aspöck H. 2004. A molecularbiological approach to the phylogenetic
position of the genus Hyperamoeba (Protozoa). J Euk Microbiol 51:433-440.
Walochnik J, Müller KD, Aspöck H, Michel R. 2005. An endocytobiont harbouring Naegleria
strain identified as N. clarki De Jonckheere, 1994. Acta Protozoologica 44:301-310.
Köhsler M, Leitner B, Blaschitz M, Michel R, Aspöck H, Walochnik J. 2006. ITS1 sequence
variabilities correlate with 18S rDNA sequence types in the genus Acanthamoeba. Parasitol
Res 98(2):86-93.
Blaha C, Duchene M, Aspöck H, Walochnik J. 2006. Comparative studies on the effect of
hexadecylphosphocholine on different strains of Trichomonas vaginalis. J Antimicrob
Chemother 57(2):273-8.
Blaschitz M, Kohsler M, Aspock H, Walochnik J. 2006. Detection of a serine proteinase gene
in Acanthamoeba genotype T6 (Amoebozoa: Lobosea). Exp Parasitol. 114(1):26-33.
Ertabaklar H, Türk M, Dayanir V, Ertuğ S, Walochnik J. 2007. Acanthamoeba keratitis due to
Acanthamoeba genotype T4 in a non-contact lens wearer in Turkey. Parasitol Res
100(2):241-6.
Köhsler M, Michel R, Lugauer, Aspöck, Walochnik J. 2007. Molecular identification and
classification of Cochlonema euryblastum, a zoopagalean parasite of Thecamoeba
quadrilineata. Mycologia 99: 215-221.
Köhsler M, Soleiman A, Auer H, Aspöck H, Walochnik J. 2007. First molecular identification
of Onchocerca jakutensis as a causative agent of a human filariosis. Emerg Inf Dis. 13:
1749-1752.
Walochnik J, Aichelburg A, Assadian O, Steuer A, Visvesvara G, Vetter N, Aspöck H. 2008.
Acanthamoeba genotype T2 as causative agent of GAE in an HIV negative patient. J Clin
Microbiol 46:338-340.
Fürnkranz U, Nagl M, Gottardi W, Köhsler M, Aspöck H, Walochnik J. 2008. Cytotoxic activity
- 109 -
of N-chlorotaurine (NCT) on Acanthamoeba spp. Antimicrobial Agents Chemother 52:470476.
Ozkoc S, Tuncay S, Bayram Delıbas S, Akisu C, Ozbek Z, Durak I, Walochnik J.
Identification of Acanthamoeba genotype T4 and Paravahlkampfia sp. from two clinical
isolates. J Med Microbiol (in press).
Blaschitz M, Gföller M, Kanzler M, Walochnik J, Stanek G. Borrelia burgdorferi sensu lato
genospecies in questing Ixodes ricinus ticks in Austria. Int J Med Microbiol 297 (Supp 1) (in
press).
Blaschitz M, Gföller M, Kanzler M, Walochnik J, Stanek G. First detection of Rickettsia
helvetica in Austria. Vector-Borne Zoonot (in press).
Müller MG, Kinne J, Schuster RK, Walochnik J. Outbreak of Microsporidiosis caused by
Enterocytozoon bieneusi in falcons. Vet Parasitol (in press).
Köhsler M, Leitsch D, Fürnkranz U, Duchêne M, Aspöck H, Walochnik J. 2008.
Acanthamoeba strains lose their abilities to encyst synchronously upon prolonged axenic
culture. Parasitol Res. (in press).
Hiti K, Walochnik J, Haller-Schober E M, Faschinger C, Aspöck H. 2002. Viability of
Acanthamoeba after exposure to a multipurpose disinfecting contact lens solution and two
hydrogen peroxide systems. Brit J Ophthalmol 86:144-146.
Hiti K, Walochnik J, Faschinger C, Haller-Schober EM, Hiti B, Aspöck H. 2003. Wirkung von
Mikrowellenbestrahlung
auf
Akanthamöben:
eine
geeignete
Möglichkeit
zur
Kontaktlinsenbehältersterilisation? Spektrum Augenheilkd 17 (3).
Michel R, Walochnik J, Aspöck H. 2003. "Pseudodidymium cryptomastigophorum nov. g.,
nov. sp.", a Hyperamoeba or a slime mould?" A combined study on morphology and 18S
rDNA sequence data. Acta Protozool 42 (4): 331-343.
Tsvetkova N, Schild M, Panaiotov S, Kurdova-Mintcheva R, Gottstein B, Walochnik J,
Aspöck H, Lucas M, Müller N. 2004. Isolation and taxonomic identification of free-living
amoebae in the environment of in Bulgaria. Parasitol Res 92(5):405-13.
Obwaller A, Schneider R, Walochnik J, Gollackner, Deutz, Janitschke, Aspöck H, Auer H.
2004. Sequence heterogeneities among cytochrome c oxidase-1 and NADH-dehydrogenase1 genes of Echinococcus granulosus isolates and their significance on strain differentiation.
Parasitology 128:569-575.
Collingro A, Walochnik J, Michel R, Horn M, Wagner M, Obwaller A, Aspöck H. 2004.
Chlamydia-related endocytobionts of free-living amoebae alter the growth rate of their hosts.
Eur Journal Protistol 40:57-60.
Strimitzer S, Obwaller A, Schmoll F, Joachim A, Walochnik J, Juncker M. 2004. Entwicklung
und Evaluierung einer Polymerasekettenreaktion (PCR) zum Nachweis von Eperythrozoon
(syn. Mycoplasma) suis. Wien Tierarztl Monat 91:120-126.
Fürnkranz U, Walochnik J, Grimm F, Deplazes P, Aspöck H. 2004. Vergleichende Versuche
zur Etablierung und Optimierung einer Leishmanien-PCR für diagnostische Zwecke. Wien
Klin Wochenschr. 116 (Suppl 4): 30-35.
- 110 -
Obwaller A, Duchene M, Walochnik J, Wiedermann G, Auer H, Aspöck H. 2004. Association
of autoantibodies against small nuclear ribonucleoproteins (snRNPs) with symptomatic
Toxocara canis infestation. Parasite Immunol 26(8-9):327-33.
De Jonckheeere JF, Brown S, Walochnik J, Aspöck H, Michel R. 2005. Morphological
investigation of three Tetramitus spp. which are phylogenetically very closely related: T.
horticolus, T. russelli n. comb. and T. pararusselli n. sp. Europ J Protistol 41:139-150.
Michel R, Müller KD, Zöller L, Walochnik J, Hartmann M, Schmid EN. 2005. Free-living
amoebae serve as a host for the Chlamydia-like bacterium Simkania negevensis. Acta
Protozool 44:113-121.
Hiti K, Walochnik J, Faschinger C, Haller-Schober EM, Aspöck H. 2005. One and Two Step
Hydrogen Peroxide Contact Lens Disinfecting Solutions against Acanthamoeba: How
effective are they? Eye 19: 1301-1305.
Petry F, Torzewski M, Bohl J, Wilhelm-Schwenkmezger T, Scheid P, Walochnik J, Michel R,
Zöller L, Werhahn K J, Bhakdi S, Lackner K J. 2006. Early Diagnosis of Acanthamoeba in
Routine Cerebrospinal Fluid Cytology. J Clin Microbiol 44(5):1903-4.
Hiti K, Walochnik J, Haller-Schober EM, Faschinger C, Aspöck H. 2006. A new Multipurpose
Contact Lens Disinfection System in Comparison with eight other Solutions – Effectiveness
against Acanthamoeba. Cornea 25(4):423-7.
Mitteregger D, Aberle SW, Makristathis A, Walochnik J, Schwarz SM, Kramer G, Marberger
M. 2007. Screening for pathogenic microorganisms in advanced benign prostatic hyperplasia
(BPH). J Urology 177 (4): 448-449.
Murphy TM, Walochnik J, Hassl A, Moriarty J, Mooney J, Toolan D, Sanchez-Miguel C,
O'loughlin A, McAuliffe A. 2007. Study on the prevalence of Toxoplasma gondii and
Neospora caninum and molecular evidence of Encephalitozoon cuniculi and
Encephalitozoon (Septata) intestinalis infections in red foxes (Vulpes vulpes) in rural Ireland.
Vet Parasitol 146(3-4):227-34.
Meersseman W, Lagrou K, Sciot R, De Jonckheere JF, Claes K, Spriet I, Haberler C,
Walochnik J, Wollants E Peetermans WE, Van Wijngaerden E. 2007. Rapidly fatal
Acanthamoeba encephalitis and treatment of cryoglobulinemia. Emerg Inf Dis 13 (3):469471.
Lorenzo-Morales J, Kliescikova J, Gómez-Pérez D, Batista N, Álvarez-Marín J, Bahaya Y,
Walochnik J, Valladares B. 2007. Early diagnosis of amoebic keratitis due to a mixed
infection with Acanthamoeba and Hartmannella. Parasitol Res 102(1):167-9.
Wöhrl S, Schnedl J, Auer H, Walochnik J, Stingl G, Geusau A. 2008. Successful treatment of
a married couple for American leishmaniasis with miltefosine. J Eur Acad Dermatol Venereol
22(2):258-9.
Schneider R, Gollackner B, Edel B, Schmid K, Wrba F, Tucek G, Walochnik J, Auer H.
Development of a new PCR protocol for the detection of species and genotypes (strains) of
Echinococcus in formalin-fixed, paraffin-embedded tissues. Int J Parasitol (in press).
Haider S, Collingro A, Walochnik J, Wagner M, Horn M. 2008. Chlamydia-like bacteria in
respiratory samples of community-acquired pneumonia patients. FEMS Letters. (in press)
- 111 -
2002
• Institute of Parasitology, VetUniversity of Zurich, Switzerland
• University Hospital of Zurich, Switzerland
• Museum for Natural History, Linz, Austria
2003
• Museum for Natural History, Vienna, Austria
2004
• ÖGTP-advanced training, AKH, Vienna, Austria
• Giftiger Dienstag, AKH, Vienna, Austria
• Department of Microbial Ecology, University of Vienna, Austria
2005
• Institute of Parasitology, University of Bern, Switzerland
• University of Budapest, Hungary
2006
• Institute of Parasitology, VetUniversity of Zurich, Switzerland
• Meeting of the Austrian Society for Biotopes, Wels, Austria
• Billrothhaus, Vienna, Austria
2007
• Robert-Koch-Institute Berlin, Germany
• Meeting of the German Society of Biological Systematics, Vienna, Austria
• Giftiger Dienstag, Ärztekammer Vienna, Austria
• St. Anna Kinderspital Vienna, Austria
• Meeting of the German Society for Entomology, Berlin, Germany
2008
• Billrothhaus, Vienna, Austria
- 112 -
Curriculum Vitae
Thomas Wekerle
Division of Transplantation, Department of Surgery
Vienna General Hospital, Medical University of Vienna
Waehringer Guertel 18, 1090 Wien, Austria
Phone: +43-1-40400-5621, Fax: +43-1-40400-6872;
Homepage: www.muw.ac.at/transplant-lab
Personal Data
Date of Birth:
26.12.1968
Place of Birth:
Vienna
Nationality:
Austria
Education
2003 – 2006
Residency in Immunology, Vienna General Hospital
1998 – 1999
Residency in Surgery, Department of Surgery, Vienna
General Hospital
1996 – 1998
Post-doctoral research fellow at the BMT-Section (Head:
Megan Sykes, M.D.) of the Transplantation Biology
Research Center (Director: David H. Sachs, M.D.),
Massachusetts General Hospital, Harvard Medical School,
Boston, USA
1994 – 1996
Residency in Surgery, Department of Surgery, Vienna
General Hospital
January 1994
Graduation (M.D.)
1987 – 1994
Career History
April 2006
Licensure as Specialist in Immunology, Austrian Medical
Chamber
February 2001
Appointment as Associate Professor of Experimental
Surgery at the University of Vienna (now Medical
University of Vienna)
October 1999 to date
Group leader at the Research Laboratories of the
Department of Surgery, Vienna General Hospital
- 113 -
2002 to date
Co-Editor-in-Chief of Transplant International
since 2007
Member of the Basic Science Committee of the European
Society of Organ Transplantation (ESOT)
2007
Participation in the 1st Scientific Advisory Council Meeting
of „Transplantation Research Integration in Europe”
(TRIE), a Specific Support Action supported by the 6th EURTD Framework Programme; Brussels
since 2007
Member of the Basic Science Committee of the European
Society of Organ Transplantation (ESOT)
2006
Member of the Scientific Program Committee for the 20th
Annual Meeting of the Austrian Society of Transplantation,
Fuschl, Austria
2004
Co-Organizer of the Early Morning Course on Applied
Immunology,
XX
International
Congress
of
The
Transplantation Society, Vienna, Austria
2004
Member
of
the
Program
Committee
for
the
XX
International Congress of The Transplantation Society,
Vienna, Austria
2003
Member of the Scientific Program Committee for the 23rd
Annual Meeting and Scientific Session of the International
Society for Heart and Lung Transplantation, Vienna,
Austria
2002 and 2003
Reviewer for the Awards Committee of the International
Society for Heart and Lung Transplantation
2001
Faculty-Member of the Basic Sciences Symposium of The
Transplantation Society, Bern, Switzerland
Awards and Fellowships
November 2005
Researcher of the Month: Medical University of Vienna
2002
Habilitation Award of the Association for the promotion of
science and research at the Vienna General Hospital
2000
Erste Bank Research Award: 1st place, Medical Chamber
of Vienna
2000
Austrotransplant-Award
of
the
Austrian
Society
of
Transplantation
2000
Young Investigator Award: American Society of Transplant
Surgeons and the American Society of Transplantation,
- 114 -
2000
1999
Young
Investigator
Award:
American
Society
of
Transplantation
1997 – 1998
Erwin Schrödinger Fellowship of the Austrian Science
Fund (FWF)
1996 – 1997
Research fellowship of the Max Kade Foundation
Memberships
since 2007
European Society of Organ Transplantation (ESOT)
since 2002
Austrian Society of Surgical Research
since 1999
Austrian Society of Transplantation
since 1999
The
Transplantation
Society
and
International
Xenotransplantation Association
since 1998
American Society of Transplantation
since 1996
International Society for Heart and Lung Transplantation
Publications
Original articles: 43
Review articles: 19
Book chapters: 3
Editorials: 6
Patent application: 1
A. Finished theses:
Dr.med.univ. Maximilian Schmid: "The influence of calcineurin-inhibitors on the deletion of
donor-reactive T-cells after bone marrow transplantation with costimulation blockade", 2002
(M.D. thesis)
Dr.med.univ. Franz Romeder: "Mycophenolate mofetil in renal transplantation – A
retrospective single centre analysis", 2005 (M.D. thesis)
Dr.rer.nat. Zvonimir Koporc: "Use of mobilized peripheral blood stem cells (mPBSC) for the
induction of mixed chimerism and tolerance", 2006 (Ph.D. thesis)
Mag.rer.nat. Ines Pree: "The role of IDO (indoleamine 2, 3-dioxygenase) in tolerance
induction through mixed chimerism in a murine transplantation model using bone marrow
transplantation and costimulation blockade", 2005 (diploma thesis)
Mag.rer.nat. Martina Gattringer: "Induction of tolerance through transplantation of Bet v 1transduced hematopoietic stem cells", since 2007 (diploma thesis)
B. Ongoing theses:
Mag.rer.nat. Nina Pilat: "The therapeutic use of T regulatory cells in models of mixed
- 115 -
chimerism", since 2005 (Ph.D. thesis)
Mag.rer.nat. Christoph Klaus: since 2006 (Ph.D. thesis)
Mag.rer.nat. Martina Gattringer: since 2007 (Ph.D. thesis)
Dr.med.univ. Elisabeth Schwaiger: since 2006 (Dr.sci.med. N090)
Haley Ramsey, MSc: since 2007 (Ph.D. thesis, N094, PhD program (DK) “inflammation and
immunity”)
"Tolerance through hematopoietic cell transplantation with costimulation blockade",
international research grant from the independent Roche Organ Transplantation Research
Foundation (ROTRF), Meggen, Switzerland, awarded in 2001, 130.000€ (period 2002-2004)
"Tolerance through the transplantation of mobilized peripheral blood stem cells: Identifying
the factors responsible for their lower tolerogenic potential under costimulation blockade",
research grant from the Jubilee Fund of the Austrian National Bank, awarded in 2004,
32.000€
"Research for the development of immunological tolerance strategies for the prevention and
treatment of IgE-mediated allergies", research agreement with Biomay Inc., Vienna, ongoing
since 2003, 300.000€ (period 2003-2008)
"Hematopoietic chimerism for the induction of tolerance"; project is part of the Special
Research Program SFB23 on "Mechanisms of the establishment and maintenance of
immunological tolerance" of the Austrian Science Fund (FWF), awarded in 2004, 451.000€
(period 2005-2008)
“Tolerance induction in organ transplantation and allergy”, Doctoral Program (Doktoratskolleg
– DK) “Inflammation and Immunity”; awarded in 2006, 269.000€ (period 2007-2010)
First, last or corresponding author manuscripts
Wekerle, T., Kurtz, J., Bigenzahn, S., Takeuchi, Y., and Sykes, M. Mechanisms of transplant
tolerance induction using costimulatory blockade. Curr Opin Immunol 14:592-600 (2002).
Wekerle, T., Blaha, P., Langer, F., Schmid, M., and Muehlbacher, F. Tolerance through bone
marrow transplantation with costimulation blockade. Transpl Immunol 9:125-33 (2002).
Wekerle, T., Blaha, P., Asari, R., Schmid, M., Kiss, C., Roth, E., and Mühlbacher, F.
Tolerance induction through mixed chimerism. Europ Surgery 34:131-5 (2002).
Wekerle, T., Nikolic, B., Pearson, D. A., Swenson, K. G., and Sykes, M. Minimal conditioning
required in a murine model of T cell depletion, thymic irradiation and high-dose bone marrow
transplantation for the induction of mixed chimerism and tolerance. Transpl Int 15:248-53
(2002).
- 116 -
Wekerle, T., Blaha, P., Koporc, Z., Bigenzahn, S., Pusch, M., and Muehlbacher, F.
Mechanisms of tolerance induction through the transplantation of donor hematopoietic stem
cells: central versus peripheral. Transplantation 75:21S-5S (2003).
Blaha, P., Bigenzahn, S., Koporc, Z., Schmid, M., Langer, F., Selzer, E., Bergmeister, H.,
Wrba, F., Kurtz, J., Kiss, C., Roth, E., Muehlbacher, F., Sykes, M., and Wekerle, T. The
influence of immunosuppressive drugs on tolerance induction through bone marrow
transplantation with costimulation blockade. Blood 101:2886-93 (2003).
Saemann, M., Muehlbacher, F., Zlabinger, G., and Wekerle, T. Selected commentary to:
Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor. Europ Surgery
36:205-6 (2004).
Wekerle, T. and Sykes, M. Induction of tolerance. Surgery 135:359-64 (2004).
Heitger, A., Blaha, P., Bigenzahn, S., Muehlbacher, F., and Wekerle, T. The influence of
immunosuppressive drugs on cell-induced graft tolerance. Curr Opin Organ Transplant
9:307-13 (2004).
Bigenzahn, S., Blaha, P., Koporc, Z., Pree, I., Selzer, E., Bergmeister, H., Wrba, F., Heusser,
C., Wagner, K., Muehlbacher, F., and Wekerle, T. The role of non-deletional tolerance
mechanisms in a murine model of mixed chimerism with costimulation blockade. Am J
Transplant 5:1237-47 (2005).
Blaha, P., Bigenzahn, S., Koporc, Z., Sykes, M., Muehlbacher, F., and Wekerle, T. Shortterm immunosuppression facilitates induction of mixed chimerism and tolerance after BMT
without cytoreductive conditioning. Transplantation 80:237-43 (2005).
Pree, I. and Wekerle, T. Inducing mixed chimerism and transplantation tolerance through
allogeneic bone marrow transplantation with costimulation blockade. In: Immunological
Tolerance: Methods and Protocols, P. J. Fairchild, Ed. (Humana Press, 2006)(in press).
Pree, I. and Wekerle, T. New approaches to prevent transplant rejection: Costimulation
blockers anti-CD40L and CTLA4Ig. Drug Discovery Today: Therapeutic Strategies 3:41-7
(2006).
Koporc, Z., Bigenzahn, S., Blaha, P., Fariborz, E., Selzer, E., Sykes, M., Muehlbacher, F.,
and Wekerle, T. Induction of mixed chimerism through transplantation of CD45-congenic
mobilized peripheral blood stem cells after nonmyeloablative irradiation. Biol Blood Marrow
Transplant 12:284-92 (2006).
Linhart, B., Bigenzahn, S., Hartl, A., Lupinek, C., Thalhamer, J., Valenta, R., and Wekerle, T.
Costimulation blockade inhibits allergic sensitization but does not affect established allergy in
a murine model of grass pollen allergy. J Immunol 178:3924-31 (2007).
Pree, I., Bigenzahn, S., Fuchs, D., Koporc, Z., Nierlich, P., Winkler, C., Brandacher, G.,
Sykes, M., Muehlbacher, F., Langer, F., and Wekerle, T. CTLA4Ig promotes the induction of
hematopoietic chimerism and tolerance independently of indoleamine-2,3-dioxygenase.
Transplantation 83:663-7 (2007).
- 117 -
Takeuchi, Y., Ito, H., Kurtz, J., Wekerle, T., Ho, L., and Sykes, M. Earlier low-dose TBI or
DST overcomes CD8+ T-cell-mediated alloresistance to allogeneic marrow in recipients of
anti-CD40L. Am. J Transplant 4:31-40 (2004).
Birsan, T., Loinig, C., Bodingbauer, M., Wekerle, T., Rockenschaub, S., Berlakovich, G.,
Soliman, T., Muehlbacher, F., and Steininger, R. Comparison between C0 and C2 monitoring
in de novo renal transplant recipients: Retrospective analysis of a single center experience.
Saemann, M. D., Zeyda, M., Stulnig, T., Böhmig, G. A., Wekerle, T., Hörl, W. H., and
Zlabinger, G. Janus kinase-3 (JAK3) inhibition: a new immunosuppressive modality for
allogeneic transplantation. Transpl Int 17:481-9 (2004).
Kurtz, J., Wekerle, T., and Sykes, M. Tolerance in mixed chimerism - a role for regulatory
cells? Trends Immunol 25:518-23 (2004).
Andres, A., Toso, C., Morel, P., Bosco, D., Bucher, P., Oberholzer, J., Mathe, Z., Mai, G.,
Wekerle, T., Berney, T., and Buhler, L. Macrophage depletion prolongs discordant but not
concordant islet xenograft survival. Transplantation 79:543-9 (2005).
Andres, A., Toso, C., Morel, P., Bosco, D., Bucher, P., Oberholzer, J., Mathe, Z., Mai, G.,
Wekerle, T., Berney, T., and Buhler, L. H. Phylogenetic disparity influences the
predominance of direct over indirect pathway of antigen presentation in islet
xenotransplantation. Transplant Proc 37:463-5 (2005).
Mai, G., Bucher, P., Morel, P., Mei, J., Bosco, D., Andres, A., Mathe, Z., Wekerle, T., Berney,
T., and Buhler, L. H. Role of CD40-CD154 pathway in the rejection of concordant and
discordant xenogeneic islets. Transplant Proc 37:460-2 (2005).
Mai, G., Bucher, P., Morel, P., Mei, J., Bosco, D., Andres, A., Mathe, Z., Wekerle, T., Berney,
T., and Buhler, L. H. Anti-CD154 mAb treatment but not recipient CD154 deficiency leads to
long-term survival of xenogeneic islet grafts. Am J Transplant 5:1021-31 (2005).
Bucher, P., Mai, G., Morel, P., Mathe, Z., Bosco, D., Pernin, N., Wekerle, T., Berney, T., and
Buhler, L. H. Transplantation of discordant xenogeneic islets using repeated therapy with
anti-CD154. Transplantation 79:1545-52 (2005).
Vincenti, F. , Larsen, C., Durrbach, A., Wekerle, T., Nashan, B., Blancho, G., Lang, P.,
Grinyo, J., Halloran, P. F., Solez, K., Hagerty, D., Levy, E., Zhou, W., Natarajan, K., and
Charpentier, B. for the belatacept study group. Costimulation blockade with belatacept in
renal transplantation. N Engl J Med 353:770-81 (2005).
Fehr, T., Takeuchi, Y., Kurtz, J., Wekerle, T., and Sykes, M. Early regulation of CD8 T cell
alloreactivity by CD4+CD25- T cells in recipients of anti-CD154 antibody and allogeneic BMT
is followed by rapid peripheral deletion of donor-reactive CD8+ T cells, precluding a role for
sustained regulation. Eur J Immunol 35:2679-90 (2005).
Perco, P., Blaha, P., Kainz, A., Mayer, B., Hauser, P., Wekerle, T., and Oberbauer, R.
- 118 -
Molecular signature of mice T lymphocytes following tolerance induction by allogeneic BMT
and CD40-CD40L costimulation blockade. Transpl Int 19:146-57 (2006).
Bodingbauer, M., Pakrah, B., Steininger, R., Berlakovich, G., Rockenschaub, S., Wekerle, T.,
and Muehlbacher, F. The advantage of allocating kidneys from old cadaveric donors to old
recipients: a single-center experience. Clin Transplant 20:471-5 (2006).
Silberhumer, G., Pokorny, H., Hetz, H., Herkner, H., Rasoul-Rockenschaub, S., Soliman, T.,
Wekerle, T. , Berlakovich, G., Steininger, R., and Muehlbacher, F. Combination of extended
donor criteria and changes in the model for end-stage liver disease score predict patient
survival and primary dysfunction in liver transplantation: A retrospective analysis.
Bodingbauer, M., Wekerle, T., Pakrah, B., Roschger, P., Peck-Radosavljevic, M.,
Silberhumer, G., Grampp, S., Rockenschaub, S., Berlakovich, G., Steininger, R., Klaushofer,
K., Oberbauer, R., and Muehlbacher, F. Prophylactic bisphosphonate treatment prevents
bone fractures after liver transplantation. Am J Transplant 7:1763-9 (2007).
Hainz, U., Jurgens, B., Seidel, M. G., Wekerle, T., and Heitger, A. Indoleamine 2,3dioxygenase in hematopoietic stem cell transplantation. Curr Drug Metab 8:267-72 (2007)
2002
• The 16th European Histocompatibility Conference, Strasbourg, Frankreich, März 2002;
"Mixed chimerism and transplantation tolerance"
• 22nd Annual Meeting and Scientific Sessions of the International Society for Heart and
Lung Transplantation, Washington DC, USA, April 2002; "Review of experimental tolerance
protocols"
• Ninth N.A.T. (Nantes/Actualités/Transplantation), Nantes, Frankreich, Juni 2002; "Tolerance
through the induction of macrochimerism"
• Austrotransplant 2002, Loipersdorf; "Immunglobuline als Therapie in der Transplantation"
2003
• "Effects of immunosuppressive drugs on tolerance induction through BMT with
costimulation blockade", Novartis Research Day, Frankfurt, Germany, 2003
• "Xenotransplantation", Austrotransplant 2003, Gosau, Austria
• "Experimental aspects of tolerance induction", Wyeth Symposium on 'Islet transplantation
and immune tolerance', Geneva, Switzerland, 2003
• "Immune tolerance - strategies, clinical application", Symposium of the Working Association
• 'Transplantation of thoracic organs' of the German Society of Cardiology, Heidelberg,
Germany, 2003
2004
• TBRC May 2004: “Studies on the role of regulation and the use of mobilized peripheral
blood stem cells in murine mixed chimerism models involving costimulation blockade”,
Boston, USA
• ROTRF symposium, XX International Congress of The Transplantation Society, "Tolerance
through hematopoietic cell transplantation with costimulation blockade", Vienna, Austria
• Seminar "From basic science to clinical application", organized by Rudolf Valenta,
“Transplantation tolerance through hematopoietic chimerism”, Vienna, Austria
- 119 -
• Ges. der Chirurgen in Wien: "Organtransplantation: Visionen und Utopien", Vienna, Austria
2005
• Gastroenterologiefortbildung, AKH Wien, "Induktion immunologischer Toleranz in der
Organtransplantation"
• Ethik-Symposium des Österreichischen Grünen Kreuz, Goldegg, "Xenotransplantation –
Eine Alternative?"
• 5th Wyeth International Transplantation Symposium on Sirolimus, Athen, "Advances in
experimental tolerance induction through hematopoietic cell transplantation"
• Akademie für Transplantationsimmunologie - 1. Seminar " Statistik und Medical Writing",
München, "Wie kommt ein Journal zustande – Sicht eines Editors"
• Symposium "Advances in solid organ and stem cell transplantation", Berlin, Charité, "Nonmyeloablative protocols for stem cell transfer to induce tolerance to organ transplants"
• 12th Congress of the European Society for Organ Transplantation (ESOT), Genf, opening
plenary session, “Peripheral or central tolerance, what is best?”
• Austrotransplant, 19. Jahrestagung, Alpbach, “Toleranzinduktion: Gegenwart, Zukunft oder
Wunschtraum?”
• Hesperis Course, ESOT, Wien, "Experimental tolerance protocols"
2006
• XXV Congress of the European Academy of Allergology and Clinical Immunology, EAACI
2006, Wien, "Progress towards clinical tolerance induction"
• Seminar Statistik und Medical Writing, Akademie für Transplantationsimmunologie,
Astellas, München, "Wie kommt ein Journal zustande - Sicht eines Editors"
• Wissenschaftliches Symposium: "30 Jahre Kinder-Dialyse Wien", Wien, "Derzeitiger Stand
der Toleranzinduktion"
• Astellas Transplant360 Wien "Tolerance"
• 37. Kongress der (Dt.) Ges. f. Nephrologie, Essen, "Möglichkeiten der Toleranzinduktion bei
Organtransplantation"
• Österr. Ges. für Nephrologie Jahrestagung 2006, Semmering, "Die Rolle von
Costimulations-Blockern – einer neuen Klasse an Biologicals – in der Zukunft der
Nierentransplantation"
•
30.
Seminar
der
Österr.
Ges.
für
Experimentelle
Chirurgie,
Gosau,
"Transplantationsimmunologie"
• Universitäres Transplantationszentrum Hamburg,
Fortbilungsveranstaltung
der
Transplantations-Akademie,
Hamburg,
Deutschland,
"Toleranzinduktion
in
der
Organtransplantation: Standortbestimmung"
2007
• “Toleranz: Eine Standortbestimmung”, invited seminar at the Medical Univ. of Innsbruck,
March 2007
•“Toleranzinduktion:
Realistisch
oder
Utopie?”,
2.
Interdisziplinäres
Tübinger
Transplantationsgespräch, Tübingen, Germany, April 2007
• “Tolerance: Basic principles and experimental models”, Hesperis Course of ESOT, St.
Gallen, Switzerland, November 2007
- 120 -
Curriculum Vitae
Institute of Specific Prophylaxis and Tropical Medicine, Center for Physiology,
Pathophysiology and Immunology, Medical University of Vienna, Kinderspitalgasse 15, 1090
Wien, Austria; Phone: +43-1-404 90/64890, Fax: +43-1-404 90/64899;
Homepage: www.meduniwien.ac.at/tropenmedizin
Personal Data
Date of Birth:
06.08.1965
Place of Birth:
Vienna
Nationality
Austria
Education
01/2004
Special degree (Facharzt) in “Specific Prophylaxis and
Tropical Hygiene”
01/2002
Special degree (Facharzt) in “Immunology”
2001 - 2002
Physician in training at the Department of Internal
Medicine and Department of Clinical Pharmacology of the
University of Vienna, General Hospital Vienna, Austria
1999 - 2003
Physician in training in „Specific Prophylaxis and Tropical
Hygiene“ at the University of Vienna, Austria
1996 – 1998
Physician in training in „Immunology“ at the University of
Vienna, Austria, and at the Allergy Outpatient Clinic 1100
Vienna
05/1993 – 12/1995
PhD-Thesis at the Department of Clinical Immunology,
University Göteborg, Sweden
11/1990 – 05/1993
Master-Thesis at the Department of Clinical Immunology,
University Göteborg, Sweden
10/1990
Graduation from the Faculty of Medicine, University
Vienna, with “Medical doctor” (MD)
1975 – 1983
High School (Gymnasium) and Graduation (Matura),
Vienna, Austria
1971 – 1975
Primary School, Vienna, Austria
Career History
since 10/2006
University Professor for Vaccinology
10/2004
Head of the Department of Specific Prophylaxis and
- 121 -
Tropical Medicine at the Center for Physiology,
Pathophysiology and Immunology, Medical University,
Vienna
03/2000
Associate Professor and leader of the researche group
“Mucosal Immunity and Vaccination”
11/1999
Venia docendi at the University of Vienna, Medical School
1999 - 2000
University Assistant at the Department of General and
Experimental Pathology, University of Vienna
1996 - 1999
Research Assistant at the Department of General and
Experimental Pathology, University of Vienna
12/1995
Doctor of Philosophy (PhD9, University of Göteborg,
Sweden
05/1993
Master of Science (M. Med. Sci.)
Since 05/2007
Board Member of the “International Archives of Allergy and
Clinical Immunology”
since 12/2005
Member of the Austrian Advisory Committee of
Immunization Practice (AACIP) of the Austrian Supreme
Board of Health of the Federal Ministry of Health, Women
& Adolescence
since 09/2005
Board Member of the Austria Society of Tropcial Medicine
and Parasitology
Since 11/2003
Chair of the committee “Vaccinology” (“Standeskommittee
für Impfwesen”)
2006
2005
Poster prize at the 26th Collegium Internationale
Allergologicum, Malta, 5th-10th May 2006
K. Hufnagl, C. Wild, H. Breiteneder, O. Scheiner, M.
Wallner, F. Ferreira, U. Wiedermann. Development of a
mucosal polyvalent allergy vaccine for primary prevention
of multi-sensitization (poster)
Sanofi Aventis award to Stefan Wagner
“Vaccination with a human high molecular weight
melanoma-associated antigen mimotope induces a
humoral response inhibiting melanoma cell growth in vitro”.
Wagner S, Hafner C, Allwardt D, Jasinska J, Ferrone S,
Zielinski CC, Scheiner O, Wiedermann U, Pehamberger H,
- 122 -
Breiteneder H. J Immunol. 2005 15;174(2):976-82
Awards from the Forschungsentwicklungspreis des Fonds
der
Stadt
Wien für Innovative Interdisziplinäre
Krebsforschung to
2004
Jasinska J, Wagner S, Radauer C, Sedivy R, Brodowicz T,
Wiltschke C, Breiteneder H, Pehamberger H, Scheiner O,
Wiedermann U*, Zielinski CC. 2003. Inhibition of tumor cell
growth by antibodies induced after vaccination with
peptides derived from the extracellular domain of Her2/neu. Int. J. Cancer. 107: 976-983.
Hafner C., H. Breiteneder, S. Ferrone, C. Thallinger, S.
Wagner, WM. Schmidt, M. Kundi, K. Wolff, C. C. Zielinski,
O. Scheiner, U. Wiedermann*, and H. Pehamberger. 2004.
Suppression of human melanoma tumor growth in SCID
mice by a human high molecular weight-melanoma
associated antigen (HMW-MAA) specific monoclonal
antibody. Int. J. Cancer Dec 1;
Poster Award of the Austrian Society of Allergy and
Immunology for the presentation, Salzburg Dec 2003:
2003
“Studies on regulatory mechanisms of intranasal tolerance
using recombinant Ves v 5, a major wasp venom allergen”,
by Winkler B, Bolwig C, Sepälä U, Spangfort M, Ebner C
and Wiedermann U.
1990 - 1995
Fellowship from the University of Göteborg, Sweden for a
PhD-program
Sources of funding in last 6 years (2002-2008) Peer-reviewed projects (FWF, EU and
equivalent projects)
Period
Organization
Short Title
03/2008 –
Intercell
Infektionsepidemiologie von streptococcus
02/2009
pneumoniae
2007 - 2009 ÖNB
Genet. Typisierung d. Keuchhustenerregers
K€/year
35
45
Bordetella Pertussis bei österr. Patienten
2007 - 2009 Nestlé
Prenatal and perinatal intervention against
182
allergic diseases
2006 - 2008 BioLife Science
Multiepitope vaccine against breast cancer
158
2005 –
SFB – Mucosal tolerance induction: a
732
FWF
2012
strategy for prevention and therapy of type I
allergy
2004 - 2006 Nestlé
Allergene prevention with probiotic
182
preparations/recombinant probiotics
2004 - 2006 Amadeus travel-grant Lactic acid bacteria as expression systems
5
- 123 -
for vaccine antigens
2006
2002 –
Fonds des
Entwicklung einer eßbaren Vakzine gegen
Bürgermeisters Wien
Allergien
EU grant LABDEL
Oral Va. Lactic acid bacteria
EU Project TRAFSA
Therapeutic recombinant allergens from
28
52
2004
2000 –
2002
317
structual allergology
Dr.rer.nat., Dr.sci.med. Dr. techn. or PhD supervisions in last 6 years (2002-2008) Only
students in your lab, no external
Period
Name of student
Topic
1999-2000
Birgit Wagner (MD thesis)
Mucoal tolerance as therapy of type I allergy
2003 - 2005 Carmen Wild (PhD theis)
Production, characterization and in vivo testing of
novel allergen chimers
2004 –
Martin Sturm (Diploma
Mucosal vaccination against Type I allergy: a new
2005
thesis)
treatment approach using lactic acid bacteria as
delivery system for hypoallergenic molecules
2004 –
Maria Korinek
2005
(Diploma thesis)
2005 -
Elisabeth Hoflehner (PhDthesis)
2007 -
Angelika Wagner (MD-PhD
Edible vaccines
“Production and Characterization of allergen
chimers for mucosal treatment of
allergic diseases”
Immunomodulation by Toxoplasma gondii
thesis)
2008-
Markus Mandl (PhD thesis)
Pre-peri-and postnatal intervention by probtiotics
Publications
Grönlund, H., S. Vrtala, U. Wiedermann, G. Dekan, D. Kraft, R. Valenta, M. Van HageHamsten. 2002. Carbohydrate-based particles: a new adjuvant for allergen-specific
immunotherapy. Immunology 107(4): 523-9.
Winkler, B., C. Bolwig, U. Seppala, M. D. Spangfort, C. Ebner, and U. Wiedermann*.
2003.Allergen-specific immunosuppression by mucosal treatment with recombinant
Ves v 5, a major allergen of Vespula vulgaris venom, in a murine model of wasp
venom allergy. Immunology 110:376.
Repa, A., C. Grangette, C. Daniel, R. Hochreiter, K. Hoffmann-Sommergruber, J. Thalhamer,
D. Kraft, H. Breiteneder, A. Mercenier, and U. Wiedermann*. 2003. Mucosal co-application of
lactic acid bacteria and allergen induces counter-regulatory immune responses in a murine
model of birch pollen allergy. Vaccine 22:87.
Jasinska, J., S. Wagner, C. Radauer, R. Sedivy, T. Brodowicz, C. Wiltschke, H. Breiteneder,
- 124 -
H. Pehamberger, O. Scheiner, U. Wiedermann*, and C. C. Zielinski. 2003. Inhibition of tumor
cell growth by antibodies induced after vaccination with peptides derived from the
extracellular domain of Her-2/neu. Int J Cancer 107:976.
Wiedermann, U*. 2003. Mucosal immunity--mucosal tolerance. A strategy for treatment of
allergic diseases. Chem Immunol Allergy 82:11.
Hufnagl, K., B. Wagner, B. Winkler, K. Baier, R. Hochreiter, J. Thalhamer, D. Kraft, O.
Scheiner, H. Breiteneder, and U. Wiedermann*. 2003. Induction of mucosal tolerance with
recombinant Hev b 1 and recombinant Hev b 3 for prevention of latex allergy in BALB/c mice.
Clin Exp Immunol 133:170.
Melzer, H., K. Baier, F. Felici, B. U. von Specht, G. Wiedermann, H. Kollaritsch, U.
Wiedermann, and M. Duchene. 2003. Humoral immune response against
proteophosphoglycan surface antigens of Entamoeba histolytica elicited by immunization
with synthetic mimotope peptides. FEMS Immunol Med Microbiol 37:179.
Kozakova, H., L. A. Hanson, R. Stepankova, H. Kahu, U. I. Dahlgren, and U. Wiedermann*.
2003. Vitamin A deficiency leads to severe functional disturbance of the intestinal epithelium
enzymes associated with diarrhoea and increased bacterial translocation in gnotobiotic rats.
Microbes Infect 5:405.
Hanniffy, S., U. Wiedermann, A. Repa, A. Mercenier, C. Daniel, J. Fioramonti, H. Tlaskolova,
H. Kozakova, H. Israelsen, S. Madsen, A. Vrang, P. Hols, J. Delcour, P. Bron, M.
Kleerebezem, and J. Wells. 2004. Potential and opportunities for use of recombinant lactic
acid bacteria in human health. Adv Appl Microbiol 56:1.
Focke, M., B. Linhart, A. Hartl, U. Wiedermann, W. R. Sperr, P. Valent, J. Thalhamer, D.
Kraft, and R. Valenta. 2004. Non-anaphylactic surface-exposed peptides of the major birch
pollen allergen, Bet v 1, for preventive vaccination. Clin Exp Allergy 34:1525.
Repa, A., C. Wild, K. Hufnagl, B. Winkler, B. Bohle, A. Pollak, and U. Wiedermann*. 2004.
Influence of the route of sensitization on local and systemic immune responses in a murine
model of type I allergy. Clin Exp Immunol 137:12.
Westritschnig, K., M. Focke, P. Verdino, W. Goessler, W. Keller, A. Twardosz, A. Mari, F.
Horak, U. Wiedermann, A. Hartl, J. Thalhamer, W. R. Sperr, P. Valent, and R. Valenta. 2004.
Generation of an allergy vaccine by disruption of the three-dimensional structure of the
cross-reactive calcium-binding allergen, Phl p 7. J Immunol 172:5684.
Wagner, B., K. Hufnagl, C. Radauer, S. Wagner, K. Baier, O. Scheiner, U. Wiedermann, and
H. Breiteneder. 2004. Expression of the B subunit of the heat-labile enterotoxin of
Escherichia coli in tobacco mosaic virus-infected Nicotiana benthamiana plants and its
characterization as mucosal immunogen and adjuvant. J Immunol Methods 287:203.
Herz, U., H. Renz, and U. Wiedermann*. 2004. Animal models of type I allergy using
recombinant allergens. Methods 32:271.
Wiedermann, U*. 2005. Prophylaxis and therapy of allergy by mucosal tolerance induction
with recombinant allergens or allergen constructs. Curr Drug Targets Inflamm Allergy 4:577.
Hufnagl, K., B. Winkler, M. Focke, R. Valenta, O. Scheiner, H. Renz, and U. Wiedermann*.
2005. Intranasal tolerance induction with polypeptides derived from 3 noncross-reactive
major aeroallergens prevents allergic polysensitization in mice. J Allergy Clin Immunol
116:370.
- 125 -
Linhart, B., A. Hartl, B. Jahn-Schmid, P. Verdino, W. Keller, M. T. Krauth, P. Valent, F.
Horak, U. Wiedermann, J. Thalhamer, C. Ebner, D. Kraft, and R. Valenta. 2005. A hybrid
molecule resembling the epitope spectrum of grass pollen for allergy vaccination. J Allergy
Clin Immunol 115:1010.
Hafner, C., S. Wagner, J. Jasinska, D. Allwardt, O. Scheiner, K. Wolff, H. Pehamberger, U.
Wiedermann, and H. Breiteneder. 2005. Epitope-specific antibody response to Mel-CAM
induced by mimotope immunization. J Invest Dermatol 124:125.
Wagner, S., C. Hafner, D. Allwardt, J. Jasinska, S. Ferrone, C. C. Zielinski, O. Scheiner, U.
Wiedermann, H. Pehamberger, and H. Breiteneder. 2005. Vaccination with a human high
molecular weight melanoma-associated antigen mimotope induces a humoral response
inhibiting melanoma cell growth in vitro. J Immunol 174:976.
Hafner, C., H. Breiteneder, S. Ferrone, C. Thallinger, S. Wagner, W. M. Schmidt, J. Jasinska,
M. Kundi, K. Wolff, C. C. Zielinski, O. Scheiner, U. Wiedermann*, and H. Pehamberger.
2005. Suppression of human melanoma tumor growth in SCID mice by a human high
molecular weight-melanoma associated antigen (HMW-MAA) specific monoclonal antibody.
Int J Cancer 114:426.
Wiedermann-Schmidt*, U., and W. Maurer. 2005. Adjuvants and additives in vaccines-medical relevance. Wien Klin Wochenschr 117:510.
Wiedermann, U., and H. Kollaritsch. 2006. Vaccines against traveler's diarrhoea and
rotavirus disease - a review. Wien Klin Wochenschr 118:2.
Rendi-Wagner, P., M. Kundi, A. Mikolasek, I. Mutz, K. Zwiauer, U. Wiedermann, A. Vecsei,
and H. Kollaritsch. 2006. Active hospital-based surveillance of rotavirus diarrhea in Austrian
children, period 1997 to 2003. Wien Klin Wochenschr 118:280.
Daniel, C., A. Repa, C. Wild, A. Pollak, B. Pot, H. Breiteneder, U. Wiedermann*, and A.
Mercenier. 2006. Modulation of allergic immune responses by mucosal application of
recombinant lactic acid bacteria producing the major birch pollen allergen Bet v 1. Allergy
61:812.
Winkler, B., K. Hufnagl, A. Spittler, M. Ploder, E. Kallay, S. Vrtala, R. Valenta, M. Kundi, H.
Renz, and U. Wiedermann*. 2006. The role of Foxp3+ T cells in long-term efficacy of
prophylactic and therapeutic mucosal tolerance induction in mice. Allergy 61:173.
Tasanor, O., D. Engelmeier, B. Brem, U. Wiedermann-Schmidt, H. Greger, and W. H.
Wernsdorfer. 2006. Development of a pharmacodynamic screening model with Crithidia
fasciculata. Wien Klin Wochenschr 118:42.
Rendi-Wagner, P., M. Korinek, B. Winkler, M. Kundi, H. Kollaritsch, and U. Wiedermann*.
2007. Persistence of seroprotection 10 years after primary hepatitis A vaccination in an
unselected study population. Vaccine 25:927.
Rendi-Wagner, P., M. Paulke-Korinek, M. Kundi, U. Wiedermann, B. Laaber, and H.
Kollaritsch. 2007. Antibody persistence following booster vaccination against tick-borne
encephalitis: 3-year post-booster follow-up. Vaccine 25:5097.
Wiedermann, U.*, and A. Mercenier. 2007. New allergy intervention strategies: hitting the
mucosal road. Clin Exp Allergy 37:473.
- 126 -
Kollaritsch, H., and U. Wiedermann. 2007. Examples for vaccines against diarrheal diseases-rotavirus and traveller's diarrhea. Wien Med Wochenschr 157:102.
Wagner, S., J. Jasinska, H. Breiteneder, M. Kundi, H. Pehamberger, O. Scheiner, C. C.
Zielinski, and U. Wiedermann*. 2007. Delayed tumor onset and reduced tumor growth
progression after immunization with a Her-2/neu multi-peptide vaccine and IL-12 in c-neu
transgenic mice. Breast Cancer Res Treat.
Wild, C., M. Wallner, K. Hufnagl, H. Fuchs, K. Hoffmann-Sommergruber, H. Breiteneder, O.
Scheiner, F. Ferreira, and U. Wiedermann*. 2007. A recombinant allergen chimer as novel
mucosal vaccine candidate for prevention of multi-sensitivities. Allergy 62:33.
Daniel, C., Repa, A., Mercenier, A., U. Wiedermann, J. Wells. 2007. The European LABDEL
project and its relevance to the prevention and treatment of allergies. Allerg. 62/11: 12371242
Bublin, M., E. Hoflehner, B. Wagner, C. Radauer, S. Wagner, K. Hufnagl, D. Allwarth,
Scheiner, U. Wiedermann*, H. Breiteneder.2007. Use of a genetic cholera toxin B
subunit/allergen-fusion molecule as mucosal delivery system with immunosuppressive
activity against Th2 immune responses. Vaccine 25(50):8395-404
Repa, A., H. Kozakova, T. Hudcovic, R. Stepankova, T. Hrncir, H. Tlaskalova-Hogenova, A.
Pollak, U. Wiedermann. 2008. Susceptibility to nasal and oral tolerance induction of the
major birch pollen allergen Bet v 1 is not dependent on the presence of the microflora.
Immunol. Letters 117(1):50-56
Rendi-Wagner, P., M. Paulke-Korinek, M. Kundi, U. Wiedermann, B. Laaber, H. Kollaritsch.
2008. Seroprotection 4 years following booster vaccination against tick-born encephalitis. Int.
J. Med Microbiology, Epub ahead of print.
Karin Hufnagl, PhD, Margit Focke, PhD, Florian Gruber, PhD, Peter Hufnagl, PhD, Gerhard
Loupal, DVM Otto Scheiner, PhD, Ursula Wiedermann, MD, PhD. 2008. Airway inflammation
induced after allergic poly-sensitization can be prevented by mucosal but not by systemic
administration of poly-peptides. Clin. Exp. Allergy, In press.
Neimert-Andersson, T., S.Thunberg, L. Swedin, U. Wiedermann, G. Jacobsson-Ekman, S.
Dahlén, A. Scheynius, H. Grönlund, M. van Hage , G. Gafvelin G. Carbohydrate-based
particles reduce allergic inflammation in a mouse model for cat allergy. Allergy, in press.
Invited Talks 2002-2008 (Ärztefortbildungen)
2002
Internationales Pädiatrisches Symposium Obergurgl, Jan 2002
„Allergie und Impfungen“
Immunologischer Fortbildungstag, Weitra, June 2002
„Impferfolgsuntersuchungen“
Reisemedizinische Konsensustagung, Wien, Oct. 2002
„Sinn und Unsinn serologischer Untersuchungen“
2003
1. Wiener Pädiatr. Infektionssymposium, Kinderklinik Wien, Nov. 2003
„Pneumokokkenerkrankung und Impfung“
- 127 -
2004
Immunological Symposium (BMGF), Steyr, Austria, March 2004
“Immunologische Grundlagen des Impfwesens”
4. Reisemedizinische Konsensustagung, Leongang, Styria, September 2004
“Hilfs- und Zusatzstoffe von Impfstoffen – medizinische Relevanz“
Impfsymposium des Grünen Kreuzes, Gmunden, October 2004
„Impfreaktionen und Nebenwirkungen durch Inhaltsstoffe“
19. Pädiatrischer Impftag, Linz, November 2004
„Mukosale Immunität – Zukunft der Impfstrategien“
2005
2. Wiener Pädiatr. Infektionssymposium, Kinderklinik Wien, Febr. 2005
„Neue Impfstoffe und neue Impfentwicklungen“
Impfsymposium des österr. Bundesheeres, Grünes Kreuz, Salzburg, April 2005
„Neue Impfstrategien“
14. Österr. Impftag, Salzburg, April 2005
„Neue Impfstrategien: die Zukunft von nasalen und oralen Vakzinen“
Impfsymposium des Grünen Kreuzes, Gmunden Oct. 200
„Impfungen gegen Reisedurchfallserreger: Dukoral, Einsatz und Wirkung“
39th Annual meeting of the Austrian Society of Tropical Medicine and Parasitology, Vienna,
17-19 Nov.
„Impfstoffe gegen Reisedurchfall: ETEC and Rotavirusinfektionen“
Symposium on Pneumococcal Diseases, 14th Dec 2005, Vienna
“Epidemiology of pneumococcal diseases – benefits of vaccination”
2006
15. Österr. Impftag, 25th March 2006
“Wieviele Impfdosen sind genug?” (Hib, Meningokokken, Hep. B)
Impffortbildung der Ärztekammer Niederösterreich, 19th April 2006
„Impfen aktuell“
Symposium on Vaccination in Prematures, GNPI Vienna, 20th May 2006 (chair)
“Österreichischer Impfplan 2006”
3. Wiener Pädiatr. Infektionssymposium 2006, GNPI Vienna, 20th May 2006
“Welche neuen Impfstoffe für Kinder und Jugendliche sind zu erwarten”
2007
Pädiatr. Immunolog. Symposium u. Pädiatr. Kongreß, Jänner 2007
“Invasive Pneumokokkenerkrankungen”
Pädiatr. Immunolog. Symposium u. Pädiatr. Kongreß, Jänner 2007
„Empirie od. evidenzbasierende Medizin?“
ISW-Expert Meeting on FSME, Jänner 2007
- 128 -
“Travel Expert Advisery Board on TBE-First Outcome
Bundesheer Symposium Salzburg, März 2007
“Choleraimpfung – Dukoral
Bundesheer Symposium Salzburg, März 2007
„Wie gefährlich ist impfen wirklich?“
Österr. Impftag Salzburg, März 2007
„Ist impfen wirklich gefährlich?“
Österr. Impftag Salzburg, März 2007
„Hep. A Immunität 10 Jahre nach Grundimmunisierung“
Impftagung Bregenz, Juni 2007
“Impfdosen Empirie oder evidenzbasierende Medizin”
4. Wiener Infektionssymposium, September 2007
„Neue Impfungen – Neue Impfentwicklungen“
Impfsymposium in Gmunden, September 2007
„Brustkrebsvakzine – von der Entwicklung zur klinischen Testung“
41. Jahrestagung der Österr. Gesellschaft für Tropenmedizin und Parasitologie, Nov. 2007
„Neue Impfungen – Neue Adjuvantien“
Pressefrühstück “Kick off Meeting des Sprechergremiums von Forum Impfschutz”, Nov. 2007
„Schutz vor Epidemien durch ausreichende Durchimpfungsrate“
Expertenmeetin „Ambulant erworbene Pneumonie“, Dezember 2007
„Pneumokokkenimpfung“
Wiener Impftag, Jan 2008
„neue Impfungen, neue Adjuvantien“
Reise- und Tropenmedizinische Tagung, Innsbruck, Jan. 2008
„Wie gefährlich ist Impfen wirklich?“
Fortbildungsveranstaltung der Univ. Ärzte AKH, Febr. 2008
„Impfen aktuell – wann soll was geimpft werden?“
ESIDOG, März 2008
„Immunologische Grundlagen des Impfwesens“
Invited lectures at Scientific Meetings 2002-2008
American Academy of Allergy, Asthma and Immunology, San Diego, USA, March 2000
“Oral tolerance and its relation to allergic disease”
Gastvortrag beim Immunologischen Seminar an der Medizinischen Fakultät der Universität,
Marburg, Dec. 2000.
“Mukosale Vakzination, Mukosale Toleranz”
Annual meeting of the Society of Immunology and Allergy, Deutsche Gesellschaft für HNO,
Ulm, Deutschland. Nov. 2000
- 129 -
“Mukosale Adjuvantien”
European Commission - Joint Research Center, Workshop on GMOs, Ispra, Italy, Febr. 2001
“Use of animal models in allergy research”
Deutsche Gesellschaft für Allergologie und Immunologie; Universität Bochum, Bochum,
Deutschland , May 2002
„Mukosale Toleranzinduktion“
24th Symposium of the Collegium International Allergologicum, Bermuda, Nov. 2002
“From mucosal tolerance induction to edible vaccines – possible treatment strategies against
allergy?”
Berna Biotech, Bern, Switzerland, Februar 2004
„Hepatitis A vaccination – characterization and modulation of immune responses in mice and
men“
ALK Abello, Kopenhagen, Demark, April 2004
„Mucosal tolerance induction: a treatment strategy against allergy with multiple sensitivities“
FRM Workshop “Frontier in Allergology Research” Paris May 2004
“Animal Models using recombinant allergens”
EU-workshop Brussels “Food allergy in Europe, Future Prospectives” Brussels,
June 2004
“Future prospectives for immunotherapy and oral vaccination”
Symposium, Institute Pasteur de Lille, May 2005
„Mucosal tolerance induction: a strategy for prevention and therapy of type I allergy“
CESP/EAP European Academy of Pediatrics, Dec 2005, Brussels
“Mucosal immunity – impact on nasopharyngeal carriage and on viral shedding at mucosal
respiratory surfaces”
EMEA (European Medicines Agency), London, Jan 2006
Workshop on “Regulatory and scientific issues related to concomitant administration of
vaccine”
Mucosal tolerance induction: a strategy for prevention and therapy of type I allergy.
Symposium on Immunoregulation, Institute Pasteur de Lille, May 2005
Mucosal immunity – impact on nasopharyngeal carriage and on viral shedding at mucosal
respiratory surfaces. CESP/EAP European Academy of Pediatrics, Brussels, 19-20 Dec
2005
Mechanisms of Mucosal Tolerance Induction. XXV EAACI, Vienna, Austria, 10.-14.6.2006
Mucosal Tolerance as treatment strategy against allergic diseases. 5th Meeting of the
Mucosal Immunology Group (EMIG), Praque, Czech Republic, 5-7 Oct. 2006
Humoral and Cellular Immune responses 10 years after hepatitis A primary vaccination. 16th
Annual Austrian Symposium of Vaccination, Salzburg, 23-24 March 2007.
Mucosal tolerance. XXVI EAACI, Göteborg, Sweden, 9.- 13.6.2007.
Mucosal tolerance – a treatment strategy against allergies. Seminarreihe "Immunologie,
Allergologie, Pneumologie" an der Uni-Klinik Giessen und Marburg, Prof. H. Renz; Marburg,
- 130 -
Deutschland; 25.-26. Juni 2007.
10th Conference of the Internat. Society of Travel Medicine, Mai 2007
“Travellers Diarrhoea Vaccines – past, present, future
26. EAACI Congress in Göteburg, Juni 2007
“Mucosal Tolerance Induction”
Invited Lecture at Univ. Marburg, Deutschland, Juni 2007
“Mucosal Tolerance as a Treatment strategy against allergies”
Invited Lecture Institute of Immunology and Infect. Diseases, R. Maizels, Oktober 2007
“Mucosal Tolerance for Treatment of Allergies”
Invited Lecture Institute Cell Biology, Univ. Amsterdam, M. Kapsenberg Dezember 2007
“Treatment of allergies on the bases of Mucosal Tolerance Induction”
World Immunregulation Meeting, Davos, March 2008
“Mucosal tolerance and Intestinal homeostasis” (chair)
- 131 -
Curriculum Vitae
Gerhard J. Zlabinger
Division of Clinical and Experimental Immunology, Institute of Immunology, Center for
8a, 1090 Wien, Austria;
Phone: +43-1-4277-64971, Fax: +43-1-4277-64972;
Homepage: www.meduniwien.ac.at/immunologie/content/research/zlabinger.htm
Personal Data
Date of Birth:
30.09.1955
Place of Birth:
Traun
Nationality
Austria
Education
1981 - 1988
Medical Specialization in Immunology
1975 - 1981
Study of Medicine, University of Vienna
1974
Matura at Realistisches Gymnasium, Linz
Career History
07/2007
Full Professor of Clinical and Experimental Immunology
09/2004
Head of Institute of Immunology
1992
School
1987 – 1988
Visiting Fellow at the Department of Internal Medicine II,
University of Vienna Austria
1986
Group Leader, Institute of Immunology, University of
Vienna
since 09/2007
Curriculumdirektor Humanmedizin
2000 - present
Scientific Director of the Academy for Biomedical
Scientists at the general Hospital of Vienna
Awards
2005
Landeskulturpreis Öberösterreich for Natural Sciences
1993
Förderungspreis der Stadt Wien
- 132 -
1993
Dr. Kardinal Innitzer Förderungspreis
1993
Austrotransplantpreis
1991
Förderungspreis der Ersten österr. Sparkasse
1991
Förderungspreis der Österr. Ges. für Nephrologie.
1990
Shaper & Brummer Award for Coumarin
Investigators,
1990
Kolassapreis
1989
Talentförderungsprämie des Landes OÖ
1987
Staatspreis für Rheumatologie
1985
Staatspreis für Rheumatologie
Memberships
Austrotransplant
Austrian Society for Nephrology
Austrian Society for Laboratory Medicine
The Transplantation Society
Period
Organization
2008 - 2010 Else Kröner Stiftung
Short Title
K€/year
Immunological Hallmarks of humoral
59
rejection
2007 - 2010 FWF
Identification of functional receptor for Tamm
48
Horsfall Protein
2001 - 2004 FWF
Molecular characterization of the antiinflammatory and immunosuppressive
effects of butyrate
Period
Name of student
Topic
2006 –
Johannes Hofer
Immunomodulatory effects of C4d
Johannes Kovarik
Molecular mechanisms of butyrate
Markus Hölzl
Identification THP receptors
present
2007 –
present
2008 –
present
113
- 133 -
Publications
85 peer reviewed publications in scientific journals, 42 reviwes, book chapters and other
publications, > 30 invited lectures
Säemann MD, Parolini O., Böhmig GA, Kelemen P., Krieger PM, Neumüller J, Knarr K,
Kammlander W, Hörl WH, Diakos C, Stuhlmeier K, Zlabinger GJ. (2002) Bacterial metabolite
interference with maturation of human monocyte-derived dendritic cells. J Leukocyte Biol 71:
238-246.
Diakos C, Prieschl EE, Säemann MD, Novotny V, Böhmig GA, Csonga R, Baumruker T,
Zlabinger GJ (2002) Novel mode of interference with nuclear factor of activated T-cells
regulation in T-cells by the bacterial metabolite n-butyrate. J. Biol Chem 27: 24243-51.
Säemann MD, Böhmig GA, Zlabinger GJ (2002) Short-chain fatty acids:bacterial mediators
of a balanced host-microbial relationship in the human gut. Wien Klin Wochenschr 114: 289300.
Säemann MD, Zeyda M, Diakos C, Szekeres A, Böhmig GA, Kelemen P, Parolini O,
Stockinger H, Prieschl EE, Stuhlnig T, Baumruker T, Zlabinger GJ. (2003) Suppression of
early T-cell receptor-triggered cellular activation by the Janus kinase inhibitor WHI-P154.
Transplantation 75: 1864 – 72.
Saemann MD, Diakos C, Kelemen P, Kriehuber E, Zeyda M, Böhmig GA, Hörl WH,
Baumruker T, Zlabinger GJ. Prevention of CD40-triggered dendritic cell maturation and
induction of T-cell hyporeactivity by targeting of Janus kinase 3. Am J Transplant. 3: 1341-9
2003.
Säemann MD, Zlabinger GJ. How to make clinical use of bacterial evasion strategies. Eur J
Clin Invest 33: 189-90, 2003.
Säemann MD, Kelemen P, Böhmig GA, Hörl WH, Zlabinger GJ. Hyporesponsiveness in
Alloreactive T-cells by NF-kappaB Inhibitor-Treated Dendritic Cells: Resistance to
Calcineurin Inhibition. Am J Transplant 4:1448-58, 2004.
Säemann MD, Zeyda M, Stulnig TM, Böhmig GA, Wekerle T, Hörl WH, Zlabinger GJ. Janus
kinase-3 (JAK3) inhibition: a novel immunosuppressive option for allogeneic transplantation.
Transplant Int. 17:481-9, 2004.
Säemann, MD., Weichhart T, Zeyda M, Staffler G, Schunn M, Stuhlmeier KM, Sobanov Y,
Stulnig TM, Akira S, von Gabain A, von Ahsen U, Hörl W, and Zlabinger GJ. Tamm-Horsfall
glycoprotein links innate immune cell activation with adaptive immunity via a TLR4dependent mechanism. J Clin Invest 115:468-75, 2005.
Säemann MD, Weichhart T, Hörl WH, Zlabinger GJ. Tamm-Horsfall Glycoprotein: A
multilayered defense molecule against urinary tract infection. Eur J Clin Invest, 35:227-35,
2005.
Diakos C, Prieschl EE, Saemann MD, Bohmig GA, Csonga R, Sobanov Y, Baumruker T,
Zlabinger GJ. n-Butyrate inhibits Jun NH(2)-terminal kinase activation and cytokine
- 134 -
transcription in mast cells. Biochem Biophys Res Commun. 349:863-8, 2006
Stefanova T, Nikolova N, Michailova A, Mitov I, Iancov I, Zlabinger GJ, Neychev H Enhanced
resistance to Salmonella enterica serovar Typhimurium infection in mice after coumarin
treatment. Microbes Infect 9:7-14, 2007
Chiampanichayakul S, Szekeres A, Khunkaewla P, Moosom S, Leksa V, Drbal K, Zlabinger
GJ, Hofer-Warbinek, R, Stockinger H, Kasinrerk W Engagement of Na, K-ATPase beta3
subunit by a specific mAb suppresses T and B lymphocyte activation. Int Immunol 14: 140714, 2002
Selenko-Gebauer N, Majdic O, Szekeres A, Höfler G, Guthann E, Korthäuer U, Zlabinger GJ,
Pickl WF, Stockinger H, Knapp W, Stöckl J. B7-H1 (PD-L1) on dendritic cells is involved in
the induction and maintenance of T-cell anergy. J Immunol 170:3637-44, 2003.
Stollberger C, Finsterer J, Zlabinger GJ, Weihsengruber F, Redtenbacher S, Bonner G,
Herkner K, Deutsch M.
Antineutrophil
cytoplasmic
autoantibody-negative
antiproteinase 3 syndrome presenting as vasculitis, endocarditis, polyneuropathy and
Dupuytren's contracture. J Heart Valve Dis. 12: 530-4, 2003.
Staffler G, Szekeres A, Schutz GJ, Saemann MD, Prager E, Zeyda M, Drbal K, Zlabinger GJ,
Stulnig TM, Stockinger H. Selective inhibition of T cell activation via CD147 through novel
modulation of lipid rafts. J Immunol 171: 1707-14, 2003.
Zeyda M, Szekeres AB, Saemann MD, Geyeregger R, Stockinger H, Zlabinger GJ,
Waldhausl W, Stulnig TM. Suppression of T cell signaling by polyunsaturated fatty acids:
selectivity in inhibition of mitogen-activated protein kinase and nuclear factor activation. J
Immunol 170: 6033-9, 2003.
Wahrmann M, Exner M, Regele H, Derfler K, Körmöczi GF, Lhotta K, Zlabinger GJ, Böhmig
GA. Flow cytometry based detection of HLA alloantibody mediated classical complement
activation. J Immunol Methods 275: 149-60, 2003
Steinberger P, Majdic O, Derdak SV, Pfistershammer K, Kirchberger S, Klauser C, Zlabinger
G, Pickl WF, Stöckl J, Knapp W. Molecular characterization of human 4Ig-B7-H3, a member
of the B7 family with four Ig-like domains. J Immunol. 172:2352-9, 2004.
Koller H, Hochegger K, Zlabinger GJ, Lhotta K, Mayer G, Rosenkranz AR. Apoptosis of
human polymorphonuclear neutrophils accelerated by dialysis membranes via the activation
of the complement system. Nephrol Dial Transplant. 19:3104-11, 2004.
Pfistershammer K, Majdic O, Stöckl J, Zlabinger G, Kirchberger S, Steinberger P, Knapp W.
CD63 as an activation-linked T cell costimulatory element. J Immunol. 173:6000-8, 2004.
Zeyda M, Säemann MD, Geyeregger R, Zlabinger GJ, Waldhäusl W, Stulnig TM.
Polyunsaturated fatty acids inhibit dendritic cells function without impairment of NF-kB. J Biol
Chem, 280:14293-301,2005.
Geyeregger R, Zeyda M, Zlabinger GJ, Waldhäusl W, Stulnig TM. Polyunsaturated fatty
acids interfere with formation of the immunological synapse. J Leukoc Biol. 77: 680-8, 2005.
Weichhart T, Zlabinger GJ, Säemann MD. The multiple functions of Tamm-Horsfall Protein in
- 135 -
health and disease: a mystery clears up. Wien Klin Wochenschr 117:316-22, 2005.
Kirsch BM, Zeyda M, Stuhlmeier K, Grisar J, Smolen JS, Watschinger B, Stulnig TM, Hörl
WH, Zlabinger GJ, Säemann MD The active metabolite of leflunomide, A77 1726, interferes
with dendritic cell function. Arthritis Research & Therapy, 7:R694-R703, 2005.
Bluml S, Kirchberger S, Bochkov VN, Kronke G, Stuhlmeier K, Majdic O, Zlabinger GJ,
Knapp W, Binder BR, Stockl J, Leitinger N. Oxidized Phospholipids Negatively Regulate
Dendritic Cell Maturation Induced by TLRs and CD40. J Immunol. 175:501-8, 2005.
Zeyda M, Poglitsch M, Geyeregger R, Smolen JS, Zlabinger GJ, Horl WH, Waldhausl W,
Stulnig TM, Saemann MD. Disruption of the interaction of T cells with antigen-presenting
cells by the active leflunomide metabolite teriflunomide: involvement of impaired integrin
activation and immunologic synapse formation. Arthritis Rheum. 52:2730-9, 2005.
Kirchberger S, Majdic O, Steinberger P, Bluml S, Pfistershammer K, Zlabinger G, Deszcz L,
Kuechler E, Knapp W, Stockl J. Human rhinoviruses inhibit the accessory function of
dendritic cells by inducing sialoadhesin and B7-H1 expression. J Immunol. 175:1145-52.
2005
Zeyda M, Kirsch BM, Geyeregger R, Stuhlmeier KM, Zlabinger GJ, Horl WH, Saemann MD,
Stulnig TM. Inhibition of human dendritic cell maturation and function by the novel
immunosuppressant FK778. Transplantation 80:1105-11. 2005
Pfistershammer K, Klauser C, Pickl WF, Stockl J, Leitner J, Zlabinger G, Majdic O,
Steinberger P. No evidence for dualism in function and receptors. PD-L2/B7-DC is an
inhibitory regulator of human T cell activation. Eur J Immunol 36:1104-13, 2006
Zeyda M, Geyeregger R, Poglitsch M, Weichhart T, Zlabinger GJ, Koyasu S, Horl WH,
Stulnig TM, Watschinger B, Saemann MD. Impairment of T cell interactions with antigenpresenting cells by immunosuppressive drugs reveals involvement of calcineurin and NF{kappa}B in immunological synapse formation. J Leukoc Biol. 81:319-27, 2007.
Mechtcheriakova D, Wlachos A, Sobanov J, Kopp T, Reuschel R, Bornancin F, Cai R,
Zemann B, Urtz N, Stingl G, Zlabinger G, Woisetschlager M, Baumruker T, Billich A.
Sphingosine 1-phosphate phosphatase 2 is induced during inflammatory responses. Cell
Signal. 19:748-60, 2007
Mechtcheriakova D, Wlachos A, Sobanov J, Bornancin F, Zlabinger G, Baumruker T, Billich
A FTY720-phosphate is dephosphorylated by lipid phosphate phosphatase 3. FEBS Lett.
7581:3063-8, 2007
Geyeregger R, Zeyda M, Bauer W, Kriehuber E, Saemann MD, Zlabinger GJ, Maurer D,
Stulnig TM. Liver X receptors regulate dendritic cell phenotype and function through blocked
induction of the actin-bundling protein fascin. Blood 109:4288-95, 2007
Hochegger K, Eller P, Huber JM, Bernhard D, Mayer G, Zlabinger GJ, Rosenkranz AR
Expression of granzyme A in human polymorphonuclear neutrophils. Immunology. 121:16673, 2007
Zeyda M, Farmer D, Todoric J, Aszmann O, Speiser M, Gyori G, Zlabinger GJ, Stulnig TM
Human adipose tissue macrophages are of an anti-inflammatory phenotype but capable of
excessive pro-inflammatory mediator production. Int J Obes (Lond). 31: 1420-8, 2007
Pfistershammer K, Klauser C, Leitner J, Stöckl J, Majdic O, Weichhart T, Sobanov Y,
- 136 -
Bochkov V, Säemann M, Zlabinger G, Steinberger P. Identification of the scavenger
receptors SREC-I, Cla-1 (SR-BI), and SR-AI as cellular receptors for Tamm-Horsfall protein.
J Leukoc Biol. 83:131-8, 2008
- 137 -
6.2 Teachers
Herbert Auer
133
Adelheid Elbe-Bürger
139
Thomas Felzmann
143
Gottfried Fischer
147
151
Renate Fuchs
155
Ulrich Jäger
160
Peter Pietschmann
169
Clemens Scheinecker
177
Veronika Sexl
180
Maria Sibilia
184
Peter Steinberger
188
Günter Steiner
191
Johannes Stöckl
197
Martin Willheim
201
- 138 -
Curriculum Vitae
Herbert Auer
Department of Medical Parasitology, Clinical Institute of Hygiene and Medical Microbiology,
Medical University of Vienna, Kinderspitalgasse 15, 1095 Vienna, Austria
Phone: +43 1 40490-79443, Fax: +43 1 40490-79435
Homepage: http://www.meduniwien.ac.at/hygiene/
Personal Data
Date of Birth:
21.02.1953
Place of Birth:
Zams/Tyrol
Nationality
Austria
Education
1971-1977
PhD studies (Zoology, Botany, Limnology), University of
Innsbruck
1971
University entrance qualification, Gymnasium
Landeck/Tyrol
Career History
10/2004
Leader of the Dept. Med. Parasitology
10/1997
Associate Professor
01/1991
Habilitation in Med. Parasitology, University of Vienna
Medical School
Awards
1987
Filmpreis (wissenschaftlicher Film) Budweis und Barcelona
„Echinococcus multilocularis: Protoscolices in vivo und in
vitro.“
2003
Hovorka
Medal,
Slovak
Academy
of
Helminthological Institute Kosice/Slovak Republic
Science,
- 139 -
Memberships
Austrian Society of Tropical Medicine and Parasitology (Member of the Executive Board:
since 11/1983; as Treasurer, Secretary, President and Vice-President)
German Society of Parasitology
Period
Name of student
Topic
1995-1998
Barbara Bauder
Experimentelle Untersuchungen zur B- und TZell-Immunantwort
bei
primärer
alveolärer
Echinokokkose
1995-1999
Andreas Obwaller
Toxocarosis in humans: Antibodies and antigens
involved in the humoral immune response
Publications
Deutz A, Fuchs K, Auer H, Schuller W, Nowotny N, Kerbl U, Aspöck H, Köfer J. (2002):
Seroepidemiologische Untersuchungen disponierter Personen auf ausgewählte
Kontaktzoonosen. Fleischwirtschaft 82 (1), 101 – 104.
Kinceková J, Auer H, eiterová K, Dubinský P, Szilagyiová M, Lauko L, Aspöck H. (2002): The
- 140 -
first case of autochthonous human alveolar echinococcosis in the Slovak Republic (Case
report). Mitt. Österr. Ges. Tropenmed. Parasitol. 23, 33-38.
Westritschnig K, Sibanda E, Thomas W, Auer H, Aspöck H, Pittner S, Vrtala S, Spitzauer S,
Kraft D, Valenta R. (2003): Analysis of the sensitization profile towards allergens in central
Africa. Clin. Exp. Allergy 33: 22-27.
Kern P, Bardonnet K, Renner E, Auer H, Pawlowski Z, Ammann RW, Vuitton DA, Kern P.
(2003): European echinococcosis registry: human alveolar echinococcosis, Europe, 19822000. Emerg Infect Dis 2003 Mar;9(3), 343-9.
Deutz A, Fuchs K, Schuller W, Nowotny N, Auer H, Aspöck H, Stünzner D, Kerbl U, Klement
Ch, Köfer J. (2003): Seroepidemiologische Untersuchung von Jägern auf Zoonosen in
Südostösterreich – Prävalenzen, Risikopotentiale und Vorbeugemaßnahmen. Berl. Münch.
Tierärztl. Wschr. 116: 306-311.
Auer H. (2003): Toxocara-Infestationen und Toxokarose in Mitteleuropa: Eine Übersicht. In:
Infektiologie – Aktuelle Aspekte (O. Janata, E. Reisinger, Hrsg.). Jahrbuch 2003/2004, pmVerlag: 77-92.
Deutz A, Fuchs K, Nowotny N, Auer H, Schuller W, Stünzner D, Aspöck H, Kerbl U, Köfer J
(2003): Seroepidemiologische Untersuchungen von Jägern auf Zoonosen – Vergleich mit
Untersuchungen bei Tierärzten, Landwirten und Schlachthofarbeitern. Wien. Klin. Wschr.
115 Suppl 3):61-67.
Auer H, Vander-Möse A, Aspöck H (2003): Die verwirrende Vielfalt der IgM-Tests in der
Diagnostik von Toxopalsma-Infektionen: Versuch einer optimalen Strategie. Wien. Klin.
Wschr. 115 (Suppl 3): 18-22.
Rauhofer U, Prager G, Hörmann M, Auer H, Kaserer K, Niederle B (2003): Cystic
echinococcosis of the thyroid gland in children and adults. Thyroid 13, 497-502 (Impact
2000: 2,047)
Westritschnig, Sibanda A, Thomas W, Auer H, Aspöck H, Pittner G, Vrtala S, Spitzauer S,
- 141 -
Kraft D, Valenta R (2003): Analysis of the sensitization profile towards allergens in central
Africa. Clin. Exp. Allergy. 33: 22-27.
Obwaller A, Schneider R, Walochnik J, Gollackner B, Deutz A, Janitschke K, Aspöck H, Auer
H. (2004): Echinococcus granulosus strain differentiation based on sequence heterogeneity
in mitochondrial genes of cytochrome c oxidase-1 and NADH dehydrogenase-1. Parasitology
128: 569-575.
Auer H, Aspöck H (2004): Nosologie und Epidemiologie der Toxokarose des Menschen – die
aktuelle Situation in Österreich. Wien Klin Wochenschr 116 (Suppl. 4): 7-18.
Obwaller A, Duchêne M, Walochnik J, Wiedermann G, Auer H, Aspöck H. (2005):
Association of autoantibodies against small nuclear ribonucleoproteins (snRNPs) with
symptomatic Toxocara canis infestation. Parasite Immunol 26 (8-9): 327-333.
Auer H, Aspöck H. (2005): Vertikale Transmission von Helminthen beim Menschen. Nova
Acta Leopoldina 89 (334): 351-363.
Aspöck H, Auer H, Walochnik J. (2005): Die Prävention der pränatalen Toxoplasmose:
Strategien, Stand der Kenntnis, aktuelle Probleme. Nova Acta Leopoldina 89 (334): 229-268.
Juncker-Voss M, Prosl H, Lussy H, Enzenberg U, Auer H, Lassnig H, Müller M, Nowotny N.
(2005): Untersuchungen auf Antikörper gegen Zoonoseerreger bei Angestellten des Wiener
Tiergartens Schönbrunn. Berl. Münch. Tierärtztl. Wschr. Heft 09/10: 404-409.
Deutz A, Fuchs K, Auer H, Kerbl U, Aspöck H, Köfer J. (2005): Toxocara-infestations in
Austria: a study on the risk of infection of farmers, slaughterhouse staff, huntes and
veterinarians. Parasitol Res. 97: 390-394.
Auer H, Vander-Möse A, Picher O, Aspöck H. (2005): Toxoplasmose-Ringversuche in
Österreich: Ergebnisse und Grenzen des serologischen Schwangeren-Screenings. Wiener
Klinische Wochenschrift 117: 20-28.
Auer H. (2005): Die Trichinellose des Menschen in Österreich. Vet. Med. Austria/Wien.
Tierärztl. Mschr 92: 288-294.
- 142 -
Auer H, Aspöck H. (2006): Die Diagnostik der Toxocara-Infestationen und der Toxokarose
des Menschen. Journal of Laboratory Medicine 30: 1-12.
Finsterer J, Mei Li , Rasmkogeler K, Auer H. (2006): Chronic Long-Standing Headache due
to Neurocysticercosis. – Headache, 46: 523-524.
Auer H. (2006): Die Bedeutung laboratoriumsdiagnostischer Untersuchungen für die Klinik,
Epidemiologie und Prävention der alveolären Echinokokkose – Erfahrungen zweier
Jahrzehnte in Österreich. - Wien. Klin. Wochenschr 118: 18-26.
Hörweg CH., Sattmann H., Auer H. (2006): Cercarial dermatitis in Austria: Questionnaires as
useful tools to estimate risk factors. - Wien. Klin. Wochenschr 118: 77-80.
Cetin E, Sotoudeh M, Auer H, Stanek G. (2006): Paradigm Burgenland: Risk of Borrelia
burgdorferi sensu lato infection indicated by variable seroprevalence rates in hunters. – Wien
Klin Wochenschr 118/21-22: 677-681.
Kinčeková J, Hrčková G, Auer H, Szilágyiová M, Hudačková J, Stanislayová M, Poláček H,
Šimeková K. (2006): Clinical and serological study of human alveolar echinococcosis in
Slovakia in relation to the outcome of chemotherapy. – Helminthologia 43, 4: 213-219.
Koehsler M, Soleiman A, Aspöck H, Auer H, Walochnik J. (2007): Onchocerca jakutensis
Filariasis in Humans. – Emerg Infect Dis. 13: 1749-1752.
Hrčkova G, Velebný S, Obwaller A, Auer H, Kogan G. (2007): Evaluation of follow-up of
therapy with fenbendazole incorportated into stabilized liposomes and immunomodulator
glucan in mice infected with Toxocara canis larvae. – Acta Tropica 104: 122-132.
Schnedl J, Auer H, Fischer M, Tomaso H, Pustelnik T, Mooseder G. (2007): Kutane
Leishmaniose – Import aus Belize. – Wien KlinWochenschr 119: 102-105.
Auer H, Leskowschek H, Engler J, Leitner G, Wentzel Ch, Wolkerstorfer W, Schneider R.
- 143 -
(2007): Epidemiologie und Nosologie der Anisakiose, einer in Mitteleuropa selten
diagnostizierten Helminthozoonose – zwei Fallberichte. – Wien Klin Wochenschr 119: 106109.
Finsterer J, Auer H. (2007): Neurotoxocarosis. – Rev. Inst. Med. trop. S. Paulo 49: 279-287.
Wöhrl S, Schnedl J, Auer H, Walochnik J, Stingl G, Geusau A. (2007): Successful treatment
of a married couple for American leishmaniasis with miltefosine. – Jorunal of the European
Academy of Dermatology and Venerology 22: 258-259.
Schneider R, Gollackner B, Edel B, Schmid K, Wrba F, Tucek G, Walochnik J, Auer H.
Development of a new PCR protocol for the detection of species and genotypes (strains) of
Echinococcus in formalin-fixed, paraffin-embedded tissues Int J Parasitol. 2007 Dec 4 [Epub
ahead of print]
- 144 -
Curriculum Vitae
Adelheid Elbe-Bürger
Division of Immunology, Allergy and Infectious Diseases, Department of Dermatology,
Vienna Competence Center, Medical University of Vienna, Lazarettgasse 19, 1090 Vienna,
Austria;
Phone: +43-1-40160-63001, Fax: +43-1-40160-963005;
Homepage: www.meduniwien.ac.at/immundermatologie/?main
Personal Data
Date of Birth:
11.12.1961
Place of Birth:
Globasnitz
Nationality
Austria
Education
1984 – 1987
PhD studies (Cellular Immunology, Immunodermatology),
Department of Dermatology, University of Vienna Medical
School, and University of Vienna, Faculty of Natural
Sciences
1980 – 1984
Studies in Biology, University of Vienna
1980
University entrance qualification,
Bundesoberstufenrealgymnasium Klagenfurt
Career History
Since 1997
Associate Professor (a.o.Univ.Prof.)
01/1996
Habilitation in Immunology and Immunodermatology,
1992 - 1995
Faculty position (Univ. Ass.)
Group Leader, Department of Dermatology I, University of
1988 - 1992
Postdoctoral fellow at the Department of Dermatology I,
and at the Laboratory of Molecular Biology of Retroviruses,
Memorial Sloan-Kettering Cancer Center, New York, USA
1984 - 1988
PhD thesis performed at the Department of Dermatology I,
Division of Immunobiology, University of Vienna Medical
School
- 145 -
Board Member of the Austrian Society of Allergology and
Immunology
1996 - 1997
Awards
1993
Karl Landsteiner Award, Austrian Society of Allergology
and Immunology
1988
Thesis Award, Austrian Society of Allergology and
Immunology
Memberships
Arbeitsgemeinschaft Dermatologische Forschung (ADF; German Society for Investigative
Dermatology)
Deutsche Gesellschaft für Stammzellforschung
European Society for Dermatological Research (ESDR)
ITERA – Life-Sciences Forum
Österreichische
Gesellschaft
für
Transplantation,
Transfusion
und
Genetik
(AUSTROTRANSPLANT)
Österreichische Gesellschaft für Allergologie und Immunologie (ÖGAI; Austrian Society for
Allergology and Immunology)
Österreichische Gesellschaft für Dermatologie und Venerologie (ÖGDV; Austrian Society of
Dermatology and Venerology)
Period
Organization
2006 - 2009 FWF
2008 - 2008 HJST
Short Title
K€/year
Ontogeny of human cutaneous
dendritic cells
Effects of glucocorticosteroids on neonatal
81
5
and infant skin
2005 - 2007 HJST
Isolation, purification and ex vivo expansion
of human dermal stem/progenitor cells
2004 - 2008 FWF
Dermal hematopoietic stem cells
68
2003 - 2004 HJST
Characterization of human dermal
hematopoietic stem cells
10
2000 - 2003 FWF
Search
for
stem/progenitor cells
62
Langerhans
3
- 146 -
Period
Name of student
2000 - 2004 Souyet Chang-Rodriguez
Topic
Phenotypical,
maturational
and
functional
characterization of dendritic epidermal leukocytes
in fetal and neonatal mice
2001 - 2004 Wolfram Hötzenecker
Effects of topical immunomodulators on the
immune system of the skin
2001 - 2005 Simone Meindl
Characterization, purification and differentiation
potential of cells expressing hematopoietic stem
cell markers in newborn and adult mouse skin
2004 -
Christine Vaculik
present
2008 –
present
Characterization
of
human
dermal
cells
exypressing stem cell markers
Nousheen Iram
Molecular analysis of Toll like receptors in
differentiating human skin cells
Publications
41 peer reviewed publications in scientific journals, 4 reviews, 10 book chapters, 4 varia,
>250 presentations at national and international meetings
Elbe-Bürger A., Egyed A., Olt S., Klubal R., Mann U., Rappersberger K., Rot A., Stingl G.
(2002). Overexpression of IL-4 alters the homeostasis in the skin. J Invest Dermatol,
118:767-778.
Hoetzenecker W., Meingassner J.G., Ecker R., Stingl G., Stuetz A., Elbe-Bürger A. (2004).
Corticosteroids but not pimecrolimus affect viability, maturation and immune function of
murine epidermal Langerhans cells. J Invest Dermatol, 122:673-684.
Chang-Rodriguez S., Ecker R., Stingl G., Elbe-Bürger A. (2004). Autocrine IL-10 partially
prevents differentiation of neonatal dendritic epidermal leukocytes into Langerhans cells. J
Leukoc Biol, 76:657-666.
Elbe-Bürger A., and Stingl G. (2004). Dendritic cells: role in skin immunity and potential
clinical uses. Ann Dermatol Venereol. 131:93-103.
Meindl S., Rot A., Hoetzenecker W., Kato S., Cross H., Elbe-Bürger A. (2005). Vitamin D
receptor ablation alters skin architecture and homeostasis of dendritic epidermal T cells. Br J
Dermatol, 152: 231-241.
Chang-Rodriguez S., Hoetzenecker W., Schwärzler C., Biedermann T., Saeland S., ElbeBürger A. (2005). Fetal and neonatal murine skin harbors Langerhans cell precursors. J
Leukoc Biol, 77:352-360.
Hoetzenecker W., Ecker R., Kopp T., Stuetz A., Stingl G., Elbe-Bürger A. (2005).
Pimecrolimus leads to an apoptosis-induced depletion of T cells but not Langerhans cells in
patients with atopic dermatitis. J Allergy Clin Immunol, 115:1276-1283.
- 147 -
Hoetzenecker W., Meindl S., Stuetz A., Stingl G., Elbe-Bürger A. (2006). Both pimecrolimus
and corticosteroids deplete plasmacytoid dendritic cells in patients with atopic dermatitis. J
Invest Dermatol, 126:2141-2144.
Meindl S., Schmidt U., Vaculik C., Elbe-Bürger A. (2006). Characterization, isolation and
differentiation of murine skin cells expressing hematopoietic stem cell markers. J Leukoc Biol,
80:816-826.
Meingassner J.G., Kowalsky E., Schwendinger H., Elbe-Bürger A., Stütz A. (2003).
Pimecrolimus does not affect Langerhans cells in murine epidermis, in contrast to
corticosteroids. Br J Dermatol, 149:853-857.
Ortiz-Urda S., Elbe-Bürger A., Smolle J., Marquart Y., Chudnovsky Y., Ridky T.W., Bernstein
P., Wolff K., Rappersberger K. (2003). The plant lectin wheat germ agglutinin inhibits the
binding of pemphigus foliaceus autoantibodies to desmoglein 1 in a majority of patients and
prevents pathomechanisms of pemphigus foliaceus in vitro and in vivo. J Immunol,
171:6244-6250.
Tripp C., Chang-Rodriguez S., Stoitzner P., Holzmann S., Stössel H., Saeland S., Koch F.,
Elbe-Bürger A., Romani N. (2004). Ontogeny of Langerin / CD207 expression in the
epidermis of mice. J Invest Dermatol, 122:670-672.
Abrahamsberg C., Fuchs P., Osmanagic-Myers S., Fischer I., Propst F., Elbe-Bürger A.,
Wiche G. (2005). Targeted ablation of plectin isoform 1 uncovers role of cytolinker proteins in
leukocyte recruitment. PNAS, 102:18449-18454.
2002
• Klinik für Pathophysiologie, Wien, Österreich
2003
• Novartis Forschungsinstitut, Wien
2004
• ISAC XXII International Congress. Montpellier, Frankreich
2005
• 6. GD Jahrestagung, Wien
• 35th ESDR Annual Meeting. Tübingen, Deutschland
2006
• Universitätshautklinik Innsbruck
- 148 -
Curriculum Vitae
Thomas Felzmann
Laboratory of Tumour Immunology, St. Anna Children’s Cancer Research Institute,
Kinderspitalgasse 6, 1090 Vienna, Austria;
Phone: +43-1-40170-4060, Fax: +43-1-40170-7150;
Homepage: www.ccri.at
Personal Data
Date of Birth:
15.11.1960
Place of Birth:
Vienna
Nationality
Austria
Education
2007
Habilitation in Immunology, Medical University Vienna
2003-2005
Executive MBA program of the Danube University Krems,
graduation as Master of Business Administration,
November 25, 2005
1999
Board certification as Clinical Immunologist
1986-1989
Training in group dynamics
1980-1987
Medical University, Vienna, A, graduation as Medical
Doctor, December 11, 1987
1975-1980
Secondary College for Chemical Technology,
specialization in Biochemistry and Biochemical
Technology, Vienna, A, graduation, June 3, 1980
Career History
2003-
Founder and CEO, I-Med Cancer Immune Therapy GmbH
1995-
Group leader, Laboratory of Tumor Immunology, St. Anna
Children’s Cancer Research Institute, Vienna, A
1995-1998
Clinical training in pediatric oncology at the St. Anna
Children’s Hospital, Vienna, A
1992-1995
Research Fellow at the Clinical Gene Therapy Branch,
National Human Genome Research Institute, National
Institute of Health, Bethesda, MD, USA
1991-1992
Clinical training in oncology at the I. Medical Department,
Wilhelminenspital, Vienna, A
- 149 -
1988-1992
Postdoctoral fellow at the Institute of Immunology, Medical
University, Vienna, A
1987-1989
Physician at the blood bank of the Austria Red Cross,
Vienna, A.
1987
Social worker as ambulance physician for the Austria Red
Cross, Vienna, A.
1975-1987
Various full and part time jobs as a working student
Awards
2003
Fellowship for the Executive MBA program of the Danube
University Krems, A
1994
Fogarty Fellowship, National Institute of Health, Bethesda,
MD, USA
1992
Max Kade Fellowship, Austrian Academy of Science
Memberships
Period
Organization
2005 - 2006 Austrian Research
Short Title
K€/year
Gemodec
450
2003 - 2006 EU FP6
Dendritophages
500
2002 - 2008 Vienna Busniess
Clinical Development of a DC Cancer
Promotion Fund
Agency
2001 - 2006 Austrian Research
1000
Vaccine
Biology of DC Cancer Vaccination
500
2000 - 2002 Mayor of Vienna
Xenogenisation of Tumour Cells
200
1999 - 2001 Austrian National
Genetic Engineering of Tumour Cells
200
Promotion Fund
Bank
Period
Name of student
2000 - 2004 Katharina Hüttner
Topic
Development of a mouse tumour model for
dendritic cell cancer vaccination
2004 - 2008 Mareike Lindbauer
Knock down of IDO in a mouse tumour model to
improve dendritic cell cancer vaccination
- 150 -
2006 - 2007 Petra Paul
Two-step maturation of dendritic cells
2007-2008
Romana Luger
Lentiviral engineering of dendritic cells
2007-2008
Michael Traxlmayr
Immun eregulation by γδ T-cells.
Publications
20 peer reviewed publications in scientific journals, 3 international patent families
Dohnal A, Witt V, Hugel H, Holter W, Gadner H, Felzmann T.Phase I study of tumor Agloaded IL-12 secreting semi-mature DC for the treatment of pediatric cancer. Cytotherapy.
2007 Oct;9(8):755-70
Hüttner KG, Breuer SK, Paul P, Majdic O, Heitger A, Felzmann T. Generation of potent antitumor immunity in mice by interleukin-12-secreting dendritic cells. Cancer Immunol
Immunother. 2005 Jan;54(1):67-77.
Felzmann T, Hüttner KG, Breuer SK, Wimmer D, Ressmann G, Wagner D, Paul P, Lehner
M, Heitger A, Holter W. Semi-mature IL-12 secreting dendritic cells present exogenous
antigen to trigger cytolytic immune responses. Cancer Immunol Immunother. 2005
Aug;54(8):769-80.
Felzmann T, Witt V, Wimmer D, Ressmann G, Wagner D, Paul P, Huttner K, Fritsch G.
Monocyte enrichment from leukapharesis products for the generation of DCs by plastic
adherence, or by positive or negative selection. Cytotherapy. 2003;5(5):391-8.
Felzmann T, Gadner H, Holter W. Dendritic cells as adjuvants in antitumor immune therapy.
Onkologie. 2002 Oct;25(5):456-64.
Felzmann T, Buchberger M, Lehner M, Printz D, Kircheis R, Wagner E, Gadner H, Holter W.
Functional maturation of dendritic cells by exposure to CD40L transgenic tumor cells,
fibroblasts or keratinocytes. Cancer Lett. 2001 Jul 26;168(2):145-54.
Felzmann T, Buchberger M, Jechlinger M, Kircheis R, Wagner E, Gadner H. Xenogenization
by tetanus toxoid loading into lymphoblastoid cell lines and primary human tumor cells
mediated by polycations and liposomes. Cancer Lett. 2000 Dec 20;161(2):241-50.
Felzmann T, Ramsey WJ, Blaese RM. Anti-tumor immunity generated by tumor cells
engineered to express B7-1 via retroviral or adenoviral gene transfer. Cancer Lett. 1999 Jan
8;135(1):1-10.
Felzmann T, Ramsey WJ, Blaese RM. Characterization of the antitumor immune response
generated by treatment of murine tumors with recombinant adenoviruses expressing HSVtk,
IL-2, IL-6 or B7-1. Gene Ther. 1997 Dec;4(12):1322-9.
Felzmann T, Gisslinger H, Ludwig H. Immunological findings in patients with myelodysplastic
syndrome. Leuk Lymphoma. 1994 Oct;15(3-4):201-8. Review.
Felzmann T, Gisslinger H, Krieger O, Majdic O, Ludwig H, Koller U. Immunophenotypic
characterization of myelomonocytic cells in patients with myelodysplastic syndrome. Br J
Haematol. 1993 Jul;84(3):428-35.
- 151 -
Felzmann T, Gadd S, Majdic O, Maurer D, Petera P, Smolen J, Knapp W. Analysis of
function-associated receptor molecules on peripheral blood and synovial fluid granulocytes
from patients with rheumatoid and reactive arthritis. J Clin Immunol. 1991 Jul;11(4):205-12.
Lehner M, Stockl J, Majdic O, Knapp W, Huttner K, Felzmann T, Holter W. MHC class II
antigen signaling induces homotypic and heterotypic cluster formation of human mature
monocyte derived dendritic cells in the absence of cell death. Hum Immunol. 2003
Aug;64(8):762-70.
Lehner M, Felzmann T, Clodi K, Holter W. Type I interferons in combination with bacterial
stimuli induce apoptosis of monocyte-derived dendritic cells. Blood. 2001 Aug 1;98(3):73642.
Kircheis R, Kichler A, Wallner G, Kursa M, Ogris M, Felzmann T, Buchberger M, Wagner E.
Coupling of cell-binding ligands to polyethylenimine for targeted gene delivery. Gene Ther.
1997 May;4(5):409-18.
Maurer D, Felzmann T, Holter W, Petera P, Smolen J, Knapp W. Evidence for the presence
of activated CD4 T cells with naive phenotype in the peripheral blood of patients with
rheumatoid arthritis. Clin Exp Immunol. 1992 Mar;87(3):429-34.
Gadd SJ, Felzmann T, Majdic O, Maurer D, Petera P, Chen WJ, Smolen J, Knapp W.
Phenotypic analysis of functionally associated molecules on peripheral blood and synovial
fluid monocytes from arthritis patients. Rheumatol Int. 1992;12(4):153-7.
Szekeres T, Fritzer M, Pillwein K, Felzmann T, Chiba P. Cell cycle dependent regulation of
IMP dehydrogenase activity and effect of tiazofurin. Life Sci. 1992;51(16):1309-15.
Maurer D, Fischer GF, Felzmann T, Majdic O, Gschwantler E, Hinterberger W, Wagner A,
Knapp W. Ratio of complement receptor over Fc-receptor III expression: a sensitive
parameter to monitor granulocyte-macrophage colony-stimulating factor effects on
neutrophils. Ann Hematol. 1991 Apr;62(4):135-40.
Maurer D, Felzmann T, Knapp W. A single laser flow cytometry method to evaluate the
binding of three antibodies. J Immunol Methods. 1990 Dec 31;135(1-2):43-7.
- 152 -
Curriculum Vitae
Gottfried Fischer
Division of Blood Group Serology, Department for Blood Group Serology and Transfusion
Medicine, Medical University of Vienna, Währinger Gürtel 18-20, 1090 Wien, Austria;
Phone: +43-1-40400 5320, Fax: +43-1-40400 5321;
Homepage: n.e.
Personal Data
Date of Birth:
16.09.1960
Place of Birth:
Vienna
Nationality
Austria
Education
1985
Promotion Dr. med. Univ
1978 – 1985
Studies in Medicine, University of Vienna
1978
University entrance qualification, BG Bruck/Leitha
Career History
1993
Habilitation in Blood Group Serology, University of Vienna
Medical School
Since 1987
Assistant Doctor at the Institute for Blood Group Serology
1985 – 1987
Post Doctoral Stay at the Institute for Immunology,
University of Vienna Medical School, Group Prof. Knapp
2002-2007
Commissioner for Region 05, Accreditation Committee of
the European Federation for Immunogenetics
Since 2007 – present
Chairman of the Accreditation Committee of the European
Federation for Immunogenetics
Awards
1991-1993
Erwin-Schrödinger Postdoctoral Fellowship, FWF
Memberships
Austrian Society for Allergology and Immunology, Deutsche Gesellschaft für Immungenetik
- 153 -
Period
Organization
2005 - 2008 EU
Short Title
K€/year
EU Marie Curie Research & Training
40
Network (TRANSNET)
None
Publications
>25 peer reviewed publications in scientific journals, >2 book chapters, >5 invited lectures, 0
patents
Ludajic, K., Balavarca , Y., Bickeböller H., Pohlreich D., Kouba M., Dobrovolna M, Vrana M.,
Rosenmayr A., Fae, I., Fischer, G.F, Kalhs P. & Greinix H.T. (2008) Impact of HLA-DPB1
Allelic and Single Amino Acid Mismatches on HSCT. Br. J Haematology, in press
Ludajic, K., Fae, I. & Fischer, G.F. (2006) Characterization of a new HLA-DPB1 allele,
DPB1*010103. Tissue Antigens, 67, 255-256.
Greinix, H.T., Fae, I., Schneider, B., Rosenmayr, A., Mitterschiffthaler, A., Pelzmann, B.,
Kalhs, P., Lechner, K., Mayr, W.R. & Fischer, G.F. (2005) Impact of HLA class I highresolution mismatches on chronic graft-versus-host disease and survival of patients given
hematopoietic stem cell grafts from unrelated donors. Bone Marrow Transplant, 35, 5762.
Fischer, G. (2002) Immunogenetic selection of donors for haematopoietic stem cell
transplantation: an approach. Transpl Immunol, 10, 223-225.
Leb, V.M., Jahn-Schmid, B., Schmetterer, K.G., Kueng, H.J., Haiderer, D., Neunkirchner, A.,
Fischer, G.F., Nissler, K., Hartl, A., Thalhamer, J., Bohle, B., Seed, B. & Pickl, W.F.
(2008) Molecular and functional analysis of the antigen receptor of Art v 1-specific helper
T lymphocytes. J Allergy Clin Immunol, 121, 64-71.
Mrazek, F., Fae, I., Ambruzova, Z., Raida, L., Kriegova, E., Indrak, K., Fischer, G.F. &
Petrek, M. (2006) A single amino acid exchange shifts the serological reactivity of the
novel HLA-B*4442 allele product from HLA-B44 to HLA-B21. Int J Immunogenet, 33, 197200.
Penn, D.J., Oberzaucher, E., Grammer, K., Fischer, G., Soini, H.A., Wiesler, D., Novotny,
M.V., Dixon, S.J., Xu, Y. & Brereton, R.G. (2007) Individual and gender fingerprints in
human body odour. J R Soc Interface, 4, 331-340.
Tiercy, J.M., Fischer, G. & Setterholm, M. (2007) Quality control for registry HLA data. Tissue
Antigens, 69 Suppl 1, 13-14.
Vidan-Jeras, B., Ambroz, N., Fae, I., Kemperle, I. & Fischer, G. (2007) HLA-B*350802, a
novel allele, which has arisen by silent mutation at codon 67. Tissue Antigens, 69, 363.
Worel, N., Greinix, H.T., Supper, V., Leitner, G., Mitterbauer, M., Rabitsch, W., Fischer, G.,
Rosenmayr, A., Hocker, P. & Kalhs, P. (2007) Prophylactic red blood cell exchange for
- 154 -
prevention of severe immune hemolysis in minor ABO-mismatched allogeneic peripheral
blood progenitor cell transplantation after reduced-intensity conditioning. Transfusion, 47,
1494-1502.
Danzer, M., Polin, H., Proll, J., Hofer, K., Fae, I., Fischer, G.F. & Gabriel, C. (2007) Highthroughput sequence-based typing strategy for HLA-DRB1 based on real-time
polymerase chain reaction. Hum Immunol, 68, 915-917.
Karvunidis, T., Jindra, P., Fischer, G., Venigova, P., Dorner, A. & Koza, V. (2007)
Identification of a novel HLA-DRB1*14 allele, HLA-DRB1*1458, by sequence-based
typing. Tissue Antigens, 70, 348-349.
Meraner, P., Horejsi, V., Wolpl, A., Fischer, G.F., Stingl, G. & Maurer, D. (2007) Dendritic
cells sensitize TCRs through self-MHC-mediated Src family kinase activation. J Immunol,
178, 2262-2271.
Vidan-Jeras, B., Kunilo, S., Fae, I., Kandus, A. & Fischer, G.F. (2006) A novel HLA-B*2730
allele found in a Slovene patient affected with IgA nephropathy. Int J Immunogenet, 33,
371-373.
Danzer, M., Polin, H., Fae, I., Fischer, G.F. & Gabriel, C. (2006) Exon 1-4 sequence analysis
of a novel HLA-A allele, HLA-A*2458. Tissue Antigens, 68, 177-178.
Bohle, B., Zwolfer, B., Fischer, G.F., Seppala, U., Kinaciyan, T., Bolwig, C., Spangfort, M.D.
& Ebner, C. (2005) Characterization of the human T cell response to antigen 5 from
Vespula vulgaris (Ves v 5). Clin Exp Allergy, 35, 367-373.
Jahn-Schmid, B., Fischer, G.F., Bohle, B., Fae, I., Gadermaier, G., Dedic, A., Ferreira, F. &
Ebner, C. (2005) Antigen presentation of the immunodominant T-cell epitope of the major
mugwort pollen allergen, Art v 1, is associated with the expression of HLA-DRB1 *01. J
Allergy Clin Immunol, 115, 399-404.
Mrazek, F., Fae, I., Ambruzova, Z., Raida, L., Indrak, K., Petrek, M. & Fischer, G.F. (2005) A
novel HLA-B*420502 allele identified by PCR-SSO/SSP routine typing and confirmed by
Sequencing-based typing. Tissue Antigens, 65, 275-277.
Danzer, M., Leitner, D., Gangl, E., Fae, I., Fischer, G.F. & Gabriel, C. (2004) A novel HLADRB1*13 allele (DRB1*1357) identified by polymerase chain reaction with sequencespecific primers and direct sequencing. Tissue Antigens, 64, 213-214.
Fae, I., Lau, M., Voorter, C., Mayr, W.R. & Fischer, G.F. (2004) HLA-B*8102*, a new allele
found in an external proficiency testing scheme. Tissue Antigens, 64, 608-610.
Voorter, C.E., Fischer, G.F. & van den Berg-Loonen, E.M. (2004) Identification of a new
HLA-C allele, Cw*0316, by sequence-based typing. Tissue Antigens, 63, 484-486.
Weiwad, M., Werner, A., Rucknagel, P., Schierhorn, A., Kullertz, G. & Fischer, G. (2004)
Catalysis of proline-directed protein phosphorylation by peptidyl-prolyl cis/trans
isomerases. J Mol Biol, 339, 635-646.
Bohle, B., Radakovics, A., Jahn-Schmid, B., Hoffmann-Sommergruber, K., Fischer, G.F. &
Ebner, C. (2003) Bet v 1, the major birch pollen allergen, initiates sensitization to Api g 1,
the major allergen in celery: evidence at the T cell level. Eur J Immunol, 33, 3303-3310.
Spatz, M., Eibl, N., Hink, S., Wolf, H.M., Fischer, G.F., Mayr, W.R., Schernthaner, G. & Eibl,
M.M. (2003) Impaired primary immune response in type-1 diabetes. Functional
impairment at the level of APCs and T-cells. Cell Immunol, 221, 15-26.
Vogelsang, H., Panzer, S., Mayr, W.R., Granditsch, G. & Fischer, G.F. (2003) Distribution of
HLA class I alleles differs in celiac disease patients according to age of onset. Dig Dis
Sci, 48, 611-614.
Winter, D., Fiebiger, E., Meraner, P., Auer, H., Brna, C., Strohal, R., Trautinger, F., Knobler,
R., Fischer, G.F., Stingl, G. & Maurer, D. (2003) Definition of TCR epitopes for CTLmediated attack of cutaneous T cell lymphoma. J Immunol, 171, 2714-2724.
Jahn-Schmid, B., Kelemen, P., Himly, M., Bohle, B., Fischer, G., Ferreira, F. & Ebner, C.
(2002) The T cell response to Art v 1, the major mugwort pollen allergen, is dominated by
- 155 -
one epitope. J Immunol, 169, 6005-6011.
Worel, N., Biener, D., Kalhs, P., Mitterbauer, M., Keil, F., Schulenburg, A., Hocker, P.,
Dieckmann, K., Fischer, G., Rosenmayr, A., Linkesch, W., Hinterberger, W., Lechner, K.
& Greinix, H.T. (2002) Long-term outcome and quality of life of patients who are alive and
in complete remission more than two years after allogeneic and syngeneic stem cell
transplantation. Bone Marrow Transplant, 30, 619-626.
Worel, N., Greinix, H.T., Keil, F., Mitterbauer, M., Lechner, K., Fischer, G., Mayr, W., Hocker,
P. & Kalhs, P. (2002) Severe immune hemolysis after minor ABO-mismatched allogeneic
peripheral blood progenitor cell transplantation occurs more frequently after
nonmyeloablative than myeloablative conditioning. Transfusion, 42, 1293-1301.
2005
• Invited talk at the DGI Tagung, Dresden
2006
• Invited talk at the DGI Tagung, Innsbruck
2007
• Invited talk at the Balcanic Immunogentics Conference, Bukarest
2008
• Invited Talk at the East West Conference, Prague
- 156 -
Curriculum Vitae
Department of Pediatrics & Adolescent Medicine, Division of General Pediatrics &
Neonatology, Medical University of Vienna, Währinger Gürtel 18-20, 1090 Wien, Austria;
Phone: +43-1-40400-3232, Fax: +43-1-40400-3238;
Homepage: www.meduniwien.ac.at/kikli
Personal Data
Date of Birth:
07.12.1960
Place of Birth:
Pittsburgh, Pa., U.S.A.
Nationality
Austria
Education
1988
Graduation as Doctor Medicinae (M.D.)
1979-1988
Graduate studies at the University of Vienna Medical
School
1971-1979
High school in Vienna, Austria
1966-1971
French elementary school (Lycée français de Vienne) in
Vienna, Austria
Career History
since 2007
Consultant for Pediatric Immunology at the St. Anna
Children’s Hospital, Vienna, Austria
since 2005
Head of the Pediatric Immunology Outpatient Ward at the
Department of Pediatrics, Medical University of Vienna
since 2005
Group leader of the Working Group Pediatric & Neonatal
Immunology at the Department of Pediatrics, Medical
University of Vienna, Austria
since 11/2004
Associate Professor of Pediatrics (a.o.Univ.Prof)
11/2004
Habilitation in Pediatrics, Medical University of Vienna
since 2002
Medical specialist for Immunology
2001
Guest Scientist at the Institute of Immunology, Medical
since 2000
Medical specialist for Pediatrics & Adolescent Medicine
1992 – 1999
Resident in pediatrics at the Dept. of Pediatrics, Univ. of
- 157 -
Vienna. Special training in clinical immunology and
allergology/pulmology
1996 – 1998
Research Fellow (Erwin Schrödinger Grant of the Austrian
Science Fund) at the Dept. of Pediatric Immunology
(Head: Prof. Dr. G.A. Holländer), Basel, CH. Topic: The
role of CD40-mediated costimulation in T-cell activation
and tolerance (in a mouse allogeneic transplantation
model)
1991 – 1992
Research Fellow
(Otto Loewi-Grant of the Austrian
Science Fund) at the Dept. of Pediatrics, Univ. of Vienna,
working on T-cell regulation of allergic diseases (model:
bee venom allergy) and on the allergenic profile of
recombinant bee venom Phospholipase A2, the major beevenom allergen
1988 – 1991
Research fellow at the Dept. of Dermatology, Univ. of
Vienna, Ludwig Boltzmann-Institute for cell biology in
immunodermatological reactions (Head: Prof. Dr. T.A.
Luger), working on the cytokine regulation of inflammatory
immune reponses in the skin
2003
4th Advanced Vaccinology Course at the Fondation
Mérieux
1999
Guest Scientist at the Scripps Research Institute, La Jolla,
USA, working on immunomodulatory therapies by DNA
vaccines and antibody-cytokine fusion proteins
1996 – 1998
Research Fellow (Erwin Schrödinger Grant of the Austrian
Science Fund) at the Dept. of Pediatric Immunology
(Head: Prof.Dr.G.A. Holländer), Basel, CH
Awards
2006
Scientific award of the GNPI (Gesellschaft für
Neonatologie und Pädiatrische Intensivmedizin) for the
original publication (first author) ‚Monocyte Toll-like
receptor 4 expression and LPS-induced cytokine
- 158 -
production increase during gestational aging’
2005
Poster-Award (last author) at the Annual Meeting of the
Austrian Society of Pediatrics Sept.2005; „ Impaired
Immune Responses to Bacterial Cell Wall Components in
Preterm Newborns“
1999
Hofrat von Domanig Award of the Van Swieten
Gesellschaft to work as guest-scientist at the Scripps
Research Institute, La Jolla, USA, with immunomodulating
therapies through DNA-vaccines and antibody-cytokine
fusion proteins
Memberships
Working Group for Pediatric Immunology (API)
Austrian Society of Pediatrics
European Society for Pediatric Infectious Diseases (ESPID)
Van Swieten Gesellschaft
Research Topics
Neonatal and Pediatric Immunology, Immunological Immaturity and Immunodeficiencies,
Preventive and therapeutic strategies against infectious diseases, vaccine failures due to
immunodefiency and strategies to prevent such failures, vaccine adjuvant strategies and
vaccine delivery systems (experimentally: DNA-vaccines)
Publications
22 peer reviewed publications in scientific journals, 4 reviews & book chapters
Peer reviewed manuscripts 2002-2008 (original research)
Sadeghi K., Berger A., Langgartner M., Prusa A.R., Hayde M., Herkner K., Pollak A., Spittler
A., Förster-Waldl E. Immaturity of infection control in preterm and term newborns is
associated with impaired TLR signaling. J Infect Dis. 195: 296–302 (2007)
Fest S., Huebener N., Weixler S., Zeng Y., Strandsby A., Bleeke M., Volkmer-Engert R.,
Landgraf
C., Gaedicke G., Riemer A., Jensen-Jarolim E., Michalsky E., Jaeger I.S.,
Preissner R., Förster-Waldl E., Lode H.N.. Characterisation of GD2 Peptide Mimotope
DNA Vaccines effective against spontaneous neuroblastoma metastasis. Cancer Res.
66 (21): 10567-75 (2006)
Riemer A.B., Förster-Waldl E., Brämswig K., Pollak A., Zielinski C.C., Pehamberger H., Lode
H.N., Scheiner O., Jensen-Jarolim E. Induction of IgG antibodies against the GD2
carbohydrate tumor antigen by vaccination with peptide mimotopes. Eur J Immunol.
- 159 -
36(5):1267-74 (2006)
Förster-Waldl E., K. Sadeghi, D. Tamandl, B. Gerhold, U. Hallwirth, K. Rohrmeister, M.
Hayde, K. Herkner, G. Boltz-Nitulescu, A. Pollak, and A. Spittler. Monocyte Toll-like
receptor 4 expression and LPS-induced cytokine production increase during
gestational aging. Pediatr Res. 58 (1):121-24. (2005)
Förster-Waldl, E., A.B. Riemer, A.K. Dehof, D. Neumann, K. Brämswig, G. BoltzNitulescu, H. Pehamberger, C.C. Zielinski, O. Scheiner, A. Pollak, H. Lode, E. JensenJarolim. Isolation and structural analysis of peptide mimotopes for the
disialoganglioside GD2, a neuroblastoma tumor antigen. Mol Immunol. 42(3):319-25
(2005)
Szalai K., Schöll I., Förster-Waldl E., Riemer AB, Boltz-Nitulescu G, Polito L, Bolognesi A.,
Stirpe F., Jensen-Jarolim E. Occupational sensitization to ribosome-inactivating
proteins (RIPs) in Researchers. Clin Exp Allergy 35 (10):1354-60 (2005)
Schöll I, Weissenböck A, Förster-Waldl E, Untersmayr E, Walter F, Willheim M, BoltzNitulescu G, Scheiner O, Gabor F, Jensen-Jarolim E: Allergen-loaded biodegradable
PLGA nanoparticles downregulate an ongoing Th2-response in the Balb/c mouse model.
Clin.Exp.Allergy 34(2):315-21 (2004)
Schuller E, Förster-Waldl E, Slavc I, Maurer W: Immunity against vaccine-preventable
potentially neurotropic diseases in children treated for malignant brain tumours with
HIT-91 chemo- and radiotherapy. Eur J Cancer 40(2):236-44 (2004)
Förster-Waldl E, Marchetti M, Schöll I, Focke M, Radauer C, Kinaciyan T, Nentwich I,
Schmid ER, Boltz-Nitulescu G, Scheiner O, Jensen-Jarolim E: Type I Allergy to Elderberry
is elicited by a 33.2 kDa Allergen with significant Homology to Ribosomal Inactivating
Proteins (RIPs). Clin.Exp.Allergy, 33: 1703-10 (2003)
Untersmayr E, Schöll I, Swoboda I, Beil W, Förster-Waldl E, Walter F, Riemer A, Kraml G,
Kinaciyan T, Spitzauer S, Boltz-Nitulescu G, Scheiner O, Jensen-Jarolim E: Antacid
medication inhibits digestion of dietary proteins and causes food allergy: a fish allergy
model in Balb/c mice. J Allergy Clin Immunol. 112:616-23 (2003)
Förster-Waldl E, Cokoja L, Förster O, Maurer W: Mannose binding lectin: comparison of
two assays for the quantification of MBL in serum of pediatric patients. J Immunol
Methods. 276(1-2):143-46 (2003)
Schöll I, Wiedermann U, Förster-Waldl E, Ganglberger E, Baier K, Boltz-Nitulescu G,
Scheiner O, Ebner C, Jensen-Jarolim E: Phage-displayed Bet mim 1, a mimotope of the
major birch pollen allergen Bet v 1, induces B-cell responses to the natural antigen
using bystander T-cell help. Clin.Exp.Allergy 32:1583-88 (2002)
- 160 -
Curriculum Vitae
Renate Fuchs
Research Group for Cell Biology, Division of Cellular and Molecular Pathophysiology,
Department of Pathophysiology, Center for Physiology, Pathophysiology and Immunology,
Medical University of Vienna, Waehringer Guertel 18-20, 1090 Vienna, Austria;
Phone: +43 1 40400-5127, Fax: +43 1 40400-5130
Homepage: www.meduniwien.ac.at/ipp
Personal Data
Date of Birth:
24.12.1950
Place of Birth:
Vienna
Nationality
Austria
Education
2.5.1984
Ph.D. (Dr.rer.nat.techn.) University of Agriculture, Vienna,
Austria
1977-1983
Thesis:”Influence of vitamin D on chick small intestinal
transport systems (interrupted by 2 maternal leaves)
7.7.1977
Master of Science in Food- and Biotechnology (Dipl.Ing.)
1976-1977
Diploma Thesis: „Glucosidehydrolases“
1969-1977
Food- and Biotechnology, University of Agriculture,
Vienna, Austria
1961-1969
High School; graduation with distinction
Career History
2004 - present
Associate Professor, Department of Pathophysiology,
Medical University of Vienna, Austria
1994
Title: “tit. Ao.Prof.”
1991
Head of Research Group for Cell Biology
1990-2004
Associate Professor, Department of General and
Experimental Pathology – 2000 renamed Department of
Pathophysiology
1.3.1990
Habilitation (Venia docendi) in Experimental Pathology,
Univ. Vienna, Austria
1989-1990
Assistant Professor, Department of General and
Experimental Pathology, Univ. Vienna
- 161 -
1986-1989
Research Associate, Department of General and
Experimental Pathology, Univ. Vienna, Austria
1985-1986
Post-doctoral Associate, Dept. Cell Biology, Yale Univ.,
New Haven, USA
1984-1985
Post-doctoral Fellow: Dept. Cell Biology, Yale Univ., New
Haven, USA
1983
Visiting Scientist at the Max Planck-Institute of Biophysics,
Frankfurt, Germany
1979
Visiting Scientist at the Max Planck-Institute of Biophysics,
Frankfurt, Germany
1977-1984
Department of General and Experimental Pathology, Univ.
Vienna, Austria
1990 - present
Supervision of 14 Ph.D and 8 diploma students
1990 - present
Reviewer for the following journals: MBC, JBC, EMBO J,
Traffic, J Virol, Virology, Mol Ther, Clin Exp Allergy, Exp.
Gerontol, Int. Hepatol.
1990 - present
Grant reviewer for: Academy of Finland (chairman), ESF,
ETH Swiss, CNRS France, German-Israel Foundation for
Scientific Research, British Research Council (BBSRC),
OeNB
Awards
1996
Hoechst Research Award
1990
Kardinal-Innitzer-Förderungspreis
1988
Hans Popper Award of the American Liver Association
1986
1984 - 1986
Max-Kade Fellowship
1980
Memberships
American Society for Cell Biology
American Society for Microbiology, Section Virology
Period
Organization
Short Title
K€/year
- 162 -
2004-2007
FWF 17590
Rhinovirus RNA uncoating and membrane
152
translocation
2004
AP00032OFF
Visualization of placental membrane
Aktion Österreich-
transporters
6
Tschechien
2000-2004
Virologie-Fonds
Viral receptors in human rhinovirus infection
44
Kooperation Dr. Blaas
1999-2002
OeNB 7511
Elektrophysiology of virus infection
6
2000-2004
FWF 14079-MED
hFcRn expression in the placenta
58
Period
Name of student
Topic
1999-2003
Leitner Karl
hFcRn/Beta-2-Mikroglobulin (β2m) expression in
human placental sycytiotrophoblasts
2000-2004
Baravalle Günther
Characterization of the intracellular pathways
and requirements for infection of the minor group
human rhinovirus serotype 2
2000-2004
Exner Bettina
1999-2007
Brabec Marianne
Functional expression of the human neonatal Fcreceptor, hFcRn, in Ewing´s sarcoma
Mechanism of entry and RNA release of human
rhinovirus serotype 2 (HRV2)
2003
Busch Bernhard
2005-
Berka Ursula
FcRn mediated IgG-transport
Human rhinovirus RNA translokation
present
Publications
52 peer reviewed publications in scientific journals; 16 publications: book chapters,
handbooks and proceedings; 28 invited lectures.
Ellinger, I., Klapper, H., Courtoy, P.J., Vaerman, J.P.and Fuchs, R. (2002). Different
temperature-sensitivity of endosomes involved in transport to lysosomes and transcytosis in
rat hepatocytes: Analysis by free-flow electrophoresis. Electrophoresis, 23, 2117-2129.
Leitner, K., Ellinger, A., Zimmer, K.P., Ellinger, I. and Fuchs, R. (2002). Localization of ß2microglobulin in term villous syncytiotrophoblasts. Histochem. Cell Biol, 117, 187-193.
Brabec, M., Baravalle, G., Blaas, D. and Fuchs, R (2003). Conformational changes, plasma
membrane penetration and infection of human rhinovirus 2: role of receptors and low pH. J
Virol, 77, 5370-5377.
Baravalle, G., Snyers, L., Brabec, M., Blaas, D. and Fuchs, R. (2004). Human rhinovirus type
- 163 -
2-antibody complexes enter and infect cells via Fc-gamma receptor IIB1. J. Virol., 78, 27292735.
Fuchs, R., Ellinger, I. (2004). Endocytic and transcytotic processes in
syncytiotrophoblast: role in nutrient transport to the human fetus. Traffic, 5, 725-738.
villous
Brabec, M., Schober, D., Wagner, E., Bayer, N., Murphy, R.F. and Blaas, D. (2005). Opening
of size-selective pores in endosomes during human rhinovirus serotype 2 in vivo uncoating
monitored by single-organelle flow analysis. J Virol, 79, 1008-1016.
Baravalle, G., Schober, D., Huber, M., Bayer, N., Murphy, R.F. and Fuchs, R. (2005).
Transferrin recycling and dextran transport to lysosomes is differentially affected by
bafilomycin, nocodazole, and low temperature. Cell Tissue Res, 320, 99-113.
Ellinger, I., Reischer, H., Lehner, C., Leitner, K., Hunziker, W. and Fuchs, R. (2005).
Overexpression of the human neonatal Fc-receptor alpha-chain in trophoblast-derived BeWo
cells increases cellular retention of beta2-microglobulin. Placenta ,26,171-182.
Brabec, M., Blaas, D. and Fuchs, R. (2006) Wortmannin delays transfer of human rhinovirus
serotype 2 to late endocytic compartments. Biochem Biophys Res Commun, 348,741-749.
Brabec-Zaruba, M., Blaas, D. and Fuchs, R (2007). Induction of autophagy does not affect
human rhinovirus type 2 production. J Virol, 81,10815-10817.
Goncalves, C., Mennesson, E., Fuchs, R., Gorvel, J.P., Midoux, P., Pichon, C. (2004)
Macropinocytosis of polyplexes and recycling of plasmid via the clathrin-dependent pathway
impair the transfection efficiency of human hepatocarcinoma cells. Mol Ther, 10, 373-385.
Roth-Walter, F., Scholl, I., Untersmayr, E., Fuchs, R., Boltz-Nitulescu, G., Weissenbock A., et
al. (2004). M cell targeting with Aleuria aurantia lectin as a novel approach for oral allergen
immunotherapy. J Allergy Clin Immunol, 114, 1362-1368.
2002
• 23.8.-25.8.2002:Virus-cell interactions, Tvarminne, Finnland "Receptor independent
uncoating of the minor group human rhinovirus HRV2”
2003
•
•
24.2.2003: Institut für Molekulare Pathologie, Universität Louvain, Brüssel „Influence of
bafilomycin and nocodazole on HRV2 entry pathways“
26.2.2003: Institut für Med. Biochemie, Univ. Wien „HRV2 entry and uncoating“
2004
•
2005
•
•
•
26.11.2004: Frauenklinik Graz; „IgG Transport in der Plazenta“
9.2.2005: Kongreß “The brush border membrane”, Fulda, Deutschland; “IgG transport
across epithelia mediated by the human neonatal Fc-Receptor, hFcRn”
1.8.2005: Kongreß “Virus Cell Interactions”, Seli, Finnland; “Entry and replication of
human rhinoviruses”
24.8.2005: Microscopy Conference – Dreiländertagung, Davos, Schweiz; “Dynamics
of human rhinovirus infections”
- 164 -
•
•
2006
•
•
•
•
2007
•
2008
•
2.10. 2005: GRC Summer School, Hannover, Deutschland; “Entry and replication of
3.10. 2005: Dept. Biochemie, Universität Hannover, Deutschland; “IgG transport in
the human placenta”
17.6.-22.6.2006: FASEB Research Conference on Virus Assembly; Vermont
Academy, VT, USA; “Entry and uncoating of human rhinoviruses.
6.-9.9.2006: IFPA Meeting 2006, Kobe, Japan; “IgG transport in placental
trophoblasts”
26.11.-1.12.2006: EUROPIC 2006, Inari, Finnland; “Entry and uncoating of human
rhinoviruses
19.8.2005: Kongreß “Virus Cell Interactions”, Seli, Finnland; “Entry and replication of
19.8.-21.8.2007: Kongreß Virus Cell Interactions, Archipelago Research Institute,
Seli, Finland: Entry and RNA release of the minor group virus HRV2.
8. 2.2008: Univ. Cambridge, GB : Mechanism of human rhinovirus infections
- 165 -
Curriculum Vitae
Ulrich Jäger
Department of Internal Medicine I, Division of Hematology, Medical University of Vienna,
Waehringer Guertel 18-20, 1090 Wien, Austria;
Phone: +43-1-40400-4409, Fax: +43-1-40400-4030
Personal Data
Date of Birth:
04.06.1956
Place of Birth:
Lienz
Nationality
Austria
Education
1996
Specialist of Hematology and Oncology
1990
Internist
1974 - 1982
University of Vienna, Medical School
Career History
Since 2004
Professor of Hematology
2001 - 2004
Director of Hematology Outpatient Service
1994
Habilitation in Internal Medicine, University of Vienna
Medical School
1989 - 2001
Clinical studies: Minimal residual disease in lymphoma and
leukaemia
1989 - present
Group Leader - Div. of. Hematology, University of Vienna:
Oncogene Laboratory. Scientific projects: Molecular
biology of lymphoma and leukemia, mechanism of
1986 - 1989
chromosomal translocations
Howard Hughes Medical Institute, Washington University,
St. Louis, MO, USA (Prof. S.J.Korsmeyer) – Scientific
projects: Molecular biology of lymphoma
1984-1986
Scientific projects in Hematology/Immunology
1984-1990
Specialized training in Hematology/Hemostaseology
(Board certification:28-05-1996)
1982-1990
Training in General Internal Medicine, University of Vienna
Medical School (Board certification: 07-08-90
- 166 -
2005 -
Member of the Habilitations Commission (conservative) of
2005 -
the Medical University of Vienna
Editor of the Educational series of the Wiener Klinische
Wochenschrift
2001 – 2006
Organizer: Young Investigators Meeting of the Austrian
Society of Hematology and Oncology
2000
Secretary of the Annual Meeting of the Austrian Society of
Hematology and Oncology
1998 - 1999
Postgradual Course in Medical Management
Awards
2003, 2004
Aventis-Award
2002
Award of the „Erste Bank“
1996
Award of the Austrian Cancer Society
1993, 1998, 2002, 2003
Wilhelm Tuerk Award of the Austrian Society of
Hematology and Oncology
Memberships
Austrian Society of Hematology and Oncology
Austrian Society of Medicine
American Society of Hematology
European Society of Hematology
Society on Progress in Medicine
Period
Organization
Short Title
2003-2005
ÖAW
CeMM 20010 “Genetic instability of the
K€/year
104
immune system”
2006-2008
bm:bwk
Oncogenomics – GEN-AU CHILD
2006-2010
AGMT
NHL-13
55
114
Period
Name of student
Topic
2006-2009
Dr. Edit Porpaczy
Biological function and signaling cascade of lipoprotein
lipase in B-cell chronic lymphocytic leukemia (N094)
- 167 -
Publications
192 peer reviewed publications in scientific journals, 10 book chapters, > 70 invited lectures
• Skrabs C, Müller C, Agis H, Mannhalter C, Jaeger U. Treatment of HBV carrying
lymphoma patients with Rituximab and CHOP: A diagnostic and therapeutic challenge.
Leukemia 2002; 16: 1884-1886.
• Kainz B, Heintel D, Marculescu R, Schwarzinger I, Sperr W, Le T, Fonatsch C, Haas OA,
Mannhalter C, Lechner K, Jaeger U. Variable prognostic value of FLT3 internal tandem
duplications in patients with de novo AML and a normal karyotype, t(15;17), t(8;21), or
inv(16). Hematol J/Haematologica 2002; 3: 283-289.
• Heintel D, Streubel B, Welzel N, Le T, Schwarzinger I, Haas OA, Simonitsch I, Lechner K,
Jaeger U. Burkitt Lymphoma following splenic marginal zone lymphoma: Evidence for two
independent B-cell clones. Cancer Genet Cytogen 2003; 141: 86-88.
• Jaeger U, Kainz B. Monitoring Minimal Residual Disease in AML: The right time for Real
Time. Ann Hematol 2003; 82: 139-147.
• Jaeger U. Innovative strategies in lymphoma therapy. Wien Klin Wochenschr 2003; 115:
13-14.
• Simonitsch-Klupp I, Skrabs C, Hauser I, Ott G, Drach J, Ackermann J, Kaufmann J,
Weltermann A, Greinix HT, Skrabs C, Dittrich C, Lutz D, Pötter R, Mannhalter C, Lechner
K, Chott A, Jaeger U. Diffuse Large B-Cell Lymphomas with Plasmablastic/Plasmacytoid
features are associated with TP53 deletions and poor clinical outcome. Leukemia 2004;
18: 146-155.
• Heintel D, Kroemer E, Kienle D , Schwarzinger I, Gleiß A , Schwarzmeier J, Marculescu R,
Le T, Mannhalter C , Gaiger A, Stilgenbauer S, Fonatsch C, Jaeger U. Expression of
activation-induced cytidine deaminase (AID) mRNA is a marker for IGVH gene mutational
status and cytogenetic aberrations in patients with chronic lymphocytic leukemia.
Leukemia 2004; 18: 756-762.
• Mitterbauer G, Mannhalter C, Skrabs C, Mitterbauer M, Simonitsch I, Winkler K, Lechner
K, Chott A, Jaeger U. Prognostic value of molecular staging by PCR-amplification of
immunoglobulin gene rearrangements in diffuse large B-cell lymphoma (DLBCL).
Leukemia 2004; 18: 1102-1107.
• Gaiger A, Heintel D, Jäger U. Novel Molecular Diagnostic and Therapeutic Targets in
Chronic Lymphocytic Leukemia. Eur J Clin Invest 2004; 34 Suppl 2: 25-30.
• Heintel D, Kienle D, Shehata M, Kröber A, Kroemer E, Schwarzinger I, Mitteregger D, Gleiß
A, Mannhalter C, Chott A, Schwarzmeier J, Fonatsch C, Gaiger A, Döhner H, Stilgenbauer
S, Jäger U. High expression of lipoprotein lipase in poor risk B-cell chronic lymphocytic
leukemia. Leukemia 2005; 19: 1216-1223.
• Schützinger C, Gaiger A, Thalhammer R, Vesely M, Fritsche-Polanz R, Schwarzinger I,
Öhler L, Simonitsch-Klupp I, Reinhard F, Jäger U. Remission of pure red cell aplasia in Tcell receptor γδ-large granular lymphocyte leukemia after therapy with low-dose
alemtuzumab. Leukemia 2005; 19: 2005-2008.
• Bilban M, Heintel D, Scharl T, Wölfel T, Auer MM, Porpaczy E, Kainz B, Krober A, Carey
VJ, Shehata M, Zielinski C, Pickl W, Stilgenbauer S, Gaiger A, Wagner O, Jäger U.
Deregulated expression of fat and muscle genes in B-cell chronic lymphocytic leukemia
with high lipoprotein lipase expression. Leukemia 2006; 20:1080-8.
• Hauswirth AW, Skrabs C, Schützinger C, Gaiger A, Lechner K, Jäger U. Autoimmune
haemolytic anaemias (AIHA), Evans’ syndrome and pure red cell aplasia (PRCA) in NonHodgkin lymphomas. Leuk Lymph 2007; 48: 1139-1149
• Kainz B, Shehata M, Bilban M, Kienle D, Heintel D, Krömer-Holzinger E, Le T, Kröber A,
Heller G, Schwarzinger I, Demirtas D, Chott A, Döhner H, Zöchbauer-Müller S, Fonatsch
C, Zielinski C, Stilgenbauer S, Gaiger A, Wagner O, Jäger U. Overexpression of the
- 168 -
•
•
•
•
paternally expressed gene 10 (PEG10) from the imprinted locus on chromosome 7q21 in
high-risk B-cell chronic lymphocytic leukaemia. Int J Cancer 2007; 121: 1984-1993
Coiffier B, Tabacof J, Shen ZX, Jäger U. Aggressive non-Hodgkin’s lymphoma – longterm survival for all patients? Hematology Meeting Reports 2007; 1: 27-41
Hauswirth A, Skrabs C, Schützinger C, Raderer M, Lechner K, Jäger U. Autoimmune
thrombocytopenia in Non-Hodgkin lymphomas. Haematol/ Hematol J 2007; 93: 447-450.
Schützinger C, Esterbauer H, Hron G, Skrabs C, Uffmann M, Raderer M, Hauswirth A,
Mannhalter C, Dieckmann K, Wagner O, Formanek M, Stift A, Friedl J, Gaiger A, Chott A,
Jäger U. Prognostic value of T-cell receptor γ rearrangement in peripheral blood or bone
marrow of patients with peripheral T-cell lymphomas. Leuk Lymphoma 2008; 49: 237-246
Hauswirth AW, Jäger U. Impact of cytogenetic and molecular prognostic markers on the
clinical management of chronic lymphocytic leukaemia. Haematol/Hematol J 2008; 93: 1419.
• Marculescu R, Le T, Simon P, Jaeger U, Nadel B. V(D)J-mediated translocations in
lymphoid neoplasms: A functional assessment of genomic instability by cryptic sites. J
Exp Med 2002; 195: 85-98.
• Marculescu R, Le T, Böcskör S, Mitterbauer G, Chott A, Mannhalter C, Jaeger U, Nadel B.
Alternative end-joining in follicular lymphomas’ t(14;18) translocation. Leukemia 2002; 16:
120-126.
• Becherer A, Mitterbauer M, Jaeger U, Kalhs P, Greinix HAT, Karanikas G, Pötzi C,
Raderer M, Dudzak R, Kletter K. Positron emission tomography with [18F]2-Fluoro-D-2Deoxyglucose (FDG-PET) for relapse prediction of malignant lymphoma after high-dose
therapy with stem cell support. Leukemia 2002; 16: 260-267.
• Filipits M, Jaeger U, Pohl G, Stranzl T, Simonitsch I, Kaider A, Skrabs C, Pirker R. Cyclin
D3 is a predictive and prognostic factor in diffuse large B-cell lymphoma. Clin Cancer Res
2002; 8: 729-733.
• Thalhammer-Scherrer R, Mitterbauer G, Simonitsch I, Jaeger U, Lechner K, Schneider B,
Fonatsch C, Schwarzinger I. The immunophenotype of 325 adult acute leukemias:
relationship to morphologic and molecular classification and proposal for a minimal
screening program highly predictive for lineage discrimination. Am J Clin Pathol 2002;
117: 380-389.
• Agis H, Weltermann A, Fonatsch C, Haas O, Mitterbauer G, Müllauer L, Schreiber S,
Schwarzinger I, Juretzka W, Valent P, Jaeger U, Lechner K, Geissler K. A comparative
study on demographic, hematological, and cytogenetic findings and prognosis in acute
myeloid leukemia with and without leukemia cutis. Ann Hematol 2002; 81: 90-95.
• Österborg A, Brandberg Y, Molostova V, Iosawa G, Abdulkadyrov K, Hedenus M,
Messinger
D
for
the
Epoetin
Beta
Hematology
Study
Group
(including Jaeger U). Randomized, Double-Blind, Placebo-Controlled Trial of
Recombinant Human Erythropoietin, Epoetin Beta, in Hematologic Malignancies. J Clin
Oncol 2002; 20: 2486-2494.
• Selenko N, Majdic O, Jaeger U, Sillaber C, Stöckl J, Knapp W. Cross priming of cytotoxic
T-cells promoted by apoptosis inducing tumor cell reactive antibodies? J Clin Immunol
2002; 22: 124-130.
• Sperr WR, Stehberger B, Wimazal F, Baghestanian M, Schwartz LB, Kundi M, Semper H,
Jordan JH, Chott A, Drach J, Jaeger U, Geissler K, Greschniok A, Horny HP, Lechner K,
Valent P. Serum tryptase measurements in patients with myelodysplastic syndromes.
Leuk Lymphoma 2002; 43: 1097-1105.
• Raderer M, Chott A, Drach J, Montalban C, Dragosics B, Jaeger U, Puspok A,
Osterreicher C, Zielinski CC. Chemotherapy for management of localised high-grade
gastric B-cell lymphoma: how much is necessary? Ann Oncol 2002; 13: 1094-1098.
• Parolini O, Kagerbauer B, Simonitsch-Klupp I, Ambros P, Jaeger U, Mann G, Haas OA,
- 169 -
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
Morra M, Gadner H, Terhorst C, Knapp W, Holter W. Analysis of SH2D1A mutations in
patients with severe Epstein-Barr virus infections, Burkitt's lymphoma, and Hodgkin's
lymphoma. Ann Hematol 2002; 81: 441-447.
Tirelli U, Spina M, Jaeger U, Nigra E, Blanc PL, Liberati AM, Benci A, Sparano JA.
Infusional CDE with rituximab for the treatment of human immunodeficiency virusassociated non-Hodgkin's lymphoma: preliminary results of a phase I/II study. Recent
Results in Cancer Res 2002; 159: 149-153.
Hallek M, Bergmann M, Brittinger G, Dohner H, Dreger P, Herold M, Hopfinger G, Jäger
U, Knauf W, Nerl C, Rummel M, Schmitt B, Wendtner CM, Emmerich B. Chronisch
lymphatische Leukämie und verwandte Leukämien: Aktuelle Therapiekonzepte. Internist
2002; 43: 1245-1254.
Spina M, Sparano JA, Jaeger U, Rossi G, Tirelli U. Rituximab and chemotherapy is highly
effective in patients with CD20-positive non-Hodgkin's lymphoma and HIV infection. AIDS
2003; 17: 137-138.
Marculescu R, Vanura K, Le T, Simon P, Jäger U, Nadel B. Distinct t(7;9)(q34;q32)
breakpoints in healthy individuals and T-ALL patients: Signal joint reactivity as a novel
pathway of V(D)J-mediated oncogene activation. Nat Genet 2003; 33: 342-344.
Feierl E, Dejaco C, Heintel D, Wagner A, Chatwani S, Stelzhammer R, Hammer J, Jaeger
U, Thurnher S, End A. Arterial bleeding of the esophagus associated with diffuse large Bcell lymphoma. Gastrointest Endosc 2003; 57: 387-388.
Hauser AC, Brichta A, Pabinger-Fasching I, Jaeger U, Lechner K. Fibrinolytic therapy with
r-tPA in a patient with paroxysmal nocturnal hemoglobinuria and Budd-Chiari syndrome.
Ann Hematol 2003; 82: 299-302.
Hoffmann M, Kletter K, Becherer A, Jäger U, Chott A, Raderer M. 18F-fluorodeoxyglucose
positron emission tomography (18F-FDG-PET) for staging and follow-up of marginal zone
B-cell lymphoma. Oncology 2003; 64: 336-340.
Berer A, Kainz B, Jäger U, Jäger E, Stengg S, Streubel B, Fonatsch C, Mitterbauer G,
Lechner K, Geissler K, Ohler L. Relation of in vitro growth characteristics to cytogenetics
and treatment outcome in acute myeloid leukemia: prognostic significance in patients with
a normal karyotype. Int J Hematol 2003; 78: 241-247.
Becherer A, Jaeger U, Kletter K. Prognostic value of FDG-PET in malignant lymphoma. Q
J Nucl Med 2003; 47: 14-21.
Becherer A, Jaeger U, Kletter K. Prognostic value of FDG-PET in malignant lymphoma. Q
J Nucl Med 2003; 47: 14-21.
Vanura K, Marculescu R, Le T, Jaeger U, Nadel B. Physiological and Physiopathological
Roles of Signal Joint Reactivity. Recent Research Developments in Immunology 2003; 5:
167-178.
Weltermann A, Fonatsch C, Haas OA, Greinix HT, Kalhs P, Mitterbauer G, Jaeger U,
Geissler K, Valent P, Sperr W, Knoebl P, Schwarzinger I, Gleiss A, Kainz B, Lechner K.
The Impact of Cytogenetics on the Prognosis of Adults with de novo AML in First Relapse.
Leukemia 2004; 18: 293-302.
Hoffmann M, Chott A, Püspök A, Jäger U, Kletter U, Raderer M. 18F-fluoro-deoxy-glucose
positron emission tomography (18F-FDG-PET) does not visualize follicular lymphoma of
the duodenum. Ann Hematol 2004; 83: 276-278.
Mitterbauer M, Mitterbauer-Hohendanner G, Sperr WR, Kalhs P, Greinix HT, Fonatsch C,
Haas OA, Jäger U, Mannhalter C, Lechner K. Molecular disease eradication is a
prerequisite for long-term remission in patients with t(8;21) positive acute myeloid
leukemia: A single center study. Leuk Lymphoma 2004; 45: 971-977.
Sperr WR, Piribauer M, Wimazal F, Fonatsch C, Thalhammer-Scherrer R, Schwarzinger I,
Geissler K, Knobl P, Jäger U, Lechner K, Valent P. A novel effective and safe
consolidation for patients over 60 years with acute myeloid leukemia: intermediate dose
cytarabine (2 x 1 g/m2 on days 1, 3, and 5). Clin Cancer Res 2004; 10: 3965-3971.
Schmidt HH, Strehl S, Thaler D, Strunk D, Sill H, Linkesch W, Jäger U, Sperr W, Greinix
HT, König M, Emberger W, Haas OA. RT-PCR and FISH analysis of acute myeloid
leukemia with t(8;16)(p11;p13) and chimeric MOZ and CBP transcripts: Breakpoint cluster
- 170 -
region and clinical implications. Leukemia 2004; 18: 1115-1121.
• Streubel B, Chott A, Huber D, Exner M, Jäger U, Wagner O, Schwarzinger I. Lymphomaspecific genetic aberrations in microvascular endothelial cells in B-cell lymphomas. N Engl
J Med 2004; 351: 250-259.
• Langerak A, Nadel B, de Torbal A, Wolvers-Tettero ILM, van Gastel-Mol EJ, Verhaaf B,
Jäger U, Van Dongen JJ. Unraveling the consecutive recombination events in the human
IGκ locus. J Immunol 2004; 173: 3878-3888.
• Füreder W, Filipits M, Sperr WR, Kainz B, Jäger U, Fonatsch C, Schwarzinger I, Haas
OA, Pirker R, Lechner K. Highly refractory acute myeloid leukemia. Wien Klin Wochenschr
2004; 116: 561-564.
• Kaufmann H, Ackermann J, Baldia C, Nösslinger T, Wieser R, Seidl S, Sagaster V,
Gisslinger H, Jäger U, Pfeilstöcker M, Zielinski C, Drach J. Both IgH translocations and
chromosome 13q deletions are early events in monoclonal gammopathy of undetermined
significance and do not evolve during transition to multiple myeloma. Leukemia 2004; 18:
1879-1882.
• Hallek M, Bergmann M, Emmerich B for the German CLL Study Group (Incl. Jäger U).
Chronic lymphocytic leukaemia: Up-dated recommendations on diagnosis and treatment.
Onkologie 2004; 27: 97-104.
• Ziegler S, Sperr W, Knöbl P, Lehr S, Weltermann A, Jäger U, Valent P, Lechner K.
Symptomatic venous thromboembolism in acute leukemia. Incidence, risk factors and
impact on prognosis. Thromb Res 2005; 115: 59-64.
• Spina M, Jaeger U, Sparano JA, Talamini R, Simonelli C, Michieli M, Rossi G, Nigra E,
Berretta M, Cattaneo C, Rieger AC, Vaccher E, Tirelli U. Rituximab plus infusional
cyclophosphamide, doxorubicin, and etoposide in HIV-associated non-Hodgkin
lymphoma: pooled results from 3 phase II trials. Blood 2005; 105: 1891-1897.
• Kainz B, Fonatsch C, Schwarzinger I, Sperr WR, Jäger U, Gaiger A. Limited value of FLT3
mRNA expression in the bone marrow for prognosis and monitoring of patients with acute
myeloid leukaemia. Hematol J / Haematologica 2005; 90: 695-696.
• Johnson SA, Owen RG, Oscier DG, Leblond V, Levy V, Jaeger U, Seymour JF. Phase III
study of chlorambucil versus fludarabine as initial therapy for Waldenstrom’s
macroglobulinemia and related disorders. Clin Lymphoma 2005; 5: 294-297.
• Raderer M, Streubel B, Wöhrer S, Püspök A, Jäger U, Formanek M, Chott A. High relapse
rate in patients with MALT lymphoma warrants lifelong follow-up. Clin Cancer Res 2005;
11: 3349-3352.
• Kienle DL, Korz C, Hosch B, Benner A, Mertens D, Habermann A, Kröber A, Jäger U,
Lichter P, Döhner H, Stilgenbauer S. Evidence for distinct pathomechanisms in genetic
subgroups of chronic lymphocytic leukemia revealed by quantitative expression analysis
of cell cycle, activation, and apoptosis-associated genes. J Clin Oncol 2005; 23: 37803792.
• Böhm A, Piribauer M, Wimazal F, Geissler K, Gisslinger H, Knöbl P, Jäger U, Fonatsch C,
Kyrle PA, Valent P, Lechner K, Sperr WR. High dose intermittent ARA-C (HiDAC) for
consolidation of patients with de novo AML: a single center experience. Leuk Res 2005;
29: 609-615.
• Sperr WR, Mitterbauer M, Mitterbauer G, Kundi M, Jäger U, Lechner K, Valent P.
Quantitation of minimal residual disease in acute myeloid leukemia by tryptase monitoring
identifies a group of patients with a high risk of relapse. Clin Cancer Res 2005; 11: 65366543.
• Woehrer S, Hejna M, Skrabs C, Drach J, Zielinski CC, Jaeger U, Raderer M. Rituximab,
Ara-C, dexamethasone and oxaliplatin is safe and active in heavily pretreated patients
with diffuse large B-cell lymphoma. Oncology 2005; 69: 499-502.
• Raderer M, Wöhrer S, Bartsch R, Prager G, Drach J, Hejna M, Gaiger A, Turetschek K,
Jaeger U, Streubel B, Zielinski CC. Phase II study of oxaliplatin for treatment of patients
with mucosa-associated lymphoid tissue lymphoma. J Clin Oncol 2005; 23: 8442-8446.
• Schwarzmeier JD, Hubmann R, Düchler M, Jäger U, Shehata M. Regulation of CD23
expression by Notch2 in B-cell chronic lymphocytic leukemia. Leukemia Lymphoma 2005;
- 171 -
46: 157-165.
• Eichhorst BF, Busch R, Hopfinger G, Pasold R, Hensel M, Steinbrecher C, Siehl S, Jäger
U, Bergmann M, Schweighofer C, Wendtner CM, Brittinger G, Emmerich B, Hallek M.
Fludarabine plus cyclophosphamide versus fludarabine alone in first line therapy of
younger patients with chronic lymphocytic leukemia. Blood 2006; 107: 885-891.
• Kienle D, Benner A, Kröber A, Winkler D, Mertens D, Bühler A, Seiler T, Jäger U, Lichter
P, Döhner H, Stilgenbauer S. Distinct gene expression patterns in chronic lymphocytic
leukemia defined by usage of specific VH genes. Blood 2006; 107: 2090-2093.
• Grünberger B, Wöhrer S, Streubel B, Formanek M, Petkov V, Püspök A, Häfner M, Hejna
M, Jäger U, Chott A, Raderer M. Antibiotic treatment is not effective in patients infected
with Helicobacter pylori suffering from extragastric MALT lymphoma. J Clin Oncol 2006;
24: 1370-1375.
• Wöhrer S, Jäger U, Kletter K, Becherer A, Hauswirth A, Turetschek K, Raderer M,
Hoffmann M. 18F-fluoro-deoxy-glucose positron emission tomography (18F-FDG-PET)
visualizes follicular lymphoma irrespective of grading. Ann Oncol 2006; 17: 780-784.
• Pfreundschuh M, Trümper L, Österborg A, Pettengell R, Trneny M, Imrie K, Ma D, Gill D,
Walewski J, Zinzani PL, Stahel R, Kvaloy S, Shpilberg O, Jäger U, Hansen M, Lehtinen T,
López-Guillermo A, Corrado C, Scheliga A, Milpied N, Mendila M, Rashford M, Kuhnt E,
Löffler M, for the MabThera International Trial (MInT) Group. CHOP-like chemotherapy
plus rituximab versus CHOP-like chemotherapy alone in young patients with goodprognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera
International (MInT) Study Group. Lancet Oncology 2006; 7: 379-391.
• Raderer M, Wöhrer S, Streubel B, Troch M, Turetschek K, Jäger U, Skrabs C, Gaiger A,
Drach J, Püspök A, Formanek M, Hoffmann M, Hauff W, Chott A. Assessment of disease
dissemination in gastric compared with extragastric mucosa-associated lymphoid tissue
lymphoma using extensive staging: a single-center experience. J Clin Oncol 2006; 24:
3136-3141
• Strehl S, König M, Meyer C, Schneider B, Harbott J, Jäger U, von Bergh AR, Loncarevic
IF, Jarosova M, Schmidt HH, Moore SD, Marschalek R, Haas OA. Molecular dissection of
t(11;17) in acute myeloid leukemia reveals a variety of gene fusions with heterogeneous
fusion transcripts and multiple splice variants. Genes Chromosomes Cancer 2006; 45:
1041-1049
• Raderer M, Wöhrer S, Streubel B, Drach J, Jäger U, Turetschek K, Troch M, Püspök A,
Zielinski
CC,
Chott
A.
Activity
of
rituximab
lus
cyclophosphamide,
doxorubicin/mitoxantrone, vincristine and prednisone in patients with relapsed MALT
lymphoma. Oncology 2006; 70: 411-417
• Marculescu R, Vanura K, Montpellier B, Roulland S, Le T, Navarro JM, Jäger U, McBlane
F, Nadel B. Recombinase, chromosomal translocations and lymphoid neoplasia: targeting
mistakes and repair failures. DNA Repair 2006; 5: 1246-1258.
• Smolen JS, Keystone EC, Emry P, Breedveld FC, Betteridge N, Burmester GR, Dougados
M, Ferraccioli G, Jaeger U, Klareskog L, Kvien TK, Martin-Mola E, Pavelka K; Working
Group on the Rituximab Consensus Statement. Consensus statement on the use of
rituximab in patients with rheumatoid arthritis. Ann Rheum Dis 2007; 66: 143-150
• Wöhrer S, Troch M, Zwerina J, Schett G, Skrabs C, Gaiger A, Jäger U, Zielinski C,
Raderer M. Influence of rituximab, cyclophosphamide, doxorubicin, vincristine and
prednisone on serologic parameters and clinical course in lymphoma patients with
autoimmune diseases. Ann Oncol 2007; 18: 647-651
• Choquet S, Trappe R, Leblond V, Jäger U, Davi F, Oertel S. CHOP-21 for the treatment
of post-transplant lymphoproliferative disorders (PTLD) following solid organ
transplantation. Haematologica 2007; 92: 273-274
• Vanura K, Montpellier B, Le T, Spicuglia S, Navarro JM, Cabaud O, Roulland S, Vachez
E, Prinz I, Ferrier P, Marculescu R, Jäger U, Nadel B. In vivo reinsertion of excised
episomes by the V(D)J recombinase: a potential threat to genomic stability. PLoS Biol
2007 Feb 13;5(3):e43
• Heintel D, Zojer N, Schreder M, Strasser-Weippl K, Kainz B, Vesely M, Gisslinger H,
- 172 -
Drach J, Gaiger A, Jäger U, Ludwig H. Expression of MUM1/IRF4 mRNA as a prognostic
marker in patients with multiple myeloma. Leukemia 2007 Aug 9; (Epub ahead of print)
• Aichberger KJ, Herndlhofer S, Agis H, Sperr WR, Esterbauer H, Rabitsch W, Knöbl P,
Haas OA, Thalhammer R, Schwarzinger I, Sillaber C, Jäger U, Valent P. Liposomal
cytarabine for treatment of myeloid central nervous system relapse in chronic myeloid
leukaemia occurring during imatinib therapy. Eur J Clin Invest 2007; 37: 808-813
• Agis H, Sperr WR, Herndlhofer S, Semper H, Pirc-Danoewinata H, Haas OA, Mannhalter
C, Esterbauer H, Geissler K, Sillaber C, Jäger U, Valent P. Clinical and prognostic
significance of histamine monitoring in patients with CML during treatment with imatinib
(STI571). Ann Oncol 2007; 18: 1834-1841
• Vales A, Kondo R, Aichberger KJ, Mayerhofer M, Kainz B, Sperr WR, Sillaber C, Jäger U,
Valent P. Myeloid leukemias express a broad spectrum of FEGF receptors including
neuropilin-1 (NRP-1) and NRP-2. Leuk Lymphoma 2007; 48: 1997-2007
2002
• „MRD bei Lymphomen“. Symposion: Minimale residuelle Erkrankung bei soliden Tumoren
und Hämoblastosen. Retz, 28. 2. - 1. 3. 2002.
• „Antikörpertherapie bei Lymphomen“. Wissenschaftliche Sitzung der Gesellschaft für
Innere Medizin für Wien und Niederösterreich, Wien, 21. 3. 2002.
• „Mechanismen der Entstehung von Translokationen bei lymphatischen Neoplasien“;
Frühjahrstagung der ÖGHO, Linz 25. 4. – 27. 4. 2002.
• „Antikörpertherapie bei hämatologischen Erkrankungen“. 33.Jahrestagung der
Österreichischen Gesellschaft für Innere Medizin. Salzburg, 19. - 21. 9. 2002.
• „Lymphome im Rahmen von AIDS“. 13.Österreichischer AIDS Kongress. Wien, 8. - 9. 11.
2002.
• “Treatment modalities for Morbus Waldenström“. IV.International Workshop of the
German CLL study group. Kloster Irsee, 13. - 15. 2. 2002.
2003
• ”EBV und AIDS-assoziierte Lymphome”. Deutsch - Österreichischer AIDS Kongress.
Hamburg, 16. 5. 2003.
2004
• „EBV/Infektion und PTLD nach Organtransplantation2. ÖGN Wintermeeting. Flachau, 31.
3. – 3. 4. 2004.
• „Lymphome“. State of the Art, Diagnostik und Therapie. Österreichische Gesellschaft für
Innere Medizin. 25. 3. 2004.
• „VDJ-mediated translocations in leukemia and lymphoma“. “From Basic Science to
Clinical Application”. Wien, 3. 9. 2004.
• „Molekulare Pathogenese von Lymphomen“. 2. Jahrestagung der Österreichischen
Gesellschaften für Klinische Chemie und Laboratoriumsmedizin. Salzburg, 29. 9. – 2. 10.
2004.
• „NHL inkl. CLL, M. Hodgkin: Staging, Therapie (inkl. Kosten), Prognose“. Seminar. 20. 9.
und 27. 9. 2004.
• „Monoklonale Antikörper“. 35. Jahrestagung der Österreichischen Gesellschaft für Innere
Medizin. Wien, 16. – 18. 9. 2004.
• „Prognosefaktoren bei NHL“. Herbsttagung der Österreichischen Gesellschaft für
Pathologie. Retz, 15. – 16. 10. 2004.
• „IgVH mutational status and LGL in CLL“. V. International Workshop of the German CLL
Study Group. Irsee, 24. – 26. 9. 2004.
• „Molekulare Diagnostik bei NHL“. Gemeinsame Jahrestagung der Deutschen,
Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Onkologie.
- 173 -
Innsbruck, 2. – 6. 10. 2004.
• „Stehen wir vor einem Paradigmenwechsel in der Therapie der CLL und der indolenten
Lymphome?“. Satelliten-Symposium „Überleben verlängern bei CLL und indolenten
Lymphomen – Ferne Vision oder baldige Realität?“. Innsbruck, 3. 10. 2004.
• „Hematological malignancies“. 29. ESMO Kongress. Wien, 29. 10. – 2. 11. 2004.
2006
• Vorsitze und zusammenfassende Vorträge. 4. MabThera Winterworkshop. Schladming,
13. – 15. 1. 2006.
• „Klinische Aspekte der Erhaltungstherapie“. Symposium „Überlebensverlängerung beim
follikulären NHL“ im Rahmen der Frühjahrstagung der Österreichischen Gesellschaft für
Hämatologie und Onkologie. Wels, 27. – 29. April 2006.
• „Follikuläres Lymphom: Was ist jetzt State-of-the-Art?“. MabThera Meeting. Wien, 15. –
16. 9. 2006.
• “Lymphome”. Wissenschaftliche Sitzung “Hämatologie im Alter”. Gesellschaft der Ärzte.
Wien, 16. 11. 2006
• „PI3K“. Studientreffen. Basel, 24. April 2006.
• Educational “Aggressive Non-Hodgkin Lymphome”. Annual Joint Meeting of the German,
Austrian and Swiss Societies of Hematology and Oncology 2005. Hannover, 1.-.5.October
2005.
• Vorsitz und Vortrag beim Meeting “Challenging Cases in Hematologic Malignancy” des
Oncology Network Europe (ONE). Wien, 23. 9. 2006.
• Vorsitz und Vortrag “Current treatment strategies for B-CLL”. Satellitensymposium
“Clinical Aspects of B-CLL and Related Entities”. Wien, 9. 10. 2006.
2007
• Vortrag “Update NHL-13” sowie Zusammenfassung der Sitzung “MCL + Autoimmun”. 5.
MabThera Winterworkshop. Schladming, 12. – 14. 1. 2007.
• Vortrag “What is the role of maintenance therapy in aggressive lymphoma?” beim Expert
Investigator Forum “Maintaining life: optimal strategies to improve survival”. Lissabon, 20.
– 22. 4. 2007.
• Educational “Genetics in CLL: Impact for prognosis and treatment decisions”. EHAKongress. Wien, 7. – 10. 6. 2007.
• Vortrag “Novel molecular risk factors and targets in CLL”. 3rd Joint Meeting on
Experimental and Clinical Cancer Research Translational Research. Wien, 11. – 12. 10.
2007.
• Organisation und abschließender Vortrag sowie Vortrag “Was ist die CLL? Risiko- und
Prognosefaktoren, Krankheitsverlauf der CLL” beim Patienteninformationstag. 20.
Arbeitstreffen der Deutschen CLL Studiengruppe. Wien, 9. – 10. 11. 2007.
• Diskutant zum Thema “Clinical trial sponsorship”. Vienna Initiative to Save European
Academic Research II (VISEAR II). Wien, 12. 11. 2007.
• Vortrag “Mabthera in maintenance therapy”. NHL-13 Study Meeting. Sarajevo, 15. 11.
2007.
• Vortrag “Overview of prognostic factors”. Annual Education Day des UK CLL Forum. 19.
11. 2007.
- 174 -
Curriculum Vitae
Peter Pietschmann
Department of Pathopyhsiology, Medical University of Vienna, Währinger Gürtel 18-20, A –
1090 Vienna, Austria,
Phone +43-1-40400-51-26; Fax: +43-1-40-400-51-30;
E-mail [email protected]
Personal Data
Date of Birth:
May 13, 1960
Place of Birth:
Vienna
Nationality
Austria
Education
2002
Appointment as Associate Professor of Pathophysiology,
Medical School,University of Vienna
2001
Certification as Specialist of Pathophysiology
1994
Certification as Specialist of Rheumatology
1992
Appointment as Associate Professor of Internal Medicine,
Medical School,University of Vienna
1990
Certification as Specialist of Internal Medicine
1984
Graduation as Medical Doctor
1979 – 1984
Medical School, University of Vienna
1978 – 1979
Military Service
1970-1978
Secondary School (Vienna)
1966-1970
Elementary School (Vienna)
Career History
2007- present
Head of the Division of Cellular and Molecular
Pathophysiology
2006 – present
Deputy Head of the Department of Pathophysiology
2006 - 2007
Head of the Division of Molecular and Biochemical
Pathology
2002 – present
Associate Professor of Pathophysiology at the Department
of Pathophysiology,Medical University of Vienna
1999-present
Head of the “Bone, Cartilage and Connective Tissue
Research Group”
1998-present
Department of Pathophysiology (former Department of
- 175 -
General and Experimental Pathology), University of
Vienna (since 2004: Medical University of Vienna)
1997-1998
Institute of Immunology, University of Vienna
1992-1997
Division of Rheumatology/Department of Internal Medicine
3, University of Vienna
1992-present
Associate Professor of Internal Medicine,(Medical)
1991-1992
Rheumatic Diseases Division, Department of Internal
Medicine, Southwestern Medical Center at Dallas,
University of Texas, Dallas, TX, USA
1990-1991
Department of General and Experimental Pathology,
1984-1990
Department of Medicine 2, University of Vienna
2007-present
President of the Austrian Society for Geriatrics and
Gerontology
2000-present
Treasurer of the Austrian Society for Bone and Mineral
Research
1998-present
Board member of the Austrian Society for Geriatrics and
Gerontology
1993-present
Scientific colaborationwith the Luwdig Boltzmann Institute
of Aging Research, Vienna
Awards
1986
Paracelsus Award Austrian Society for Internal Medicine
1996
Young Investigator Award World congress on
Osteoporosis
Memberships
American Society for Bone and Mineral Research
Austrian Society for Bone and Mineral Research (Member of the Board)
Austrian Society for Geriatrics and Gerontology (Member of the Board)
Society for Internal Medicine of Vienna and Lower Austria
Austrian Society for Endocrinology and Metabolism
Austrian Society for Cytometry
Austrian Diabetes Society
Medical Society of Vienna
- 176 -
Affiliation with the Ludwig Boltzmann Institute for Aging Research, Vienna
Sources of funding in last 5 years (2000-2005) Only FWF and equivalent projects
Period
Organization
Short Title
K€
2007-2009
Jubiläumsfonds-
Vergleichsstudie von Hüftknochen
47
FWF
Cathepsin S: ein Modulator in der
82
Forschungsprojekt
Osteoimmunologie
projekt der
Österreichischen
Nationalbank,
ProjektNr. 12544
2007-2009
P20239-B13
2002-2004
Medizinisch-
Die Wirkung von Bone morphogenetic
wissenschaftlicher
protein-5 auf die Generation von
Fonds
des Osteoklasten in Knochenmarkskulturen.
Bürgermeisters
der
26
Bundeshauptstadt
Wien, Projekt # 2240
2002-2004
Hochschuljubiläumsst The role of lymphocyte subpopulations in
iftung der Stadt Wien, osteoclast
Projekt # H-
generation
in
murine
4
bone
marrow cultures.
1166/2003
2001 –
FWF
Extended studies on the modulation of the
2005
Forschungsprojekt
ageing processes in the rat by physical
P16060-B05 (Co-
exercise and food restriction
2001
2000-2001
aplicant)
Medizinischwissenschaftlicher
Fonds des
Bürgermeisters der
Bundeshauptstadt
Wien
Jubiläumsfonds der
Österreichischen
-
Die Bedeutung des Vitamin D-Rezeptors für
die Zytokinproduktion von T-Lymphozyten
The relationship of cytokines, sex steroids
and bone turnover in aging men and women.
6
36
Nationalbank
Dr. rer.nat., Dr. sci.med.Dr. techn. or PhD supervisions in the last 6 years (2002-2008)
Period
Name of student
Topic
- 177 -
2005-2008
Daniela Stupphann
Bone metabolism in HLA-B27 transgenic rats,
an animal model for spondyloathropathies
2005-present
Brigitte Behal
Meta-Analysis of the spontaneous course of
osteoporosis
2006-present
Janina Patsch
Microarchitecture of bone in osteoporotic men:
relation
with
osteoblastic
gene
expression
of
osteoblast
patterns and treatment effects
2006-present
Martina Rauner
Molecular
mechanism
differentiation: relevance to senile osteoporosis
Publications
104 original publications and 20 reviews in peer reviewed scientific journals, 10 book
chapters, over 200 invited lectures,
Pietschmann P, Hahn P, Kudlacek S, Thomas R, Peterlik M (2000) Surface markers and
transendothelial migration of dendritic cells from elderly subjects. Exp Gerontol 35: 213 - 224
Redlich K, Ziegler S, Kiener HP, Spitzauer S, Stohlawetz P, Bernecker P, Kainberger F,
Grampp S, Kudlacek S, Woloszczuk W, Smolen JS, Pietschmann P (2000) Bone mineral
density and biochemical parameters of bone metabolism in female patients with systemic
lupus erythematosus. Ann Rheum Dis 59: 308 – 310
Pietschmann P, Stöckl J, Draxler S, Majdic O, Knapp W (2000) Functional and phenotypic
characterization of dendritic cells generated in human plasma supplemented medium. Scand
J Immunol 51: 377 – 383
Grisar J, Hahn P, Brosch S, Peterlik M, Smolen JS, Pietschmann P (2001) Phenotypic
characteristics of human monocytes undergoing transendothelial migration. Arthritis Res 3:
127 - 132
Pietschmann P, Kudlacek S, Grisar J, Spitzauer S, Woloszczuk W, Willvonseder R, Peterlik
M (2001) Bone turnover markers and sex hormones in men with idiopathic osteoporosis. Eur
J Clin Invest 31: 444 – 451
Pietschmann P, Grisar J, Thien R, Willheim M, Kerschan-Schindl K, Preisinger E, Peterlik M
(2001) Immune phenotype and intracellular cytokine production of peripheral blood
mononuclear cells from postmenopausal patients with osteoporotic fractures. Exp Gerontol
36: 1749-1759
Grisar J, Bernecker PM, Aringer M, Redlich K, Sedlak M, Wolozcszuk W, Spitzauer S,
Grampp S, Kainberger F, Ebner W, Smolen JS, Pietschmann P (2002). Ankylosing
spondylitis, psoriatic arthritis, and reactive arthritis show increased bone resorption, but differ
with regard to bone formation. J Rheumatol 29: 1430 – 1436
- 178 -
Lernbass I, Wutzl A, Grisar J, Schett G, Redlich K, Spitzauer S, Grampp S, Imhof H, Peterlik
M, Pietschmann P (2002) Quantitative ultrasound in the assessment of bone status of
patients suffering from rheumatic diseases. Skeletal Radiol 31: 270 – 276
Kerschan-Schindl K, Strametz-Juranek J, Heinze G, Grampp S, Biegelmayer C, Pacher R,
Maurer G, Fialka-Moser V, Pietschmann P (2003) Pathogenesis of bone loss in heart
transplant candidates and recipients. J Heart Lung Transpl 22: 843 – 850
Pietschmann P, Gollob E, Brosch S, Hahn P, Kudlacek S, Willheim M, Woloszczuk W,
Peterlik M, Tragl KH (2003) The effect of age and gender on cytokine production by human
peripheral blood mononuclear cells and markers of bone metabolism. Exp Gerontol 38: 1119
– 1127
Kerschan-Schindl K, Mitterbauer M, Füreder W, Kudlacek S, Grampp S, Biegelmayer C,
Fialka-Moser V, Pietschmann P, Kahls P (2004) Post- transplant complications – Bone
metabolism in patients more than five years after bone marrow transplantation. Bone Marrow
Transplantation 34:491-496
Sipos W, Willheim M, Hofbauer G, Pietschmann P (2005) Evaluation of the suitability of
monoclonal antibodies for flow cytometric intracellular cytokine detection in peripheral blood
lymphocytes. J Vet Med A 52: 55-60
Kerschan-Schindl K, Hawa G, Kudlacek S, Woloszczuk W, Pietschmann P (2005) Serum
levels of cathepsin K decrease with age in both women and men. Exp Gerontol 40: 532 –
535
Sipos W, Duvigneau JC, Hofbauer G, Schmoll F, Baravalle G, Hartl R, Exel B,
Dobretsberger M, Pietschmann P (2005) Characterization of the cytokine pattern of porcine
bone marrow-derived cells treated with 1α,25(OH)2D3. J Vet Med A52: 382-387
Wutzl A, Brozek W, Lernbass I, Rauner M, Hofbauer G, Schopper C, Watzinger F, Peterlik
M, Pietschmann P (2006) Bone morphogenetic proteins 5 and g stimulate osteoclast
generation. J Biomed Mater Res A 77 (1): 75-83
Mikosch P, Igerc I, Kudlacek S, Woloszczuk W, Gallowitsch HJ, Kresnik E, Stettner H,
Grimm G, Lind P, Pietschmann P (2006) Receptor activator of nuclear factor κB ligand and
osteoprotegerin in men with thyroid cancer. Eur J Clin Invest 36: 566-573
Brosch S, Shehata M, Hofbauer G, Peterlik M, Pietschmann P (2006) Alendronate stimulates
expression of functional surface molecules ICAM-1, HLA-DR and B7-2 on human
monocytes. Osteol 15: 188-196
Rauner M, Winzer M, Stupphann D, Krenbek D, Pietschmann P (2007) RANKL and OPG
gene expression in bone marrow stromal cells and calvarial osteoblasts in mouse and rat.
Osteol 16: 19-28
Pietschmann P, Skalicky M, Kneissel M, Rauner M, Hofbauer G, Stupphann D, Viidik A
(2007) Bone structure and metabolism in a rodent model of male senile osteoporosis. Exp
Gerontol 42: 1099-1108
Mikosch P, Kerschan-Schindl K, Woloszczuk W, Stettner H, Kudlacek S, Kresnik E,
Gallowitsch HJ, Lind P, Pietschmann P (2008)High cathepsin K levels in men with
differentiated thyroid cancer on suppressive L-thyroxine therapy. Thyroid 18:27-33.
Kerschan-Schindl K, Ruzicka M, Mahr S, Paireder M, Krestan C, Gleiss A, Bieglmayer C,
- 179 -
Fialka-Moser V, Pacher R, Grimm M, Pietschmann P (2008) Unexpected low incidence of
vertebral fractures in heart transplant recipients: analysis of bone turnover. Transpl Int
21:255-262.
Kerschan-Schindl K, Wendlova J, Kudlacek S, Gleiss A, Woloszczuk W, Pietschmann P
(2008) Serum levels of receptor activator of nuclear factor kappaB ligand (RANKL) in healthy
women and men. Exp Clin Endocrinol Diabetes, Epub ahead of print
Stupphann D, Rauner M, Krenbek D, Patsch J, Pirker T, Muschitz C, Resch H, Pietschmann
P (2008) Intracellular and surface RANKL are differentially regulated in patients with
ankylosing spondylitis. Rheumatology Int: in press
Orwoll E, Ettinger M, Weiss S, Miller P, Kendler D, Graham J, Adami S, Weber K, Lorenc R,
Pietschmann P, Silverman S, Felsenberg D, Vandormael K, Daifotis A, Lombardi A (2000)
Alendronate treatment of osteoporosis in men. N Engl J Med 343: 604 – 610
Barnas U, Schmidt A, Seidl G, Kaider A, Pietschmann P, Mayer G (2001) A comparison of
quantitative computed tomography and dual X-ray absorptiometry for evaluation of bone
mineral density in patients on chronic hemodialysis. Am J Kidney Dis 37: 1247 – 1252
Kallay E, Pietschmann P, Toyokuni S, Bajna E, Hahn P, Mazzucco K, Bieglmayer C, Kato S,
Cross HS (2001) Characterization of a vitamin D receptor knockout mouse as a model of
colorectal hyperproliferation and DNA damage. Carcinogenesis 22: 1429-1435
Redlich K, Hayer S, Maier A, Dunstan CR, Tohidast-Akrad M, Lang S, Türk B, Pietschmann
P, Woloszczuk W, Haralambous S, Kollias G, Steiner G, Smolen JS, Schett G (2002) Tumor
necrosis factor α-mediated joint destruction is inhibited by targeting osteoclasts with
osteoprotegerin. Arthritis Rheum 46: 785 – 792
Kudlacek S, Schneider B, Woloszczuk W, Pietschmann P, Willvonseder R (2003) Serum
levels of osteoprotegerin increase with age in a healthy adult population. Bone 32: 681 –686
Sipos W, Duvigneau CJ, Pietschmann P, Willheim M, Höller K, Hartl RT, Wahl K, Steinborn
R, Gemeiner M, Schmoll F (2003) Parameters of humoral and cellular immunity following
vaccination of pigs with a European modified-live strain of porcine reproductive and
respiratory syndrome virus (PRRSV), Viral Immunol 16: 335 – 346
Schett G, Kiechl S, Redlich K, Oberhollenzer F, Weger S, Egger G, Mayr A, Jocher J, Xu Q,
Pietschmann P, Teitelbaum S, Smolen J, Willeit J (2004) Soluble RANKL and risk of nontraumatic fracture. JAMA 291: 1108 – 1113
Kotzmann H, Riedl M, Pietschmann P, Schmidt A, Schuster E, Kreuzer S, Kainberger F,
Frisch H, Geyer G, Hörl WH, Mayer G, Luger A (2004) Effects of 12 months of recombinant
growth hormone therapy on parameters of bone metabolism and bone mineral density in
patients on chronic hemodialysis. J Nephrol 17: 87 – 94
Sipos W, Duvigneau JC, Willheim M, Schilcher F, Hartl RT, Hofbauer G, Exel B,
Pietschmann P, Schmoll F (2004) Systemic cytokine profile in feeder pigs suffering from
natural postweaning multisystemic wasting syndrome (PMWS) as determined by
semiquantitative RT-PCR and flow cytometric intracellular cytokine detection. Vet Immunol
Immunopathol 99: 63 – 71
- 180 -
Grisar J, Aringer M, Köller MD, Stummvoll GH, Eselböck D, Zwölfer B, Steiner CW, Zierhut
B, Wagner L, Pietschmann P, Smolen JS (2004) Leflunomide inhibits transendothelial
migration of peripheral blood mononuclear cells. Ann Rheum Dis 63: 1632-1637
Cavanagh LL, Boyce A, Smith L, Padmanabha J, Filgueira L, Pietschmann P, Thomas R
(2005) Rheumatoid arthritis synovium contains plasmacytoid dendritic cells. Arthritis Res
Ther 7: R230-40
Karanikas G, Schütz M, Wahl K, Paul M, Kontur S, Pietschmann P, Kletter K, Dudczak R,
Willheim M (2005) Relation of anti-TPO antibody titre and T-lymphocyte cytokine production
patterns in Hashimoto’s thyroiditis. Clin Endocrinol 63: 191 – 196
Thien R, Baier K, Pietschmann P, Peterlik M, Willheim M (2005) Interactions of 1α,25dihydroxyvitamin D3 with IL-12 and IL-4 on cytokine expression of human T lymphocytes. J
Allergy Clin Immunol 116: 683 – 689
Sipos W, Duvigneau JC, Pietschmann P, Schilcher F, Hofbauer G, Hartl RT, Schmoll F
(2005) Porcine dermatitis and nephropathy syndrome (PDNS) is associated with a systemic
cytokine expression profile indicative of proinflammation and a Th1 bias. Vet Immunol
Immunopathol, A52: 382-387
Gugatschka M, Dobnig H, Fahrleitner-Pammer A, Pietschmann P, Kudlacek S, Strele A,
Obermayer-Pietsch B (2005) Molecularly-defined malabsorption, milk consumption and
anthropometric differences in adult males. Q J Med 98: 857-863
Fischer P, Gruenblatt E, Pietschmann P, Tragl KH (2006) Serotonin Transporter
Polymorphism and LDL-Cholesterol. Mol Psychiatry 11 (8): 707-709
Wutzl A, Eisenmenger G, Hoffmann M, Czerny C, Moser D, Pietschmann P, Ewers R,
Baumann A. (2006) Osteonecrosis of the jaws and bisphosphonate treatment in cancer
patients. Wien Klin Wochenschr 118 (15-16): 473-478
Gugatschka M, Hoeller A, Fahrleitner-Pammer A, Dobnig H, Pietschmann P, Kudlacek S,
Obermayer-Pietsch B (2007) Calcium supply, bone mineral density and genetically defined
lactose maldigestion in a cohort of elderly men. J Endocrinol Invest 30 (1): 46-51
Reviews:
Kudlacek S, Willvonseder R, Stohlawetz P, Hahn P, Pietschmann P (2000) Immunology and
aging. The aging male 3: 137 – 142
Resch H, Gollob E, Kudlacek S, Pietschmann P (2001) Die Osteoporose beim Mann. Wien
Med Wschr 151: 457-463
Pietschmann
P
(2001)
Geschlechtsunterschiede
bei
pathophysiologische Grundlagen. Wien Med Wschr 151: 573-575
Gelenkserkrankungen:
Mitringer A, Pietschmann P (2002) Osteoporose bei prämenopausalen Frauen. Wien Med
Wschr 152: 586 - 590
Dimai HP, Pietschmann P, Resch H, Klaushofer K (2002) Leitfaden zur medikamentösen
Therapie der postmenopausalen Osteoporose. Wien Med Wschr 152: 596 - 612
Brosch S, Redlich K, Pietschmann P. (2003) Pathogenese der Osteoporose bei chronischer
- 181 -
Polyarthritis. Acta Med Austriaca 30: 1 – 5
Pietschmann P, Kerschan-Schindl K (2004) Osteoporosis: Gender specific aspects. Wien
Med Wschr 154/17-18: 411- 415
Rauner M, Sipos W, Pietschmann P (2007) Osteoimmunology. Int Arch Allergy Immunol 143:
31-48
Patsch J, Muschitz C, Resch H, Pietschmann P (2007) Of mice and men: pathophysiology of
male osteoporosis. JMHG 4(1): 87-93
Bröll H, Resch H, Pietschmann P, Sieghart S, Dobnig H, Erlacher L, Finkenstedt G, Holzer
G, Pecherstorfer M, Pirich C (2007) Konsensus-Statement: Therapie der postmenopausalen
Osteoporose -Anwendungsbereiche von parenteralen Bisphosphonaten. J Miner Stoffwechs
1: 45-48
Patsch J, Pietschmann P (2007) Controversial question- does histomorphometry still have a
role to play?. Medicographia 29(2): 151
Burckhardt P, Concin H, Dimai H, Dobnig H, Erlacher L, Finkensedt G, Gasser R, Holzer G,
Klaushofer K, Kotz R, Kraenzlin M, Minne HW, Obermayer-Pietsch B, Peichl P, Pietschmann
P, Roschger P, Schütz W, Sieghart S, Windhager R (2007) Med ahead consensusOsteoporose- Stellenwert der PTH-Therapie. Österreichische Ärztezeitung (Suppl März): 310
Sipos W, Pietschmann P. Rauner M (2008) Strategies for novel therapeutic approaches
targeting ytokines and signaling pathways of osteoclasto-and osteoblastgenesis in the fight
against immune-mediated bone and joint diseases. Curr Med Chem 15(2); 127-136
- 182 -
Curriculum Vitae
Clemens Scheinecker
Division of Rheumatology, Internal Medicine III, Medical University of Vienna, Währinger
Gürtel 18-20, A-1090 Vienna, Austria
Phone: +43 1 40400 4300, Fax: +43 1 40400 4306
Homepage: http://www.meduniwien.ac.at/rheuma/
Personal Data
Date of Birth:
12.03.1966
Place of Birth:
Eisenstadt
Nationality
Austria
Education
1984 – 1991
Academic studies of medicine at the University of Vienna,
Austria
Graduation to Doctor medicinae: 19.12.1991
1984
University entrance qualification, BG – BRG Oberschützen
Career History
Since 2004
Associate (a.o. Univ. Prof.) Professor of Internal Medicine
9/2004
Habilitation in Internal Medicine
2004
Specialist in Internal Medicine
2000 - 2003
Postdoctoral fellowship at the Laboratory of Immunology,
Lymphocyte Biology Section, National Institute of Allergy
and Infectious Diseases (NIAID), National Institutes of
Health (NIH), Bethesda, MD, USA
1999 - 2000
Training in Internal Medicine at the University of Vienna,
General Hospital of Vienna, Div. of Rheumatology, Clinic
for Internal Medicine III
1996 - 1999
Training in Internal Medicine at the Lainz Hospital, II. Dept.
of Medicine with Rheumatology, Vienna
1995 - 1996
Training in General Medicine at the Wilhelminenspital, I.
Dept. of Medicine with Oncology, Vienna
- 183 -
1992 - 1995
Postdoctoral fellowship at the Institute of Immunology,
Awards
2005
“Habilitationspreis 2005 des Vereins zur Förderung von
Wissenschaft und Forschung in den neuen
Unversitätskliniken am Allgemeinen Krankenhaus der
Stadt Wien (vfwf)
2005
Fellows Award for Research Excellence, National Institutes
of Health, Fellows Committee, Bethesda, MD, USA
2001
Erwin Schrödinger Postdoctoral Fellowship, FWF,
“Analysis of the regulatory mechanism involved in support
of peripheral tolerance for tissue specific self-antigens”, #
J2059
2000
Erwin Schrödinger Postdoctoral Fellowship, FWF,
“Analysis of the regulatory role of dendritic cells in support
of peripheral self tolerance”, # J1863
Memberships
Austrian Society of Rheumatology
Period
Organization
Short Title
2008-2010
ÖNB Jubiläumsfond
„Die Wirkung von Abatacept und Rituximab
K€/year
35
auf regulatorische T Zellen in der
Rheumatoiden Arthritis“ # AP12754ONB
2005 - 2008 FWF
“Analysis of T cell –antigen presenting cell
81
interaction in collagen induced arthritis (CIA)
and effect of cell based immunomodulatory
therapies“, # P18374-B13.
Period
Name of student
2004 - 2005 Michael Bonelli
Topic
Analysis of regulatory T cells under steady state
and autoimmune conditions
- 184 -
2004 - 2006 Sonia Herman
Untersuchung der Interaktion von regulatorischen
T-Zellen und Dendritischen Zellen, in Hinblick auf
Phänotyp und Funktion.
Publications
26 peer reviewed publications in scientific journals, 3 book chapters,
1.
Fritsch R, Eselbock D, Skriner K, Jahn-Schmid B, Scheinecker C, Bohle B, TohidastAkrad M, Hayer S, Neumuller J, Pinol-Roma S, Smolen JS, Steiner G: Characterization
of autoreactive T cells to the autoantigens heterogeneous nuclear ribonucleoprotein A2
(RA33) and filaggrin in patients with rheumatoid arthritis. J Immunol. Jul 15;169(2):106876, 2002.
2.
Scheinecker C, McHugh R, Shevach EM, Germain RN: Constitutive presentation of a
natural tissue autoantigen exclusively by dendritic cells in the draining lymph node. J
Exp Med. 2002 Oct 21;196(8):1079-90. Comment in: J Exp Med. 2002 Oct
21;196(8):1013-6.
3.
Köller M, Zwölfer B, Steiner G, Smolen J and Scheinecker C: Phenotypic and functional
deficiencies of monocyte derived dendritic cells in systemic lupus erythematodes (SLE)
patients. Int Immunol. Nov;16(11):1595-604, 2004.
4.
Scheinecker C: Application of in vivo microscopy: evaluating the immune response in
living animals Arthritis Res Ther; 7(6):246-52, 2005 Review.
5.
Castellino F, Huang AY, Altan-Bonnet G, Stoll S, Scheinecker C, Germain RN:
Chemokines enhance immunity by guiding naive CD8+ T cells to sites of CD4+ T celldendritic cell interaction. Nature. Apr 13;440(7086):890-5, 2006.
6.
Diarra D, Stolina M, Polzer K, Zwerina J, Ominsky MS, Dwyer D, Korb A, Smolen J,
Hoffmann M, Scheinecker C, van der Heide D, Landewe R, Lacey D, Richards WG,
Schett G: Dickkopf-1 is a master regulator of joint remodeling. Nature Med,
Mar;13(2):156-163, 2007.
7.
Zwerina J, Redlich K, Polzer K, Joosten L, Kroenke G, Distler J, Hess A, Pundt N, Pap
T, Hoffmann O, Gasser J, Scheinecker C, Smolen JS, van den Berg W, Schett G.: TNFinduced structural joint damage is mediated by IL-1. Proc Natl Acad Sci., 104:11742-7,
2007.
8.
Bonelli M, von Dalwigk K, Savitskaya A, Smolen JS, and Scheinecker C: Foxp3
expression in CD4+ T cells of patients with systemic lupus erythematosus (SLE): A
comparative phenotypic analysis. Ann Rheum Dis. 2007 Aug 29; [Epub ahead of print]
9.
Zenz R, Eferl R, Scheinecker C, Redlich K, Smolen J, Schonthaler HB, Kenner L,
Tschachler E, Wagner EF: Activator protein 1 (Fos/Jun) functions in inflammatory bone
and skin disease. Arthritis Res Ther. 2008 Jan 18;10(1):201 [Epub ahead of print]
- 185 -
Curriculum Vitae
Veronika Sexl
Institute of Pharmacology, Centre for Biomolecular Medicine and Pharmacology, Medical
University of Vienna, Währinger Strasse 13a, A-1090 Vienna, Austria;
Phone +43 1 4277 64137; Fax +43 1 4277 9641
Personal Data
Date of Birth:
27.2.1966
Place of Birth:
Vienna
Nationality
Austria
Education
1992 - 2002
training as medical specialist in Pharmacology and
Toxicology
1984-1992
studies of Human Medicine
1976-1984
secondary school: Bundesgymnasium XIX, Vienna
Career History
12/07
Full Professor for Signaltransduction and Development of
Molecular Targeted Therapies, Medical University of
Vienna
2001 – present
associate Professor at the Department of Pharmacology,
Medical University of Vienna, Head of the Working Group
Experimental Hemato-Oncology
2000
Materenity leave
1998-1999
Postdocteral fellow ship, St. Judes Childrens Research
Hospital, Memphis, TN, USA, with Prof. James N Ihle, Dpt
of Biochemistry
1996-1997
Erwin Schroedinger postdoctoral fellowship, St. Judes
Childrens Research Hospital, Memphis, TN, USA, with
Charles Sherr, Dpt Tumor Cell Biology
1996
short-term visiting fellow, Hutchinson Cancer Research
Center, Seattle, WA, USA, with Prof. James Roberts
1992-1996
university assistent, Institute of Pharmacology, University
of Vienna
1990-1992
Voluntary thesis and laboratory work in the laboratory of
Prof. W Base, Dpt of Internal Medicine Vienna University
- 186 -
Clinics
2002-present
Lecturer for Pharmacology and Toxicology at the
Fachhochschule für Biotechnologie, Krems
2005-2007
Lecturer for Pharmacology at the Paracelsus Medical
University (PMU) in Salzburg, Austria
Awards
1989-1992
Award for outstanding performance “Leistungsstipendium”,
Medical Dpt, University of Vienna
2003
Award for innovative interdisciplinary cancer research of
the city of Vienna
2004
Award for innovative interdisciplinary cancer research of
the city of Vienna
2004
Billroth Award of the Medical Society
2005
Sanofi-Aventis-Award
2006
Novartis Arward for Medicine
2006
Alos Sonnleitner Award of the Austrian Academy of
Science
Memberships
Austrian Pharmacological Society (APHAR)
Elected member of the European Academy of Science
Period
Organization
Short Title
K€/year
2001-2003
FWF
IFN gamma dependent tumor surveillance
40
2002-2005
FWF
AP-1 and leukemia
60
2004-05
OENB
PI3K and leukemia
50
2005-09
SFB 28-10
Jaks and Stats
90
2005-09
GenAU
Functional Pharmaco-Genomics and -
70
proteomics
2007-10
FWF
Cdk6-a therapeutic target in leukemia
Period
Name of student
Topic
2002-2006
Rene G Ott
JunB and B lymphoid leukemia
90
- 187 -
2004-
Andrea Hölbl
Stat5 in Abelson induced leukemia
2004-
Olivia Simma
Role of Tyk2 in immune functions
2004-
Christian Schuster
Tyk2 and Emu-myc induced tumors
2006-
Karoline Kollmann
Cdk6 and leukemia formation
2006-
Eva Eckelhart
Jak2 and Abelson induced malignancies
2007-
Eva-Maria Putz
Stat1 – tumor suppressor or promoter?
2007-
Nina Neugebauer
Stat1 in mammary tumor formation
Publications
35 peer reviewed publications in scientific journals, about 20 invited lectures
Klinger M, Kudlacek O, Seidel MG, Freissmuth M, Sexl V (2002). MAP Kinase Stimulation by
cAMP Does Not Require RAP1 but SRC Family Kinases. J Biol Chem 277:32490-7
Sexl V, Kovacic B, Piekorz R, Moriggl R, Stoiber D, Hoffmeyer A, Liebminger R, Kudlacek O,
Weisz E, Rothammer K, Ihle JN (2003). Jak1 deficiency leads to enhanced Abelsoninduced B-cell tumor formation. Blood 101: 4937-43.
Szremska A, Kenner L, Weisz E, Passegué E, Artwohl M , Freissmuth M, Stoxreiter R,
Theussl HC, Baumgartner Parzer S , Moriggl R, Wagner EF, Sexl V (2003). JunB
inhibits proliferation and transformation in B lymphoid cells. Blood, 102:4159-4165.
Klinger M, Farhan H, Just H, Drobny H, Himmler G, Loibner H, Mudde GC, Freissmuth M,
Sexl V. Antibodies directed against Lewis-Y antigen inhibit signaling of Lewis-Y
modified ErbB receptors (2004).Cancer Res;64(3):1087-93.
Stoiber D, Kovacic B, Schuster C, Schellack C, Karaghiosoff M, Kreibich R, Weisz E, Artwohl
M, Kleine O, Müller M, Baumgartner-Parzer S, Ghysdael J, Freissmuth M, Sexl V.
Tyk2 is a key regulator of the surveillance of B-lymphoid tumors (2004). J Clin Invest.
114:1650-1658.
Hölbl A, Kovacic B, Kerenyi MA, Simma O, Warsch W, Cui Y, Beug H, Hennighausen L,
Moriggl R, Sexl V. Clarifying the role of Stat5 in lymphoid development and Abelson
induced transformation (2006). Blood 107:4898-906.
Kovacic B, Stoiber D, Moriggl R, Weisz E, Ott RG, Kreibich R, Levy DE, Beug H, Freissmuth
M, Sexl V. STAT1 acts as a tumor promoter for leukaemia development (2006).
Cancer Cell 10:77-87.
Ott RG, Simma O, Kollmann K, Weisz E, Zebedin EM, Schorpp-Kistner M, Heller G,
Zochbauer S, Wagner EF, Freissmuth M, Sexl V. Jun Bis a gatekeeper for B-lymphoid
leukemia (2007). Oncogene 26: 4863-71.
Schuster C, Fernbach N, Rix U, Superti-Furga G, Holy M, Freissmuth M, Sitte HH, Sexl V.
Selective serotonin reuptake.-inhibitors – a new modality for the treatment of
lymphoma/leukemia? (2007). Biochem.Pharmacol. 74: 424-35.
- 188 -
Piekorz RP, Hoffmeyer A, Duntsch CD, McKay C, Nakajima H, Sexl V, Snyder L,
Rehg J, Ihle JN (2002). The centrosomal protein TACC3 is essential for hematopoietic
stem cell function and genetically interfaces with p53-regulated apoptosis. EMBO J
21:653-664.
Shelburne C, McCoy M, Piekorz R, Sexl V, Gillespie S, Bailey D, Gharse A, Mirmonsef P, N
Mann M, Kashyap M, Wright H, Chong H, Bouton L, Ramirez C, Lantz C, Ryan J
(2002). Stat5: an essential regulator of mast cell biology. Mol Immunol 38:1187-1191.
Shelburne CP, McCoy ME, Piekorz R, Sexl V, Roh KH, Jacobs-Helber SM, Gillespie SR,
Bailey DP, Mirmonsef P, Mann MN, Kashyap M, Wright H, Chong H, Bouton L,
Ramirez C, Lantz C, Ryan J (2003). Stat5 expression is critical for mast cell
development and survival. Blood 102:1290-1297.
Moriggl R, Sexl V, Kenner L, Duntsch C, Stangl K, Gingras S, Hoffmeyer A, Bauer A, Piekorz
R, Wang D, Bunting KD, Wagner EF, Sonneck K, Valent P, Ihle JN, Beug H. Stat5
Tetramers formation is associated with leukemogenesis (2005). Cancer Cell. 7:87-99.
Hoeller C, Pratscher B, Thallinger C, Winter D, Fink D, Kovacic B, Sexl V, Wachek V, Gleave
ME, Pehamberger H, Jansen B. Clusterin confers drug-resistance in melanoma cells
(2005). J Invest Dermat. 124:1300-7.
Höller C, Thallinger C, Pratscher B, Bister MD, Schicher N, Loewe R, Heere-Ress E, Roka F,
Sexl V, Pehamberger H. The non receptor associated tyrosine kinase p72Syk is a
regulator of metastatic behaviour in human melanoma cells (2005). J Invest Dermat.
124: 1293-9.
Staber PB, Veley P, Haq N, Ott RG, Funato K, Bambach I, Fuchs C, Schauer S, Linkesch W,
Hrzenjak A, Dirks WG, Sexl V, Bergler H, Kadin ME, Sternberg DW, Kenner L, Hoefler
G. The oncoprotein NPM-ALK of anaplastic large cell lymphoma induces JUNB
transcription via ERK1/2 and JunB translation via mTOR signalling (2007). Blood,
110:3374-83.
Mayerhofer M, Gleixner KV, Mayerhofer J, Hoermann G, Jaeger E, Aichberger K, Ott RG,
Greish K, Nakamura H, Derdak S, Samorapoompichit P, Pickl WF, Sexl V, Esterbauer
H, Schwarzinger I, Sillaber C, MaedaH, Valent P. Targeting of heat shock protein 32
(HsP32)/heme oxygenase-1 (HO-1) in leukemic cells in chronic myleoid leukemia: a
novel approach to overcome resistance against imatinib. (2007). Blood; epub ahead of
print.
- 189 -
Curriculum Vitae
Maria Sibilia
Institute for Cancer Research, Department of Medicine I, Medical University of Vienna,
Borschkegasse 8a, A-1090 Vienna, Austria
Phone: 43 1 40160-63011, Fax: +43 1 40160-963005
http://www.meduniwien.ac.at/innere-med-1/krebsforschung
http://www.meduniwien.ac.at/phd-iai/
http://www.meduniwien.ac.at/sfb23/
Personal Data
Date of Birth:
26.11.1963
Place of Birth:
Chur
Nationality
Switzerland
Education
1970 – 1984
1984 – 1989
1986 – 1989
1990 – 1992
1993 – 1996
1996 – 1998
01/1999
07/2002
04/2007
Awards
1990 - 1992
Schools in Thusis and Chur (GR), Switzerland.
Study of Biological Sciences, University of Pavia, Italy, with
honours.
Experimental thesis (Laurea), Department of Genetics and
Microbiology, University of Pavia, Italy.
Ph.D. Studies in Genetics and Molecular Biology,
University of Pavia and Department of Biotechnology and
Virology, Brescia, Italy.
Postdoctoral fellow at the Institute of Molecular Pathology
(IMP), Vienna, Austria.
Staff Scientist at the Institute of Molecular Pathology (IMP),
Vienna, Austria.
Assistant Professor / Group Leader (Univ. Ass.) at the
Department of Dermatology, DIAID, University of Vienna
Medical School, Vienna, Austria.
Habilitation in Molecular Biology and Genetics, University
of Vienna Medical School.
Associate Professor (a.o. Univ. Prof.) at the Department of
Dermatology, DIAID, University of Vienna Medical School,
Vienna, Austria.
Professor for Cellular and Molecular Tumorbiology,
Institute for Cancer Research, Department of Medicine I,
Medical University of Vienna, Vienna, Austria
Graduate Student Fellowship from the “Fondazione Istituto
Zooprofilattico Sperimentale Brescia”.
- 190 -
1992 - 1994
12/2000
11/2002
05/2003
10/2005
Postdoctoral fellowship from the “Associazione Italiana per
la Ricerca sul Cancro (AIRC)”.
ÖGDV-Unilever Dermatology Prize 2000
Habilitation prize “Verein zur Förderung von Wissenschaft
und Forschung in den Neuen Universitätskliniken am AKH
der Stadt Wien” (VFWF).
Otto-Kraupp-Prize: 1st Prize for the best Habilitation in
Austria for the year 2002.
Alois-Sonnleitner Prize, Austrian Academy of Sciences
(ÖAW) for outstanding achievements in Cancer Research.
Publications
Research papers:
M. B. Boniotti, C. Wirblich, M. Sibilia, G. Mayers, H.-J. Thiel and C. Rossi. “Identification and
characterisation of a 3C-like protease from Rabbit Hemorrhagic Disease Virus, a Calicivirus”,
J. Virology 68, 6487-6495 (1994).
M. Sibilia, M.B. Boniotti, P. Angoscini, L. Capucci and C. Rossi. “Two independent pathways
of expression lead to self-assembly of the Rabbit Hemorrhagic Disease Virus capsid protein”,
J. Virology 69, 5812-5815 (1995).
C. Wirblich, M. Sibilia, M.B. Boniotti, C. Rossi, H.-J. Thiel and G. Mayers. “3C-like protease
of Rabbit Hemorrhagic Disease Virus: Identification of cleavage sites in the ORF1 polyprotein
and analysis of cleavage specificity”, J. Virology 69, 7159-7168 (1995).
M. Sibilia and E. F. Wagner. “Strain-dependent epithelial defects in mice lacking the EGF
receptor”, Science 269, 234-238 (1995).
M. Sibilia, J. P. Steinbach, L. Stingl, A. Aguzzi and E. F. Wagner. “A strain-independent
postnatal neurodegeneration in mice lacking the EGF receptor”, EMBO J. 17, 719-731,
(1998).
V. Tropepe, M. Sibilia, B. G. Ciruna, J. Rossant, E. F. Wagner and D. van der Kooy. “Distinct
neural stem cells proliferate in response to EGF and FGF in the developing mouse
telencephalon”, Dev. Biology 208, 166-188 (1999).
A. Behrens, M. Sibilia and E. F. Wagner. “Amino-terminal phosphorylation of c-Jun regulates
stress-induced apoptosis and cellular proliferation” Nature Genetics 21, 326-329 (1999).
R. Eferl, M. Sibilia, F. Hilberg, A. Fuchsbichler, I. Kufferath, B. Guertl, R. Zenz, E. F. Wagner
and K. Zatloukal. “Functions of c-Jun in liver and heart development”, J. Cell Biol. 145,
1049-1061 (1999).
M. Sibilia*, A. Fleischmann, A. Behrens, L. Stingl, J. Carroll, F. M. Watt, J. Schlessinger and
E. F. Wagner*. “The EGF receptor provides an essential survival signal for SOS-dependent
skin tumor development”, Cell 102, 211-220 (2000). (*corresponding authors)
A. Behrens, W. Jochum, M. Sibilia and E. F. Wagner. “Oncogenic transformation by ras and
fos is mediated by c-Jun N-terminal phosphorylation“, Oncogene 19, 2657-2663 (2000).
S. W. Stoll, S. Kansra, S. Peshick, D. W. Fry, W. R. Leopold, J. F. Wiesen, M. Sibilia, T.
Zhang, Z. Werb, R. Derynck, E. F. Wagner and J. T. Elder. "Differential utilization and
localization of ErbB receptor tyrosine kinases in skin compared to normal and malignant
- 191 -
keratinocytes", Neoplasia 3,339-350, 2001.
A. H. F. M. Peters, D. O'Carroll, H. Scherthan, K. Mechtler, S. Sauer, C. Schöfer, K.
Weipoltshammer, M. Pagani, M. Lachner, A. Kohlmaier, S. Opravil, M. Doyle, M. Sibilia and
T. Jenuwein. "Loss of the Suv39h Histone Methyltransferases impairs mammalian
heterochromatin and genome stability", Cell 107, 323-337 (2001).
A. Behrens*, M. Sibilia*, J. P. David, U. Möhle-Steinlein, F. Tronche, G. Schütz and E. F.
Wagner. “Impaired postnatal hepatocyte proliferation and liver regeneration in mice lacking cjun in the liver”, EMBO J. 21, 1782-1790, (2002). (*equally contributing authors)
M. Sibilia, B. Wagner, A. Hoebertz, C. Elliott, S. Marino, W. Jochum and E. F. Wagner.
“Mice humanized for the EGF receptor display hypomorphic phenotypes in skin, bone and
heart”, Development 130, 4515-4525, (2003).
R. Zenz, H. Scheuch, P. Martin, C. Frank, R. Eferl, L. Kenner, M. Sibilia and E. F. Wagner.
“c-Jun regulates eyelid closure and skin tumor development through EGFR signaling”, Dev.
Cell 4, 879-889, (2003).
F. Palamara, S. Meindl, M. Holcmann, P. Lührs, G. Stingl and M. Sibilia. “Identification and
characterization of ‘pDC-like cells’ in normal mouse skin and melanomas treated with
Imiquimod”, J. Immunology 173, 3051-3061, (2004).
B. Wagner, A. Natarajan, S. Grünaug, R. Kroismayr, E.F. Wagner and M. Sibilia. “Neuronal
survival depends on EGF receptor signaling in cortical but not midbrain astrocytes”, EMBO J.
25, 752-762, (2006).
K. Fortschegger, B. Wagner, R. Voglauer, H. Katinger, M. Sibilia and J. Grillari. “Early
Embryonic Lethality of Mice Lacking the Essential Protein SNEV”, Mol. Cell Biol. 27, 31233130 (2007).
A. Natarajan, B. Wagner and M. Sibilia. “The EGF receptor is required for efficient liver
regeneration”, PNAS, 104:17081-17086 (2007).
E. Schraml, R. Voglauer, K. Fortschegger, M. Sibilia, I. Stelzer, J. Grillari and K.
Schauenstein. “Haploinsufficiency of SNEV causes defects of hematopoietic stem cells
functions“, Stem Cells Dev., in press (2008)
U. Schmidt, N. Boucheron, E. Eckelhart, I. Bilic, M. Kneidinger, B. Unger, M. Hammer, M.
Sibilia, P. Valent and W. Ellmeier. “The protein tyrosine kinase Tec regulates mast cell
function“, J. Immunology, accepted pending revision (2008).
M. Holcmann, B. Drobits, P. Lührs, G. Stingl, D. Maurer and M. Sibilia. “Tolerance induction
in the skin under homeostatic conditions“, J. Immunology, accepted pending revision
(2008).
Book chapters and reviews
C. Rossi, M. B. Boniotti, M. Sibilia, L. Capucci. “Expression by a recombinant Baculovirus of
the capsid protein VP60 from the Rabbit Hemorrhagic Disease Virus results in assembly of
empty capsids and production of an effective Vaccine”, in ‘State of the Art of the Italian
Research in Biotechnology applied to Veterinary Sciences‘, Vol 35, 45-55 (1993).
M. Sibilia and E. F. Wagner. “Transgenic animals”, European Review, Vol 4, No. 4, 371391 (1996).
- 192 -
E. F. Wagner and M. Sibilia. “Transgenics revisited”, Trends in Genetics, 13, 501-502
Book Comment to ‘Transgenic Animals: Generation and Use’ ed. L.M. Houdebine, Harwood
Academic Publishers (1997).
M. Sibilia, R. Kroismayr, A. Natarajan, B. M. Lichtenberger, M. Hecking, M. Holcmann. “The
Epidermal Growth Factor Receptor: from development to tumorigenesis“. Differentiation,
75, 770-787 (2007)
- 193 -
Curriculum Vitae
Peter Steinberger
Division of Immune Receptors and T cell Activation, Institute of Immunology, Center for
8a, 1090 Wien, Austria;
Phone: +43 1 4277-64941, Fax: +43 1 4277-9649;
Homepage: www.meduniwien.ac.at/immunologie/ellmeier
Personal Data
Date of Birth:
28.11.1965
Place of Birth:
Leoben, Austria
Nationality
Austria
Education
1992 – 1995
Ph.D. in Biochemistry at the University of Vienna,
1988 – 1992
Diploma degree in Zoology and Biochemistry; University of
Vienna
1986 – 1988
Prediploma in Biology; University of Graz
1985
University entrance qualification, HBLA Raumberg
Career History
06/2007
Habilitation at the Medical University of Vienna
Since 03/2007
Independent group leader at the Institute of Immunology
Since 06/2006
Permanent research position at the Institute of
Immunology
Since 02/2000
Institute of Immunology in the group of Prof. Walter Knapp
and since 08/2004 in the group of Prof. Johannes Stöckl
06/1996-12/1999
Postdoctoral Studies at The Scripps Research Institute in
the group of Professor Dr. Carlos F. Barbas III.
1992-1995
PhD Thesis at the Dept. of Pathophysiology in the group of
Professor Rudolf Valenta
06/1998
Austrian National Award for Alternatives to Animal
Experimentation
1997-1998
Erwin Schroedinger Fellowship from the Austrian Science
- 194 -
Foundation
12/1995
Award for Ph. D. thesis of the Austrian Society of Allergy
09/1995
and Clinical Immunology
Travel award from the Austrian Society for Allergology and
Immunology
Memberships
Period
Organization
2008 - 2010 ONB
Short Title
K€/year
Alternative costimulators in CD28-negative T
37
cells
2006 - 2008 FWF
Role of B7-H3 during T cell activation
70
2005 - 2008 CCRI
DC-reactive antibodies
55
2004 - 2006 ONB
Search for HSP-Receptors
40
Period
Name of student
Topic
01/2006-
Judith Leitner
Identification of tumour antigens using antibodies
present
induced by DC-based vaccines
Publications
Scientific papers: 34
Reviews: 4
Book Chapters: 5
1
2
3.
4.
Pfistershammer, K, Klauser, C., Leitner, J., Stöckl, J, Majdic, O., Weichhart, T.,
Sobanov, J., Bochkov, V., Säemann, M., Zlabinger, G., Steinberger, P* Identification
of the Scavenger Receptors SREC-I, SR-B1/Cla-1 and SR-A-1 as cellular receptors
for Tamm-Horsfall Protein. J Leukoc Biol. 2008. 83: 131-8.
Pfistershammer, K., Klauser, C., Pickl, W. F., Stockl, J., Leitner, J., Zlabinger, G.,
Majdic, O. and Steinberger, P*., No evidence for dualism in function and receptors:
PD-L2/B7-DC is an inhibitory regulator of human T cell activation. Eur J Immunol
2006. 36: 1104-1113.
Steinberger, P*., O. Majdic, S. V. Derdak, K. Pfistershammer, S. Kirchberger, C.
Klauser, G. Zlabinger, W. F. Pickl, J. Stockl, and W. Knapp. 2004. Molecular
characterization of human 4Ig-B7-H3, a member of the B7 family with four Ig-like
domains. J Immunol 172:2352.
Steinberger, P.*, A. Szekeres, S. Wille, J. Stockl, N. Selenko, E. Prager, G. Staffler,
O. Madic, H. Stockinger, and W. Knapp. 2002. Identification of human CD93 as the
- 195 -
phagocytic C1q receptor (C1qRp) by expression cloning. J Leukoc Biol 71:133.
* corresponding author
1.
Flicker, S., Steinberger, P., Eibensteiner, P. B., Lebecque, S., Kraft., D., and
Valenta, R. Molecular characterization of a human IgG4 antibody specific for the
major birch pollen allergen, Bet v 1. Clin. Exp. Allergy. in press
2.
Swan, C. H., Buhler, B., Steinberger, P., Tschan, M. P., Barbas, C. F., 3rd and
Torbett, B. E., T-cell protection and enrichment through lentiviral CCR5 intrabody
gene delivery. Gene Ther 2007. 14: 626.
3.
Flicker, S., Steinberger, P., Ball, T., Krauth, M. T., Verdino, P., Valent, P., Almo, S.
and Valenta, R., Spatial clustering of the IgE epitopes on the major timothy grass
pollen allergen Phl p 1: importance for allergenic activity. J Allergy Clin Immunol
2006. 117: 1336-1343.
4.
Kirchberger, S., O. Majdic, P. Steinberger, S. Bluml, K. Pfistershammer, G.
Zlabinger, L. Deszcz, E. Kuechler, W. Knapp, and J. Stockl. 2005. Human
rhinoviruses inhibit the accessory function of dendritic cells by inducing sialoadhesin
and B7-H1 expression. J Immunol 175:1145.
5.
Pfistershammer, K., O. Majdic, J. Stockl, G. Zlabinger, S. Kirchberger, P.
Steinberger, and W. Knapp. 2004. CD63 as an activation-linked T cell costimulatory
element. J Immunol 173:6000.
6.
Selenko-Gebauer, N., O. Majdic, A. Szekeres, G. Hofler, E. Guthann, U. Korthauer,
G. Zlabinger, P. Steinberger, W. F. Pickl, H. Stockinger, W. Knapp, and J. Stockl.
2003. B7-H1 (programmed death-1 ligand) on dendritic cells is involved in the
induction and maintenance of T cell anergy. J Immunol 170:3637.
7.
Flicker, S., P. Steinberger, L. Norderhaug, W. R. Sperr, Y. Majlesi, P. Valent, D.
Kraft, and R. Valenta. 2002. Conversion of grass pollen allergen-specific human IgE
into a protective IgG(1) antibody. Eur J Immunol 32:2156.
- 196 -
Curriculum Vitae
Günter Steiner
Division of Rheumatology, Internal Medicine III, Medical University of Vienna,
Währinger Gürtel 18, A 1090 Vienna; E-mail: [email protected]
Personal Data
Date of Birth:
29.10.1953
Place of Birth:
Vienna
Nationality
Austrian
Education
1981-1986
PhD studies (Biochemistry) at the Institute of Biochemstry,
1979-1981
Diploma thesis at the Institute of Biochemstry, University of
1973-1979
1964-1972
High school, Bundesgymnasium 21, Vienna
Career History
2000-
Associate Professor (a.o.Univ.Prof), Head of Laboratory,
Division of Rheumatology, Univ. of Vienna Medical School
2000
Habilitation in Biochemistry, Univ. of Vienna Medical School
1995-2000
Group leader, Division of Rheumatology, Internal Medicine III,
Univ. of Vienna Medical School
1989-1995
Group leader, Ludwig Boltzmann-Institute for Rheumatology,
Vienna
1986-1989
Postdoctoral Fellow, Ludwig Boltzmann-Institute for Clinical
Endocrinology, Vienna
2005-present
Member of the International Organizing Committee of the
International Congress on Autoimmunity
2002-2006
Board member, Austrian Society for Biochemistry and
Molecular Biology
2002-2005
Scientific programme committee member, European League
against Arthritis and Rheumatism (EULAR)
2001
Coorganizer, European Workshop for Rheumatoloy Research
- 197 -
2000 - present
International Advisory Board, Dresden Symposium on
Autoantibodies
1999
Coorganizer, 4th European Conference on SLE
1997
Advisory board, 10th EULAR Workshop
1992
Coorganizer, Int. Symposium on Ribonucleoproteins
1991
Coorganizer, Int. Workshop on Cytokines in Rheumatology
Awards
1997, 2000
Austrian State Award for Rheumatology
1992
Young Investigator´s Award of the European Workshop for
Rheumatology Research (EWRR)
1990
Forschungsförderungspreis der 1. Österr. Sparkasse
1987
Theodor Körner Award
Memberships
Austrian Society for Biochemistry and Molecular Biology
Period
Organization
Short Title
K€/year
2008 - 2012 EU
MASTERSWITCH (Integrated Project)
2006 - 2011 EU
AUTOCURE (Integrated Project)
2005 - 2007 ÖAW
CeMM 20060
121
2003 - 2004 ÖAW
CeMM 20060
152
2002
CeMM 20060
43
SFB 017/F1705: RNA Fate and Function
49
ÖAW
2001 - 2007 FWF
160
90
PhD supervisions in last 6 years (2002-2008)
Period
Name of student
1999 - 2003 Silvia Hayer
Topic
Molecular and cellular mechanisms leading to
autoimmune responses and tissue destruction in
rheumatoid arthritis
2002 - 2004 Atijeh Valai
Interactions of hnRNP I and hnRNP K with
autoantibodies and human Y1 RNA
2004-2008
Markus Hoffmann
The role of the autoantigen hnRNP-A2/B1 (RA33)
in the pathogenesis of rheumatoid arthritis
- 198 -
Publications
86 peer reviewed publications in scientific journals, 20 book chapters, > 30 invited lectures
First, last or corresponding author manuscripts
Fritsch R, Eselböck D, Skriner K, Jahn-Schmid B, Scheinecker C, Bohle B, Tohidast-Akrad
M, Hayer S, Neumüller J, Pinol-Roma S, Smolen J, Steiner G. Characterization of
autoreactive T cells to the autoantigens RA33 (hnRNP A2) and filaggrin in patients with
rheumatoid arthritis. J Immunol 169:1068-1076; 2002.
Steiner G, Shovman O, Skriner K, Gilburd B, Langevitz P, Miholits M, Hoet R, Levy Y,
Hoefler E, Smolen JS, Shoenfeld Y. Idiotypic manipulation with anti-RA33 antibody
preparation in mice induces the production of anti-RA33 hnRNP autoantibodies and transient
spread to snRNP complex of spliceosome. Clin Exp Rheumatol 20:517-524; 2002.
Schett G, Smolen J, Hiessberger H, Hoefler E, Fournel S, Muller S, Rubin RL, Steiner G. The
autoimmune response to chromatin antigens in systemic lupus erythematosus (SLE):
autoantibodies against histone H1 are a highly specific marker for SLE associated with
increased disease activity. Lupus 11:704-715; 2002.
Schett G, Steiner CW, Xu Q, Smolen JS, Steiner G. TNFα mediates susceptibility to heatinduced apoptosis by protein phosphatase-mediated downregulation of the HSF-1/hsp70
stress response. Cell Death Diff 10:1126-1136; 2003.
Smolen JS, Steiner G. Current and future therapeutic strategies for rheumatoid arthritis.
Nature Rev Drug Disc 2:473-488; 2003.
Belisova A, Semrad K, Kocian G, Mayer O, Waigmann E, Schroeder R, Steiner G. RNA
chaperone activity of protein components of human Ro RNPs. RNA 11, 1084-1094; 2005.
Nell VPK, Machold KM, Stamm TA, Eberl G, Heinzl H, Uffmann M, Smolen JS, Steiner G.
Autoantibody profiling as early diagnostic and prognostic tool for rheumatoid arthritis. Ann
Rheum Dis 64:1731-6; 2005.
Hayer S, Tohidast-Akrad M, Haralambous S, Jahn-Schmid B, Skriner K, Trembleau S,
Dumortier H, Pinol-Roma S; Redlich K, Schett G, Muller S, Kollias G, Smolen J, Steiner G.
Aberrant expression of the autoantigen hnRNP-A2/B1 (RA33) and spontaneous formation of
rheumatoid arthritis associated anti-RA33 autoantibodies in TNFα transgenic mice. J
Immunol 175:8327-36; 2005.
Fritsch-Stork R, Mullegger D, Skriner K, Jahn-Schmid B, Smolen JS, Steiner G. The
spliceosomal autoantigen heterogeneous nuclear ribonucleoprotein A2 (hnRNP-A2) is a
major T cell autoantigen in patients with systemic lupus erythematosus.
Arthritis Res Ther. 8:R118; 2006.
Steiner G. Autoantibodies and autoreactive T cells in rheumatoid arthritis: pathogenetic
players and diagnostic tools. Clin Rev Allergy Immunol. 32:23-36; 2007.
Hoffmann MH, Tuncel J, Skriner K, Tohidast-Akrad M, Türk B, Pinol-Roma S|, Serre G,
Schett G, Smolen JS, Holmdahl R, Steiner G. The human autoantigen hnRNP-A2 (RA33) is
a major stimulator of autoimmunity in rats with pristane-induced arthritis. J Immunol.
179:7568-7576; 2007.
Skriner K, Hueber W, Süleymanoglu E, Höfler E, Kren V, Smolen J, Steiner G.The regulator
of TNFα mRNA decay AU-rich element binding factor 1 (AUF1) is targeted by autoantibodies
of patients with systemic rheumatic diseases. Arthritis Rheum 58:511-520; 2008.
- 199 -
Stummvoll GH, Fritsch RD, Meyer B, Hoefler E, Aringer M, Smolen JS, Steiner G.
Characterization of cellular and humoral autoimmune responses to histone H1 and core
histones in human systemic lupus erythematosus. Ann Rheum Dis; Epub ahead of print;
March 2008.
Jimenez-Boj E, Kedersha N, Tohidast-Akrad M, Karlhofer FM, Stummvoll G, Zimmermann C,
Ulrich W, Guiducci S, Hoefler E, Aringer M, Schett G, Matucci-Cerinic M, Smolen J, Steiner
G. Autoantibodies to the translational suppressors TIA-1 and TIAR in patients with rheumatic
diseases. Increased prevalence in systemic lupus erythematosus and systemic sclerosis and
correlation with clinical features. Arthritis Rheum, in press.
Co-author manuscripts
Redlich K, Hayer S, Maier A, Dunstan CR, Lang S, Tohidast-Akrad M, Türk B, Pietschmann
P, Woloszczuk W, Haralambos S, Kollias G, Steiner G, Smolen JS, Schett G. TNF-αmediated joint destruction is inhibited by targeting osteoclasts with osteoprotegerin. Arthritis
Rheum 46:785-792; 2002.
Aringer M, Feierl E, Steiner G, Stummvoll GH, Hoefler E, Steiner CW, Radda I, Smolen JS,
Graninger WB. Increased bioactive TNF in human systemic lupus erythematosus:
associations with cell death. Lupus 11:102-108; 2002.
Union A, Meheus L, Humbel RL, Conrad K, Steiner G, Moereels H, Pottel H, Serre G, de
Keyser F. Identification of citrullinated rheumatoid arthritis-specific epitopes in natural
filaggrin relevant for anti-filaggrin autoantibody detection by Line Immunoassay. Arthritis
Rheum. 46:1185-1195; 2002.
Redlich K, Hayer S, Ricci R, David J-P, Tohidast-Akrad M, Kollias G, Steiner G, Smolen JS,
Wagner EF, Schett G. Osteoclasts are essential for TNF -mediated joint destruction. J Clin
Invest 110:1419-1427; 2002.
Schett G, Redlich K, Hayer S, Zwerina J, Bolon B, Dunstan C, Görtz B, Schulz A,
Bergmeister H, Kollias G, Steiner G, Smolen JS. Osteoprotegerin protects from generalized
bone loss in TNF-transgenic mice. Arthritis Rheum 48:2042-2051; 2003.
Redlich K, Schett G, Steiner G, Hayer S, Wagner EF, Smolen JS. Rheumatoid arthritis
therapy after tumor necrosis factor and interleukin-1 blockade. Arthritis Rheum 48: 33083319; 2003.
Zwerina J, Hayer S, Tohidast-Akrad M, Bergmeister H, Redlich K, Feige U, Dunstan C,
Kollias G, Steiner G, Smolen J, Schett G. Single and combined inhibition of TNF, IL-1 and
RANKL pathways in TNF-induced arthritis: effects on synovial inflammation, bone erosion
and cartilage destruction. Arthritis Rheum 50: 277-290; 2004.
Redlich K, Gortz B, Hayer S, Zwerina J, Doerr N, Kostenuik P, Bergmeister H, Kollias G,
Steiner G, Smolen JS, Schett G. Repair of local bone erosions and reversal of systemic bone
loss upon therapy with anti-tumor necrosis factor in combination with osteoprotegerin or
parathyroid hormone in tumor necrosis factor-mediated arthritis. Am J Pathol 164: 543-555;
2004.
Redlich K, Görtz B, Hayer S, Zwerina J, Kollias G, Steiner G, Smolen JS, Schett G.
Overexpression of tumor necrosis factor causes bilateral sacroiliitis. Arthritis Rheum 50:
1001-1005; 2004.
Görtz B, Hayer S, Redlich K, Zwerina J, Tohidast-Akrad M, Türk B, Hartmann C, Kollias G,
Steiner G, Smolen JS, Schett G. Arthritis induces lymphocytic bone marrow inflammation
and endosteal bone formation. J Bone Miner Res 19: 980-988; 2004.
- 200 -
Koller M, Zwolfer B, Steiner G, Smolen JS, Scheinecker C. Phenotypic and functional
deficiencies of monocyte-derived dendritic cells in systemic lupus erythematosus (SLE)
patients. Int Immunol 16:1595-604; 2004.
Aringer M, Graninger WB, Steiner G, Smolen JS. Safety and efficacy of tumor necrosis factor
alpha blockade in systemic lupus erythematosus: An open-label study. Arthritis Rheum 50:
3161-3169; 2004.
Köller M, Hayer S, Redlich K, Ricci R, David JP, Steiner G, Smolen JS, Wagner EF, Schett
G. JNK1 is not essential for TNF-mediated joint disease. Arthritis Res. Ther.:R166-73, 2005.
Hayer S, Steiner G, Görtz B, Reiter E, Tohidast-Akrad M, Amling M, Hoffmann O, Redlich K,
Zwerina J, Skriner K, Hilberg F, Wagner EF, Smolen JS, Schett G. CD44 as a regulator of
inflammatory bone loss. J Exp Med 201:903-914, 2005.
Grisar J, Aletaha D, Steiner CW, Kapral T, Steiner S, Seidinger D, Weigel G, Schwarzinger I,
Wolozcszuk W, Steiner G, Smolen JS. Depletion of endothelial progenitor cells in the
peripheral blood of patients with rheumatoid arthritis. Circulation 111:204-11, 2005.
Smolen JS, Redlich K, Zwerina J, Aletaha D, Steiner G, Schett G. Pro-inflammatory
cytokines in rheumatoid arthritis: pathogenetic and therapeutic aspects. Clin Rev Allergy
Immunol 28:239-48; 2005.
Machold KP, Stamm TA, Nell VP, Pflugbeil S, Aletaha D, Steiner G, Uffmann M, Smolen JS.
Very recent onset rheumatoid arthritis: clinical and serological patient characteristics
associated with radiographic progression over the first years of disease. Rheumatology
46:342-349; 2007.
Aringer M, Steiner G, Graninger WB, Hofler E, Steiner CW, Smolen JS. Effects of short-term
infliximab therapy on autoantibodies in systemic lupus erythematosus. Arthritis Rheum.
56:274-279; 2007.
Grisar JC, Aletaha D, Steiner CW, Kapral T, Steiner S, Saemann M, Schwarzinger I, Buranyi
B, Steiner G, Smolen JS. Endothelial progenitor cells in active rheumatoid arthritis: Effects of
TNF and of glucocorticoid therapy. Ann Rheum Dis. 66:1284-8;2007.
Rozman B, Euènik S, Sodin-Semrl S, Czirják L, Varjú C, Distler O, Huscher D, Aringer M,
Steiner G, Matucci-Cerinic M, Guiducci S, Stamenkoviæ B, Stankoviæ A, Kveder T.
Prevalence and clinical associations of anti-KU antibodies in patients with systemic sclerosis:
a European EUSTAR - initiated multicentre case-control study. Ann Rheum Dis, Epub ahead
of print, Dec. 2007.
Book chapters
Steiner G, Skriner K, Fabini G, Jimenez-Boj E, Kedersha N, Zimmermann C, Tohidast-Akrad
M, Schett G, Fritsch R, Höfler E, Anderson P, Smolen J. Translational regulators as
autoantigens in systemic autoimmune diseases. In: Autoantigens, Autoantibodies,
Autoimmunity; Volume 3. Conrad K, Fritzler M, Meurer M, Sack U, Shoenfeld Y, eds. Pabst
Science Publishers, Lengerich, pp 116-121; 2002.
Steiner G, Conrad K. Autoantigene. In: Molekularmedizinische Grundlagen von
rheumatischen Erkrankungen. Ganten D, Ruckpaul K eds. Springer Verlag Berlin Heidelberg
New York, pp123-164; 2003.
Steiner G. Autoantibodies in rheumatoid arthritis. In: Rheumatology, 3rd edition. Hochberg
MC, Silman AJ, Smolen JS, Weinblatt ME, Weisman MH eds. Harcourt Sciences Ltd, pp833842; 2003.
Steiner G, Belisova A, Valai A, Hayer S, Höfler E, Smolen J. Reflections about structure,
function and pathogenetic significance of Ro ribonucleoproteins. In: Autoantigens,
Autoantibodies, Autoimmunity; Volume 4. Conrad K, Bachmann MP, Chan EKL, Fritzler MJ,
- 201 -
Humbel RL, Sack U, Shoenfeld Y. eds. Pabst Science Publishers, Lengerich, pp 236-242;
2004.
Steiner G, Smolen J. Anti-RA33 autoantibodies (antibodies to the hetereogeneous nuclear
ribonucleoprotein A2). In: Autoantibodies 2nd edition. Shoenfeld Y, Gershwin E, Meroni P-L
eds. Elsevier BV, pp 211-216; 2007.
Steiner G, Hoffmann M, Hayer S, Fritsch R, Smolen J. Autoimmune responses in
experimental models of rheumatoid arthritis. In: Autoantigens, Autoantibodies, Autoimmunity;
Volume 5. Conrad K, Chan EKL, Fritzler MJ, Humbel RL, Sack U, Shoenfeld Y., Wiik AS eds.
Pabst Science Publishers, Lengerich, pp 45-53; 2007.
Voll R, Steiner G. Autoantikörper - Diagnostik und Pathogenese. In: Aktuelle
Therapieoptionen beim systemischen Lupus erythematodes. Aringer M ed. Uni-Med Verlag,
pp16-24; 2007.
Steiner G, Serre G. Autoantibodies in rheumatoid arthritis. In: Rheumatology, 4tth edition.
Hochberg MC, Silman AJ, Smolen JS, Weinblatt ME, Weisman MH eds. Mosby Elsevier,
pp 819-827; 2008.
Diagnostic criteria for early rheumatoid arthritis, Vienna, 25.-27. 1.2002.
International Congress on Autoimmunity, Geneva, 20.-24.2. 002.
First Meeting of the Global Arthritis Research Network, Luzern, 4.-6.4.2002.
Dresden Symposium on Autoantibodies, Dresden, 4.-7.9.2002.
European Workshop for Rheumatology Research, Marseille, 1.3.2003.
International Symposium on Autoimmunity; Vienna, 4.4.2003.
International Workshop on Autoantibodies and Autoimmunity; Berlin, 12.9.2003.
Workshop for Use of New Technologies in Rheumatology Research; Stockholm, 3.10.2003.
Yale University School of Medicine; New Haven, 7.5.2004.
Dresden Symposium on Autoantibodies; Dresden, 1.-4.9.2004.
Austrian Proteome Form; Wien, 14.-15.10.2004.
Kennedy Institute of Rheumatology; London, 7.3.2005.
Annual European Congress of Rheumatology, Vienna, 8.-11.6.2005.
International Workshop on Autoantibodies and Autoimmunity, Gainesville, 29.9.-2.10.2005.
Workshop New Trends in Rheumatology, Kühtai, 30.3.-1.4. 2006.
First International Aesku.Kipp Institute Symposium Autoimmunity, Wendelsheim, 6.5.2006.
34. Kongress der Deutschen Gesellschaft für Rheumatologie, Wiesbaden, 18.-21.10.2006.
Menarini Diagnostics International Symposium on Autoimmunity, Sorrento, 27.-28.11.2006.
Third Cellaid Symposium, Florence, 20-22.2. 2007.
Eighth Dresden Symposium on Autoantibodies, Dresden, 12.-15.9.2007.
Jahrestagung der ÖGLKC und der DGKL, Vienna, 19.-21.9.2007.
European Workshop for Rheumatology Research, Toulouse, 28.2.-1.3.2008.
- 202 -
Curriculum Vitae
Johannes Stöckl
Division of Immune-Regulation, Institute of Immunology, Center for Physiology,
Pathophysiology and Immunology, Medical University of Vienna, Borschkegasse 8a, 1090
Vienna, Austria;
Phone: +43 1 4277-64951, Fax: +43 1 4277-9649;
Homepage: www.meduniwien.ac.at/immunologie
Personal Data
Date of Birth:
15.12.1965
Place of Birth:
Vienna
Nationality
Austria
Education
1992 – 1994
PhD studies (Immunology), University of Vienna
1992
Diploma thesis at the Institute of Immunology, in Vienna
1985 – 1991
Studies in Microbiology, University of Vienna
1984
University entrance qualification, BGR Hollabrunn
Career History
Since 10/2003
School, Associate Professor (a.o.Univ.Prof)
Since 2000
University Assistant (Group leader)
1994 - 2000
Postdoctoral Fellow, University of Vienna Medical School
2003 – present
Member of the Editorial Board, JCMM
2004 - present
Board Member of the Austrian Society of Allegology and
Immunology
Awards
2006
Wissenschaftspreis 2006 des Landes Niederösterreich
2004
Otto-Kraup Preis (Habilitation), sponsored by Aventis
2002
Aventis Prize
2001
1997
Karl Landsteiner Prize (Austrian Society of Allergology and
- 203 -
Immunology)
1993
Thesis Prize (Austrian Society of Allergology and
Immunology)
Memberships
Period
Organization
Short Title
K€/year
2007 - 2009 FWF
Regulatory T cells and SREC-I
95
2007 - 2009 FWF
68
Vision fund (together with Maria Sibilia)
2005 - 2007 FWF
110
Subproject 7
2004 - 2007 WWTF
Oxidized phospholipids and DC
175
1995 - 2004 FWF
SFB-05-02: Polarized phagocyte
105
differentiation
2000 - 2004 K-Plus BMT
Molecular Analysis of Dendritic Cell Function
100
Period
Name of student
2002 - 2006 Stefanie Kirchberger
Topic
Modulation of immune cell function by human
rhinoviruses
2004 - 2007 Nina Gundacker
Effects of oxidized phospholipids on dendritic cell
protein expression
2007 -
Maria Seyerl
present
2008 -
Novel pathways of anergy induction in human T
cells
Catharina Schrauf
Recognition of viral RNA by DC
present
Publications
43 peer reviewed publications in scientific journals, 3 book chapters, 18 invited lectures, 2
patents
1.
Selenko, N., O. Majdic, U. Jager, C. Sillaber, J. Stockl, and W. Knapp. 2002. Crosspriming of cytotoxic T cells promoted by apoptosis-inducing tumor cell reactive
- 204 -
antibodies? J Clin Immunol 22:124.
2.
Selenko-Gebauer, N., O. Majdic, A. Szekeres, G. Hofler, E. Guthann, U. Korthauer,
G. Zlabinger, P. Steinberger, W. F. Pickl, H. Stockinger, W. Knapp, and J. Stockl.
2003. B7-H1 (programmed death-1 ligand) on dendritic cells is involved in the
induction and maintenance of T cell anergy. J Immunol 170:3637.
3.
Bluml, S., S. Kirchberger, V. N. Bochkov, G. Kronke, K. Stuhlmeier, O. Majdic, G. J.
Zlabinger, W. Knapp, B. R. Binder, J. Stockl, and N. Leitinger. 2005. Oxidized
phospholipids negatively regulate dendritic cell maturation induced by TLRs and
CD40. J Immunol 175:501.
4.
Kirchberger, S., O. Majdic, P. Steinberger, S. Bluml, K. Pfistershammer, G. Zlabinger,
L. Deszcz, E. Kuechler, W. Knapp, and J. Stockl. 2005. Human rhinoviruses inhibit
the accessory function of dendritic cells by inducing sialoadhesin and B7-H1
expression. J Immunol 175:1145.
5.
Kirchberger, S., H. Vetr, O. Majdic, H. Stockinger, and J. Stockl. 2006. Engagement
of ICAM-1 by major group rhinoviruses activates the LFA-1/ICAM-3 cell adhesion
pathway in mononuclear phagocytes. Immunobiology 211:537.
6.
Kirchberger, S., O. Majdic, and J. Stockl. 2007. Modulation of the immune system by
human rhinoviruses. Int Arch Allergy Immunol 142:1.
7.
Seyerl, M., S. Bluml, S. Kirchberger, V. N. Bochkov, O. Oskolkova, O. Majdic, and J.
Stockl. 2008. Oxidized phospholipids induce anergy in human peripheral blood T
cells. Eur J Immunol 38:778.
1.
Schoppmann, S. F., P. Birner, J. Stockl, R. Kalt, R. Ullrich, C. Caucig, E. Kriehuber,
K. Nagy, K. Alitalo, and D. Kerjaschki. 2002. Tumor-associated macrophages express
lymphatic endothelial growth factors and are related to peritumoral
lymphangiogenesis. Am J Pathol 161:947.
2.
Steinberger, P., A. Szekeres, S. Wille, J. Stockl, N. Selenko, E. Prager, G. Staffler, O.
Madic, H. Stockinger, and W. Knapp. 2002. Identification of human CD93 as the
phagocytic C1q receptor (C1qRp) by expression cloning. J Leukoc Biol 71:133.
3.
Lehner, M., J. Stockl, O. Majdic, W. Knapp, K. Huttner, T. Felzmann, and W. Holter.
2003. MHC class II antigen signaling induces homotypic and heterotypic cluster
formation of human mature monocyte derived dendritic cells in the absence of cell
death. Hum Immunol 64:762.
4.
Pfistershammer, K., O. Majdic, J. Stockl, G. Zlabinger, S. Kirchberger, P. Steinberger,
and W. Knapp. 2004. CD63 as an activation-linked T cell costimulatory element. J
Immunol 173:6000.
5.
Steinberger, P., O. Majdic, S. V. Derdak, K. Pfistershammer, S. Kirchberger, C.
Klauser, G. Zlabinger, W. F. Pickl, J. Stockl, and W. Knapp. 2004. Molecular
characterization of human 4Ig-B7-H3, a member of the B7 family with four Ig-like
domains. J Immunol 172:2352.
6.
Traxler, E., E. Bayer, J. Stockl, T. Mohr, C. Lenz, and C. Gerner. 2004. Towards a
standardized human proteome database: quantitative proteome profiling of living
cells. Proteomics 4:1314.
7.
Gundacker, N., E. Bayer, E. Traxler, H. Zwickl, M. Kubicek, J. Stockl, and C. Gerner.
2006. Knowledge-based proteome profiling: considering identified proteins to
evaluate separation efficiency by 2-D PAGE. Electrophoresis 27:2712.
- 205 -
8.
Pfistershammer, K., C. Klauser, W. F. Pickl, J. Stockl, J. Leitner, G. Zlabinger, O.
Majdic, and P. Steinberger. 2006. No evidence for dualism in function and receptors:
PD-L2/B7-DC is an inhibitory regulator of human T cell activation. Eur J Immunol
36:1104.
9.
Pfistershammer, K., J. Stockl, J. Siekmann, P. L. Turecek, H. P. Schwarz, and B. M.
Reipert. 2006. Recombinant factor VIII and factor VIII-von Willebrand factor complex
do not present danger signals for human dendritic cells. Thromb Haemost 96:309.
10.
Koesters, C., B. Unger, I. Bilic, U. Schmidt, S. Bluml, B. Lichtenberger, M. Schreiber,
J. Stockl, and W. Ellmeier. 2007. Regulation of dendritic cell differentiation and subset
distribution by the zinc finger protein CTCF. Immunol Lett 109:165.
2002
• ENT-meeting, AKH, Vienna, Austria
2003
• EMDS meeting, Leicester, UK
2004
• University of Innsbruck, Austria
2005
• Vienna Biocenter, Austria
2006
• Semmelweis University, Budapest, Hungary
2007
• Medical University of Innsbruck, Austria
2008
• Novo Nordisk, Kopenhagen, Denmark
- 206 -
Curriculum Vitae
Martin Willheim
Division of Cellular and Molecular Pathophysiology, Institute of Pathophysiology, Center for
Physiology, Pathophysiology and Immunology, Medical University of Vienna, Währinger
Gürtel 18-20, 1090 Wien, Austria;
Phone: +43 1 40400-5133, Fax: +43 1 40400-5130;
Personal Data
Date of Birth:
31.08.1962
Place of Birth:
Linz
Nationality
Austria
Education
2006
Certification as Specialist of Pathophysiology
2005
Certification as Specialist of Laboratory Medicine
1980 – 1994
Studies in Medicine, Medical Faculty, University of Vienna
Career History
Since 2001
2001
Venia docendi in „Pathophysiology“
since 2001
Head of the research group „Cytokine research“, Institute
of Pathophysiology, Medical University of Vienna
since 04/2005
Institute of Pathophysiology, Medical University of Vienna
10/2001 – 03/2005
Clinical Institute of Medical and Chemical Laboratory
Diagnostics, Medical University of Vienna (Resident)
10/2000 – 09/2001
Division of Rheumatology, Department of Internal
Medicine III, Medical University of Vienna (Resident)
03 – 09/2000
Error! Not a valid link. (Resident)
12/1995 – 02/2000
Institute of Pathophysiology, Medical University of Vienna
(Resident)
2006 - present
Head of the Core Unit Cytometry, Medical University of
Vienna
02/2001 – present
President of the Austrian Society for Cytometry
- 207 -
Awards
2005
B.R.A.H.M.S Forschungspreis für
Schilddrüsenerkrankungen 2005
Memberships
Austrian Society for Cytometry
International Society for Analytical Cytology
Austrian Society for Bone and Mineral Research
Period
Organization
Short Title
K€/year
2007
Medizinisch
Tumorstammzellen im malignen Melanom
15
Medizinisch
Anti-TPO Autoantikörper Spiegel und
15
Wissenschaftlicher
Zytokin-Produktionsmuster von
Fonds des
Lymphozyten als mögliche Indikatoren der
Bürgermeisters der
Aktivität einer Hashimoto Thyreoiditis unter
Bundeshauptstadt
dem Einfluss einer L-Thyroxin
Wien
Substitutionstherapie
Wissenschaftlicher
Fonds des
Bürgermeisters der
Bundeshauptstadt
Wien
2006
Period
Name of student
Topic
Thien Ralf
2004-2007
Ernstbrunner Lino
Änderung der Wirkung von 1α,25(OH)2 Vitamin
D3 auf das Zytokin-Produktionsmuster von T
Lymphozyten im Laufe der kindlichen Entwicklung
03/2007 -
Maldonado Eduardo
present
Effect of the short–term thyrotropin increase after
administration of Recombinant Human
Thyrotropin (Thyrogen) on T lymphocyte cytokine
production pattern and bone metabolism in
healthy subjects
11/2007 present
Semrad Ursula
Extended cytokine profiling of functional human
peripheral blood CD4+ T lymphocytes (Th1, Th2
- 208 -
and Th17) and the effect of different microenvironments on their differentiation
Publications
76 peer reviewed publications in scientific journals
1α,25(OH)2D3 inhibits not only Th1 but also Th2 differentiation in human cord blood T cells.
Josefa Pichler, Marianne Gerstmayr, Zsolt Szépfalusi, Radvan Urbanek, Meinrad Peterlik
and Martin Willheim
Pediatr Res, 52:12-8, 2002
Donor dependent, interferon-gamma induced HLA-DR expression on human neutrophils in
vivo.
Reinisch W, Lichtenberger C, Steger G, Tillinger W, Scheiner O, Gangl A, Maurer D,
Willheim M.
Clin Exp Immunol. 2003 Sep;133(3):476-84.
T-lymphocyte cytokine production patterns in nonimmune severe hypothyroid state and after
thyroid hormone replacement therapy.
Karanikas G, John P, Wahl K, Schuetz M, Dudczak R, Willheim M.
Thyroid. 2004 Jul;14(7):488-92.
Relation of anti-TPO Autoantibody Titer and T Lymphocyte Cytokine Production Patterns in
Hashimoto’s Thyroiditis.
Karanikas G, Schütz M, Wahl K, Paul M, Kontur S, Pietschmann P, Kletter K, Dudczak R,
Willheim M.
Clin Endocrinol (Oxf). 2005 Aug;63(2):191-6.
Interactions of 1α,25-dihydroxyvitamin D3 with interleukin-12 and interleukin-4 on cytokine
expression of human T lymphocytes.
Thien R, Baier K, Pietschmann P, Peterlik M, Willheim M.
J Allergy Clin Immunol 2005, 116/3, pp 683-689.
T lymphocyte cytokine production patterns in hashimoto patients with elevated calcitonin
levels and their relationship to tumor initiation.
Matthias Schütz, Heying Duan, Katharina Wahl, Christian Pirich, Anna Antoni, Spyridoula
Kommata, Kurt Kletter, Robert Dudczak, Georgios Karanikas, Martin Willheim
Anticancer Res., 2006 Nov-Dec;26(6B):4591-6.
No immunological benefit of Selenium in consecutive patients with autoimmune thyroiditis
Georgios Karanikas, Matthias Schuetz, Sylvester Kontur, Heying Duan, Spyridoula
Kommata, Robert Schoen, Anna Antoni, Kurt Kletter, Robert Dudczak, and Martin Willheim
Thyroid, accepted July 2007

IMMUNOLOGY Thesis Program of the PhD

Transcription

Documents pareils

Staff guidelines for the use of the technological laboratories and the

W CTE 2016

Einladung zur 2. Max Neuburger Lecture

Press release Vienna, 24 September 2015 Who dares wins

INFORMATIONABOUTPATIE NTC O- PAYMENTS

Conference Programme #POPSCI2015 International Conference on

Studies in Historical Geography and Cultural Heritage Instructions